Commonwealth Coat of Arms of Australia

 

Therapeutic Goods (Poisons Standard—October 2023) Instrument 2023

I, Michelle McLaughlin, as delegate of the Secretary of the Department of Health and Aged Care, make the following instrument.

Dated 22 September 2023

Michelle McLaughlin

Acting Assistant Secretary
Regulatory Engagement Branch
Health Products Regulation Group
Department of Health and Aged Care

 

 

 

 

Contents

Reader’s guide

Introduction

Classification

Principles of scheduling

Reading the schedules

Availability of poisons

Appendices

Appendix A (General exemptions)

Appendix B (Substances considered not to require control by scheduling)

Appendix C (blank)

Appendix D (Additional controls on possession or supply of poisons included in Schedule 4 or 8)

Appendix E (First aid instructions for poisons)

Appendix F (Warning statements and general safety directions for poisons)

Appendix G (Dilute preparations)

Appendix H (Schedule 3 medicines permitted to be advertised)

Appendix I (blank)

Appendix J (Conditions for availability and use of certain poisons included in Schedule 7)

Appendix K (Human medicines required to be labelled with a sedation warning)

Appendix L (Requirements for dispensing labels for medicines)

Appendix M (blank)

Poisons Information Centre telephone numbers for first aid instructions, warning statements and general safety directions for poisons

Part 1—Preliminary and interpretation

1  Name

2  Commencement

3  Authority

4  Repeal and transitional provisions

5  Reader’s guide and Index

6  Definitions

7  References to substances

8  References to concentration, strength or quantity of substances

9  References to boiling or distillation temperatures

10  References to standards

Part 2—Controls on substances

Division 1—Preliminary

11  Application of Part 2

12  Preparations containing poisons included in different schedules

Division 2—Labels

Subdivision A—General

13  General requirements

14  Immediate wrapper

Subdivision B—Primary packs and immediate containers

15  Primary packs and immediate containers

16  Signal words

17  Cautionary statement—possession without authority illegal

18  Cautionary statement—keep out of reach of children

19  Cautionary statement—fire and explosion hazard

20  Cautionary statement—burns skin and throat

21  Cautionary statements for aqueous solution of paraquat

22  Cautionary statement—read safety directions

23  Cautionary statement—flammable

24  Cautionary statement—for animal treatment only

25  Cautionary statement—do not swallow

26  Approved name and quantity, proportion or strength

27  Statement—an anticholinesterase compound

28  Directions for use

29  Safety directions

30  Warning statements

31  First aid

32  Name and address of manufacturer or distributor

33  Warning statements and sedation warnings for certain medicines for human use

Subdivision C—Statements of quantity, proportion or strength

34  Statements of quantity, proportion or strength

Subdivision D—Exemptions from labelling requirements

35  Selected containers and measure packs

36  Ampoules, prefilled syringes and injection vials

37  Transport containers and wrappings

38  Dispensary, industrial, laboratory and manufacturing poisons

39  Exemptions from label requirements in certain circumstances

40  Dispensed medicines

41  Gas cylinders

42  Paints

43  Camphor and naphthalene

Subdivision E—Prohibitions

44  Prohibitions

Division 3—Containers

45  General requirements

46  Containers for poisons other than poisons included in Schedule 5

47  Containers for poisons included in Schedule 5

48  Approved containers

49  Childresistant closures

50  Poisons included in Schedule 8

51  Exemptions

52  Camphor and naphthalene

53  Prohibitions—use of containers for poisons

Division 4—Storage

54  General storage requirements

Division 5—Disposal

55  General disposal requirements

Division 6—Record keeping

56  General recordkeeping requirements

Division 7—Advertising

57  General advertising requirements

Division 8—Supply, prescribing, possession or use

58  Poisons included in Schedule 2

59  Poisons included in Schedule 3

60  Poisons included in Schedule 4

61  Poisons included in Schedules 5 and 6

62  Poisons included in Schedule 7

63  Poisons included in Schedule 10

64  Poisons included in Schedule 4 or 8 and Appendix D

65  Hawking

Division 9—Paints and tinters

66  General requirements

67  Definition of first group paint

68  Definition of second group paint

Schedule 1—Blank

Schedule 2—Pharmacy medicines

Schedule 3—Pharmacist only medicines

Schedule 4—Prescription only medicines and prescription animal remedies

Schedule 5—Caution

Schedule 6—Poisons

Schedule 7—Dangerous poisons

Schedule 8—Controlled drugs

Schedule 9—Prohibited substances

Schedule 10—Substances of such danger to health as to warrant prohibition of supply and use

Appendix A—General exemptions

1  Exempt preparations and products

Appendix B—Substances considered not to require control by scheduling

1  Reasons for including substances in the table in clause 3

2  Areas of use in relation to substances included in the table in clause 3

3  Substances exempt in certain uses

Appendix C—Blank

Appendix D—Additional controls on possession or supply of poisons included in Schedule 4 or 8

1  Poisons available for human use only from or on the prescription or order of an authorised medical practitioner

2  Poisons available for human use only from or on the prescription or order of a specialist physician or a dermatologist

3  Poisons available only from or on the prescription or order of a medical practitioner approved or authorised under section 19 of the Act

4  Poisons available only from or on the order of a specialist physician

5  Poisons for which possession without authority is illegal

6  Poisons available for human use only from or on the prescription or order of a specialist physician

7  Poisons available for human use only from or on the prescription or order of a dermatologist

8  Poisons available for initial treatment of a patient only if authorised by certain health practitioners

9  Poisons which must be stored in a locked container to prevent unauthorised access

10  Poisons available only when prescribed or authorised in certain circumstances

Appendix E—First aid instructions for poisons

1  Standard statements for first aid instructions

2  Poisons information centre contact information in statements

3  First aid instructions for poisons

Appendix F—Warning statements and general safety directions for poisons

1  Warning statements

2  Safety directions—general

3  Poisons information centre contact information in statements

4  Poisons that must be labelled with warning statements and safety directions

Appendix G—Dilute preparations

1  Substances exempt at or below certain concentrations

Appendix H—Schedule 3 medicines permitted to be advertised

1  Schedule 3 medicines permitted to be advertised

Appendix I—Blank

Appendix J—Conditions for availability and use of certain poisons included in Schedule 7

1  Conditions for supply of certain poisons included in Schedule 7

Appendix K—Human medicines required to be labelled with a sedation warning

1  Human medicines required to be labelled with a sedation warning

Appendix L—Requirements for dispensing labels for medicines

1  General

2  Additional warning statements for certain human medicines

Appendix M—Additional controls or supply requirements for poisons included in Schedule 3 to allow them to be provided by a pharmacist

Index 

Reader’s guide

 

Introduction

This instrument is made under paragraph 52D(2)(b) of the Therapeutic Goods Act 1989 (the Act), and is a compilation of decisions made under section 52D of the Act. This instrument should be read in conjunction with the Scheduling Policy Framework (the SPF) of the Australian Health Ministers’ Advisory Council. Further information on the scheduling amendments and the SPF can be viewed on the Therapeutic Goods Administration’s website (www.tga.gov.au). Refer to section 6 for definitions of specific terms used in this document including “medicine” and “poison” (noting that the definition of poison includes medicine).

This instrument serves 2 key purposes.

Firstly, this instrument contains the decisions of the Secretary of the Department of Health and Aged Care or the Secretary’s delegates regarding the classification of poisons into Schedules, as recommendations to Australian States and Territories. The scheduling classification sets the level of control on the availability of poisons. The scheduling of poisons is implemented through relevant State and Territory legislation. Certain advertising, labelling and packaging requirements may also be a consequence of scheduling, but are the subject of other Commonwealth registration schemes.

Secondly, this instrument includes provisions for labelling, containers, storage, disposal, recordkeeping, supply and possession of poisons in general which are intended to be adopted for use in each jurisdiction of Australia. Other government agencies may also impose controls on certain products.

The requirements for labelling and containers in this instrument are intended to integrate with existing legislative instruments for labelling and containers. Advertising, labelling and packaging of therapeutic goods and agricultural and veterinary chemicals are also dealt with through the respective product registration schemes provided for in Commonwealth legislation.

Poisons which are packed and sold solely for industrial, manufacturing, laboratory or dispensary use are exempt from all labelling requirements included in this instrument as they are covered by labelling requirements under applicable jurisdictional Work Health and Safety laws, as amended from time to time. Note, however that this exemption does not extend to controls on supply of these poisons.

This instrument is presented with a view to promoting uniform:

The various Commonwealth Acts, legislative instruments and other documents, which integrate with this instrument include the following:

Classification

Poisons are classified according to the Schedules in which they are included. The following is a general description of the Schedules. For the legal definitions, however, it is necessary to check with each relevant State or Territory authority.

 

Schedule

Title

Description

Schedule 1

Blank

This Schedule is intentionally blank.

Schedule 2

Pharmacy medicines

Substances, the safe use of which may require advice from a pharmacist and which should be available from a pharmacy or, where a pharmacy service is not available, from a licensed person.

Schedule 3

Pharmacist only medicines

Substances, the safe use of which requires professional advice but which should be available to the public from a pharmacist without a prescription.

Schedule 4

Prescription only medicines and prescription animal remedies

Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a pharmacist on prescription.

Schedule 5

Caution

Substances with a low potential for causing harm, the extent of which can be reduced through the use of appropriate packaging with simple warnings and safety directions on the label.

Schedule 6

Poisons

Substances with a moderate potential for causing harm, the extent of which can be reduced through the use of distinctive packaging with strong warnings and safety directions on the label.

Schedule 7

Dangerous poisons

Substances with a high potential for causing harm at low exposure and which require special precautions during manufacture, handling or use. These poisons should be available only to specialised or authorised users who have the skills necessary to handle them safely. Special regulations restricting their availability, possession, storage or use may apply.

Schedule 8

Controlled drugs

Substances which should be available for use but require restriction of manufacture, supply, distribution, possession and use to reduce abuse, misuse and physical or psychological dependence.

Schedule 9

Prohibited substances

Substances which may be abused or misused, the manufacture, possession, supply or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.

Schedule 10 (previously Appendix C)

Substances of such danger to health as to warrant prohibition of supply and use

Substances which are prohibited for the purpose or purposes listed for each poison.

Principles of scheduling

Poisons are not scheduled on the basis of a universal scale of toxicity. Although toxicity is one of the factors considered, and is itself a complex of factors, the decision to include a substance in a particular Schedule also takes into account many other criteria such as the purpose of use, potential for abuse, safety in use and the need for the substance.

This instrument lists poisons in 10 Schedules according to the degree of control recommended to be exercised over their availability to the public.

Poisons for therapeutic use (medicines) are mostly included in Schedules 2, 3, 4 and 8 with progression through these Schedules signifying increasingly restrictive regulatory controls.

For some medicines and agricultural, domestic and industrial poisons, Schedules 5, 6 and 7 represent increasingly stricter container and labelling requirements with special regulatory controls over the availability of the poisons listed in Schedule 7. Products for domestic use must not include poisons listed in Schedule 7.

Schedule 9 contains substances that should be available only for teaching, training, medical or scientific research including clinical trials conducted with the approval of Commonwealth and/or State and Territory health authorities. Although appearing as a Schedule in this instrument, the method by which it is implemented in the States and Territories may vary.

Schedule 10 (previously Appendix C) contains a list of substances or preparations, the supply or use of which should be prohibited because of their known dangerous properties.

Substances in products which have been considered for scheduling, but have been exempted from this instrument, may be listed in either Appendix A (general exemptions) or Appendix B (substances considered not to require control by scheduling).

Reading the schedules

Schedule entries have been designed to be as simple as possible while retaining readability, legal integrity and as much freedom from ambiguity and contradiction as possible. As a result, they are expressed in a number of ways, though this number has been kept to a minimum. It is necessary to keep this variety of expression in mind when searching or interpreting Schedule entries.

Firstly, poisons are scheduled individually using their approved names wherever practicable although exceptions are necessary in some cases. Some of those are mentioned below. Older group entries are revised and replaced by individual entries as time permits, although in some of these cases a group term has also been retained to deal with any members of the group or class that may have escaped attention but should be scheduled.

Secondly, Schedule entries have been expressed in either positive or negative terms and care must be taken to distinguish between the 2 different forms of expression. Thus, selenium is in Schedule 6 only when one of the clauses in this Schedule entry applies, while fluorides are in Schedule 6 unless one of the exempting clauses applies.

Where exceptions are included in an entry, these have been emphasised by printing the word “except” in bold type.

Where the Schedule entries for a poison make a specific exclusion or exemption, the requirements of this instrument do not apply to that poison within the constraints of that exclusion or exemption although controls under other legislation, such as pesticide registration, may apply.

Where a Schedule entry for a poison requires a specific statement to be included on a label as a condition for a product to qualify for an exemption (“reverse scheduling”), then in cases where it is impracticable for a supplier to use the exact wording of such a statement, its wording may be varied provided that the full intent and meaning of the statement is not changed.

Where a poison has been included in more than one Schedule, the principal entry, where practicable, has been included in the most restrictive Schedule with references to the other Schedule(s) involved.

It is important to remember that a Schedule entry includes preparations containing the poison in any concentration and all salts and derivatives of the poison unless it specifically states otherwise (see section 7).

It is important to note that a substance is not classed as a derivative on the basis of a single, prescriptive set of criteria. Classification of a substance as a derivative of a scheduled poison relies on a balanced consideration of factors to decide if a substance has a similar nature (e.g. structurally, pharmacologically, and toxicologically) to a scheduled poison or is readily converted (either physically or chemically) to a scheduled poison. However, a substance is only considered a derivative of a scheduled poison if it is not individually listed elsewhere in the Schedules, or captured by a more restrictive group or class entry. Additionally, some entries specifically exclude derivatives. Once a substance is determined to be a derivative of a scheduled poison, the same scheduling requirements as the scheduled poison, including limits on access, supply and availability, will apply.

Finally, when using this instrument to determine the scheduling status of a poison, it may be necessary to search each relevant Schedule as well as Appendices A, B and the Index. In this process, if the poison is not found under its “approved name” it may be shown under a group term such as:

 

Group

Example

the parent acid of salts

“oxalic acid” to find sodium oxalate

the radical of a salt

“chromates” to find potassium chromate

the element

“arsenic” to find arsenic trioxide

a chemical group with similar toxicological or pharmacological activity

“hydrocarbons, liquid” to find kerosene

a pharmacological group

“anabolic steroidal agents” to find “androsterone”

Availability of poisons

The purpose of classification is to group substances into Schedules that require similar regulatory controls over their availability.

These Schedules have been developed over a long period and contain poisons that may be obsolete for various reasons. Also, as part of the move to harmonise the Australian and New Zealand classifications, many substances have been added to the Schedules for that purpose, irrespective of their availability in either country.

Inclusion of a poison in a Schedule indicates the degree of control required if it is marketed. It does not:

Appendices

Some substances in certain circumstances are also subject to exemptions or additional restrictions as described in the Appendices of this instrument. The table below summarises the purpose of each of the Appendices and the controls imposed on substances included in them.

 

Appendix

Title

Purpose/controls imposed

Appendix A

General exemptions

List of preparations and products exempted from this instrument.

Appendix B

Substances considered not to require control by scheduling

List of poisons exempted from scheduling.

Appendix C

Appendix is intentionally left blank

See Schedule 10.

Appendix D

Additional controls on possession or supply of poisons included in Schedule 4 or 8

List of poisons included in Schedule 4 or 8 where additional specified controls apply on possession or supply.

Appendix E

First aid instructions for poisons

First aid instructions for poisons (other than agricultural and veterinary chemicals and chemicals packed and sold solely for industrial, dispensary, manufacturing or laboratory use).

Appendix F

Warning statements and general safety directions for poisons

Warning statements and general safety directions for poisons (other than human medicines, agricultural and veterinary chemicals and chemicals packed and sold solely for industrial, dispensary, manufacturing or laboratory use).

Appendix G

Dilute preparations

Concentration cutoffs for specified poisons, below which the requirements of this instrument do not apply

Appendix H

Schedule 3 medicines permitted to be advertised

List of medicines included in Schedule 3 that are permitted to be advertised to the public.

Appendix I

Appendix is intentionally left blank

 

Appendix J

Conditions for availability and use of Schedule 7 poisons

List of poisons included in Schedule 7 where additional specified conditions apply to their availability and use.

Appendix K

Human medicines required to be labelled with a sedation warning

List of poisons in medicines for human use required to be labelled with a warning regarding their sedation potential.

Appendix L

Requirements for dispensing labels for medicines

Requirements applying to labels attached to medicines at the time of dispensing.

Appendix M

Additional controls or supply requirements for poisons included in Schedule 3 to allow them to be provided by a pharmacist

Appendix is intentionally left blank and is reserved for future use.

 

Appendix A (General exemptions)

Appendix A lists preparations and products that are exempted from this instrument.

Appendix B (Substances considered not to require control by scheduling)

Substances for which the available information suggests that inclusion in the Poisons Schedules is not necessary, or not the most appropriate means of controlling the risk to public health, have been considered at various times.

Inclusion in Appendix B indicates that a decision has been taken not to include substances anywhere in the Schedules, either for a specific purpose, or generally. It is an inclusive, but not an exhaustive, list (that is, there may be substances not included in the Schedules, and not included in Appendix B, which may be hazardous or nonhazardous, but have not been considered in relation to the need for scheduling).

Substances may be included in Appendix B because they have intrinsically low toxicity, or where other factors suggest that the potential public health risk would be minimal. Factors which are considered when determining an Appendix B entry include:

The list of substances included in Appendix B was developed from scheduling files and historical records. For transparency, where the reason for entry and/or purpose or use for the substance was apparent in the consideration, this has been included in the columns “Reason for Entry” and “Area of Use”.

Inclusion in Appendix B will not prevent reconsideration of the scheduling of a substance where adverse information becomes available about the Appendix B entry for that substance.

Applications are considered for scheduling. Applications for inclusion in Appendix B will not be accepted.

Appendix C (blank)

Appendix C is intentionally blank.

Appendix D (Additional controls on possession or supply of poisons included in Schedule 4 or 8)

Appendix D lists poisons included in Schedule 4 or 8 where additional specified controls apply on possession or supply.

Appendix E (First aid instructions for poisons)

Under poisons legislation, scheduled substances and their preparations are required to be labelled with appropriate directions for first aid attention in case of poisoning. It is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the first aid instructions included on the label of a poison are appropriate for a specific product. Standard statements have been prepared as a guide for health authorities and manufacturers in drafting suitable first aid directions for this purpose. Standard statements specified in Appendix E may be varied provided that the intent is not changed.

The directions listed for any particular substance may require modification to take into account combination of that substance with other substances, both toxic and nontoxic, in a formulation, as well as the physical form and presentation of the product. Any such modification should be concise and readily understood.

The First Aid Instructions include action to be taken in case of eye contamination from substances recognised as causing direct poisoning via the eye, causing severe eye damage or requiring prolonged flushing to free the absorbed substance from the eye tissue. However, it is recognised that many other substances or preparations will require a statement of varying nature depending on the detailed formulation. While the necessity to flush the eyes in case of accident will be so selfevident as not to justify label space in many instances, a statement such as “If in eyes rinse well with water” may be appropriate.

Appendix F (Warning statements and general safety directions for poisons)

It is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the purchaser or user of a product is given sufficient information to be able to use it correctly and safely.

Under poisons legislation, scheduled substances, which may be harmful to the user, must be labelled with appropriate warning statements and/or safety directions. The selection of warning statements and safety directions will depend on the formulation of the product, and the use for which it is sold or supplied. Warning statements and safety directions have been prepared as a guide for this purpose.

The wording of warning statements and safety directions specified in Appendix F may be varied provided that the intent is not changed. Additional statements also may be added to ensure that the user of a product is sufficiently advised of its harmful nature and how to avoid any deleterious effects.

Appendix G (Dilute preparations)

Appendix G lists concentration cutoffs for specified substances, below which the requirements of this instrument do not apply.

Appendix H (Schedule 3 medicines permitted to be advertised)

Appendix H lists medicines included in Schedule 3 that are permitted to be advertised to the public.

Appendix I (blank)

Appendix I is intentionally blank.

Appendix J (Conditions for availability and use of certain poisons included in Schedule 7)

All poisons included in Appendix J are not to be available except to authorised or licensed persons.

The use of a poison may be restricted for a particular purpose. Controls recommended for the Schedule 7 poisons included in Appendix J may be implemented through poisons controls or other State or Territory legislation.

Appendix K (Human medicines required to be labelled with a sedation warning)

Medicines for human use that contain a poison included in Appendix K are required to be labelled with a warning regarding their sedation potential.

Appendix L (Requirements for dispensing labels for medicines)

Appendix L sets out the requirements for labels attached to medicines at the time of dispensing.

Appendix M (blank)

Appendix M is intentionally blank and is reserved for future use.

Poisons Information Centre telephone numbers for first aid instructions, warning statements and general safety directions for poisons

Companies should use the Poisons Information Centre telephone number(s) (Australia 13 11 26; New Zealand 0800 764 766) appropriate to the country(ies) of sale for the product.

Companies wishing to use a poisons information centre telephone number other than the national telephone numbers for Australia and New Zealand must meet the following criteria:

1. the poisons information service whose number is used must be attended by adequately trained staff for 24 hour emergency poisons information; and

2. calls must be logged and submitted for incorporation into the official collection of poisoning data.

Part 1Preliminary and interpretation

 

 

1  Name

 (1) This instrument is the Therapeutic Goods (Poisons Standard—October 2023) Instrument 2023.

 (2) This instrument may also be cited as the Standard for the Uniform Scheduling of Medicines and Poisons No. 42.

Note: This instrument is the current Poisons Standard for the purposes of the Act until a document is prepared in substitution for it (see sections 52A and 52D of the Act).

2  Commencement

 (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

 

Commencement information

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1.  The whole of this instrument

1 October 2023.

1 October 2023

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

  This instrument is made under paragraph 52D(2)(b) of the Therapeutic Goods Act 1989.

4  Repeal and transitional provisions

Repeal

 (1) The Therapeutic Goods (Poisons StandardJuly 2023) Instrument 2023 is repealed.

Saving—things done under the repealed instrument

 (2) If:

 (a) a thing was done for a particular purpose under the Therapeutic Goods (Poisons StandardJuly 2023) Instrument 2023 as in force immediately before that instrument was repealed; and

 (b) the thing could be done for that purpose under this instrument;

the thing has effect for the purposes of this instrument as if it had been done for that purpose under this instrument.

 (3) Without limiting subsection (2), a reference in that subsection to a thing being done includes a reference to an approval, authorisation, certificate, exemption, requirement or other instrument being given, made, granted or issued.

5  Reader’s guide and Index

 (1) The Reader’s guide is not part of this instrument.

 (2) The Index is not part of this instrument.

6  Definitions

Note 1: The following expressions used in this instrument are defined in the Act:

(a) current Poisons Standard;

(b) poison;

(c) Register;

(d) Secretary;

(e) supply;

(f) therapeutic goods.

Note 2: The definition of poison in the Act is as follows:

 poison means an ingredient, compound, material or preparation which, or the use of which, may cause death, illness or injury and includes any ingredient, compound, material or preparation referred to in a schedule to the current Poisons Standard.

  In this instrument:

Act means the Therapeutic Goods Act 1989.

agricultural chemical means:

 (a) a substance that is represented, imported, manufactured, supplied or used as a means of directly or indirectly:

 (i) destroying, stupefying, repelling, inhibiting the feeding of, or preventing infestation by or attacks of, any pest in relation to a plant, a place or a thing; or

 (ii) destroying a plant; or

 (iii) modifying the physiology of a plant or pest so as to alter its natural development, productivity, quality or reproductive capacity; or

 (iv) modifying an effect of another agricultural chemical; or

 (v) attracting a pest for the purpose of destroying it; or

 (b) an active ingredient included in a product declared by regulation under the Agricultural and Veterinary Chemicals Code Act 1994 to be an agricultural chemical product;

but does not include a veterinary chemical.

agricultural chemical product has the same meaning as in the Agricultural and Veterinary Chemicals Code set out in the Schedule to the Agricultural and Veterinary Chemicals Code Act 1994.

animal means any animal (other than a human being), whether vertebrate or not, and whether a food producing species or not, and includes mammals, birds, bees, reptiles, amphibians, fish, crustaceans and molluscs.

animal feed premix means a concentrated preparation, containing one or more poisons, for mixing with food ingredients to produce a bulk feed for a group of animals (including fish or birds), but does not include a preparation for mixing with an individual animal’s food.

appropriate authority: each of the following is an appropriate authority:

 (a) each person who is the head of the body (however described) in a State or Territory that is responsible for the administration of matters relating to health in that State or Territory;

 (b) the Deputy Secretary of the Department with responsibility for the part of the Department known as the Therapeutic Goods Administration, or their delegate;

 (c) the Chief Executive Officer of the Australian Pesticides and Veterinary Medicines Authority, or their delegate.

approved name means:

 (a) for a poison that is for human therapeutic use—the name for the poison in the Australian Approved Names List within the meaning of the Therapeutic Goods Regulations 1990; or

 (b) for a poison that is for animal or agricultural use—the name approved for use by the Australian Pesticides and Veterinary Medicines Authority under the Agricultural and Veterinary Chemicals Code set out in the Schedule to the Agricultural and Veterinary Chemicals Code Act 1994; or

 (c) for any other poison—the name for the poison mentioned in the firstoccurring of the following paragraphs that applies to the poison:

 (i) the name used for the poison in this instrument;

 (ii) the name recommended by Standards Australia as the common name for the poison;

 (iii) the English name given to the poison by the International Organization for Standardization;

 (iv) the name given to the poison by the British Standards Institution;

 (v) the English name given to the poison by the European Committee for Standardization (CEN);

 (vi) the international nonproprietary name recommended for the poison by the World Health Organization;

 (vii) the International Nomenclature Cosmetic Ingredient name for the poison listed in the International Cosmetic Ingredient Dictionary & Handbook published by the Personal Care Products Council of America;

 (viii) the accepted scientific name or the name descriptive of the true nature and origin of the poison.

Australian Dangerous Goods Code means the Australian Code for the Transport of Dangerous Goods by Road & Rail, published by the National Transport Commission, as existing from time to time.

Note: The Australian Dangerous Goods Code could in 2022 be viewed on the Commission’s website (www.ntc.gov.au).

authorised prescriber means any of the following:

 (a) a dental practitioner;

 (b) a medical practitioner;

 (c) a veterinarian;

 (d) a person for whom an authorisation, given for the purposes of this paragraph by an appropriate authority, is in effect.

blood means whole blood extracted from human donors.

blood components means therapeutic components that have been manufactured from blood (including red cells, white cells, stem cells, platelets and plasma), except for products derived through fractionation of plasma.

childresistant closure means:

 (a) a closure that complies with the requirements for a childresistant closure in Australian Standard AS 19282007, Childresistant packaging – Requirements and testing procedures for reclosable packages (ISO 8317:2015, MOD); or

 (b) a closure that complies with the requirements for childresistant closures specified in Therapeutic Goods Order No. 95  Childresistant packaging requirements for medicines 2017 (TGO 95); or

 (c) a closure that is taken to comply with the requirements mentioned in paragraph (b) under Therapeutic Goods (Standard for Nicotine Vaping Products) (TGO 110) Order 2021; or

 (d) in the case of a can fitted with a presson lid, a lid of the design known as “double tight” or “triple tight”.

Note: See also the definition of nonaccess packaging.

childresistant packaging means packaging that:

 (a) complies with the requirements of Australian Standard AS 19282007, Child resistant packaging – Requirements and testing procedures for reclosable packages (ISO 8317:2015, MOD); or

 (b) is reclosable and complies with the requirements of at least one of the following:

 (i) the International Organization for Standardization Standard ISO 8317:2015, Childresistant packaging—Requirements and testing procedures for reclosable packages;

 (ii) the British Standards Institution Standard BS EN ISO 8317:2004, Childresistant packaging—Requirements and testing procedures for reclosable packages;

 (iii) the Canadian Standards Association Standard CSA Z76.106, Reclosable ChildResistant Packages;

 (iv) the United States Code of Federal Regulations, Title 16, Section 1700.15, Poison prevention packaging standards and Section 1700.20, Testing procedure for special packaging, as in force from time to time; or

 (c) a closure that complies with the requirements for childresistant packaging specified in Therapeutic Goods Order No. 95  Childresistant packaging requirements for medicines 2017 (TGO 95); or

 (d) a closure that is taken to comply with the requirements mentioned in paragraph (c) under Therapeutic Goods (Standard for Nicotine Vaping Products) (TGO 110) Order 2021; or

 (e) is in the form of blister or strip packaging:

 (i) in which a unit of use is individually protected until the time of release; and

 (ii) that complies with section 3 (Requirements for nonreclosable packages) of Australian Standard AS 19282001, Childresistant packages.

Note: See also the definition of nonaccess packaging.

compounded in relation to a substance means combined with one or more other therapeutically active substances in such a way that it cannot be separated from them by simple dissolution or other simple physical means.

cosmetic means a substance or preparation intended for placement in contact with any external part of the human body, including:

 (a) the mucous membranes of the oral cavity; and

 (b) the teeth;

with a view to:

 (c) altering the odours of the body; or

 (d) changing its appearance; or

 (e) cleansing it; or

 (f) maintaining it in good condition; or

 (g) perfuming it; or

 (h) protecting it.

debitterised neem seed oil means highly purified oil from the neem seed containing only fatty acids and glycerides of fatty acids.

dental practitioner means a person who is registered, in a State or internal Territory, as a dental practitioner (other than a dental therapist, dental hygienist, dental prosthetist or oral health therapist).

dermal use means application to the skin primarily for localised effect.

designated solvent means the following:

 (a) acetone;

 (b) dimethylformamide;

 (c) N(Ndodecyl)2pyrrolidone;

 (d) hydrocarbons, liquid;

 (e) methanol when included in Schedule 5;

 (f) methyl ethyl ketone;

 (g) methyl isoamyl ketone;

 (h) methyl isobutyl ketone;

 (i) Nmethyl2pyrrolidone;

 (j) N(Noctyl)2pyrrolidone;

 (k) phenyl methyl ketone;

 (l) styrene;

 (m) tetrachloroethylene;

 (n) 1,1,1trichloroethane.

dispensing label, for a substance for therapeutic use, means the label attached to the immediate container of the substance at the time of dispensing.

Note: See section 40 and Appendix L.

distributor means a person who imports or supplies a poison.

divided preparation means a preparation manufactured and packed as discrete premeasured dosage units prior to supply, and includes tablets, capsules, cachets, single dose powders or single dose sachets of powders or granules.

dosage unit means an individual dose of a poison for therapeutic use and includes a tablet, capsule, cachet, single dose powder or single dose sachet of powders or granules.

drug means a poison intended for human or animal therapeutic use.

essential oils means:

 (a) products obtained from natural raw materials by distillation with water or steam or from the epicarp of citrus fruits by a mechanical process, or by dry distillation; or

 (b) oils of equivalent composition to products mentioned in paragraph (a) that are derived through synthetic means; or

 (c) prepared mixtures of oils of equivalent composition to products mentioned in paragraph (a) that comprise a mixture of synthetic and natural components.

external in relation to the use of a poison means application in the ears, eyes or nose or to a body surface other than in the mouth, rectum, vagina, urethra or other body orifice.

first group paint: see section 67.

free formaldehyde includes all hydrated and nonhydrated formaldehyde present in aqueous solution, including methylene glycol and formaldehyde released from formaldehyde donors.

graphic material means the material which is to be deposited on another material by a graphic instrument during writing, drawing or marking and includes cores of pencils, school pastels or crayons, blackboard chalks, finger or showcard colours, poster paints and watercolour blocks.

hand sanitiser preparation means an antimicrobial skin care product that:

 (a) consists of, contains or generates one or more antimicrobial active substances; and

 (b) is represented in any way to be, or is likely to be taken to be (whether because of the way in which it is presented or for any other reason):

 (i) for use on hands when soap and water are not available; and

 (ii) applied to the hands without rinsing off; and

 (iii) intended to destroy, deter, render harmless, prevent the action of, or otherwise exert a controlling effect on any microbes on the skin.

hawking means to supply (including peddle or distribute or cause to be distributed) in a public place.

height in relation to letters used for words, expressions or statements on labels means the height of capital letters or lower case letters having an ascender or a descender.

hemp seed oil means the oil obtained by cold expression from the ripened fruits (seeds) of Cannabis sativa.

immediate container includes all forms of containers in which a poison is directly packed but does not include any such container intended for consumption or any immediate wrapper.

immediate wrapper means metal foil, plastic foil, waxed paper, or any other such material not intended for consumption, when used as the first wrapper for a dosage unit or dressing.

internal use means administration:

 (a) orally, except for topical effect in the mouth; or

 (b) for absorption and the production of a systemic effect:

 (i) by way of a body orifice other than the mouth; or

 (ii) parenterally, other than by application to unbroken skin.

label:

 (a) means a written statement on a container of a poison; and

 (b) in relation to therapeutic goods, includes a display of printed information about the product:

 (i) on, or attached to, the goods; or

 (ii) on, or attached to, a container or primary pack in which the goods are supplied; or

 (iii) supplied with such a container or pack.

main label, for a container of poison, means:

 (a) the part of the label that is most likely to be displayed, presented, shown, or examined under ordinary or customary conditions of display; and

 (b) if there are 2 or more labels:

 (i) the label or the part of the label where the product name is more or most conspicuously shown; or

 (ii) if the product name is equally more or most conspicuously displayed on more than one of those labels—each of the labels on which the product name is equally more or most conspicuously displayed.

manufacturer of a poison means a person who manufactures, produces, or packs a poison.

marker dyes or pigments means any product that is added to a liquid used in agricultural or veterinary chemicals to identify or distinguish treated from untreated objects, land or organisms by temporarily imparting colour on the relevant object, land or organism through, for example, spot or boomspraying.

measure pack means a sealed container which contains a measured quantity of poison for use on one occasion as a pesticide or domestic product and one or more of which is enclosed in a primary pack.

medical practitioner means a person who is registered, in a State or internal Territory, as a medical practitioner.

medicine means any poison for therapeutic use.

midwife means a person who is registered, in a State or internal Territory, as a midwife.

nonaccess packaging, for a product that is not intended for human therapeutic use, means packaging that complies with the requirements of AS 47102001, Packages for chemicals not intended for access or contact with their contents by humans.

Note: See also the definitions of childresistant closure and childresistant packaging.

nonvolatile content in relation to a paint or tinter means that portion of a paint or tinter determined to be the nonvolatile content by Method 301.1 of Australian Standard AS 1580301.12005, Paints and related materials – Methods of test – Nonvolatile content by mass.

nurse means a person who is registered, in a State or internal Territory, as a nurse.

oromucosal use means administration to the oral mucosa, specifically the oral cavity and/or the pharynx.

paint includes any substance used or intended to be used for application as a colouring or protective coating to any surface but does not include graphic material or paints for therapeutic use.

pesticide means any substance or mixture of substances used or intended to be used:

 (a) for preventing, destroying, repelling, attracting, inhibiting or controlling any insects, rodents, birds, nematodes, bacteria, fungi, weeds or other forms of plant or animal life or viruses, which are pests; or

 (b) as a plant regulator, promoter, defoliant or desiccant for food storage, household, industrial, commercial, agricultural and nonagricultural application, but does not include veterinary drugs, stock medicines, stock feeds, stock feed additives, drugs for human use, food additives or fertilisers.

pharmacist means a person who is registered, in a State or internal Territory, as a pharmacist.

primary pack, in relation to a poison, means the pack in which the poison and its immediate container or immediate wrapper or measure pack are presented for supply.

product sample means a packed poison supplied directly to a consumer:

 (a) free of charge or for a nominal charge; and

 (b) as a mechanism to promote the supply of the product; and

 (c) in the form of:

 (i) a small pack produced specifically for the purposes of promotion; or

 (ii) a normal commercial pack that in other circumstances could be purchased by the consumer.

public place means any place where members of the public are lawfully entitled, invited or permitted to be present in their capacity as members of the public.

Note: Examples of a public place include a street, road, footway, court, alley or thoroughfare that the public may use in any residential premises or to get from door to door, place to place or house to house.

required advisory statements for medicine labels means the Therapeutic Goods (Medicines Advisory Statements) Specification 2021.

restricted flow insert means a restriction:

 (a) that is fitted or moulded in the neck of a container; and

 (b) that cannot readily be removed from the container by manual force; and

 (c) that limits the delivery of the contents of the container to drops each of which is not more than 200 microlitres.

second group paint: see section 68.

selected container means:

 (a) an injection vial having a nominal capacity of 10 ml or less; or

 (b) a single use syringe; or

 (c) any other container for substances for therapeutic use having a nominal capacity of 10 ml or less.

solid includes powder.

substance has the same meaning as in Part 63 of the Act.

Note 1: In general terms, that definition covers an ingredient, compound, material or preparation which, or the use of which, may cause death, illness or injury to persons or animals.

Note 2: See also section 7.

therapeutic use means use in or in connection with:

 (a) preventing, diagnosing, curing or alleviating a disease, ailment, defect or injury in human beings or animals; or

 (b) influencing, inhibiting or modifying a physiological process in human beings or animals; or

 (c) testing the susceptibility of human beings or animals to a disease or ailment; or

 (d) influencing, controlling or preventing conception in human beings or animals; or

 (e) testing for pregnancy in human beings or animals; or

 (f) the replacement or modification of parts of the anatomy in human beings or animals.

tinter means any pigment or admixture of pigment with other substances, in powder, semisolid or liquid form, sold or supplied for the purpose of adding to paint in order to change the colour of the paint.

topical use means application of a poison for the purpose of producing a localised effect on the surface of the organ or within the tissue to which it is applied.

toy means an object or number of objects manufactured, designed, labelled or marketed as a plaything for a child or children up to the age of 14 years.

transdermal use means application to the skin primarily for systemic effect.

veterinarian means a person who is registered under the law of a State or Territory as a veterinarian, a veterinary practitioner or a veterinary surgeon.

veterinary chemical means:

 (a) a substance that is represented as being suitable for, or is manufactured, supplied or used for, administration or application to an animal by any means, or consumption by an animal, as a way of directly or indirectly:

 (i) preventing, diagnosing, curing or alleviating a disease or condition in the animal or an infestation of the animal by a pest; or

 (ii) curing or alleviating an injury suffered by the animal; or

 (iii) modifying the physiology of the animal:

 (A) so as to alter its natural development, productivity, quality or reproductive capacity; or

 (B) so as to make it more manageable; or

 (iv) modifying the effect of another veterinary chemical; or

 (b) any vitamin, mineral substance, or additive, if, and only if, the vitamin, substance or additive is used for a purpose mentioned in paragraph (a); or

 (c) any active ingredient included in a product declared by regulation under the Agricultural and Veterinary Chemicals Code Act 1994 to be a veterinary chemical product;

but does not include an agricultural chemical.

veterinary chemical product has the same meaning as in the Agricultural and Veterinary Chemicals Code set out in the Schedule to the Agricultural and Veterinary Chemicals Code Act 1994.

7  References to substances

  In this instrument, unless the contrary intention appears, a reference to a substance includes the following:

 (a) that substance prepared from natural sources or artificially;

 (b) if the substance is a plant (other than a plant included in Schedule 8 or 9)—that plant or any part of that plant when packed or prepared for therapeutic use;

 (c) every salt, active principle or derivative of the substance, including esters and ethers, and every salt of such an active principle or derivative;

 (d) every alkaloid of the substance and every salt of such an alkaloid;

 (e) every stereoisomer of the substance and every salt of such a stereoisomer;

 (f) every recombinant form of the substance;

 (g) a preparation or admixture containing any proportion of the substance.

Note: Part 2 (controls on substances) does not apply in relation to certain substances (see section 11).

8  References to concentration, strength or quantity of substances

  In this instrument, for a reference to a concentration, strength or quantity of a substance:

 (a) if the substance is present as a salt, active principle or derivative (including an ester or ether), the concentration, strength or quantity is calculated as the equivalent amount of the substance; and

 (b) the expression “1%” means:

 (i) in the case of a liquid preparation, 1 g of the substance per 100 mL of the preparation; or

 (ii) in the case of a solid, semisolid or pressurised spray aerosol preparation, 1 g of the substance per 100 g of the preparation; and

 (iii) any expression of greater or lesser percentages shall have a corresponding meaning; and

 (c) in the case of codeine, such concentration, strength or quantity is calculated as anhydrous codeine.

9  References to boiling or distillation temperatures

  In this instrument, a reference to a boiling or distillation temperature means that temperature at an atmospheric pressure of 101.325 kPa (760 mm of mercury).

10  References to standards

  A reference in this instrument to an Australian standard, an international standard or a standard of a foreign country is a reference to that standard as it exists from time to time.

Part 2Controls on substances

Division 1Preliminary

11  Application of Part 2

  This Part applies to a substance or preparation included in a schedule to this instrument, other than the following:

 (a) a preparation or product included in the table in clause 1 of Appendix A;

 (b) a substance included in the table in clause 3 of Appendix B when used in an area, subarea or subsubarea of use specified in the table in relation to that substance;

 (c) a substance included in the table in clause 1 of Appendix G at a concentration not exceeding the concentration specified in that table in relation to that substance;

 (d) any other substance included in Schedules 1 to 6, at a concentration not exceeding 10 mg per litre or 10 mg per kilogram, unless that substance is also included in Schedule 7 or 8;

 (e) any substance present as an impurity in a pesticide, at a concentration at or below the maximum content for that substance, specified for the pesticide in the Agricultural and Veterinary Chemicals Code (Agricultural Active Constituents) Standards 2022, published by the Australian Pesticides and Veterinary Medicines Authority, as existing from time to time.

Note: For paragraph (e), the Agricultural and Veterinary Chemicals Code (Agricultural Active Constituents) Standards 2022 is a legislative instrument that could in 2023 be accessed at www.legislation.gov.au.

12  Preparations containing poisons included in different schedules

 (1) If a preparation contains 2 or more poisons, the provisions relating to each of the schedules in which those poisons are included apply to the preparation.

 (2) However, if it is not possible to comply both with a provision relating to one of those schedules and with a provision relating to another of those schedules, the provision relating to the more restrictive schedule applies, unless a contrary intention is indicated in the schedules or relevant State or Territory legislation.

 (3) The Schedules listed in order of greatest to least restrictiveness are 9, 10, 8, 4, 7, 3, 2, 6, 5.

Note: Schedule 1 is not currently in use.

Division 2Labels

Subdivision AGeneral

13  General requirements

 (1) A poison must not be supplied unless it is labelled in accordance with this Division.

 (2) Any word, expression or statement required by this instrument to be written on a label or container must be written:

 (a) on the outside face of the label or container; and

 (b) in English; and

 (c) in durable characters; and

 (d) in a colour or colours to provide a distinct contrast to the background colour; and

 (e) in letters at least 1.5 mm in height.

 (3) Paragraph (2)(e) does not apply to a word, expression or statement on a container which has a capacity of 20 ml or less, or on the label of such a container if:

 (a) an appropriate authority approves the use of smaller letters; and

 (b) the letters are at least 1 mm in height.

 (4) The label must be printed on, or securely attached to:

 (a) the outside of the immediate container; and

 (b) if the immediate container is enclosed in a primary pack—the outside of that primary pack.

14  Immediate wrapper

  If a poison is enclosed in an immediate wrapper:

 (a) the poison must be contained in a primary pack labelled in accordance with section 15; and

 (b) the immediate wrapper must be conspicuously labelled with:

 (i) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for that poison; and

 (ii) the approved name of the poison; and

 (iii) a statement of the quantity, proportion or strength of the poison in accordance with section 34.

Subdivision BPrimary packs and immediate containers

15  Primary packs and immediate containers

  This Subdivision sets out how the primary pack and immediate container of a poison must be labelled.

16  Signal words

 (1) The signal word or words for the poison, as shown in the following table, must be written:

 (a) on the first line or lines of the main label; and

 (b) in boldface sans serif capital letters of uniform thickness; and

 (c) subject to subsection (3), in letters at least half the height of the largest letter or numeral on the label; and

 (d) with nothing else other than the following written on the same line or lines:

 (i) if the poison is included in Schedule 5—a class label as specified in the Australian Dangerous Goods Code or a statement of the principal hazard of the poison;

 (ii) if the poison is not included in Schedule 5—a class label as specified in the Australian Dangerous Goods Code.

 

Signal word or words for poisons

Item

For a poison included in the following schedule …

that is to be used for the following purpose …

the signal word or words are …

1

Schedule 2

for any purpose

PHARMACY MEDICINE

2

Schedule 3

for any purpose

PHARMACIST ONLY MEDICINE

3

Schedule 4

for human use

PRESCRIPTION ONLY MEDICINE

4

Schedule 4

for animal use

PRESCRIPTION ANIMAL REMEDY

5

Schedule 5

for any purpose

CAUTION

6

Schedule 6

for any purpose

POISON

7

Schedule 7

for any purpose

DANGEROUS POISON

8

Schedule 8

for any purpose

CONTROLLED DRUG

 (2) For the purposes of paragraph (1)(c), the largest letter or numeral does not include:

 (a) a single letter or numeral which is larger than other lettering on the label; or

 (b) an affix forming part of the trade name for the poison; or

 (c) in the case of a poison for therapeutic use—numerals used to distinguish the strength of a preparation from the strengths of other preparations of the same poison.

 (3) For the purposes of paragraph (1)(c), the letters need not be larger than:

 (a) 6 mm on labels for packages having a nominal capacity of 2 L or less; or

 (b) 15 mm on labels for packages having a nominal capacity of more than 2 L.

17  Cautionary statement—possession without authority illegal

  If the poison is included in Schedule 8, the cautionary statement:

POSSESSION WITHOUT AUTHORITY ILLEGAL

must be written:

 (a) on a separate line or lines immediately below the signal words required by section 16; and

 (b) in boldface sans serif capital letters of uniform thickness; and

 (c) in letters at least fourtenths the height of the letters used for the signal words; and

 (d) with no other statement written on the same line or lines.

18  Cautionary statement—keep out of reach of children

  The cautionary statement:

KEEP OUT OF REACH OF CHILDREN

must be written:

 (a) on a separate line or lines:

 (i) immediately below the signal word or words required by section 16; or

 (ii) if the cautionary statement “POSSESSION WITHOUT AUTHORITY ILLEGAL” is required by section 17—immediately below that statement; and

 (b) in boldface sans serif capital letters of uniform thickness; and

 (c) in letters at least fourtenths the height of the letters used for the signal word or words; and

 (d) with nothing, other than a class label as specified in the Australian Dangerous Goods Code, written on the same line or lines.

19  Cautionary statement—fire and explosion hazard

 (1) If the poison is a dry chlorinating compound containing more than 10% of available chlorine, the cautionary statement:

FIRE AND EXPLOSION HAZARD

must be written:

 (a) on a separate line or lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by section 18; and

 (b) in boldface sans serif capital letters of uniform thickness; and

 (c) in letters at least fourtenths the height of the letters used for the signal word or words; and

 (d) with nothing, other than a class label as specified in the Australian Dangerous Goods Code, written on the same line or lines.

 (2) This section does not apply to a preparation certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code.

20  Cautionary statement—burns skin and throat

  If the poison is an alkaline salt in a dishwashing machine product, the cautionary statement:

BURNS SKIN AND THROAT

must be written:

 (a) on a separate line or lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by section 18; and

 (b) in boldface sans serif capital letters of uniform thickness; and

 (c) in letters at least fourtenths the height of the letters used for the signal word; and

 (d) with nothing, other than a class label as specified in the Australian Dangerous Goods Code, written on the same line or lines of the main label.

21  Cautionary statements for aqueous solution of paraquat

  If the poison is an aqueous solution of paraquat, the cautionary statements:

CAN KILL IF SWALLOWED

DO NOT PUT IN DRINK BOTTLES

KEEP LOCKED UP

must be written:

 (a) on separate lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by section 18; and

 (b) in boldface sans serif capital letters of uniform thickness; and

 (c) in letters at least fourtenths the height of the letters used for the signal words; and

 (d) with nothing, other than a class label as specified in the Australian Dangerous Goods Code, written on the same lines of the main label.

22  Cautionary statement—read safety directions

 (1) If safety directions are required on the label by section 29, the following cautionary statement:

READ SAFETY DIRECTIONS BEFORE OPENING OR USING

or the following cautionary statement:

READ SAFETY DIRECTIONS

must be written:

 (a) on a separate line or lines:

 (i) immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by section 18; or

 (ii) if one or more other cautionary statements is required to be on the line immediately below “KEEP OUT OF REACH OF CHILDREN”, immediately below that statement or those statements; and

 (b) in boldface sans serif capital letters of uniform thickness; and

 (c) in letters at least fourtenths the height of the letters used for the signal word or words; and

 (d) with nothing, other than a class label as specified in the Australian Dangerous Goods Code, written on the same line or lines.

 (2) This section does not apply to a medicine for human use that is labelled in accordance with the required advisory statements for medicine labels.

23  Cautionary statement—flammable

  If the poison meets the criteria for a “flammable liquid” in the Australian Dangerous Goods Code, the cautionary statement:

FLAMMABLE

must be written on the main label in boldface sans serif capital letters of uniform thickness, unless already present in accordance with the requirements of the Australian Dangerous Goods Code.

24  Cautionary statement—for animal treatment only

  If the poison is only for the treatment of animals, the cautionary statement:

FOR ANIMAL TREATMENT ONLY

must be written on the main label in boldface sans serif capital letters of uniform thickness.

25  Cautionary statement—do not swallow

  If the poison is included in Schedule 5 and is intended for any purpose other than internal or pesticidal use, the cautionary statement:

DO NOT SWALLOW

must be written in sans serif capital letters on the main label or as part of the directions for use.

26  Approved name and quantity, proportion or strength

 (1) The approved name of the poison and a statement of the quantity, proportion or strength of the poison in accordance with section 34 must be:

 (a) if the poison is for human therapeutic use—written on the main label in accordance with the standards for the goods specified in orders made under subsection 10(1) of the Act; or

 (b) if the poison is not for human therapeutic use—written in boldface sans serif capital letters on the main label, unless:

 (i) a list of approved names is required; and

 (ii) it is impractical to include the list on the main label; and

 (iii) it is included on another part of the label in accordance with an authorisation given by an appropriate authority.

 (2) If the poison is included in Schedule 5 and is referred to in column 1 of an item of the following table, the appropriate name in column 2 of that item may be used as the approved name.

 

Appropriate names for poisons

Item

Column 1
Poison

Column 2
Appropriate name

1

Alkaline salts

Alkaline salts

2

Amines for use as curing agents for epoxy resins (unless separately specified in the Schedules)

Aliphatic amines or aromatic amines

3

Epoxy resins, liquid

Liquid epoxy resins

4

Hydrocarbons, liquid

Liquid hydrocarbons

5

Quaternary ammonium compounds

Quaternary ammonium compound(s)

 (3) If a poison contains a mixture of designated solvents in excess of 25% of the total volume of the poison but the proportion of one or more individual designated solvents in the mixture is equal to or less than 25%, the approved names of those solvents may be expressed as follows:

 (a) where the designated solvent is a liquid hydrocarbon—as “liquid hydrocarbons”;

 (b) where the designated solvent is a ketone—as “ketones”;

 (c) in any other case—as “solvents” or “other solvents”.

27  Statement—an anticholinesterase compound

 (1) If the poison is an organophosphorus compound or carbamate for pesticidal use or for the treatment of animals, the following expression:

AN ANTICHOLINESTERASE COMPOUND

must be written immediately below the approved name or the list of declared contents on the label.

 (2) This section does not apply to:

 (a) dazomet, mancozeb, metiram, propineb, thiram, triallate, zineb or ziram; or

 (b) an organophosphorus compound or carbamate contained in impregnated plastic resin strips, medallions or granules; or

 (c) an organophosphorus compound or carbamate contained in a pressurised spray pack for household use.

28  Directions for use

  If the poison is prepared, packed or sold for a specific purpose, it must be labelled with clear and adequate directions for use, unless:

 (a) it is a medicine for human use that is labelled in accordance with:

 (i) Therapeutic Goods Order No. 91 Standard for labels of prescription and related medicines; or

 (ii) Therapeutic Goods Order No. 92 Standard for labels of nonprescription medicines; or

 (b) it is in an agricultural or veterinary chemical product labelled in compliance with the Agricultural and Veterinary Chemicals Code Act 1994; or

 (c) it is included in Schedule 4 or 8; or

 (d) all of the following apply:

 (i) it is impractical to include such directions on the label;

 (ii) the primary pack and the immediate container are labelled with the statement “DIRECTIONS FOR USE: See package insert”;

 (iii) an appropriate authority has authorised the directions for use to be written on a package insert instead of the label;

 (iv) the insert is enclosed in the primary pack.

29  Safety directions

 (1) If the poison is included in the table in clause 4 of Appendix F, it must be labelled with each safety direction required for the poison by that clause, grouped together as a distinct section of the label and prefaced by the words:

SAFETY DIRECTIONS

written in boldface capital letters.

 (2) This section does not apply to the following:

 (a) a poison that:

 (i) is a medicine for human use; and

 (ii) is labelled in accordance with the required advisory statements for medicine labels;

 (b) a poison that:

 (i) is an agricultural chemical or a veterinary chemical; and

 (ii) is a registered chemical product within the meaning of the Agricultural and Veterinary Chemicals Code set out in the Schedule to the Agricultural and Veterinary Chemicals Code Act 1994.

30  Warning statements

 (1) If the poison is included in the table in clause 4 of Appendix F, it must be labelled with each warning statement required for the poison by that clause, grouped together:

 (a) if safety directions are included on the label—immediately after the words “SAFETY DIRECTIONS”; or

 (b) if there are no safety directions—immediately preceding the directions for use.

 (2) This section does not apply to the following:

 (a) a poison that:

 (i) is a medicine for human use; and

 (ii) is labelled in accordance with the required advisory statements for medicine labels;

 (b) a poison that:

 (i) is an agricultural chemical or a veterinary chemical; and

 (ii) is a registered chemical product within the meaning of the Agricultural and Veterinary Chemicals Code set out in the Schedule to the Agricultural and Veterinary Chemicals Code Act 1994.

31  First aid

 (1) If the poison is included in the table in clause 3 of Appendix E, it must be labelled with each statement required for the poison by clause 3 of Appendix E:

 (a) grouped together and prefaced by the following words:

FIRST AID

  written in boldface capital letters; or

 (b) if a primary pack contains 2 or more immediate containers of poisons each requiring different first aid instructions:

 (i) written on each immediate container as specified in paragraph (a); and

 (ii) replaced on the primary pack with the statement:

FIRST AID: See inner packs.

 (2) This section does not apply to the following:

 (a) a poison that:

 (i) is for human internal use; and

 (ii) is included in Schedule 3, 4 or 8;

 (b) a poison that:

 (i) is a medicine for human use; and

 (ii) is labelled in accordance with the required advisory statements for medicine labels;

 (c) a poison that:

 (i) is an agricultural chemical or a veterinary chemical; and

 (ii) is a registered chemical product within the meaning of the Agricultural and Veterinary Chemicals Code set out in the Schedule to the Agricultural and Veterinary Chemicals Code Act 1994.

32  Name and address of manufacturer or distributor

 (1) The poison must be labelled with the name and address of its manufacturer or distributor. The address:

 (a) must be a physical address in Australia; and

 (b) must not be a post office, cable, telegraphic or code address.

 (2) However, if the manufacturer or distributor is a company incorporated under the law of a State or Territory, or a firm registered under a law of a State or Territory dealing with business names, the name and address may be:

 (a) the registered name of the corporation or firm, or its branch or division; and

 (b) the city or town in which a registered office of the company or firm is situated.

33  Warning statements and sedation warnings for certain medicines for human use

Warning statements for certain medicines

 (1) A dispensed medicine for human use containing a poison included in column 1 of the table in clause 2 of Appendix L must be clearly labelled with each warning statement required for the poison by that clause.

Sedation warning for certain medicines

 (2) A dispensed medicine for human use containing a poison included in Appendix K must be clearly labelled with a warning statement set out in item 39, 40 or 90 of the table in clause 1 of Appendix F.

Subdivision CStatements of quantity, proportion or strength

34  Statements of quantity, proportion or strength

 (1) The statement of the quantity, proportion or strength of a poison must be expressed in the most appropriate of the following forms:

 (a) if the poison is for human therapeutic use—the manner required by the standards for the goods specified in orders made under subsection 10(1) of the Act;

 (b) if the poison is for a purpose or purposes other than human therapeutic use—as follows:

 (i) if the poison is in a pressurised spray aerosol preparation—as the mass of the poison per stated mass of the preparation;

 (ii) if the poison is a liquid in a liquid preparation—as the mass or volume of the poison per stated volume of the preparation;

 (iii) if the poison is a liquid in a solid or semisolid preparation—as the mass or volume of the poison per stated mass of the preparation;

 (iv) if the poison is a solid or semisolid in a liquid preparation—as the mass of the poison per stated volume of the preparation;

 (v) if the poison is a solid or semisolid in a solid or semisolid preparation—as the mass of the poison per stated mass of the preparation;

 (vi) if the poison is a gas in a liquid preparation—as the mass of the poison per stated volume of the preparation;

 (vii) if the poison is a gas in a solid or semisolid preparation—as the mass of the poison per stated mass of the preparation;

 (viii) if the poison is a gas in a gaseous preparation—as the mass of the poison per stated mass of the preparation;

 (c) if the poison is a solution of a mineral acid, the proportion of the acid (unneutralised by any bases present in the preparation) in a preparation may be expressed as the unneutralised mass of the acid per stated mass of the preparation;

 (d) if the poison is an inorganic pigment, the proportion may be expressed as a percentage of the metal present using one of the following expressions as appropriate:

 (i) “contains not more than 10 per cent of (insert name of the metal)”;

 (ii) “contains not more than 30 per cent of (insert name of the metal)”;

 (iii) “contains more than 30 per cent of (insert name of the metal)”;

 (e) if the poison is included in a paint, other than a paint for therapeutic or cosmetic use, the proportion may be expressed as a range provided that the limits of the range do not differ by more than 5% of the product;

 (f) if the poison is a leadbased pigment included in automotive paint, the proportion may be expressed as the maximum content of the lead that may be present in the nonvolatile content of the paint;

 (g) if a preparation contains more than one derivative of a poison, the quantity or proportion of the poison may be expressed as the equivalent quantity or proportion of one of the derivatives present which it would contain if all of the derivatives were that derivative.

 (2) In paragraph (1)(g):

derivative includes alkaloid.

Note: For requirements to state the quantity, proportion or strength of a poison, see subparagraph 14(b)(iii), section 26 and subsubparagraphs 35(b)(ii)(B) and 36(1)(b)(ii)(A) and (2)(b)(iii)(B).

Subdivision DExemptions from labelling requirements

35  Selected containers and measure packs

  The requirements of Subdivision B do not apply to an immediate container of poison that is a measure pack or a selected container (other than an ampoule, a prefilled syringe or an injection vial to which subsections 36(1) or (2) applies) if:

 (a) the poison is therapeutic goods and is labelled in accordance with the standards for the goods specified in orders made under subsection 10(1) of the Act; or

 (b) the immediate container is:

 (i) packed in a primary pack labelled in accordance with Subdivision B; and

 (ii) labelled with:

 (A) the signal word or words for the poison as shown in the table in subsection 16(1); and

 (B) the approved name of the poison and the quantity, proportion or strength of the poison in accordance with section 34; and

 (C) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for the poison; and

 (D) if the poison is only for the treatment of animals—the cautionary statement:

FOR ANIMAL TREATMENT ONLY

  written in sans serif capital letters.

36  Ampoules, prefilled syringes and injection vials

 (1) The requirements of Subdivision B do not apply to a selected container of poison or an ampoule of poison (other than an ampoule to which subsection (2) applies) when:

 (a) the poison is therapeutic goods and is labelled in accordance with the standards for the goods specified in orders made under subsection 10(1) of the Act; or

 (b) the selected container or ampoule is:

 (i) packed in a primary pack labelled in accordance with Subdivision B; and

 (ii) labelled with:

 (A) the approved name of the poison and the quantity, proportion or strength of the poison in accordance with section 34; and

 (B) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for the poison; and

 (C) if the poison is only for the treatment of animals—the cautionary statement:

FOR ANIMAL TREATMENT ONLY

  written in sans serif capital letters.

 (2) The requirements of Subdivision B do not apply to a selected container of poison that is a plastic ampoule that is continuous with a strip of the same material and opens as it is detached from the strip when:

 (a) the poison is therapeutic goods and is labelled in accordance with the standards for the goods specified in orders made under subsection 10(1) of the Act; or

 (b) the poison is not therapeutic goods and all of the following apply:

 (i) the ampoule is packed in a primary pack labelled in accordance with Subdivision B;

 (ii) the strip is labelled in accordance with this section;

 (iii) the ampoule is labelled with:

 (A) the approved name of the poison or the trade name of the poison; and

 (B) the quantity, proportion or strength of the poison in accordance with section 34.

37  Transport containers and wrappings

  The labelling requirements of this instrument do not apply to a transparent cover, or to any wrapper, hamper, packing case, crate or other cover used solely for the purposes of transport or delivery.

38  Dispensary, industrial, laboratory and manufacturing poisons

  The labelling requirements of this instrument do not apply to a poison that:

 (a) is packed and sold solely for dispensary, industrial, laboratory or manufacturing purposes; and

 (b) is labelled in accordance with requirements under applicable jurisdictional work health and safety laws, as in force from time to time.

39  Exemptions from label requirements in certain circumstances

 (1) A requirement specified in Subdivision B or section 35 or 37 does not apply to a poison if an appropriate authority has granted a labelling exemption under this subsection in relation to that requirement for the poison.

 (2) A labelling exemption granted by an appropriate authority under subsection (1) remains in force:

 (a) if the exemption relates to a product that is indicated for the treatment or prevention of the coronavirus known as COVID19:

 (i) for the period specified in the exemption; or

 (ii) if no period is specified—until revoked by the appropriate authority; or

 (b) in any other case:

 (i) for the period, specified in the exemption, that is 12 months or less from the date of commencement of the exemption; or

 (ii) if no period is specified—12 months from the date of commencement of the exemption.

 (3) For the avoidance of doubt, this section does not apply to an authorisation given under subparagraph 28(d)(iii).

40  Dispensed medicines

  Unless otherwise specified in relevant State or Territory legislation and subject to section 33, the labelling requirements of this instrument do not apply to a medicine that:

 (a) is:

 (i) supplied by an authorised prescriber; or

 (ii) supplied on and in accordance with a prescription written by an authorised prescriber; or

 (iii) prepared and supplied by a pharmacist for an individual patient; and

 (b) is labelled in accordance with the requirements of clause 1 of Appendix L.

41  Gas cylinders

  The requirements of paragraph 16(1)(d) and paragraphs 18(d) and 22(1)(d) do not apply to a cylinder containing a poison that is a compressed gas.

42  Paints

  The requirements of Subdivision B do not apply to:

 (a) a paint (other than a paint for therapeutic or cosmetic use) that contains only poisons included in Schedule 5; or

 (b) a first group paint or second group paint that is labelled with:

 (i) the word “WARNING”, written in boldface sans serif capital letters, the height of which is not less than 5 mm, on the first line of the main label with no other words written on that line; and

 (ii) the expression “KEEP OUT OF REACH OF CHILDREN”, written in boldface sans serif capital letters, the height of which is not less than 2.5 mm, on a separate line immediately below the word “WARNING”; and

 (iii) the appropriate warnings required for the paint by clause 4 of Appendix F, written immediately below the expression “KEEP OUT OF REACH OF CHILDREN”; and

 (iv) the name and proportion of the first group or second group poisons it contains, provided that where the substance is a metal or metal salt the proportion is expressed as the metallic element present “calculated on the nonvolatile content” or “in the dried film” of the paint; or

 (c) a tinter which contains only poisons included in Schedule 5; or

 (d) a tinter that contains a poison mentioned in a table in section 67 or 68, if:

 (i) the tinter is labelled with the name and proportion of the poison; and

 (ii) if the poison is a metal or metal salt—the proportion is expressed as the metallic element present as “calculated on the nonvolatile content” or “in the dried film”.

43  Camphor and naphthalene

  The labelling requirements of paragraph 13(2)(d) and Subdivision B do not apply to a device that contains camphor or naphthalene in block, ball, disc, pellet or flake form if the device:

 (a) complies with section 52; and

 (b) is sold or supplied in a primary pack labelled in accordance with section 13 and Subdivision B.

Subdivision EProhibitions

44  Prohibitions

 (1) A label used in connection with a poison must not include:

 (a) any reference to this instrument, or any comment on, reference to, or explanation of any expression required by this instrument that directly or by implication contradicts, qualifies or modifies such expression; or

 (b) any expression or device suggesting or implying that the poison is safe, harmless, nontoxic, nonpoisonous, or is recommended or approved by a government or government authority unless required by legislation; or

 (c) any expression or device which is false or misleading in any particular concerning the safety of the poison or any of its ingredients; or

 (d) any trade name or description that:

 (i) represents any single constituent of a compound preparation; or

 (ii) misrepresents the composition or any property or quality of the poison; or

 (iii) gives any false or misleading indication of origin or place of manufacture of the poison.

 (2) A label must not be attached to the immediate container or primary pack used in connection with any poison in such a manner as to obscure any of the ribs or any expression required by this instrument to be written or embossed on the container or pack.

Division 3Containers

45  General requirements

  A poison must not be supplied unless the requirements of this Division for the immediate container for the poison are met.

46  Containers for poisons other than poisons included in Schedule 5

 (1) If a poison, other than a poison included in Schedule 5, is supplied in a container with a nominal capacity of 2 L or less, the container must comply with Australian Standard AS 22161997, Packaging for poisonous substances.

 (2) Despite subsection (1), a poison included in Schedule 6 that is an essential oil may be packed in an amber glass container which does not comply with the tactile identification requirements of Australian Standard AS 22161997, Packaging for poisonous substances, if:

 (a) other safety factors are not diminished; and

 (b) the container has a restricted flow insert and a childresistant closure.

 (3) If a poison, other than a poison included in Schedule 5, is supplied in a container with a nominal capacity of more than 2 L:

 (a) the container must comply with subsection 1.4 (General Requirements) of Australian Standard AS 22161997, Packaging for poisonous substances; and

 (b) the word “POISON” must be embossed, or indelibly written in a colour in distinct contrast to the background colour, on the side or shoulder of the container, in sans serif capital letters the height of which is at least one thirtysecond part of the length, height or width of the container, whichever is the greatest.

47  Containers for poisons included in Schedule 5

 (1) The container in which a poison included in Schedule 5 is supplied must:

 (a) comply with the container requirements of subsection 46(1) or (3); or

 (b) comply with subsection (2).

 (2) A container complies with this subsection if:

 (a) it is readily distinguishable from a container in which food (including a condiment) or drink is sold; and

 (b) it complies with subsection 1.4 (General Requirements) of Australian Standard AS 22161997, Packaging for poisonous substances, excluding paragraph 1.4.3; and

 (c) it is securely closed and, except when containing a preparation for use on one occasion only, is capable of being reclosed to prevent spillage of its contents; and

 (d) the expression “POISON”, “NOT TO BE TAKEN” or “NOT TO BE USED AS A FOOD CONTAINER” is:

 (i) embossed or indelibly written on the container; or

 (ii) printed on a label that complies with subsection (3) that is attached to the container.

 (3) For the purposes of subparagraph (2)(d)(ii), the label must be a permanent adhesive label designed to adhere to a substrate without lifting and which cannot be removed without damaging either the label or the substrate.

 (4) Despite subsection (1), the following poisons included in Schedule 5:

 (a) methylated spirit(s);

 (b) liquid hydrocarbons when packed as kerosene, lamp oil, mineral turpentine, thinners, reducers, white petroleum spirit or dry cleaning fluid;

 (c) petrol;

 (d) toluene;

 (e) xylene;

must not be supplied in a bottle or jar having a nominal capacity of 2 L or less, unless the immediate container complies with the container requirements of subsection 46(1).

48  Approved containers

  Despite subsections 46(1) and (3) and section 47, a poison may be packed in a container that does not comply with the tactile identification requirements of AS22161997 (Packaging for poisonous substances) or the requirements of paragraph 46(3)(b) or 47(2)(d) if:

 (a) other safety factors are not diminished; and

 (b) the container is for a specific purpose; and

 (c) an appropriate authority has approved the use of the container for that purpose.

49  Childresistant closures

 (1) If a poison specified in column 1 of an item of the following table is supplied in a container having a nominal capacity specified in column 2 of the item, it must be closed with a childresistant closure that:

 (a) is appropriate for the container and the poison; and

 (b) will retain its childresistant properties for the expected life of the poison.

 

Poisons that must be closed with a childresistant closure

Item

Column 1
Poison

Column 2
Nominal capacity of container

1

Alkaline salts included in Schedule 5, when packed and labelled as dishwashing machine tablets

All sizes

2

Alkaline salts included in Schedule 5, when packed and labelled as dishwashing machine liquids, solids or gels

5 L/kg or less

3

Alkaline salts included in Schedule 5, when packed and labelled as a food additive

2.5 L or less

4

Anise oil when included in Schedule 5

200 mL or less

5

Basil oil when included in Schedule 5

200 mL or less

6

Bay oil when included in Schedule 6

200 mL or less

7

Cajuput oil when included in Schedule 6

200 mL or less

8

Cassia oil when included in Schedule 5

200 mL or less

9

Cineole when included in Schedule 6

2 L or less

10

Cinnamon bark oil when included in Schedule 5

200 mL or less

11

Cinnamon leaf oil when included in Schedule 6

200 mL or less

12

Clove oil when included in Schedule 6

200 mL or less

13

CYCLOSILAZANES, DIME, ME HYDROGEN, POLYMERS WITH DIME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3(TRIETHOXYSILYL)1PROPANAMINE (CAS 475645842) when included in Schedule 6, when presented in a wipe

All sizes

14

Essential oils when included in Schedule 6 because of their natural camphor component

200 mL or less

15

Ethylene glycol when included in Schedule 6

5 L or less

16

Ethylene glycol when included in Schedule 5 in preparations containing more than 50% of ethylene glycol

5 L or less

17

Eucalyptus oil when included in Schedule 6

2 L or less

18

Eugenol when included in Schedule 6

200 mL or less

19

Fennel oil when included in Schedule 5

200 mL or less

20

Hydrocarbons, liquid, when packed as kerosene, lamp oil, mineral turpentine, thinners, reducers, white petroleum spirit or dry cleaning fluid

5 L or less

21

Hydrochloric acid when included in Schedule 6

5 L or less

22

Leptospermum scoparium oil (manuka oil) when included in Schedule 6

200 mL or less

23

Marjoram oil when included in Schedule 5

200 mL or less

24

Melaleuca oil (teatree oil) when included in Schedule 6

200 mL or less

25

Methylated spirit excluding preparations or admixtures

5 L or less

26

Methyl salicylate and preparations containing more than 50% of methyl salicylate

200 mL or less

27

Nicotine in liquid preparations when included in Schedule 4.

All sizes

28

Nutmeg oil when included in Schedule 5

200 mL or less

29

Oil of turpentine

5 L or less

30

Paracetamol included in Schedule 4, when packed and labelled for the treatment of animals

All sizes

31

Pennyroyal oil when included in Schedule 6

200 mL or less

32

Potassium hydroxide as such

2.5 L or less

33

Potassium hydroxide in oven, hot plate or drain cleaners when included in Schedule 6 except when in pressurised spray packs

5 L or less

34

DPulegone when included in Schedule 6

200 mL or less

35

Sage oil (Dalmatian) when included in Schedule 6

200 mL or less

36

Sodium hydroxide as such

2.5 L or less

37

Sodium hydroxide in oven, hot plate or drain cleaners when included in Schedule 6 except when in pressurised spray packs

5 L or less

38

Thujone when included in Schedule 6

200 mL or less

39

Thyme oil when included in Schedule 5

200 mL or less

 (2) This section does not apply to a poison included in therapeutic goods that are packaged in accordance with the standards for the goods specified in orders made under subsection 10(1) of the Act.

50  Poisons included in Schedule 8

 (1) If a poison included in Schedule 8 is supplied, it must be packaged in such a way that its primary pack is so sealed that, when the seal is broken, it is readily distinguishable from other sealed primary packs.

 (2) This paragraph does not apply to the supply of a poison included in Schedule 8:

 (a) by an authorised prescriber or other authorised supplier; or

 (b) by a pharmacist on the prescription of an authorised prescriber; or

 (c) by a pharmacist employed at a hospital, on the written requisition of:

 (i) a medical practitioner or dental practitioner; or

 (ii) the nurse or midwife in charge of the ward in which the poison is to be used or stored; or

 (d) by a nurse or midwife on the direction in writing of an authorised prescriber.

51  Exemptions

 (1) Subsections 46(1) and (3) and section 47 do not apply to the immediate container of a poison prepared, packed and sold:

 (a) for human internal or animal internal use; or

 (b) as a solid or semisolid preparation for human external or animal external use; or

 (c) as a paint, other than a paint for therapeutic or cosmetic use; or

 (d) in containers having a nominal capacity of 15 mL or less; or

 (e) for use in automatic photographic or photocopy processing machines if the container is specifically designed to fit into the machines; or

 (f) solely for dispensary, industrial, laboratory or manufacturing purposes.

 (2) Section 49 does not apply to a poison prepared, packed and sold solely for dispensary, industrial, laboratory or manufacturing purposes.

 (3) The tactile identification or embossing required by subsections 46(1) and (3) and section 47 or Australian Standard AS 22161997, Packaging for poisonous substances, do not apply to a container that is an aerosol container, a collapsible tube, or a measure pack which is a flexible sachet.

52  Camphor and naphthalene

 (1) The container requirements of subsection 46(1) do not apply to a device that contains only camphor or naphthalene in block, ball, disc, pellet or flake form for domestic use, if the device:

 (a) in normal use, prevents removal or ingestion of its contents; and

 (b) is incapable of reacting with the poison; and

 (c) is sufficiently strong to withstand the ordinary risks of handling, storage or transport; and

 (d) has the word “POISON” and the approved name of the poison embossed or indelibly printed on it.

 (2) Camphor or naphthalene must not be supplied in ball, block, disc, pellet or flake form for domestic use unless the balls, blocks, discs, pellets or flakes are enclosed in a device which prevents removal or ingestion of its contents.

53  Prohibitions—use of containers for poisons

 (1) A poison must not be supplied in a container that is embossed or indelibly marked with the name of another poison.

 (2) A container that complies with subsection 46(1) or (3) or section 47 must not be used to supply a poison for internal use.

 (3) A container that complies with subsection 46(1) or (3) or section 47 must not be used to supply food (including a condiment) or drink.

 (4) A poison must not be supplied in a container that is not readily distinguishable from a container in which food (including a condiment) or drink is sold.

Division 4Storage

54  General storage requirements

Poisons included in Schedule 2

 (1) A poison included in Schedule 2 that is stored at premises for supply to the public must be stored in such a way that public access to advice from a pharmacist is available if required.

Poisons included in Schedules 3 and 4

 (2) A poison included in Schedule 3 or 4 that is stored at premises for supply to the public must be stored in a part of the premises to which the public does not have access.

Poisons included in Schedule 6

 (3) A poison included in Schedule 6 that is stored at premises for supply by way of retail sale must be stored in such a way as to prevent access by children.

Poisons included in Schedule 7

 (4) A poison included in Schedule 7 that is stored at premises for supply by retail sale must be stored in an area of the premises, and in a manner, that allows physical access only by the following:

 (a) the owner of the retail establishment;

 (b) an employee of the owner;

 (c) a person who is legally permitted to purchase the poison and is under the supervision of the owner or an employee of the owner.

Division 5Disposal

55  General disposal requirements

  A poison included in Schedule 5, 6 or 7 must not be disposed of in any place or manner that constitutes or is likely to constitute a risk to public health or safety.

Note: Controls on the disposal of poisons included in Schedules 2, 3, 4 and 8 are dealt with in State and Territory legislation.

Division 6Record keeping

56  General recordkeeping requirements

 (1) If a poison included in Schedule 7 is supplied, a record of the following must be kept:

 (a) the name and address of the supplier and of the purchaser;

 (b) the date of the order and supply;

 (c) the approved name or trade name of the poison;

 (d) the quantity supplied or sold;

 (e) if an authorisation is required for purchase of the poison under the law of the jurisdiction in which the purchaser purchases the poison—proof that the purchaser has the required authorisation.

 (2) The records mentioned in subsection (1) must be kept for at least 5 years.

Note: Controls on record keeping for the supply of poisons included in Schedules 2, 3, 4 and 8 are dealt with in State and Territory legislation.

Division 7Advertising

57  General advertising requirements

Poisons included in Schedule 3, 4 and 8

 (1) A reference to a poison included in:

 (a) Schedule 3, unless included in Appendix H; or

 (b) Schedule 4; or

 (c) Schedule 8;

must not be included in any advertisement except in genuine professional or trade journals or other publications intended for circulation only within the medical, nursing, veterinary, dental or pharmaceutical professions or the wholesale drug industry.

Poisons included in Schedules 9 and 10

 (2) A reference to a poison included in Schedule 9 or Schedule 10 must not be included in any advertisement.

Note: Schedule 10 includes poisons previously listed in Appendix C.

Division 8Supply, prescribing, possession or use

58  Poisons included in Schedule 2

 (1) A poison included in Schedule 2 must not be supplied by a person other than:

 (a) a person who:

 (i) is a pharmacist (or an assistant under the direction of a pharmacist) or a medical practitioner, dental practitioner or veterinarian; and

 (ii) is acting in the lawful practice of the person’s profession; or

 (b) a person who is licensed to supply the poison under the law of the jurisdiction from which the person will supply the poison.

 (2) A person is not eligible to be granted a licence to supply a poison included in Schedule 2 unless:

 (a) the person is carrying on the business of supplying goods by retail sale; and

 (b) the premises from which the poison will be supplied is more than 25 km by the shortest practicable route from the nearest pharmacy; and

 (c) if required by the law of the jurisdiction from which the person will supply the poison—the person produces evidence that the person is a fit and proper person to be so licensed.

 (3) Subsection (1) does not apply to the supply of a poison included in Schedule 2 by way of wholesale dealing to:

 (a) a pharmacist, medical practitioner, dental practitioner or veterinarian; or

 (b) another person who is licensed or otherwise authorised, under the law of the jurisdiction from which the person supplies the poison, to possess or supply the poison.

59  Poisons included in Schedule 3

 (1) A poison included in Schedule 3 must not be supplied by a person other than a person who:

 (a) is a pharmacist, medical practitioner, dental practitioner or veterinarian; and

 (b) is acting in the lawful practice of the person’s profession.

 (2) The following requirements apply if a poison included in Schedule 3 is supplied:

 (a) adequate instructions for use, either written or verbal, must be provided at the time of supply;

 (b) the container of the poison must be labelled with:

 (i) the name of the supplier or the name of the pharmacy (as applicable); and

 (ii) the address from which it was supplied;

 (c) if required by the law of the jurisdiction from which the supplier supplies the poison—a record of the transaction must be made in a prescription book or other approved recording system.

 (3) This section does not apply to the supply of a poison included in Schedule 3 by way of wholesale dealing to:

 (a) a pharmacist, medical practitioner, dental practitioner or veterinarian; or

 (b) another person who is licensed or otherwise authorised, under the law of the jurisdiction from which the person supplies the poison, to possess or supply the poison.

60  Poisons included in Schedule 4

 (1) A poison included in Schedule 4 must not be supplied by a person other than:

 (a) a person who:

 (i) is a medical practitioner, dental practitioner or veterinarian; and

 (ii) is acting in the lawful practice of the person’s profession; or

 (b) a pharmacist dispensing a legal prescription for the poison; or

 (c) a pharmacist supplying the poison without a prescription as permitted by subsection (2).

 (2) A poison included in Schedule 4 may be supplied to a person (the patient) by a pharmacist without a prescription if:

 (a) the poison is not excepted from this provision by the law of the jurisdiction from which the pharmacist supplies the poison; and

 (b) the patient is under medical treatment with the poison and continuation of medication is essential; and

 (c) the quantity supplied does not exceed 3 days’ medication; and

 (d) the pharmacist is satisfied that an emergency exists.

 (3) Subsection (1) does not apply to the supply of a poison included in Schedule 4 by way of wholesale dealing to:

 (a) a pharmacist, medical practitioner, dental practitioner or veterinarian; or

 (b) another person who is licensed or otherwise authorised, under the law of the jurisdiction from which the person supplies the poison, to possess or supply the poison.

61  Poisons included in Schedules 5 and 6

 (1) A product sample containing a poison included in Schedule 5 or 6 must not be supplied in any manner unless the recipient has the opportunity to refuse at the time of supply.

 (2) A product sample containing a poison included in Schedule 5 or 6 must not be supplied in an unsolicited manner (for example by post or by attaching the sample to another product).

 (3) A product sample containing a poison included in Schedule 5 or 6 must not be supplied in a manner that does not promote disposal in accordance with Division 5.

62  Poisons included in Schedule 7

Possession or use for domestic or domestic garden purposes prohibited

 (1) A poison included in Schedule 7 must not be possessed or used for domestic or domestic garden purposes.

Supply for domestic or domestic garden purposes prohibited

 (2) A poison included in Schedule 7 must not be supplied for domestic or domestic garden purposes.

Supply of liquid preparations containing paraquat

 (3) A poison included in Schedule 7 that is a liquid preparation containing paraquat must not be supplied unless it is coloured blue or green and contains sufficient stenching agent to produce an offensive smell.

Supply if authorisation required by appropriate authority

 (4) A poison included in Schedule 7 for which an authorisation to purchase, possess or use is required by the appropriate authority must not be supplied unless the purchaser produces the required authorisation.

Product samples prohibited

 (5) A product sample containing a poison included in Schedule 7 must not be supplied.

Supply of poisons included in Appendix J

 (6) A poison included in Schedule 7 that is included in the table in clause 1 of Appendix J may be supplied only in accordance with that clause.

63  Poisons included in Schedule 10

  A poison included in Schedule 10 must not be possessed, supplied or used for a purpose indicated in relation to that poison in Schedule 10.

Note: Schedule 10 includes poisons previously listed in Appendix C.

64  Poisons included in Schedule 4 or 8 and Appendix D

 (1) This section applies to a poison included in Schedule 4 or 8.

Supply or prescribing

 (2) A poison included in a table in clause 1, 2, 3, 4, 6 or 7 of Appendix D must not be supplied, other than by way of wholesale dealing, or prescribed, except in accordance with the clause that contains the table.

 (3) A poison referred to in clause 8 or 10 of Appendix D must not be supplied, other than by way of wholesale dealing, or prescribed, except in accordance with clause 8 or 10 (as applicable) of Appendix D.

Possession

 (4) A poison included in the table in clause 5 of Appendix D must not be possessed by a person without authority under the law of the jurisdiction in which the possession occurs.

Storage

 (5) A poison included in the table in clause 9 of Appendix D must be stored in a locked container to prevent unauthorised access.

65  Hawking

  A poison included in Schedule 7 must not be supplied by way of hawking.

Note: Controls on supply by way of hawking of poisons included in Schedules 2, 3, 4 and 8 are dealt with in State and Territory legislation.

Division 9Paints and tinters

Note: Paints and tinters are poisons that were previously listed in Appendix I.

66  General requirements

 (1) A first group paint must not be manufactured, supplied or used for application to:

 (a) a roof or any surface to be used for the collection or storage of potable water; or

 (b) furniture; or

 (c) any fence, wall, post, gate or building (interior or exterior) other than a building that is used exclusively for industrial purposes or mining or as an oil terminal; or

 (d) any premises used for the manufacture, processing, preparation, packing or serving of products intended for human or animal consumption.

 (2) An antifouling paint containing more than 0.1% lead (the proportion of lead for the purposes of this section is calculated as a percentage of the element present in the nonvolatile content of the paint) must not be manufactured, supplied or used.

 (3) A paint (other than an antifouling paint) or tinter containing more than 0.009% lead (calculated as a percentage of the element present in the nonvolatile content of the paint) must not be manufactured, supplied or used.

 (4) A paint for application to toys must not be manufactured, supplied or used unless it complies with the specification for coating materials contained in Australian/New Zealand Standard AS/NZS ISO 8124.3:2012, Safety of toys Part 3: Migration of certain elements (ISO 812403:2010, MOD), published jointly by, or on behalf of, Standards Australia and Standards New Zealand.

 (5) A paint or tinter containing a pesticide other than a fungicide, algaecide, bactericide or antifouling agent must not be manufactured, supplied or used.

67  Definition of first group paint

  A paint containing a substance mentioned in column 1 of an item in the following table in the proportion (calculated as a percentage of the element present in the nonvolatile content of the paint) specified in column 2 of the item is a first group paint.

 

First group paints

Item

Column 1
Substance

Column 2
Proportion

1

ANTIMONY or antimony compounds other than antimony titanate pigments

more than 5%

2

BARIUM salts except barium sulfate or barium metaborate

more than 5%

3

CADMIUM or cadmium compounds

more than 0.1%

4

CHROMIUM as chromates of ammonia, barium, potassium sodium, strontium or zinc

more than 5%

5

SELENIUM or selenium compounds

more than 0.1%

68  Definition of second group paint

  A paint containing a substance mentioned in column 1 of an item in the following table in the proportion specified in column 2 of the item is a second group paint.

 

Second group paints

Item

Column 1
Substance

Column 2
Proportion

1

DICHLOROMETHANE (methylene chloride)

more than 5% by weight

2

ETHYLENE GLYCOL MONOALKYL ETHERS and their acetates

more than 10% by volume

3

HEXYLOXYETHANOL

more than 10% by volume

4

TOLUENE

more than 50% by volume

5

XYLENE

more than 50% by volume

Schedule 1Blank

 

 

Note: Schedule 1 is intentionally blank.

Schedule 2Pharmacy medicines

 

 

Note: See section 16, subsection 54(1) and section 58.

ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80% of acetic acid (CH3COOH) for therapeutic use.

ACETYLCYSTEINE in preparations for oral use except when labelled with a recommended daily dose of 1 g or less of acetylcysteine.

ACONITUM spp. for therapeutic use in adults:

 (a) in preparations for oral use in packs each containing 0.2 mg or less of total alkaloids except in packs containing 0.02 mg or less of total alkaloids; or

 (b) in preparations for dermal use containing 0.02% or less of total alkaloids, in packs each containing 0.2 mg or less of total alkaloids except in packs containing 0.02 mg or less of total alkaloids.

ALIMEMAZINE when combined with one or more other therapeutically active substances in solid oral preparations when:

 (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

 (b) in a daynight pack containing alimemazine in the bedtime dose where the day and night doses are in the same immediate container or immediate wrapper;

 except in preparations for the treatment of children under 2 years of age.

ALOXIPRIN.

AMOROLFINE in preparations for topical use except in preparations for the treatment of tinea pedis.

ANTAZOLINE in eye drops.

ASPIRIN except when:

 (a) included in Schedule 4, 5 or 6; or

 (b) in individually wrapped powders or sachets of granules each containing 650 mg or less of aspirin as the only therapeutically active constituent other than when combined with an effervescent agent, that are:

 (i) enclosed in a primary pack that contains 12 or less individually wrapped powders or sachets of granules; and

 (ii) compliant with the requirements of the required advisory statements for medicine labels; or

 (c) in tablets or capsules containing aspirin as the only therapeutically active constituent other than when combined with an effervescent agent, that are:

 (i) either:

 (A) packed in blister or strip packing; or

 (B) in a container with a child-resistant closure; and

 (ii) either:

 (A) in a primary pack that contains not more than 25 tablets or capsules, each containing 325 mg or less of aspirin; or

 (B) in a primary pack that contains not more than 16 tablets or capsules, each containing 500 mg or less of aspirin; or

 (C) in a primary pack that contains not more than 100 tablets or capsules, each containing 100 mg or less of aspirin, and that is labelled for the prevention of cardiovascular disease or for the inhibition of platelet aggregation; and

 (iii) compliant with the requirements of the required advisory statements for medicine labels.

ATROPA BELLADONNA (belladonna):

 (a) for external use in preparations containing 0.03% or less of total solanaceous alkaloids; or

 (b) for oral use:

 (i) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

 (ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit, when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

ATROPINE (excluding atropine methonitrate) for oral use:

 (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

 (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

AZELAIC ACID in dermal preparations.

AZELASTINE:

 (a) in preparations for nasal use; or

 (b) in topical eye preparations containing 0.05% or less of azelastine.

BECLOMETASONE in aqueous nasal sprays delivering 50 micrograms or less of beclometasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

BENZOCAINE in preparations for topical use other than eye drops:

 (a) containing 10% or less of total local anaesthetic substances, except in dermal preparations containing 2% or less of total local anaesthetic substances; or

 (b) in divided preparations containing 200 mg or less of total local anaesthetic substances per dosage unit, except in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.

BENZOYL PEROXIDE in preparations for human external therapeutic use containing 10% or less of benzoyl peroxide except in preparations containing 5% or less of benzoyl peroxide.

BENZYDAMINE in preparations for topical use, except:

 (a) in preparations for dermal use; or

 (b) in divided topical oral preparations containing 3 mg or less of benzydamine; or

 (c) in undivided topical oral preparations containing 0.3% or less of benzydamine in a primary pack containing not more than 50 mL.

BEPHENIUM SALTS.

BIFONAZOLE in preparations for dermal use except:

 (a) in preparations containing 1% or less of bifonazole for the treatment of the scalp; or

 (b) in preparations for the treatment of tinea pedis.

BRIMONIDINE in ophthalmic preparations for adult use containing not more than 0.025% of brimonidine.

BROMHEXINE.

BROMPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:

 (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

 (b) in a daynight pack containing brompheniramine in the bedtime dose where the day and night doses are in the same immediate container or immediate wrapper;

 except in preparations for the treatment of children under 2 years of age.

BUDESONIDE in aqueous nasal sprays delivering 64 micrograms or less of budesonide per actuation when the maximum recommended daily dose is no greater than 400 micrograms, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

CARBETAPENTANE except in preparations containing 0.5% or less of carbetapentane.

CARBOCISTEINE.

CETIRIZINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 6 years of age and over when:

 (a) in a primary pack containing not more than 10 days’ supply; and

 (b) labelled with a recommended daily dose not exceeding 10 mg of cetirizine.

CHLOPHEDIANOL.

CHLORBUTANOL for human use in topical preparations containing 5% or less of chlorbutanol except in preparations containing 0.5% or less of chlorbutanol.

CHLOROFORM in preparations for therapeutic use except:

 (a) when included in Schedule 4; or

 (b) in preparations containing 0.5% or less of chloroform.

CHLORPHENAMINE when combined with one or more other therapeutically active substances in oral preparations when:

 (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

 (b) in a daynight pack containing chlorphenamine in the bedtime dose where the day and night doses are in the same immediate container or immediate wrapper;

 except in preparations for the treatment of children under 2 years of age.

CHOLINE SALICYLATE in preparations for oromucosal use.

CICLOPIROX:

 (a) in preparations for dermal use containing 2% or less of ciclopirox except in preparations for the treatment of tinea pedis; or

 (b) in preparations for application to the nails containing 8% or less of ciclopirox.

CINCHOCAINE in preparations for topical use other than eye drops, containing 0.5% or less of total local anaesthetic substances.

CINNAMEDRINE.

CLOTRIMAZOLE for human use in dermal preparations and for application to the nails except in preparations for the treatment of tinea pedis.

CREOSOTE derived from wood other than beechwood for human therapeutic use, except in preparations containing 10% or less of creosote derived from wood other than beechwood.

DATURA spp. for oral use:

 (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids, or

 (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids;

 except when separately specified in these Schedules.

DATURA STRAMONIUM (stramonium) for oral use when:

 (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

 (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids;

 except for smoking or burning.

DATURA TATULA (stramonium) for oral use:

 (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

 (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids;

 except for smoking or burning.

DELPHINIUM STAPHISAGRIA except in preparations containing 0.2% or less of Delphinium staphisagria.

DESLORATADINE in preparations for oral use.

DEXCHLORPHENAMINE when combined with one or more other therapeutically active substances in oral preparations when:

 (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

 (b) in a daynight pack containing dexchlorphenamine in the bedtime dose where the day and night doses are in the same immediate container or immediate wrapper;

 except in preparations for the treatment of children under 2 years of age.

DEXTROMETHORPHAN (excluding its stereoisomers) when supplied in a pack containing 600 mg or less of dextromethorphan and with a recommended daily dose of 120 mg or less of dextromethorphan.

DIBROMOPROPAMIDINE for ophthalmic use.

DICLOFENAC when:

 (a) in divided preparations for oral use containing 12.5 mg or less of diclofenac per dosage unit in a pack containing 20 or less dosage units and labelled with a recommended daily dose of 75 mg or less of diclofenac; or

 (b) in preparations for dermal use containing 4% or less of diclofenac except in preparations for dermal use containing 2% or less of diclofenac or for the treatment of solar keratosis; or

 (c) in transdermal preparations for topical use containing 140 mg or less of diclofenac.

DIMENHYDRINATE in primary packs of 10 doses or less for the prevention or treatment of motion sickness, except in preparations for the treatment of children under 2 years of age.

DIPHENHYDRAMINE in oral preparations:

 (a) in a primary pack containing 10 dosage units or less for the prevention or treatment of motion sickness; or

 (b) when combined with one or more other therapeutically active substances when:

 (i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

 (ii) in a daynight pack containing diphenhydramine in the bedtime dose where the day and night doses are in the same immediate container or immediate wrapper;

 except in preparations for the treatment of children under 2 years of age.

DOXYLAMINE when combined with one or more other therapeutically active substances in oral preparations when:

 (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

 (b) in a daynight pack containing doxylamine in the bedtime dose where the day and night doses are in the same immediate container or immediate wrapper;

 except in preparations for the treatment of children under 2 years of age.

DUBOISIA LEICHHARDTII for oral use:

 (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

 (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

DUBOISIA MYOPOROIDES for oral use:

 (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

 (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

ECONAZOLE for human use in dermal preparations except in preparations for the treatment of tinea pedis.

ESOMEPRAZOLE in oral preparations containing 20 mg or less per dosage unit for the relief of heartburn and other symptoms of gastrooesophageal reflux disease, in packs containing not more than 14 days’ supply.

ETAFEDRINE.

ETHER for therapeutic use except:

 (a) when included in Schedule 4; or

 (b) in preparations containing 10% or less of ether.

ETHYLMORPHINE when:

 (a) compounded with one or more other therapeutically active substances:

 (i) in divided preparations containing 10 mg or less of ethylmorphine per dosage unit; or

 (ii) in undivided preparations containing 0.25% or less of ethylmorphine; and

 (b) labelled with a recommended dose not exceeding 15 mg of ethylmorphine.

ETOFENAMATE in preparations for external use.

FAMOTIDINE when sold in the manufacturer’s original pack containing not more than 14 days’ supply.

FELBINAC in preparations for external use.

FEXOFENADINE in preparations for oral use except in divided preparations:

 (a) for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

 (i) in a primary pack containing 20 dosage units or less and not more than 10 days’ supply; and

 (ii) labelled with a recommended daily dose not exceeding 120 mg of fexofenadine; or

 (b) for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

 (i) in a primary pack containing 10 dosage units or less and not more than 10 days’ supply; and

 (ii) labelled with a recommended daily dose not exceeding 180 mg of fexofenadine; or

 (c) for the treatment of seasonal allergic rhinitis and children 6 years of age and over when:

 (i) in a primary pack containing 20 dosage units or less and not more than 10 days’ supply; and

 (ii) labelled with a recommended daily dose not exceeding 60 mg of fexofenadine.

FLUORIDES for human use:

 (a) in preparations for ingestion containing 0.5 mg or less of fluoride ion per dosage unit; or

 (b) in liquid preparations for topical use containing 1000 mg/kg or less of fluoride ion, in a container with a childresistant closure:

 (i) for therapeutic use when compliant with the requirements of the required advisory statements for medicine labels except in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride when fitted with a childresistant closure and compliant with the requirements of required advisory statements for medicine labels; or

 (ii) for nontherapeutic use when labelled with warnings to the following effect:

 (A) Do not swallow; and

 (B) Do not use [this product/insert name of product] in children 6 years of age or less;

  except in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride, when fitted with a childresistant closure and labelled with warnings to the following effect:

 (C) Do not swallow; and

 (D) Do not use [this product/insert name of product] in children 6 years of age or less;

 except in preparations containing 15 mg/kg or less of fluoride ion or preparations for supply to registered dental professionals or by approval of an appropriate authority.

FLURBIPROFEN in preparations for topical oral use when:

 (a) in divided preparations containing 10 mg or less of flurbiprofen per dosage unit except when:

 (i) in a primary pack containing not more than 16 dosage units; and

 (ii) labelled only for the treatment of adults and children over 12 years; or

 (b) in undivided preparations containing either:

 (i) 0.25% or less of flurbiprofen per dose; or

 (ii) 10 mg or less of flurbiprofen per dose;

 except when:

 (iii) in a primary pack containing not more than 15 mL; and

 (iv) labelled only for the treatment of adults 18 years and over.

FLUTICASONE PROPIONATE (excluding derivatives) in aqueous nasal sprays delivering 50 micrograms or less of fluticasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

FOLIC ACID for human therapeutic use except:

 (a) when included in Schedule 4; or

 (b) in preparations containing 500 micrograms or less of folic acid per recommended daily dose.

FOLINIC ACID for human therapeutic use except:

 (a) when included in Schedule 4; or

 (b) in preparations containing 500 micrograms or less of folinic acid per recommended daily dose.

FORMALDEHYDE (excluding its derivatives) for human therapeutic use except:

 (a) in oral hygiene preparations containing 0.1% or less of free formaldehyde; or

 (b) in other preparations containing 0.2% or less of free formaldehyde.

GELSEMIUM SEMPERVIRENS.

GLUTARAL for human therapeutic use.

GUAIFENESIN in a modified release dosage form of 1200 mg or less of guaifenesin with a recommended daily dose of 2400 mg or less when not labelled for the treatment of children under 12 years of age.

HEXACHLOROPHENE in preparations for human use containing 3% or less of hexachlorophene except:

 (a) in preparations for use on infants, as specified in Schedule 4; or

 (b) in preparations for cosmetic use, as specified in Schedule 6; or

 (c) in other preparations containing 0.75% or less of hexachlorophene.

HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use:

 (a) for dermal use in preparations containing 0.5% or less of hydrocortisone, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or

 (b) for dermal use in preparations containing 1% or less of hydrocortisone, in packs containing 15 g or less of such preparations, containing an antifungal substance and no other therapeutically active constituent:

 (i) for the treatment of tinea (tinea pedis, tinea cruris, tinea corporis) and other fungal skin infections; and

 (ii) not labelled for the treatment of children under 12 years of age; or

 (c) for rectal use in preparations containing 0.5% or less of hydrocortisone, when combined with a local anaesthetic substance but no other therapeutically active constituent except unscheduled astringents:

 (i) in undivided preparations in packs of 35 g or less; or

 (ii) in packs containing 12 or less suppositories.

HYDROQUINONE (excluding monobenzone and alkyl ethers of hydroquinone included in Schedule 4) in preparations for human external therapeutic or cosmetic use containing 2% or less of hydroquinone except:

 (a) in hair preparations containing 0.3% or less of hydroquinone; or

 (b) in cosmetic nail preparations containing 0.02% or less of hydroquinone.

HYOSCINE:

 (a) for transdermal use in preparations containing 2 mg or less of total solanaceous alkaloids per dosage unit; or

 (b) for oral use:

 (i) in undivided preparations containing 0.03% or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

 (ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

HYOSCINE BUTYLBROMIDE as the only therapeutically active substance, in divided preparations for oral use, containing 20 mg or less of hyoscine butylbromide per dosage unit in a pack containing 200 mg or less of hyoscine butylbromide.

HYOSCYAMINE:

 (a) for external use in preparations containing 0.03% or less of total solanaceous alkaloids; or

 (b) for oral use:

 (i) in undivided preparations containing 0.03% or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

 (ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less total solanaceous alkaloids.

HYOSCYAMUS NIGER for oral use:

 (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

 (b) in divided preparations containing 0.3 mg of total solanaceous alkaloids or less per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids;

 except in a pack containing 0.03 mg or less of total solanaceous alkaloids.

IBUPROFEN in preparations for oral use that are labelled with a recommended daily dose of 1200 mg or less of ibuprofen, when:

 (a) in liquid preparations that are sold in the manufacturer’s original pack containing 8 g or less of ibuprofen; or

 (b) in divided immediate release preparations:

 (i) each containing 400 mg or less of ibuprofen in a primary pack containing not more than 12 dosage units; and

 (ii) that are labelled not for the treatment of children under 12 years; or

 (c) in divided preparations, each containing 200 mg or less of ibuprofen, in packs of not more than 100 dosage units except when:

 (i) ibuprofen is the only therapeutically active constituent, other than phenylephrine or when combined with an effervescent agent; and

 (ii) packed in blister or strip packaging or in a container with a child-resistant closure; and

 (iii) in a primary pack containing not more than 25 dosage units; and

 (iv) compliant with the requirements of the required advisory statements for medicine labels; and

 (v) not labelled for the treatment of children 6 years or under; and

 (vi) if combined with phenylephrine—not labelled for the treatment of children under 12 years.

INDANAZOLINE.

INDOMETACIN in preparations for external use containing 1% or less of indometacin.

IODINE:

 (a) in preparations for human internal therapeutic use containing 300 micrograms or more of iodine per recommended daily dose; or

 (b) in preparations for human external therapeutic use containing more than 2.5% of available iodine (excluding salts, derivatives or iodophors);

 except in oral preparations for use in prophylaxis and treatment in the event of radioactive iodine exposure under an emergency plan approved by an appropriate authority.

IPRATROPIUM in preparations for nasal use.

IRON COMPOUNDS (excluding iron oxides when present as an excipient, in divided preparations containing 10 mg or less of total iron oxides per dosage unit or in undivided preparations containing 1% or less of total iron oxides) for human internal use except:

 (a) when included in Schedule 4; or

 (b) when labelled with a recommended daily dose of 24 mg or less of iron:

 (i) in undivided preparations supplied in packs each containing 750 mg or less of iron; or

 (ii) in divided preparations:

 (A) containing more than 5 mg of iron per dosage unit in packs each containing 750 mg or less of iron; or

 (B) containing 5 mg or less of iron per dosage unit.

ISOCONAZOLE for human use in dermal preparations.

ISOPROPAMIDE in preparations for dermal use containing 2% or less of isopropamide.

KETOCONAZOLE in preparations for dermal use except:

 (a) in preparations containing 1% or less of ketoconazole for the treatment of the scalp; or

 (b) in preparations for the treatment of tinea pedis.

KETOTIFEN for ophthalmic use in preparations containing 0.025% or less of ketotifen.

LANSOPRAZOLE in oral preparations 15 mg or less of lansoprazole per dosage unit for the relief of heartburn and other symptoms of gastrooesophageal reflux disease, in packs containing not more than 7 days’ supply.

LEVOCABASTINE in topical eye or nasal preparations.

LEVOCETIRIZINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

 (a) in a primary pack containing not more than 5 days’ supply; and

 (b) labelled with a recommended daily dose not exceeding 5 mg of levocetirizine.

LIDOCAINE in preparations for topical use other than eye drops:

 (a) containing 10% or less of total local anaesthetic substances, except:

 (i) in dermal preparations containing 2% or less of total local anaesthetic substances; or

 (ii) in aqueous sprays for oromucosal use containing 0.6% or less of total local anaesthetic substances; or

 (b) in divided preparations containing 200 mg or less of total local anaesthetic substances, except in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.

LINDANE in preparations for human external therapeutic use containing 2% or less of lindane.

LITHIUM in preparations for dermal use containing 1% or less of lithium except:

 (a) when present as an excipient at 0.25% or less of lithium; or

 (b) in preparations containing 0.01% or less of lithium.

LOBELIA INFLATA except for smoking or burning.

LOBELINE except in preparations for smoking or burning.

LODOXAMIDE in preparations for ophthalmic use.

LOPERAMIDE in divided preparations for oral use in packs of 20 dosage units or less except in preparations containing 2 mg or less of loperamide per dosage unit, in a primary pack containing 8 dosage units or less.

LORATADINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis when:

 (a) in a primary pack containing 10 dosage units or less when labelled for adults and children 6 years and over; and

 (b) labelled with a recommended daily dose not exceeding 10 mg of loratadine.

MACROGOLS in preparations for oral use as a liquid concentrate for laxative use.

MEBENDAZOLE for human therapeutic use.

MECLOZINE in primary packs containing 12 or less tablets or capsules of meclozine for the prevention or treatment of motion sickness, except in preparations for the treatment of children under 2 years of age.

MEFENAMIC ACID in divided preparations for oral use in packs of 30 or less dosage units for the treatment of dysmenorrhoea.

MEPYRAMINE for dermal use.

MERCUROCHROME in preparations for external use containing 2% or less of mercurochrome except when included in Schedule 6.

MERCURY for external use in preparations containing 0.5% or less of mercury.

METHOXAMINE in preparations for external use except in preparations containing 1% or less of methoxamine.

METHOXYPHENAMINE.

METHYLEPHEDRINE.

MICONAZOLE for human use in dermal preparations and for application to the nails except in preparations for the treatment of tinea pedis.

MINOXIDIL in preparations for dermal use containing 5% or less of minoxidil.

MOMETASONE in aqueous nasal sprays delivering 50 micrograms or less of mometasone per actuation when the maximum recommended daily dose is no greater than 200 micrograms for the prophylaxis or treatment of allergic rhinitis for up to six months in adults and children 12 years of age and over.

NAPHAZOLINE.

NAPROXEN in divided preparations containing 250 mg or less of naproxen per dosage unit in packs of 30 or less dosage units.

NICLOSAMIDE for human therapeutic use.

NIZATIDINE when sold in the manufacturer’s original pack containing not more than 14 days’ supply.

NOSCAPINE.

NYSTATIN in dermal preparations.

OMEPRAZOLE in oral preparations containing 20 mg or less of omeprazole per dosage unit for the relief of heartburn and other symptoms of gastrooesophageal reflux disease, in packs containing not more than 7 days’ supply.

OXETACAINE (oxethazaine) in preparations for internal use.

OXICONAZOLE for dermal use except in preparations for the treatment of tinea pedis.

OXYMETAZOLINE.

OXYQUINOLINE and its nonhalogenated derivatives for human therapeutic use, except in preparations for external use containing 1% or less of such substances.

PAPAVERINE except when included in Schedule 4.

PANTOPRAZOLE in oral preparations containing 20 mg or less of pantoprazole per dosage unit for the relief of heartburn and other symptoms of gastrooesophageal reflux disease, in packs containing not more than 7 days’ supply.

PARACETAMOL for therapeutic use:

 (a) in liquid preparations for oral use containing a maximum of 10 g of paracetamol per container; or

 (b) when combined with ibuprofen in preparations for oral use when labelled with a recommended daily dose of 1200 mg or less of ibuprofen in divided doses in a primary pack containing no more than 12 dosage units per pack; or

 (c) in tablets or capsules enclosed in a primary pack containing not more than 100 tablets or capsules; or

 (d) in tablets or capsules enclosed in a primary pack containing more than 100 tablets or capsules intended only as a bulk medicine pack and labelled “For dispensing only” and “This pack is not to be supplied to a patient”; or

 (e) in individually wrapped powders or sachets of granules enclosed in a primary pack containing not more than 50 wrapped powders or sachets of granules; or

 (f) in individually wrapped powders or sachets of granules enclosed in a primary pack containing more than 50 wrapped powders or sachets of granules intended only as a bulk medicine pack and labelled “For dispensing only” and “This pack is not to be supplied to a patient”; or

 (g) in other preparations except:

 (i) when included in Schedule 3 or 4; or

 (ii) in individually wrapped powders or sachets of granules each containing 1000 mg or less of paracetamol as the only therapeutically active constituent (other than caffeine, phenylephrine and/or guaifenesin or when combined with effervescent agents) when:

 (A) enclosed in a primary pack that contains not more than 10 such powders or sachets of granules;

 (B) compliant with the requirements of the required advisory statements for medicine labels;

 (C) not labelled for the treatment of children 6 years of age or less; and

 (D) not labelled for the treatment of children under 12 years of age when combined with caffeine, phenylephrine and/or guaifenesin; or

 (iii) in tablets or capsules each containing 500 mg or less of paracetamol as the only therapeutically active constituent (other than caffeine, phenylephrine and/or guaifenesin or when combined with effervescent agents) when:

 (A) packed in blister or strip packaging or in a container with a childresistant closure;

 (B) in a primary pack containing not more than 20 tablets or capsules;

 (C) compliant with the requirements of the required advisory statements for medicine labels;

 (D) not labelled for the treatment of children 6 years of age or less; and

 (E) not labelled for the treatment of children under 12 years of age when combined with caffeine, phenylephrine and/or guaifenesin.

PARAFORMALDEHYDE (excluding its derivatives) for human therapeutic use except:

 (a) in oral hygiene preparations containing 0.1% or less of free formaldehyde; or

 (b) in other preparations containing 0.2% or less of free formaldehyde.

PHEDRAZINE.

PHENAZONE for human external use.

PHENIRAMINE:

 (a) in eye drops; or

 (b) when combined with one or more other therapeutically active substances in oral preparations when:

 (i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

 (ii) in a daynight pack containing pheniramine in the bedtime dose where the day and night doses are in the same immediate container or immediate wrapper;

 except in preparations for the treatment of children under 2 years of age.

PHENOL, or any homologue boiling below 220°C, for human therapeutic use except:

 (a) when included in Schedule 4; or

 (b) in preparations for external use containing 1% or less of phenol and in preparations for external use containing 3% or less of cresols and xylenols and other homologues of phenol.

PHENYLEPHRINE except:

 (a) when included in Schedule 4; or

 (b) in oral preparations containing 50 mg or less of phenylephrine per recommended daily dose in packs containing 250 mg or less of phenylephrine; or

 (c) in topical eye or nasal preparations containing 1% or less of phenylephrine.

PHOLCODINE:

 (a) in liquid preparations containing 0.5% or less of pholcodine and with a recommended dose not exceeding 25 mg of pholcodine; or

 (b) when compounded with one or more other therapeutically active substances in divided preparations containing 10 mg or less of pholcodine per dosage unit and with a recommended dose not exceeding 25 mg of pholcodine.

PIPERAZINE for human therapeutic use.

PODOPHYLLOTOXIN in preparations containing 0.5% or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts.

PODOPHYLLUM EMODI (podophyllin) in preparations containing 10% or less of podophyllin for human use for the treatment of warts other than anogenital warts.

PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 10% or less of podophyllin for human use for the treatment of warts other than anogenital warts.

POTASSIUM CHLORATE for therapeutic use except in preparations containing 10% or less of potassium chlorate.

PRILOCAINE in preparations for dermal use containing 10% or less of total local anaesthetic substances.

PROCYCLIDINE in preparations containing 5% or less of procyclidine for dermal use.

PROMETHAZINE in oral preparations:

 (a) in a primary pack containing 10 dosage units or less for the prevention or treatment of motion sickness; or

 (b) when combined with one or more other therapeutically active substances when:

 (i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

 (ii) in a daynight pack containing promethazine in the bedtime dose where the day and night doses are in the same immediate container or immediate wrapper;

 except in preparations for the treatment of children under 2 years of age.

PROPAMIDINE for ophthalmic use.

PYRANTEL for human therapeutic use.

PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids, for human therapeutic use in preparations containing more than 10% of such substances.

PYRITHIONE ZINC for human therapeutic use, except in preparations for the treatment of the scalp containing 2% or less of pyrithione zinc when compliant with the requirements of the required advisory statements for medicine labels.

RABEPRAZOLE in oral preparations containing 10 mg or less of rabeprazole per dosage unit for the relief of heartburn and other symptoms of gastrooesophageal reflux disease, in packs containing not more than 7 days’ supply.

RANITIDINE in preparations supplied in the manufacturer’s original pack containing not more than 14 days’ supply except:

 (a) in divided preparations for oral use containing 150 mg or less of ranitidine per dosage unit in the manufacturer’s original pack containing not more than 14 dosage units; or

 (b) in divided preparations for oral use containing 300 mg or less of ranitidine per dosage unit in the manufacturer’s original pack containing not more than 7 dosage units.

SALICYLAMIDE except when included in Schedule 4.

SELENIUM in preparations for human therapeutic use except:

 (a) for topical use containing 3.5% or less of selenium sulfide;

 (b) when included in Schedule 4; or

 (c) for oral use with a recommended daily dose of 150 micrograms or less.

SILVER for therapeutic use except:

 (a) in solutions for human oral use containing 0.3% or less of silver when compliant with the requirements of the required advisory statements for medicine labels; or

 (b) in other preparations containing 1% or less of silver.

SODIUM CROMOGLYCATE in preparations for nasal or ophthalmic use.

SODIUM NITRITE for therapeutic use (excluding when present as an excipient).

SQUILL except in preparations containing 1% or less of squill.

SULCONAZOLE in preparations for dermal use.

TERBINAFINE for dermal use except in preparations for the treatment of tinea pedis.

TETRACAINE in preparations for topical use other than eye drops, containing 10% or less of total local anaesthetic substances except in dermal preparations containing 2% or less of total local anaesthetic substances.

TETRACHLOROETHYLENE for human therapeutic use.

TETRYZOLINE.

THIABENDAZOLE for human therapeutic use.

TIOCONAZOLE in preparations for dermal use except in preparations for the treatment of tinea pedis.

TRAMAZOLINE.

TRIAMCINOLONE in aqueous nasal sprays delivering 55 micrograms or less of triamcinolone per actuation when the maximum recommended daily dose is no greater than 220 micrograms, for prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

TRIPROLIDINE when combined with one or more other therapeutically active substances in oral preparations when:

 (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

 (b) in a daynight pack containing triprolidine in the bedtime dose where the day and night doses are in the same immediate container or immediate wrapper;

 except in preparations for the treatment of children under 2 years of age.

TUAMINOHEPTANE.

TYMAZOLINE.

XYLOMETAZOLINE.

ZINC CHLORIDE for human dermal use except in preparations containing 5% or less of zinc chloride.

Schedule 3Pharmacist only medicines

 

 

Note: See sections 16 and 31, subsections 54(2) and 57(1) and section 59.

ADAPALENE in topical preparations containing 0.1% or less of adapalene for the treatment of acne vulgaris in adults and in children over 12 years of age.

ADRENALINE in preparations containing 1% or less of adrenaline except in preparations containing 0.02% or less of adrenaline unless packed and labelled for injection.

ALCLOMETASONE as the only therapeutically active substance in preparations for dermal use containing 0.05% or less of alclometasone in packs containing 30 g or less of the preparation.

ALIMEMAZINE:

 (a) in solid oral preparations except when included in Schedule 2; or

 (b) in liquid oral preparations containing 10 mg or less of alimemazine per 5 mL;

 except in preparations for the treatment of children under 2 years of age.

AMINOPHYLLINE in liquid oral preparations containing 2% or less of aminophylline.

AMYL NITRITE when in preparations for human therapeutic use and packaged in containers with childresistant closures.

ASTODRIMER SODIUM except in a condom lubricant.

AZATADINE in oral preparations.

BILASTINE in divided oral preparations containing 20 mg or less of bilastine for the treatment of adults and adolescents 12 years of age and older.

BROMPHENIRAMINE in oral preparations except:

 (a) when included in Schedule 2; or

 (b) for the treatment of children under 2 years of age.

BUCLIZINE in oral preparations.

BUTOCONAZOLE in preparations for vaginal use.

CANNABIDIOL in oral, oromucosal and sublingual preparations included in the Register when:

 (a) the cannabidiol is either plant derived or, when synthetic, only contains the ()CBD enantiomer; and

 (b) the cannabidiol comprises 98% or more of the total cannabinoid content of the preparation; and

 (c) any cannabinoids, other than cannabidiol, must be only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the preparation and of which tetrahydrocannabinol (THC) can only comprise 1% of the total cannabinoid content; and

 (d) the maximum recommended daily dose is 150 mg or less of cannabidiol; and

 (e) packed in blister or strip packaging or in a container fitted with a childresistant closure; and

 (f) in packs containing not more than 30 days’ supply; and

 (g) for persons aged 18 years and over.

CHLORAMPHENICOL for ophthalmic use only.

CHLORBUTANOL in preparations for human use except:

 (a) when included in Schedule 2; or

 (b) in preparations containing 0.5% or less of chlorbutanol.

CHLORPHENAMINE in oral preparations except:

 (a) when included in Schedule 2; or

 (b) for the treatment of children under 2 years of age.

CICLOPIROX in preparations for dermal use and for application to the nails except:

 (a) when included in Schedule 2; or

 (b) in preparations for the treatment of tinea pedis.

CIMETIDINE in a primary pack containing not more than 14 days’ supply.

CLEMASTINE in preparations for oral use.

CLOBETASONE (clobetasone17butyrate) as the only therapeutically active substance in preparations for dermal use containing 0.05% or less of clobetasone in packs containing 30 g or less of the preparation.

CLOTRIMAZOLE in preparations for vaginal use.

CYCLIZINE in divided preparations for oral use in primary packs containing 6 dosage units or less.

CYPROHEPTADINE in oral preparations.

DEXCHLORPHENAMINE in oral preparations except:

 (a) when included in Schedule 2; or

 (b) for the treatment of children under 2 years of age.

DICLOFENAC in divided preparations for oral use containing 25 mg or less of diclofenac per dosage unit in a pack containing 30 or less dosage units except when included in Schedule 2.

DIHYDROCODEINE when indicated for cough suppression and compounded with one or more other therapeutically active substances:

 (a) in divided preparations containing 10 mg or less of dihydrocodeine per dosage unit and with a recommended dose not exceeding 15 mg of dihydrocodeine; or

 (b) in undivided preparations containing 0.25% or less of dihydrocodeine with a recommended dose not exceeding 15 mg of dihydrocodeine.

DIIODOHYDROXYQUINOLINE (iodoquinol) for vaginal use.

DIMENHYDRINATE in oral preparations except when included in Schedule 2.

DIMETHINDENE in oral preparations.

DIPHENHYDRAMINE in oral preparations except:

 (a) when included in Schedule 2; or

 (b) for the treatment of children under 2 years of age.

DIPHENOXYLATE in packs of 8 or less dosage units, each dosage unit containing 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1% of the dose of diphenoxylate.

DITHRANOL for therapeutic use.

DOXYLAMINE in oral preparations except:

 (a) when included in Schedule 2; or

 (b) for the treatment of children under 2 years of age.

ECONAZOLE in preparations for vaginal use.

ELETRIPTAN for oral use in tablets containing 40 mg or less per tablet and when in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, wellestablished pattern of symptoms.

ERYTHRITYL TETRANITRATE for therapeutic use.

FAMCICLOVIR for oral use, in divided preparations containing a total dose of 1500 mg or less of famciclovir for the treatment of herpes labialis (cold sores).

FLAVOXATE.

FLUCONAZOLE in singledose oral preparations containing 150 mg or less of fluconazole for the treatment of vaginal candidiasis.

FLUORIDES for human topical use:

 (a) in liquid preparations containing 5500 mg/kg or less of fluoride ion, in a container with a childresistant closure except when included in or expressly excluded from Schedule 2; or

 (b) in nonliquid preparations containing 5500 mg/kg or less of fluoride ion except:

 (i) in preparations for therapeutic use containing 1500 mg/kg or less of fluoride ion and, when containing more than 1000 mg/kg fluoride ion, compliant with the requirements of the required advisory statements for medicine labels; or

 (ii) in preparations for nontherapeutic use containing 1500 mg/kg or less of fluoride ion and, when containing more than 1000 mg/kg fluoride ion, labelled with warnings to the following effect:

 (A) Do not swallow; and

 (B) Do not use [this product/name of product] in children six years of age or less; or

 (iii) in preparations for supply to registered dental professionals or by approval of an appropriate authority.

GLUCAGON.

GLYCERYL TRINITRATE:

 (a) in preparations for oral use; or

 (b) in preparations for rectal use.

GLYCOPYRRONIUM except when included in Schedule 4.

HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use containing 1% or less of hydrocortisone:

 (a) for dermal use, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or

 (b) for dermal use, in packs containing 2 g or less of such preparations, containing no other therapeutically active constituent other than aciclovir (5% w/w or less) in adults and adolescents (12 years of age and older); or

 (c) for rectal use when combined with a local anaesthetic substance but no other therapeutically active constituent except unscheduled astringents:

 (i) in undivided preparations, in packs of 35 g or less; or

 (ii) in packs containing 12 or less suppositories;

 except when included in Schedule 2.

HYOSCINE BUTYLBROMIDE in undivided preparations for oral use with a recommended single dose not exceeding 20 mg of hyoscine butylbromide in a pack containing 100 mg or less of hyoscine butylbromide when labelled for adults and children 6 years and over.

IBUPROFEN when:

 (a) either:

 (i) in divided preparations, each containing 400 mg or less of ibuprofen, in a primary pack containing not more than 50 dosage units; or

 (ii) in a modified release dosage form, each containing 600 mg of ibuprofen, in a primary pack containing not more than 32 dosage units; and

 (b) labelled:

 (i) with a recommended daily dose of 1200 mg or less of ibuprofen; and

 (ii) not for the treatment of children under 12 years;

 except when:

 (c) included in Schedule 2; or

 (d) in preparations for oral use that are labelled with a recommended daily dose of 1200 mg or less of ibuprofen in divided preparations, each containing 200 mg or less of ibuprofen, in a pack containing not more than 100 dosage units when:

 (i) ibuprofen is the only therapeutically active constitutent, other than phenylephrine or when combined with an effervescent agent; and

 (ii) packed in a blister or strip packaging or in a container with a child-resistant closure; and

 (iii) in a primary pack containing not more than 25 dosage units; and

 (iv) compliant with the requirements of the required advisory statements for medicine labels; and

 (v) not labelled for the treatment of children 6 years or under; and

 (vi) when combined with phenylephrine—not labelled for the treatment of children under 12 years.

INOSITOL NICOTINATE.

ISOCONAZOLE in preparations for vaginal use.

ISOSORBIDE DINITRATE in oral preparations containing 10 mg or less of isosorbide dinitrate per dosage unit.

KETOPROFEN in divided preparations for oral use containing 25 mg or less of ketoprofen per dosage unit in a pack containing 30 or less dosage units.

LANSOPRAZOLE in oral preparations containing 15 mg or less of lansoprazole per dosage unit for the relief of heartburn and other symptoms of gastrooesophageal reflux disease, in packs containing not more than 14 days’ supply except when included in Schedule 2.

LEVONORGESTREL for emergency postcoital contraception.

MACROGOLS in preparations for oral use for bowel cleansing prior to diagnostic, medical or surgical procedures.

MAGNESIUM SULFATE for human therapeutic use in divided oral preparations except when containing 1.5 g or less of magnesium sulfate per recommended daily dose.

MALATHION in preparations for human external use except in preparations containing 2% or less of malathion.

MANNITYL HEXANITRATE for therapeutic use.

MELATONIN in:

 (a) modified release tablets containing 2 mg or less of melatonin for monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep for adults aged 55 or over, in packs containing not more than 30 tablets; or

 (b) immediate release preparations containing 5 mg or less of melatonin for the treatment of jet lag in adults 18 years and over, in a primary pack containing no more than 10 dosage units.

MEPYRAMINE in oral preparations.

METHDILAZINE in oral preparations.

METOCLOPRAMIDE when combined with paracetamol in divided preparations, packed and labelled only for the treatment of nausea associated with migraine, in packs containing not more than 10 dosage units.

MICONAZOLE for human use in topical preparations:

 (a) for the treatment of oral candidiasis; or

 (b) for vaginal use.

MOMETASONE as the only therapeutically active substance in preparations for dermal use containing 0.1% or less of mometasone in packs containing 15 g or less.

NALOXONE when used for the treatment of opioid overdose.

NAPROXEN in a modified release dosage form of 600 mg or less of naproxen per dosage unit in packs of 16 or less dosage units when labelled not for the treatment of children under 12 years of age.

NICOTINIC ACID for human therapeutic use in divided preparations containing 250 mg or less of nicotinic acid per dosage unit except:

 (a) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or

 (b) nicotinamide.

NICOTINYL ALCOHOL except in preparations containing 100 mg or less of nicotinyl alcohol per dosage unit.

NYSTATIN in preparations for topical use except when included in Schedule 2.

OMEPRAZOLE in oral preparations containing 20 mg or less of omeprazole per dosage unit for the relief of heartburn and other symptoms of gastrooesophageal reflux disease, in packs containing not more than 14 days’ supply except when included in Schedule 2.

ORLISTAT in oral preparations for weightcontrol purposes containing 120 mg or less of orlistat per dosage unit.

OXICONAZOLE in preparations for vaginal use.

PANTOPRAZOLE in oral preparations containing 20 mg or less of pantoprazole per dosage unit for the relief of heartburn and other symptoms of gastrooesophageal reflux disease, in packs containing not more than 14 days’ supply except when included in Schedule 2.

PARACETAMOL:

 (a) when combined with ibuprofen in a primary pack containing 30 dosage units or less except when included in Schedule 2; or

 (b) in modified release tablets or capsules containing 665 mg or less paracetamol enclosed in a primary pack containing not more than 100 tablets or capsules; or

 (c) in modified release tablets or capsules containing 665 mg or less paracetamol enclosed in a primary pack containing more than 100 tablets or capsules intended only as a bulk medicine and labelled “For dispensing only” and “This pack is not to be supplied to a patient”; or

 (d) in liquid preparations for oral use except when in Schedule 2.

PHENIRAMINE in oral preparations except:

 (a) when included in Schedule 2; or

 (b) for the treatment of children under 2 years of age.

PODOPHYLLOTOXIN in preparations containing 1% or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2.

PODOPHYLLUM EMODI (podophyllin) in preparations containing 20% or less of podophyllin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2.

PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 20% or less of podophyllin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2.

PROCHLORPERAZINE in divided preparations for oral use in packs containing not more than 10 dosage units for the treatment of nausea associated with migraine.

PROMETHAZINE in oral preparations except:

 (a) when included in Schedule 2; or

 (b) in preparations for the treatment of children under 2 years of age.

PSEUDOEPHEDRINE (other than preparations for stimulant, appetite suppression or weightcontrol purposes) when supplied in a primary pack:

 (a) in liquid preparations containing 800 mg or less of pseudoephedrine hydrochloride (or its equivalent); or

 (b) in other preparations containing 720 mg or less of pseudoephedrine hydrochloride (or its equivalent).

RABEPRAZOLE in oral preparations containing 10 mg or less of rabeprazole per dosage unit for the relief of heartburn and other symptoms of gastrooesophageal reflux disease, in packs containing not more than 14 days’ supply except when included in Schedule 2.

RIZATRIPTAN when in divided oral preparations containing 5 mg or less per dosage unit and when sold in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, wellestablished pattern of migraine symptoms.

SALBUTAMOL as the only therapeutically active substance:

 (a) in metered aerosols delivering 100 micrograms or less of salbutamol per metered dose; or

 (b) in dry powders for inhalation delivering 200 micrograms or less of salbutamol per dose.

SALICYLIC ACID in preparations for dermal use except in preparations containing 40% or less of salicylic acid.

SANTONIN.

SODIUM PHOSPHATE in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures.

SODIUM PICOSULFATE in preparations for oral use for bowel cleansing prior to diagnostic medical or surgical procedures.

SULFACETAMIDE in preparations for ophthalmic use containing 10% or less of sulfacetamide.

SUMATRIPTAN when in divided oral preparations containing 50 mg or less per dosage unit and when sold in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, wellestablished pattern of symptoms.

TERBUTALINE as the only therapeutically active substance:

 (a) in metered aerosols delivering 250 micrograms or less of terbutaline per metered dose; or

 (b) in dry powders for inhalation delivering 500 micrograms or less of terbutaline per dose.

THEOPHYLLINE in liquid oral preparations containing 2% or less of theophylline.

TIOCONAZOLE in preparations for vaginal use.

TRIAMCINOLONE for buccal use in preparations containing 0.1% or less of triamcinolone in a pack of 5 g or less.

TRIPROLIDINE in oral preparations except:

 (a) when included in Schedule 2; or

 (b) for the treatment of children under 2 years of age.

ULIPRISTAL for emergency postcoital contraception.

VITAMIN D for human internal therapeutic use in preparations containing 175 micrograms or less of vitamin D per recommended single weekly dose except in preparations containing 25 micrograms or less of vitamin D per recommended daily dose.

ZOLMITRIPTAN when in divided oral preparations containing 2.5 mg or less per dosage unit and when sold in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, wellestablished pattern of symptoms.

Schedule 4Prescription only medicines and prescription animal remedies

 

 

Note 1: See sections 16, 28, 31 and 49, subsections 54(2) and 57(1) and section 60.

Note 2: Substances marked # are listed in Appendix D.

ABACAVIR.

ABATACEPT.

ABIRATERONE ACETATE.

ABCIXIMAB.

ABEMACICLIB.

ACALABRUTINIB.

ACAMPROSATE CALCIUM.

ACARBOSE.

ACEBUTOLOL.

ACEPROMAZINE.

ACETANILIDE and alkyl acetanilides (excluding when present as an excipient) for human therapeutic use.

ACETARSOL.

ACETAZOLAMIDE.

ACETOHEXAMIDE.

ACETYL ISOVALERYLTYLOSIN.

ACETYLCARBROMAL.

ACETYLCHOLINE.

ACETYLCYSTEINE except:

 (a) when included in Schedule 2; or

 (b) in preparations for oral use when labelled with a recommended daily dose of 1 g or less of acetylcysteine.

ACETYLDIGITOXIN.

ACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE.

ACETYLSTROPHANTHIDIN.

ACICLOVIR except in preparations containing 5% or less of aciclovir for the treatment of herpes labialis in packs containing 10 g or less.

ACIPIMOX.

# ACITRETIN.

ACLIDINIUM BROMIDE.

ACOKANTHERA OUABAIO.

ACOKANTHERA SCHIMPERI.

ACONITUM spp. except:

 (a) when included in Schedule 2; or

 (b) in preparations for oral use in adults in packs containing 0.02 mg or less of total alkaloids; or

 (c) in preparations for dermal use in adults containing 0.02% or less of total alkaloids in packs containing 0.02 mg or less of total alkaloids.

ACRIVASTINE.

ADALIMUMAB.

ADAPALENE except when included in Schedule 3.

ADEFOVIR.

ADENOSINE for human therapeutic use in preparations for injection.

ADIPHENINE.

ADONIS VERNALIS.

ADRAFINIL.

ADRENALINE except:

 (a) when included in Schedule 3; or

 (b) in preparations containing 0.02% or less of adrenaline unless packed and labelled for injection.

ADRENOCORTICAL HORMONES except when separately specified in these Schedules.

AFAMELANOTIDE.

AFATINIB DIMALEATE.

AFLIBERCEPT.

AGALSIDASE.

AGLEPRISTONE.

AGOMELATINE.

ALANYLGLUTAMINE.

ALATROFLOXACIN MESILATE.

ALBENDAZOLE except:

 (a) when included in Schedule 5 or 6; or

 (b) in intraruminal implants each containing 3.85 g or less of albendazole for the treatment of animals.

ALCLOFENAC.

ALCLOMETASONE except when included in Schedule 3.

ALCURONIUM.

ALDESLEUKIN.

ALDOSTERONE.

ALECTINIB.

# ALEFACEPT.

ALEMTUZUMAB.

ALENDRONIC ACID.

ALFACALCIDOL.

ALFUZOSIN.

ALGLUCERASE.

ALGLUCOSIDASE.

ALIMEMAZINE except when included in Schedule 2 or 3.

ALIROCUMAB.

ALISKIREN.

ALKYL NITRITES except when separately specified in these schedules.

ALLERGENS for therapeutic use.

ALLOPURINOL.

ALLYLESTRENOL.

ALOGLIPTIN.

ALOSETRON.

ALPELISIB.

ALPHA1PROTEINASE INHIBITOR (HUMAN).

ALPHADOLONE.

ALPHAXALONE.

ALPRENOLOL.

ALPROSTADIL.

ALSEROXYLON.

ALTEPLASE.

ALTRENOGEST.

ALTRETAMINE (hexamethylmelamine).

AMANTADINE.

AMBENONIUM CHLORIDE.

# AMBRISENTAN.

AMBUCETAMIDE.

AMBUTONIUM BROMIDE.

AMCINONIDE.

AMIFAMPRIDINE.

AMIFOSTINE.

AMIKACIN.

AMILORIDE.

AMINOCAPROIC ACID.

AMINOGLUTETHIMIDE.

5AMINOLEVULINIC ACID.

AMINOMETRADINE.

AMINOPHENAZONE (amidopyrine) and derivatives for the treatment of animals.

AMINOPHYLLINE except when included in Schedule 3.

AMINOPTERIN.

4AMINOPYRIDINE for therapeutic use.

AMINOREX.

AMINOSALICYLIC ACID.

AMIODARONE.

AMIPHENAZOLE.

AMISOMETRADINE.

AMISULPRIDE.

AMITRIPTYLINE.

AMLODIPINE.

AMMI VISNAGA.

AMMONIUM BROMIDE for therapeutic use.

AMOBARBITAL when packed and labelled for injection.

AMODIAQUINE.

AMOROLFINE except:

 (a) when included in Schedule 2; or

 (b) in preparations for the treatment of tinea pedis.

AMOXAPINE.

AMOXICILLIN.

AMPHOMYCIN.

AMPHOTERICIN B.

AMPICILLIN.

AMPRENAVIR.

AMRINONE.

AMSACRINE.

AMYL NITRITE except when included in Schedule 3.

AMYLOCAINE.

# ANABOLIC STEROIDAL AGENTS.

ANAGRELIDE.

ANAKINRA.

ANASTROZOLE.

ANCESTIM.

ANCROD and its immunoglobulin antidote.

ANDEXANET ALFA.

ANECORTAVE.

# ANDROGENIC STEROIDAL AGENTS.

# ANDROISOXAZOLE.

# ANDROSTANOLONE.

# ANDROSTENEDIOL.

# ANDROSTENEDIONE.

ANGIOTENSIN AMIDE.

ANIDULAFUNGIN.

ANIRACETAM.

ANISTREPLASE.

ANTAZOLINE except when included in Schedule 2.

ANTIBIOTIC SUBSTANCES except:

 (a) when separately specified in these Schedules; or

 (b) nisin.

ANTIGENS for human therapeutic use except when separately specified in this Schedule.

ANTIHISTAMINES except:

 (a) when included in Schedule 2 or 3; or

 (b) when separately specified in this Schedule.

ANTIMONY for therapeutic use except when separately specified in these Schedules.

ANTISERA (immunosera) for human use by injection except when separately specified in these Schedules.

# AOD9604 (CAS No. 221231103).

APALUTAMIDE.

APIXABAN.

APOCYNUM spp.

APOMORPHINE.

APRACLONIDINE.

APRAMYCIN.

APREMILAST.

APREPITANT.

APROTININ.

ARBUTIN (BETA) in oral preparations except herbal preparations containing 500 mg or less betaarbutin per recommended daily dose.

ARECOLINE.

ARIPIPRAZOLE.

ARMODAFINIL.

ARSENIC for human therapeutic use except when separately specified in these Schedules.

ARTEMETHER.

ARTICAINE.

ASCIMINIB.

ASENAPINE.

ASFOTASE ALFA.

ASPARAGINASE.

ASPIRIN when:

 (a) combined with caffeine, paracetamol or salicylamide; or

 (b) combined with any derivative of the substances mentioned in paragraph (a); or

 (c) for injection.

ASTEMIZOLE.

ASUNAPREVIR.

# ATAMESTANE.

ATAZANAVIR.

ATENOLOL.

ATEZOLIZUMAB.

ATIPAMEZOLE.

ATOMOXETINE.

ATORVASTATIN.

ATOSIBAN.

ATOVAQUONE.

ATRACURIUM BESILATE.

ATROPA BELLADONNA (belladonna) except when included in Schedule 2.

ATROPINE except when included in Schedule 2.

ATROPINE METHONITRATE.

AURANOFIN.

AUROTHIOMALATE SODIUM.

AVACOPAN.

AVATROMBOPAG.

AVELUMAB.

AVILAMYCIN except:

 (a) in animal feed premixes containing 15% or less of avilamycin activity; or

 (b) in animal feeds containing 50 mg/kg or less of avilamycin activity.

AVIPTADIL.

AXITINIB.

AVOPARCIN.

AZACITIDINE.

AZACYCLONOL.

AZAPERONE.

AZAPROPAZONE.

AZARIBINE.

AZATADINE except when included in Schedule 3.

AZATHIOPRINE.

AZELAIC ACID except:

 (a) when included in Schedule 2; or

 (b) in preparations containing 1% or less of azelaic acid for nonhuman use.

AZELASTINE except when included in Schedule 2.

AZITHROMYCIN.

AZLOCILLIN.

AZTREONAM.

BACAMPICILLIN.

BACITRACIN.

BACLOFEN.

BALOXAVIR MARBOXIL.

BALSALAZIDE.

BAMBERMYCIN (flavophospholipol) except:

 (a) when included in Schedule 6; or

 (b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.

BAMBUTEROL.

BAMETHAN.

BAMIPINE.

BARBITURATES except when separately specified in these Schedules.

BARICITINIB.

BASILIXIMAB.

BAZEDOXIFENE.

BECAPLERMIN.

BECLAMIDE.

BECLOMETASONE except when included in Schedule 2.

BELATACEPT.

BELIMUMAB.

BELUMOSUDIL.

BELZUTIFAN.

BEMEGRIDE.

BENACTYZINE.

BENAZEPRIL.

BENDAMUSTINE.

BENDROFLUAZIDE.

BENETHAMINE PENICILLIN.

BENORYLATE.

BENOXAPROFEN.

BENPERIDOL.

BENRALIZUMAB.

BENSERAZIDE.

BENZATHINE PENICILLIN.

BENZILONIUM.

BENZOCAINE except:

 (a) when included in Schedule 2; or

 (b) in dermal preparations containing 2% or less of total local anaesthetic substances; or

 (c) in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.

# BENZODIAZEPINE derivatives except when separately specified in these Schedules.

BENZOYL PEROXIDE in preparations for human therapeutic use except:

 (a) when included in Schedule 2; or

 (b) in preparations for external use containing 5% or less of benzoyl peroxide.

BENZPHETAMINE.

BENZTHIAZIDE.

BENZATROPINE.

BENZYDAMINE except:

 (a) when included in Schedule 2; or

 (b) in preparations for dermal use; or

 (c) in divided topical oral preparations containing 3 mg or less of benzydamine; or

 (d) in undivided topical oral preparations containing 0.3% or less of benzydamine in a primary pack containing not more than 50 mL.

BENZYLPENICILLIN.

BEPRIDIL.

BERACTANT.

BESIFLOXACIN.

BETAHISTINE.

BETAMETHASONE.

BETAXOLOL.

BETHANECHOL CHLORIDE.

BETHANIDINE.

BEVACIZUMAB.

BEVANTOLOL.

# BEXAROTENE.

BEZAFIBRATE.

BEZLOTOXUMAB.

BICALUTAMIDE.

BICTEGRAVIR.

BIFONAZOLE except:

 (a) when included in Schedule 2; or

 (b) in preparations for dermal use containing 1% or less of bifonazole for the treatment of the scalp; or

 (c) in preparations for dermal use for the treatment of tinea pedis.

BILASTINE except when included in Schedule 3.

BIMATOPROST.

BINIMETINIB.

BIPERIDEN.

BISMUTH COMPOUNDS for cosmetic use, except:

 (a) bismuth citrate when incorporated in hair colourant preparations in concentrations of 0.5 per or less; or

 (b) bismuth oxychloride.

BISMUTH COMPOUNDS for human therapeutic use, except bismuth formic iodide or bismuth subiodide in dusting powders containing 3% or less of bismuth.

BISOPROLOL.

BIVALIRUDIN.

BLEOMYCIN.

BLINATUMOMAB.

BOCEPREVIR.

# BOLANDIOL.

# BOLASTERONE.

# BOLAZINE.

# BOLDENONE (dehydrotestosterone).

# BOLENOL.

# BOLMANTALATE.

BORON, including boric acid and borax, for human therapeutic use except:

 (a) in preparations for internal use containing 6 mg or less of boron per recommended daily dose; or

 (b) in preparations for dermal use containing 0.35% or less of boron, which are not for paediatric or antifungal use; or

 (c) when present as an excipient.

BORTEZOMIB.

# BOSENTAN.

BOSUTINIB.

BOTULINUM TOXINS for human use except when separately specified in these Schedules.

BRENTUXIMAB VEDOTIN.

BRETYLIUM TOSILATE.

BREXPIPRAZOLE.

BRIGATINIB.

BRIMONIDINE except when included in Schedule 2.

BRINZOLAMIDE.

BRIVARACETAM.

# BROMAZEPAM.

BROMIDES, inorganic, for therapeutic use except when separately specified in these Schedules.

BROMOCRIPTINE.

BROMOFORM for therapeutic use.

BROMPHENIRAMINE except when included in Schedule 2 or 3.

BROMVALETONE.

BRUGMANSIA spp.

BUCLIZINE except when included in Schedule 3.

BUDESONIDE except when included in Schedule 2.

BUFEXAMAC.

BUMETANIDE.

BUPHENINE.

BUPIVACAINE except when included in Schedule 5.

BUPROPION.

BUSERELIN.

BUSPIRONE.

BUSULPHAN.

BUTACAINE.

BUTAMBEN except in dermal preparations containing 2% or less of total local anaesthetic substances.

BUTOCONAZOLE except when included in Schedule 3.

BUTRACONAZOLE.

BUTYLCHLORAL HYDRATE.

BUTYL NITRITE.

CABAZITAXEL.

CABERGOLINE.

CABOTEGRAVIR.

CABOZANTINIB.

CADMIUM COMPOUNDS for human therapeutic use.

CAFFEINE for internal therapeutic use except:

 (a) in divided preparations when labelled with a maximum recommended daily dose of no greater than 600 mg of total caffeine; or

 (b) in undivided preparations with a concentration of less than 5% of caffeine and when labelled with a maximum recommended daily dose of no greater than 600 mg of total caffeine.

CALCIFEDIOL for human internal therapeutic use except in preparations containing 10 micrograms or less of calcifediol per recommended daily dose.

CALCIPOTRIOL.

CALCITONIN.

CALCITONIN SALMON.

CALCITRIOL.

CALCIUM CARBIMIDE for therapeutic use.

CALCIUM HYDROXYLAPATITE in preparations for injection or implantation:

 (a) for tissue augmentation; or

 (b) for cosmetic use.

CALCIUM POLYSTYRENE SULPHONATE.

CALOTROPIS GIGANTEA.

CALOTROPIS PROCERA.

# CALUSTERONE.

CAMPHORATED OIL for therapeutic use.

CAMPHOTAMIDE.

CANAGLIFLOZIN.

CANAKINUMAB.

CANDESARTAN CILEXETIL.

CANDICIDIN.

CANINE TICK ANTISERUM.

CANNABIDIOL in preparations for therapeutic use or analytical and scientific research where:

 (a) cannabidiol comprises 98% or more of the total cannabinoid content of the preparation; and

 (b) any cannabinoids, other than cannabidiol, must be only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the preparation;

 except when:

 (c) included in Schedule 3; or

 (d) in hemp seed oil at a concentration of 75 mg/kg or less.

CANTHARIDIN.

CAPECITABINE.

CAPREOMYCIN.

CAPTODIAME.

CAPTOPRIL.

CAPURIDE.

CARAMIPHEN.

CARBACHOL.

CARBAMAZEPINE.

CARBARYL for human therapeutic use.

CARBAZOCHROME.

CARBENICILLIN.

CARBENOXOLONE for internal use.

CARBETOCIN.

CARBIDOPA.

CARBIMAZOLE.

CARBOCROMEN.

CARBOPLATIN.

CARBOPROST.

CARBROMAL.

CARBUTAMIDE.

CARBUTEROL.

CARFILZOMIB.

CARGLUMIC ACID (NcarbamoylLglutamic acid).

CARINDACILLIN.

CARIPRAZINE.

CARISOPRODOL.

CARMUSTINE.

CARNIDAZOLE.

CARPROFEN.

CARVEDILOL.

CASIRIVIMAB.

CASPOFUNGIN.

CATHINE.

CATUMAXOMAB.

CEDAZURIDINE.

CEFACETRILE.

CEFACLOR.

CEFADROXIL.

CEFALEXIN.

CEFALORIDINE.

CEFALOTIN.

CEFAMANDOLE.

CEFAPIRIN.

CEFAZOLIN.

CEFEPIME.

CEFETAMET.

CEFIXIME.

CEFODIZIME.

CEFONICID.

CEFOPERAZONE.

CEFOTAXIME.

CEFOTETAN.

CEFOTIAM.

CEFOVECIN for veterinary use.

CEFOXITIN.

CEFPIROME.

CEFPODOXIME.

CEFQUINOME.

CEFTAROLINE FOSAMIL.

CEFSULODIN.

CEFTAZIDIME.

CEFTIBUTEN.

CEFTIOFUR.

CEFTRIAXONE.

CEFUROXIME.

CELECOXIB.

CELIPROLOL.

CENEGERMIN.

CEPHAELIS ACUMINATA (ipecacuanha) except in preparations containing 0.2% or less of emetine.

CEPHAELIS IPECACUANHA except in preparations containing 0.2% or less of emetine.

CEPHALONIUM.

CEPHRADINE.

CERITINIB.

CERIVASTATIN.

CERLIPONASE ALFA.

CERTOLIZUMAB PEGOL.

CERULETIDE.

CETIRIZINE except

 (a) when included in Schedule 2; or

 (b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 6 years of age and over when:

 (i) in a primary pack containing not more than 10 days’ supply; and

 (ii) labelled with a recommended daily dose not exceeding 10 mg of cetirizine.

CETRORELIX.

CETUXIMAB.

CHENODEOXYCHOLIC ACID.

CHLORAL FORMAMIDE.

CHLORAL HYDRATE except in preparations for topical use containing 2% or less of chloral hydrate.

CHLORALOSE except when included in Schedule 6.

CHLORAMBUCIL.

CHLORAMPHENICOL except when included in Schedule 3.

# CHLORANDROSTENOLONE.

CHLORAZANIL.

CHLORCYCLIZINE.

# CHLORDIAZEPOXIDE.

CHLORMERODRIN.

CHLORMETHIAZOLE.

CHLORMEZANONE.

CHLOROFORM for use in anaesthesia.

# 4CHLOROMETHANDIENONE.

2(4CHLOROPHENYL)(1,2,4)TRIAZOLO[5,1A]ISOQUINOLINE.

CHLOROQUINE.

CHLOROTHIAZIDE.

CHLOROTRIANISENE.

# CHLOROXYDIENONE.

CHLORPHENAMINE except when included in Schedule 2 or 3.

CHLORPHENTERMINE.

CHLORPROMAZINE.

CHLORPROPAMIDE.

CHLORPROTHIXENE.

CHLORQUINALDOL for human topical use.

CHLORTALIDONE.

CHLORTETRACYCLINE except when included in Schedule 5.

CHLORZOXAZONE.

CHOLERA VACCINE.

CHOLIC ACID.

CHYMOPAPAIN for human therapeutic use.

CICLACILLIN.

CICLESONIDE.

CICLOPIROX except:

 (a) when included in Schedule 2 or 3; or

 (b) in preparations for the treatment of tinea pedis.

CICLOSPORIN.

CIDOFOVIR.

CILASTATIN.

CILAZAPRIL.

CILGAVIMAB.

CILOSTAZOL.

CIMETIDINE except when included in Schedule 3.

CIMICOXIB.

CINACALCET.

CINCHOCAINE except when included in Schedule 2.

CINNARIZINE.

CINOXACIN.

CIPROFLOXACIN.

CISAPRIDE.

CISATRACURIUM BESILATE.

CISPLATIN.

CITALOPRAM.

# CJC1295 (CAS No. 863288340).

CLADRIBINE.

CLANOBUTIN.

CLARITHROMYCIN.

CLAVULANIC ACID.

CLEMASTINE except when included in Schedule 3.

CLEMIZOLE.

CLENBUTEROL.

CLEVIDIPINE.

CLIDINIUM BROMIDE.

CLINDAMYCIN.

CLIOQUINOL and other halogenated derivatives of oxyquinoline for human topical use except when separately specified in this Schedule.

CLOBAZAM.

CLOBETASOL.

CLOBETASONE (clobetasone17butyrate) except when included in Schedule 3.

CLOCORTOLONE.

CLODRONIC ACID (includes sodium clodronate).

CLOFARABINE.

CLOFAZIMINE.

CLOFENAMIDE.

CLOFIBRATE.

# CLOMIFENE.

CLOMIPRAMINE.

CLOMOCYCLINE.

# CLONAZEPAM.

CLONIDINE.

CLOPAMIDE.

CLOPIDOGREL.

CLOPROSTENOL.

# CLORAZEPATE.

CLOREXOLONE.

CLORPRENALINE.

# CLOSTEBOL (4chlorotestosterone).

CLOTRIMAZOLE except:

 (a) when included in Schedule 2, 3 or 6; or

 (b) in preparations for dermal use for the treatment of tinea pedis.

CLOXACILLIN.

# CLOZAPINE.

COBALT for human therapeutic use except as dicobalt edetate in preparations for the treatment of cyanide poisoning.

COBICISTAT.

COBIMETINIB.

CODEINE when compounded with one or more other therapeutically active substances:

 (a) in divided preparations containing 30 mg or less of codeine per dosage unit; or

 (b) in undivided preparations containing 1% or less of codeine.

CODERGOCRINE.

COLCHICINE.

COLCHICUM AUTUMNALE.

COLESTIPOL.

COLESTYRAMINE for human therapeutic use.

COLFOSCERIL PALMITATE for human therapeutic use.

COLISTIN.

COLLAGEN in preparations for injection or implantation:

 (a) for tissue augmentation; or

 (b) for cosmetic use.

COLLAGENASE CLOSTRIDIUM HISTOLYTICUM.

COLURACETAM.

CONCIZUMAB.

CONVALLARIA KEISKI.

CONVALLARIA MAJALIS.

COPPER COMPOUNDS for human use except:

 (a) when separately specified in these Schedules; or

 (b) in preparations for human internal use containing 5 mg or less of copper per recommended daily dose; or

 (c) in other preparations containing 5% or less of copper compounds.

# CORIFOLLITROPIN ALFA.

CORONILLA spp.

CORTICOSTERONE.

CORTICOTROPHIN.

CORTISONE.

COTRIMOXAZOLE.

COUMARIN for therapeutic use (excluding when present as an excipient).

CRISABOROLE.

CRIZOTINIB.

CROFELEMER.

CUPRIMYXIN.

CURARE.

CYCLANDELATE.

CYCLIZINE except when included in Schedule 3.

CYCLOBENZAPRINE.

# CYCLOFENIL.

CYCLOHEXIMIDE.

CYCLOPENTHIAZIDE.

CYCLOPENTOLATE.

CYCLOPHOSPHAMIDE.

CYCLOPROPANE for therapeutic use.

CYCLOSERINE.

CYCLOTHIAZIDE.

CYCRIMINE.

CYMARIN.

CYPROHEPTADINE except when included in Schedule 3.

CYPROTERONE.

CYTARABINE.

DABRAFENIB MESILATE.

DABIGATRAN.

DACARBAZINE.

DACLATASVIR.

DACLIZUMAB.

DACTINOMYCIN.

DALFOPRISTIN.

DALTEPARIN (includes dalteparin sodium).

DANAPAROID (includes danaparoid sodium).

# DANAZOL.

DANTHRON for human use.

DANTROLENE.

DAPAGLIFLOZIN.

DAPOXETINE.

DAPSONE.

DAPTOMYCIN.

DARATUMUMAB.

# DARBEPOETIN.

DARIFENACIN.

DAROLUTAMIDE.

DARUNAVIR.

DATURA spp. except:

 (a) when included in Schedule 2; or

 (b) when separately specified in this Schedule.

DASABUVIR.

DASATINIB.

DATURA STRAMONIUM (stramonium) except:

 (a) when included in Schedule 2; or

 (b) for smoking or burning.

DATURA TATULA (stramonium) except:

 (a) when included in Schedule 2; or

 (b) for smoking or burning.

DAUNORUBICIN.

DEANOL for therapeutic use.

DEBRISOQUINE.

DECAMETHONIUM.

DECITABINE.

DEFERASIROX.

DEFERIPRONE.

DEFIBROTIDE.

DEFLAZACORT.

DEGARELIX.

# DEHYDROCHLOROMETHYLTESTOSTERONE.

DEHYDROCORTICOSTERONE.

DELAVIRDINE MESILATE.

DEMBREXINE except when included in Schedule 5.

DEMECARIUM.

DEMECLOCYCLINE.

DENGUE VACCINE.

DENOSUMAB.

DEOXYCHOLIC ACID.

DEOXYCORTONE.

DEOXYRIBONUCLEASE except:

 (a) when separately specified in this Schedule; or

 (b) for external use.

DERACOXIB.

DERMATOPHAGOIDES PTERONYSSINUS AND DERMATOPHAGOIDES FARINAE EXTRACT.

DESFERRIOXAMINE.

DESFLURANE.

DESIPRAMINE.

DESIRUDIN.

DESLANOSIDE.

DESLORATADINE except when included in Schedule 2.

DESLORELIN.

DESMOPRESSIN (D.D.A.V.P.).

DESOGESTREL.

DESONIDE.

DESOXYMETHASONE.

DESVENLAFAXINE.

DETOMIDINE.

DEUCRAVACITINIB.

DEUTETRABENAZINE.

DEXAMETHASONE.

DEXCHLORPHENAMINE except when included in Schedule 2 or 3.

DEXFENFLURAMINE.

DEXMEDETOMIDINE.

DEXTROMETHORPHAN (excluding its stereoisomers) except when included in Schedule 2.

# DEXTROPROPOXYPHENE:

 (a) in divided preparations containing 135 mg of dextropropoxyphene or less per dosage unit; or

 (b) liquid preparations containing 2.5% or less of dextropropoxyphene.

DEXTRORPHAN (excluding its stereoisomers).

DIAMTHAZOLE.

DIAVERIDINE.

# DIAZEPAM.

DIAZOXIDE.

DIBENZEPIN.

DIBOTERMIN.

DIBROMOPROPAMIDINE for therapeutic use except when included in Schedule 2.

DICHLORALPHENAZONE.

DICHLOROPHEN for human therapeutic use.

DICHLORPHENAMIDE.

DICLOFENAC except:

 (a) when included in Schedule 2 or 3; or

 (b) in preparations for dermal use unless:

 (i) for the treatment of solar keratosis; or

 (ii) containing more than 4% of diclofenac.

DICLOXACILLIN.

DICYCLOMINE.

DIDANOSINE.

DIENESTROL.

DIENOGEST.

DIETHAZINE.

DIETHYLCARBAMAZINE for human therapeutic use.

DIETHYLPROPION.

DIFELIKEFALIN.

DIFENOXIN in preparations containing, per dosage unit, 0.5 mg or less of difenoxin and a quantity of atropine sulfate equivalent to at least 5% of the dose of difenoxin.

DIFLORASONE.

DIFLOXACIN.

DIFLUCORTOLONE.

DIFLUNISAL.

DIGITALIS LANATA.

DIGITALIS PURPUREA.

DIGITOXIN.

DIGOXIN.

DIGOXINSPECIFIC ANTIBODY FRAGMENT F (Ab).

DIHYDRALAZINE.

DIHYDROCODEINE when compounded with one or more other therapeutically active substances:

 (a) in divided preparations containing not more than 100 mg of dihydrocodeine per dosage unit; or

 (b) in undivided preparations with a concentration of not more than 2.5% of dihydrocodeine;

 except when included in Schedule 3.

DIHYDROERGOTOXINE.

# DIHYDROLONE.

DIHYDROSTREPTOMYCIN.

DIHYDROTACHYSTEROL.

DIIODOHYDROXYQUINOLINE (iodoquinol) except:

 (a) when included in Schedule 3; or

 (b) for human internal use.

DIISOPROPYLAMINE DICHLOROACETATE.

DILTIAZEM.

DIMENHYDRINATE except when included in Schedule 2 or 3.

DIMERCAPROL.

# DIMETHANDROSTANOLONE.

# DIMETHAZINE.

DIMETHINDENE except when included in Schedule 3.

DIMETHOTHIAZINE.

DIMETHOXANATE.

DIMETHYL FUMARATE.

DIMETHYL SULFOXIDE (excluding dimethyl sulfone) for therapeutic use except:

 (a) when included in Schedule 6; or

 (b) in in vitro test kits; or

 (c) when used as a flavour component in compliance with the current Therapeutic Goods (Permissible Ingredients) determination for listed medicines.

DIMETRIDAZOLE.

DIMIRACETAM.

2,4DINITROCHLOROBENZENE for therapeutic use.

DINITROCRESOLS for therapeutic use except when separately specified in these Schedules.

DINITRONAPHTHOLS for therapeutic use except when separately specified in these Schedules.

DINITROPHENOLS for therapeutic use.

DINITROTHYMOLS for therapeutic use except when separately specified in these Schedules.

# DINOPROST.

# DINOPROSTONE.

DIPERODON.

DIPHEMANIL except in preparations for dermal use.

DIPHENHYDRAMINE except when included in Schedule 2 or 3.

DIPHENIDOL.

DIPHENOXYLATE in preparations containing, per dosage unit, 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1% of the dose of diphenoxylate except when included in Schedule 3.

DIPHENYLPYRALINE.

DIPHTHERIA TOXOID.

DIPIVEFRIN.

DIPYRIDAMOLE.

DIRITHROMYCIN.

DIRLOTAPIDE.

DIROXIMEL FUMARATE.

DISOPHENOL.

DISOPYRAMIDE.

DISTIGMINE.

DISULFIRAM for therapeutic use.

DISULPHAMIDE.

DITHIAZANINE except when included in Schedule 6.

DITIOCARB.

DOBUTAMINE.

DOCETAXEL.

DOFETILIDE.

DOLASETRON.

DOLUTEGRAVIR.

DOMPERIDONE.

DONEPEZIL.

DOPAMINE.

DOPEXAMINE.

DORAVIRINE.

DORIPENEM.

DORNASE.

DORZOLAMIDE.

DOSULEPIN.

DOXANTRAZOLE.

DOXAPRAM.

DOXAZOSIN.

DOXEPIN.

DOXORUBICIN.

DOXYCYCLINE.

DOXYLAMINE except when included in Schedule 2 or 3.

DRONEDARONE.

DROPERIDOL.

DROSPIRENONE.

# DROSTANOLONE.

DROTRECOGIN.

DUBOISIA LEICHHARDTII except when included in Schedule 2.

DUBOISIA MYOPOROIDES except when included in Schedule 2.

DULAGLUTIDE.

DULOXETINE.

DUPILUMAB.

DURVALUMAB.

DUTASTERIDE.

DYDROGESTERONE.

ECONAZOLE except:

 (a) when included in Schedule 2, 3 or 6; or

 (b) in preparations for dermal use for the treatment of tinea pedis.

ECOTHIOPATE (includes ecothiopate iodide).

ECTYLUREA.

ECULIZUMAB.

EDARAVONE.

EDETIC ACID for human therapeutic use except:

 (a) in preparations containing 0.25% or less of edetic acid; or

 (b) as dicobalt edetate in preparations for the treatment of cyanide poisoning; or

 (c) in contact lens preparations.

EDOXUDINE.

EDROPHONIUM.

EFALIZUMAB.

EFAVIRENZ.

EFLORNITHINE.

ELBASVIR.

ELETRIPTAN except when included in Schedule 3.

ELEXACAFTOR.

ELOSULFASE ALFA.

ELOTUZUMAB.

ELTENAC.

ELTROMBOPAG.

ELUXADOLINE.

ELVITEGRAVIR.

EMEPRONIUM.

EMETINE except in preparations containing 0.2% or less of emetine.

EMPAGLIFLOZIN.

EMTRICITABINE.

ENALAPRIL.

ENASIDENIB.

ENCORAFENIB.

# ENESTEBOL.

ENFLURANE for therapeutic use.

ENFORTUMAB VEDOTIN.

ENFUVIRTIDE.

# ENOBOSARM.

ENOXACIN.

ENOXAPARIN.

ENOXIMONE.

ENPROSTIL.

ENROFLOXACIN.

ENTACAPONE.

ENTECAVIR.

ENTRECTINIB.

ENZALUTAMIDE.

EPHEDRA spp. except in preparations containing 0.001% or less of ephedrine.

# EPHEDRINE.

EPICILLIN.

EPINASTINE.

EPIRUBICIN.

# EPITIOSTANOL.

EPLERENONE.

# EPOETINS.

EPOPROSTENOL.

EPROSARTAN.

EPTIFIBATIDE.

ERENUMAB.

ERGOMETRINE.

ERGOT.

ERGOTAMINE.

ERGOTOXINE.

ERIBULIN MESILATE.

ERLOTINIB.

ERTAPENEM.

ERTUGLIFLOZIN.

ERYSIMUM spp.

ERYTHROMYCIN.

# ERYTHROPOIETIN.

# ERYTHROPOIETINS except when separately specified in these Schedules.

ESCITALOPRAM.

ESLICARBAZEPINE ACETATE.

ESMOLOL.

ESOMEPRAZOLE except when included in Schedule 2.

ESTETROL MONOHYDRATE.

ESTRADIOL except when included in Schedule 5.

ESTRIOL.

ESTRAMUSTINE.

ESTROGENS except when separately specified in these Schedules.

ESTRONE.

ESTROPIPATE (piperazine estrone sulfate).

ETACRYNIC ACID.

ETANERCEPT.

ETHAMBUTOL.

ETHAMIVAN.

ETHCHLORVYNOL.

ETHER for use in anaesthesia.

ETHINAMATE.

ETHINYLESTRADIOL.

ETHIONAMIDE.

# ETHISTERONE.

ETHOGLUCID.

ETHOHEPTAZINE.

ETHOPROPAZINE.

ETHOSUXIMIDE.

ETHOTOIN.

ETHOXZOLAMIDE.

ETHYL CHLORIDE for human therapeutic use.

# ETHYLDIENOLONE.

ETHYLMORPHINE when compounded with one or more other therapeutically active substances:

 (a) in divided preparations containing not more than 100 mg of ethylmorphine per dosage unit; or

 (b) in undivided preparations with a concentration of not more than 2.5% of ethylmorphine;

 except when included in Schedule 2.

# ETHYLESTRENOL.

ETIDOCAINE.

ETIDRONIC ACID (includes etidronate disodium):

 (a) for internal use; or

 (b) in topical preparations except in preparations containing 1% or less of etidronic acid.

ETILEFRIN.

ETIPROSTON.

ETODOLAC.

ETOFENAMATE except when included in Schedule 2.

ETONOGESTREL.

ETOPOSIDE.

ETORICOXIB.

ETRAVIRINE.

# ETRETINATE.

ETYNODIOL.

EVEROLIMUS.

EXEMESTANE.

EXENATIDE.

EZETIMIBE.

FAMCICLOVIR except when included in Schedule 3.

FAMOTIDINE except when included in Schedule 2.

FARICIMAB.

FASORACETAM.

FEBUXOSTAT.

FELBINAC except when included in Schedule 2.

FELODIPINE.

FELYPRESSIN.

FENBUFEN.

FENCAMFAMIN.

FENCLOFENAC.

FENFLURAMINE.

FENOFIBRATE.

FENOLDOPAM.

FENOPROFEN.

FENOTEROL.

FENPIPRAMIDE.

FENPIPRANE.

FENPROPOREX.

FENPROSTALENE.

FERRIC DERISOMALTOSE.

FEXOFENADINE except:

 (a) when included in Schedule 2; or

 (b) in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

 (i) in a primary pack containing 20 dosage units or less and not more than 10 days’ supply; and

 (ii) labelled with a recommended daily dose not exceeding 120 mg of fexofenadine; or

 (c) for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

 (i) in a primary pack containing 10 dosage units or less and not more than 10 days’ supply; and

 (ii) labelled with a recommended daily dose not exceeding 180 mg of fexofenadine; or

 (d) for the treatment of seasonal allergic rhinitis and children 6 years of age and over when:

 (i) in a primary pack containing 20 dosage units or less and not more than 10 days’ supply; and

 (ii) labelled with a recommended daily dose not exceeding 60 mg of fexofenadine.

FIBRINOLYSIN except for external use.

# FIBROBLAST GROWTH FACTORS.

FIDAXOMICIN.

FILGOTINIB.

FILGRASTIM.

FINASTERIDE.

FINERENONE.

FINGOLIMOD.

FIROCOXIB.

FLECAINIDE.

FLEROXACIN.

FLOCTAFENINE.

FLORFENICOL.

FLUANISONE.

FLUCLOROLONE.

FLUCLOXACILLIN.

FLUCONAZOLE except when included in Schedule 3.

FLUCYTOSINE.

FLUDARABINE.

FLUDROCORTISONE.

FLUFENAMIC ACID.

FLUMAZENIL.

FLUMETASONE.

FLUMETHIAZIDE.

FLUNISOLIDE.

FLUNIXIN MEGLUMINE.

FLUOCINOLONE.

FLUOCINONIDE.

FLUOCORTIN.

FLUOCORTOLONE.

FLUORESCEIN in preparations for injection.

FLUORIDES in preparations for human use except when included in or expressly excluded from Schedule 2 or 3.

FLUOROMETHOLONE.

FLUOROURACIL.

FLUOXETINE.

# FLUOXYMESTERONE.

FLUPENTIXOL.

FLUPHENAZINE.

FLUPROSTENOL.

FLURALANER in injectable preparations for use in companion animals.

FLURANDRENOLONE.

# FLURAZEPAM.

FLURBIPROFEN except when:

 (a) included in Schedule 2; or

 (b) in divided preparations for topical oral use that contain 10 mg or less of flurbiprofen per dosage unit and that are:

 (i) in a primary pack containing not more than 16 dosage units; and

 (ii) labelled only for the treatment of adults and children over 12 years; or

 (c) in undivided preparations for topical oral use containing either:

 (i) 0.25% or less of flurbiprofen per dose; or

 (ii) 10 mg or less of flurbiprofen per dose; and

 that are:

 (iii) in a primary pack containing not more than 15 mL; and

 (iv) labelled only for the treatment of adults 18 years and over.

FLUROXENE for human therapeutic use.

FLUSPIRILENE.

FLUTAMIDE.

FLUTICASONE except when included in Schedule 2.

FLUVASTATIN.

FLUVOXAMINE.

FOLIC ACID in preparations for human use for injection.

FOLINIC ACID in preparations for human use for injection.

FOLLICLESTIMULATING HORMONE except when separately specified in this Schedule.

# FOLLISTATIN.

# FOLLITROPIN ALFA.

# FOLLITROPIN BETA.

# FOLLITROPIN DELTA.

FOMEPIZOLE.

FOMIVIRSEN.

FONDAPARINUX.

# FORMEBOLONE.

FORMESTANE.

FORMOTEROL

FOSAMPRENAVIR.

FOSAPREPITANT.

FOSCARNET.

FOSFESTROL (diethylstilbestrol diphosphate).

FOSFOMYCIN.

FOSINOPRIL.

FOSNETUPITANT.

FOSPHENYTOIN.

FOSTEMSAVIR.

FOTEMUSTINE.

FRAMYCETIN.

FULVESTRANT.

FURALTADONE.

# FURAZABOL.

FURAZOLIDONE.

FUROSEMIDE (frusemide).

FUSIDIC ACID.

GABAPENTIN.

GALANTAMINE.

GALANTHUS spp.

GALCANEZUMAB.

GALLAMINE.

GALSULFASE.

GANCICLOVIR.

GANIRELIX.

GATIFLOXACIN.

GRAZOPREVIR.

GEFITINIB.

GEMCITABINE.

GEMEPROST.

GEMFIBROZIL.

GEMIFLOXACIN.

GEMTUZUMAB OZOGAMICIN.

GENTAMICIN.

GESTODENE.

GESTONORONE.

# GESTRINONE.

GHRH INJECTABLE PLASMID.

GILTERITINIB.

GITALIN.

GIVOSIRAN.

GLATIRAMER ACETATE.

GLECAPREVIR.

GLIBENCLAMIDE.

GLIBORNURIDE.

GLICLAZIDE.

GLIMEPIRIDE.

GLIPIZIDE.

GLIPTINS except when separately specified in these Schedules.

GLISOXEPIDE.

GLOFITAMAB.

GLUTATHIONE for parenteral use.

# GLUTETHIMIDE.

GLYCERYL TRINITRATE except when included in Schedule 3.

GLYCOPYRRONIUM in preparations for injection.

GLYMIDINE.

GnRH VACCINE.

GOLIMUMAB.

GONADORELIN.

GONADOTROPHIC HORMONES except when separately specified in this Schedule.

GOSERELIN.

GRAMICIDIN.

GRANISETRON.

GRAPIPRANT.

GREPAFLOXACIN.

GRISEOFULVIN.

# GROWTH HORMONE RELEASING HORMONES* (GHRHs).

# GROWTH HORMONE RELEASING PEPTIDES (GHRPs).

# GROWTH HORMONE RELEASING PEPTIDE6 (GHRP6).

# GROWTH HORMONE SECRETAGOGUES* (GHSs).

GUAIFENESIN for human therapeutic use except:

 (a) when included in Schedule 2; or

 (b) in oral liquid preparations containing 2% or less of guaifenesin; or

 (c) in divided preparations containing 200 mg or less of guaifenesin per dosage unit.

GUANABENZ.

GUANACLINE.

GUANETHIDINE.

GUANFACINE.

GUANIDINE for therapeutic use.

GUSELKUMAB.

HACHIMYCIN.

HAEMATIN.

HAEMOPHILUS INFLUENZAE VACCINE.

HALCINONIDE.

HALOFANTRINE.

HALOFENATE.

HALOFUGINONE in preparations containing 0.1% or less of halofuginone for the treatment of animals.

HALOPERIDOL.

HALOTHANE for therapeutic use.

HEMEROCALLIS (Hemerocallis flava).

HEPARINS for internal use except when separately specified in this Schedule.

HEPATITIS A VACCINE.

HEPATITIS B VACCINE.

HETACILLIN.

HEXACHLOROPHENE:

 (a) in preparations for use on infants; or

 (b) in other preparations except:

 (i) when included in Schedule 2 or 6; or

 (ii) in preparations containing 0.75% or less of hexachlorophene.

HEXAMETHONIUM.

# HEXARELIN.

HEXETIDINE for human internal use.

HEXOBENDINE.

HEXOCYCLIUM.

HEXOPRENALINE.

HEXYL AMINOLEVULINATE (AS HYDROCHLORIDE).

HISTAMINE for therapeutic use except in preparations containing 0.5% or less of histamine.

HMGCoA REDUCTASE INHIBITORS (including "statins") except when separately specified in these Schedules.

HOMATROPINE.

HUMAN CHORIONIC GONADOTROPHIN except in pregnancy test kits.

HUMAN PAPILLOMAVIRUS VACCINE.

HYALURONIC ACID AND ITS POLYMERS in preparations for injection or implantation.

HYDRALAZINE.

HYDRARGAPHEN.

HYDROCHLOROTHIAZIDE.

HYDROCORTISONE:

 (a) for human use except when included in Schedule 2 or 3; or

 (b) for the treatment of animals.

HYDROCYANIC ACID for therapeutic use.

HYDROFLUMETHIAZIDE.

HYDROQUINONE (other than its alkyl ethers separately specified in this Schedule) in preparations for human therapeutic or cosmetic use except:

 (a) when included in Schedule 2; or

 (b) in hair preparations containing 0.3% or less of hydroquinone; or

 (c) in cosmetic nail preparations containing 0.02% or less of hydroquinone.

HYDROXYCARBAMIDE.

# HYDROXYCHLOROQUINE.

HYDROXYEPHEDRINE.

HYDROXYPHENAMATE.

HYDROXYPROGESTERONE.

# HYDROXYSTENOZOL.

HYDROXYZINE.

HYGROMYCIN.

HYOSCINE except when included in Schedule 2.

HYOSCYAMINE except when included in Schedule 2.

HYOSCINE BUTYLBROMIDE except when included in Schedule 2 or Schedule 3.

HYOSCYAMUS NIGER except:

 (a) when included in Schedule 2; or

 (b) in a pack containing 0.03 mg or less of total solanaceous alkaloids.

HYPOTHALAMIC RELEASING FACTORS except when separately specified in this Schedule.

HYPROMELLOSE in preparations for injection.

IBAFLOXACIN for veterinary use.

IBANDRONIC ACID.

IBOGAINE.

IBRITUMOMAB.

IBRUTINIB.

IBUFENAC.

IBUPROFEN except when:

 (a) included in Schedule 2 or 3; or

 (b) in preparations for dermal use; or

 (c) in preparations for oral use that are labelled with a recommended daily dose of 1200 mg or less of ibuprofen in divided preparations, each containing 200 mg or less of ibuprofen, in a pack containing not more than 100 dosage units when:

 (i) ibuprofen is the only therapeutically active constituent, other than phenylephrine or when combined with an effervescent agent; and

 (ii) packed in blister or strip packaging or in a container with a child-resistant closure; and

 (iii) in a primary pack containing not more than 25 dosage units; and

 (iv) compliant with the requirements of the required advisory statements for medicine labels; and

 (v) not labelled for the treatment of children 6 years and under; and

 (vi) if combined with phenylephrine—not labelled for the treatment of children under 12 years.

# IBUTAMOREN.

IBUTEROL.

IBUTILIDE.

ICATIBANT.

IDARUBICIN.

IDARUCIZUMAB.

IDEBENONE.

IDOXURIDINE except in preparations containing 0.5% or less of idoxuridine for dermal use.

IDURSULFASE.

IFOSFAMIDE.

ILOPROST.

IMATINIB.

IMDEVIMAB.

IMEPITOIN.

IMIDAPRIL.

IMIGLUCERASE.

IMIPENEM.

IMIPRAMINE.

IMIQUIMOD.

IMLIFIDASE.

IMMUNOGLOBULINS for human parenteral use except when separately specified in these Schedules.

INCLISIRAN.

INDACATEROL.

INDAPAMIDE.

INDINAVIR.

INDOMETACIN except when included in Schedule 2.

INDOPROFEN.

INDORAMIN.

INFIGRATINIB.

INFLIXIMAB.

INFLUENZA AND CORYZA VACCINES:

 (a) for parenteral use; or

 (b) for nasal administration.

INGENOL MEBUTATE.

INOTUZUMAB OZOGAMICIN.

INSULIN DEGLUDEC.

INSULIN GLARGINE.

# INSULINLIKE GROWTH FACTOR I.

# INSULINLIKE GROWTH FACTORS except when separately specified in this Schedule.

INSULINS.

INTERFERONS.

INTERLEUKINS except when separately specified in these Schedules.

IODOTHIOURACIL.

# IPAMORELIN.

IPILIMUMAB.

IPRATROPIUM except when included in Schedule 2.

IPRIFLAVONE.

IPRINDOLE.

IPRONIAZID.

IRBESARTAN.

IRINOTECAN.

IRON COMPOUNDS in injectable preparations for human use.

ISAVUCONAZOLE.

ISOAMINILE.

ISOAMYL NITRITE.

ISOBUTYL NITRITE.

ISOCARBOXAZID.

ISOCONAZOLE except when included in Schedule 2, 3 or 6.

ISOETARINE.

ISOFLURANE for therapeutic use.

ISOMETHEPTENE.

ISONIAZID.

ISOPRENALINE.

ISOPRINOSINE.

ISOPROPAMIDE except when included in Schedule 2.

ISOSORBIDE DINITRATE except when included in Schedule 3.

ISOSORBIDE MONONITRATE.

# ISOTRETINOIN.

ISOXICAM.

ISOXSUPRINE.

ISRADIPINE.

ITRACONAZOLE.

IVABRADINE.

IVACAFTOR.

IVERMECTIN:

 (a) for human use; or

 (b) for the treatment of mange in dogs.

IVOSIDENIB.

IXABEPILONE.

IXAZOMIB.

IXEKIZUMAB.

JAPANESE ENCEPHALITIS VACCINE.

KANAMYCIN.

KETANSERIN except in topical veterinary preparations containing 0.5% or less of ketanserin.

# KETAZOLAM.

KETOCONAZOLE except:

 (a) when included in Schedule 2; or

 (b) in preparations for dermal use containing 1% or less of ketoconazole for the treatment of the scalp; or

 (c) in preparations for dermal use for the treatment of tinea pedis.

KETOPROFEN except:

 (a) in preparations for dermal use; or

 (b) when included in Schedule 3.

KETOROLAC (includes ketorolac trometamol).

KETOTIFEN except when included in Schedule 2.

KHELLIN.

KITASAMYCIN except:

 (a) when included in Schedule 5; or

 (b) in animal feeds for growth promotion containing 100 mg/kg or less of antibiotic substances.

LABETALOL.

LACIDIPINE.

LACOSAMIDE.

LAMIVUDINE.

LAMOTRIGINE.

LANADELUMAB.

LANATOSIDES.

LANREOTIDE.

LANSOPRAZOLE except when included in Schedule 2 or 3.

LANTHANUM for therapeutic use.

LAPATINIB.

LARONIDASE.

LAROPIPRANT.

LAROTRECTINIB.

LATAMOXEF.

LATANOPROST.

LAUDEXIUM.

LAUROMACROGOLS in preparations for injection except:

 (a) when present as an excipient; or

 (b) when separately specified in these Schedules.

LEAD for human therapeutic use.

LEDIPASVIR.

LEFETAMINE.

LEFLUNOMIDE.

LEMBOREXANT.

LENACAPAVIR.

# LENALIDOMIDE.

LENOGRASTIM.

LENVATINIB.

LEPIRUDIN.

LEPTAZOL.

LERCANIDIPINE.

LESINURAD.

LETERMOVIR.

LETROZOLE.

LEUPRORELIN.

LEVALLORPHAN.

LEVAMISOLE:

 (a) for human therapeutic use; or

 (b) in preparations for the prevention or treatment of heartworm in dogs.

LEVETIRACETAM.

LEVOBUNOLOL.

LEVOBUPIVACAINE.

LEVOCABASTINE except when included in Schedule 2.

LEVOCETIRIZINE except:

 (a) when included in Schedule 2; or

 (b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

 (i) in a primary pack containing not more than 5 days’ supply; and

 (ii) labelled with a recommended daily dose not exceeding 5 mg of levocetirizine.

LEVODOPA.

LEVOMEPROMAZINE.

LEVOMILNACIPRAN.

LEVONORGESTREL except when included in Schedule 3.

LEVOSIMENDAN.

LIDOCAINE except:

 (a) when included in Schedules 2 or 5; or

 (b) in dermal preparations containing 2% or less of total local anaesthetic substances per dosage unit; or

 (c) in lozenges containing 30 mg or less of total anaesthetic substances per dosage unit.

LIDOFLAZINE.

LIFITEGRAST.

LINACLOTIDE.

LINAGLIPTIN.

LINCOMYCIN.

LINDANE for human therapeutic use except when included in Schedule 2.

LINEZOLID.

LIOTHYRONINE.

LIPEGFILGRASTIM.

LIRAGLUTIDE.

LISINOPRIL.

LISURIDE.

LITHIUM for therapeutic use except:

 (a) when included in Schedule 2; or

 (b) when present as an excipient in preparations for dermal use containing 0.25% or less of lithium; or

 (c) in preparations containing 0.01% or less of lithium.

LIXISENATIDE.

LODOXAMIDE except when included in Schedule 2.

LOFEXIDINE.

LOGIPARIN for internal use.

LOMEFLOXACIN.

LOMUSTINE.

LOPERAMIDE except:

 (a) when included in Schedule 2; or

 (b) in divided oral preparations containing 2 mg or less of loperamide per dosage unit, in a primary pack containing 8 dosage units or less.

LOPINAVIR.

# LOPRAZOLAM.

LORACARBEF.

LORATADINE except:

 (a) when included in Schedule 2; or

 (b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 6 years of age and over, when:

 (i) in a primary pack containing 10 dosage units or less; and

 (ii) labelled with a recommended daily dose not exceeding 10 mg of loratadine.

# LORAZEPAM.

LORLATINIB.

# LORMETAZEPAM.

LOSARTAN.

LOTEPREDNOL.

LOXAPINE.

LUMACAFTOR.

LUMEFANTRINE.

LUMIRACOXIB.

LURASIDONE.

LURBINECTEDIN.

LUSPATERCEPT.

# LUTEINISING HORMONE except in ovulation test kits.

LYMECYCLINE.

MACITENTAN for human use.

MAFENIDE except when included in Schedule 6.

MANDRAGORA OFFICINARUM.

MANNOMUSTINE.

MAPROTILINE.

MARAVIROC.

MARBOFLOXACIN.

MAROPITANT.

MAVACAMTEN.

MAVACOXIB.

MAZINDOL.

MEASLES VACCINE.

MEBANAZINE.

MEBEVERINE.

MEBHYDROLIN.

# MEBOLAZINE.

MEBUTAMATE.

MECAMYLAMINE.

MECASERMIN.

MECILLINAM.

MECLOCYCLINE.

MECLOFENAMATE.

MECLOFENOXATE.

MECLOZINE except when included in Schedule 2.

# MEDAZEPAM.

MEDETOMIDINE.

MEDIGOXIN (methyldigoxin).

MEDROXYPROGESTERONE.

MEDRYSONE.

MEFENAMIC ACID except when included in Schedule 2.

MEFENOREX.

MEFLOQUINE.

MEFRUSIDE.

MEGESTROL.

MELAGATRAN.

MELANOTAN II.

MELATONIN for human use except when included in Schedule 3.

MELENGESTROL except when included in Schedule 6.

MELOXICAM except when included in Schedule 6.

MELPHALAN.

MEMANTINE.

MENINGOCOCCAL VACCINE.

MENINGOCOCCAL GROUP B VACCINE.

MENOTROPHIN.

MEPACRINE.

MEPENZOLATE.

MEPHENESIN.

MEPHENTERMINE.

MEPINDOLOL.

# MEPITIOSTANE.

MEPIVACAINE.

MEPROBAMATE.

MEPTAZINOL.

MEPYRAMINE except when included in Schedule 2 or 3.

MEQUITAZINE.

MERCAPTAMINE for human therapeutic use.

MERCAPTOMERIN.

MERCAPTOPURINE.

MERCUROCHROME except when included in Schedule 2 or 6.

MERCURY for cosmetic or therapeutic use except:

 (a) when separately specified in these Schedules; or

 (b) in a sealed device which prevents access to the mercury.

MEROPENEM.

MERSALYL.

# MESABOLONE.

MESALAZINE.

MESNA.

# MESTANOLONE (androstalone).

# MESTEROLONE.

MESTRANOL.

# METANDIENONE.

METARAMINOL.

# METENOLONE.

METERGOLINE.

METFORMIN.

METHACHOLINE.

METHACYCLINE.

METHALLENESTRIL.

# METHANDRIOL.

METHANTHELINIUM.

METHAZOLAMIDE.

METHDILAZINE except when included in Schedule 3.

# METHENOLONE.

METHICILLIN.

METHIMAZOLE.

METHISAZONE.

METHIXENE.

METHOCARBAMOL.

METHOHEXITONE.

METHOIN.

METHOTREXATE.

METHOXAMINE except:

 (a) when included in Schedule 2; or

 (b) in preparations for external use containing 1% or less of methoxamine.

METHOXSALEN.

METHOXYFLURANE.

METHSUXIMIDE.

METHYCLOTHIAZIDE.

METHYL AMINOLEVULINATE.

#METHYLANDROSTANOLONE.

# METHYLCLOSTEBOL.

METHYLDOPA.

METHYLENE BLUE in preparations for injection.

METHYLERGOMETRINE.

METHYLMERCURY for therapeutic use.

METHYLNALTREXONE.

METHYLPENTYNOL.

METHYLPHENOBARBITAL.

METHYLPHENYLPIRACETAM.

METHYLPREDNISOLONE.

METHYLROSANILINIUM CHLORIDE for human use except when used as a dermal marker.

METHYL SALICYLATE in preparations for internal therapeutic use.

# METHYLTESTOSTERONE.

METHYLTHIOURACIL.

# METHYLTRIENOLONE.

METHYPRYLONE.

METHYSERGIDE.

METOCLOPRAMIDE except when included in Schedule 3.

METOLAZONE.

METOPROLOL.

# METRIBOLONE.

METRIFONATE (trichlorfon) for human therapeutic use.

METRONIDAZOLE.

METYRAPONE.

MEXILETINE.

MEZLOCILLIN.

MIANSERIN.

MIBEFRADIL.

# MIBOLERONE.

MICAFUNGIN.

MICONAZOLE except:

 (a) when included in Schedule 2, 3 or 6; or

 (b) in preparations for dermal use for the treatment of tinea pedis.

# MIDAZOLAM.

MIDOSTAURIN.

MIDODRINE.

MIFEPRISTONE.

MIGALASTAT.

MIGLITOL.

MIGLUSTAT.

MILBEMYCIN OXIME except when included in Schedule 5.

MILNACIPRAN.

MILRINONE.

MINOCYCLINE.

MINOXIDIL except when included in Schedule 2.

MIRABEGRON.

MIRIKIZUMAB.

MIRTAZAPINE.

MISOPROSTOL.

MITOBRONITOL.

MITOMYCIN.

MITOTANE.

MITOXANTRONE.

MITRATAPIDE.

MIVACURIUM CHLORIDE.

MOBOCERTINIB.

MOCLOBEMIDE.

MODAFINIL.

MOLGRAMOSTIM.

MOLINDONE.

MOLNUPIRAVIR.

MOMETASONE except when included in Schedule 2 or Schedule 3.

MONENSIN except:

 (a) when included in Schedule 5 or 6; or

 (b) in animal feeds containing 360 mg/kg or less of antibiotic substances.

MONOBENZONE and alkyl ethers of hydroquinone for human therapeutic use or cosmetic use except in cosmetic nail preparations containing 0.02% or less of monobenzone or alkyl ethers of hydroquinone.

MONOCLONAL ANTIBODIES for therapeutic use except:

 (a) in diagnostic test kits; or

 (b) when separately specified in these Schedules.

MONOETHANOLAMINE in preparations for injection.

MONTELUKAST.

MOPERONE.

MORAZONE.

MORICIZINE.

MOTRAZEPAM.

MOTRETINIDE.

MOXIDECTIN in preparations for injection containing 10% or less of moxidectin except when included in Schedule 5 or 6.

MOXIFLOXACIN.

MOXONIDINE.

MUMPS VACCINE.

MUPIROCIN.

MURAGLITAZAR.

MUROMONAB.

MUSTINE (nitrogen mustard).

MYCOPHENOLIC ACID (includes mycophenolate mofetil).

NABUMETONE.

NADOLOL.

NADROPARIN.

NAFARELIN.

NAFTIDROFURYL.

NALBUPHINE.

NALIDIXIC ACID.

NALMEFENE.

NALORPHINE.

NALOXEGOL.

NALOXONE except when in Schedule 3.

NALTREXONE.

# NANDROLONE.

NAPROXEN except when included in Schedule 2 or 3.

NARASIN except:

 (a) when included in Schedule 6; or

 (b) in animal feeds containing 100 mg/kg or less of antibiotic substances.

NARATRIPTAN.

NATALIZUMAB.

NATAMYCIN except for use as a food additive.

NATEGLINIDE.

NEBACUMAB.

NEBIVOLOL.

NEBRACETAM.

NEDOCROMIL.

NEFAZODONE.

NEFIRACETAM.

NEFOPAM.

NELFINAVIR (includes nelfinavir mesilate).

NEOMYCIN.

NEOSTIGMINE.

NEPAFENAC.

NERATINIB.

NERIUM OLEANDER.

NESIRITIDE.

NETILMICIN.

NETUPITANT.

NEVIRAPINE.

NIALAMIDE.

NICARDIPINE.

NICERGOLINE.

NICOFURANOSE.

NICORANDIL.

# NICOTINE in preparations for human use except:

 (a) in preparations for oromucosal or transdermal administration for human therapeutic use as an aid in withdrawal from tobacco smoking; or

 (b) in tobacco prepared and packed for smoking.

NICOTINIC ACID for human therapeutic use except:

 (a) when separately specified in these Schedules; or

 (b) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or

 (c) nicotinamide.

NICOUMALONE.

NIFEDIPINE.

NIFENAZONE.

NIKETHAMIDE.

NILOTINIB.

NILUTAMIDE.

NIMESULIDE.

NIMODIPINE.

NIMORAZOLE.

NINTEDANIB.

NIRAPARIB.

NIRIDAZOLE.

NIRMATRELVIR.

NISOLDIPINE.

NITISINONE.

# NITRAZEPAM.

NITRENDIPINE.

NITRIC OXIDE for human therapeutic use.

NITROFURANTOIN.

NITROFURAZONE.

NITROUS OXIDE for therapeutic use.

NITROXOLINE.

NIVOLUMAB.

NIZATIDINE except when included in Schedule 2.

NOMEGESTROL.

NOMIFENSINE.

NORADRENALINE.

# 19NORANDROSTENEDIOL.

# 19NORANDROSTENEDIONE.

# NORANDROSTENOLONE.

# NORBOLETHONE.

# NORCLOSTEBOL.

NORELGESTROMIN.

# NORETHANDROLONE.

NORETHISTERONE.

NORFLOXACIN.

NORGESTREL.

NORIBOGAINE.

NORMAL HUMAN IMMUNOGLOBULIN.

# NORMETHANDRONE.

NORTRIPTYLINE.

NOVOBIOCIN.

NOXIPTYLINE.

NUSINERSEN.

NYSTATIN except when included in Schedule 2 or 3.

OBETICHOLIC ACID.

OCLACITINIB.

OCRELIZUMAB.

OCRIPLASMIN.

OCTAMYLAMINE.

OCTATROPINE.

OCTREOTIDE.

OCTYL NITRITE.

OFATUMUMAB.

OFLOXACIN.

OLANZAPINE.

OLAPARIB.

OLARATUMAB.

OLEANDOMYCIN except:

 (a) when included in Schedule 5; or

 (b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.

OLEANDRIN.

OLIPUDASE ALFA.

OLMESARTAN.

OLODATEROL.

OLOPATADINE.

OLSALAZINE.

OMALIZUMAB.

OMBERACETAM.

OMBITASVIR.

OMEGA3ACID ETHYL ESTERS (excluding salts and derivatives) for human therapeutic use, for the treatment of postmyocardial infarction and/or hypertriglyceridaemia.

OMEPRAZOLE except when included in Schedule 2 or 3.

ONASEMNOGENE ABEPARVOVEC.

ONDANSETRON.

OPICAPONE.

OPIPRAMOL.

ORBIFLOXACIN.

ORCIPRENALINE.

ORGANOPHOSPHORUS COMPOUNDS with anticholinesterase activity for human therapeutic use except:

 (a) when separately specified in these Schedules; or

 (b) in preparations containing 2% or less of malathion for external use.

ORLISTAT except when included in Schedule 3.

ORNIDAZOLE.

ORNIPRESSIN.

ORPHENADRINE.

ORTHOPTERIN.

OSELTAMIVIR.

OSILODROSTAT.

OSIMERTINIB.

OUABAIN.

# OVANDROTONE.

# OXABOLONE.

OXACILLIN.

OXALIPLATIN.

# OXANDROLONE.

OXAPROZIN.

# OXAZEPAM.

OXCARBAZEPINE.

OXEDRINE for human internal use except in preparations labelled with a recommended daily dose of 30 mg or less of oxedrine.

OXETACAINE (oxethazaine) except when included in Schedule 2.

OXICONAZOLE except:

 (a) when included in Schedule 2 or 3; or

 (b) in preparations for the treatment of tinea pedis.

OXIRACETAM.

OXITROPIUM.

OXOLAMINE.

OXOLINIC ACID.

OXPRENOLOL.

OXYBUPROCAINE.

OXYBUTYNIN.

# OXYMESTERONE.

# OXYMETHOLONE.

OXYPHENBUTAZONE.

OXYPHENCYCLIMINE.

OXYPHENONIUM.

OXYTETRACYCLINE except when included in Schedule 5.

OXYTOCIN.

OZANIMOD.

PACLITAXEL.

PALBOCICLIB.

PALIFERMIN.

PALIPERIDONE.

PALIVIZUMAB.

PALONOSETRON.

PAMAQUIN.

PAMIDRONIC ACID (includes pamidronate disodium).

PANCREATIC ENZYMES except:

 (a) in preparations containing 20,000 BP units or less of lipase activity per dosage unit; or

 (b) when separately specified in these Schedules.

PANCURONIUM.

PANITUMUMAB.

PANOBINOSTAT.

PANTOPRAZOLE except when included in Schedule 2 or 3.

PAPAVERINE in preparations for injection.

PARACETAMOL:

 (a) when combined with aspirin or salicylamide or any derivative of these substances except when separately specified in these Schedules; or

 (b) when combined with ibuprofen in a primary pack containing more than 30 dosage units; or

 (c) in modified release tablets or capsules containing more than 665 mg paracetamol; or

 (d) in nonmodified release tablets or capsules containing more than 500 mg paracetamol; or

 (e) in individually wrapped powders or sachets of granules each containing more than 1000 mg paracetamol; or

 (f) in tablets or capsules enclosed in a primary pack containing more than 100 tablets or capsules except in Schedule 2 or Schedule 3; or

 (g) in individually wrapped powders or sachets of granules enclosed in a primary pack containing more than 50 wrapped powders or sachets of granules except when included in Schedule 2; or

 (h) for injection; or

 (i) for the treatment of animals.

PARALDEHYDE.

PARAMETHADIONE.

PARAMETHASONE.

PARECOXIB.

PARICALCITOL.

PARITAPREVIR.

PAROMOMYCIN.

PAROXETINE.

PASIREOTIDE.

PATIROMER SORBITEX CALCIUM.

PATISIRAN.

PAZOPANIB.

PECAZINE.

PEFLOXACIN.

PEGAPTANIB.

PEGASPARGASE.

PEGCETACOPLAN.

PEGFILGRASTIM.

PEGINTERFERON.

PEGVALIASE.

PEGVISOMANT.

PEMBROLIZUMAB.

PEMETREXED.

PEMIGATINIB.

PEMOLINE.

PEMPIDINE.

PENBUTOLOL.

PENCICLOVIR except in preparations containing 1% or less of penciclovir for the treatment of herpes labialis in packs containing 10 g or less.

PENETHAMATE.

PENICILLAMINE.

PENTAERYTHRITYL TETRANITRATE.

PENTAGASTRIN.

PENTAMETHONIUM.

PENTAMIDINE (includes pentamidine isetionate).

PENTHIENATE.

# PENTOBARBITAL when packed and labelled for injection.

PENTOLINIUM.

PENTOSAN POLYSULFATE SODIUM.

PENTOXIFYLLINE.

PERAMIVIR.

# PERAMPANEL.

PERGOLIDE.

PERHEXILINE.

PERICIAZINE.

PERINDOPRIL.

PERMETHRIN for human therapeutic use except in preparations containing 5% or less of permethrin.

PERPHENAZINE.

PERTUSSIS ANTIGEN.

PERTUZUMAB.

PHENACEMIDE.

PHENACETIN for therapeutic use (excluding when present as an excipient).

PHENAGLYCODOL.

PHENAZONE except when included in Schedule 2 or 5.

PHENAZOPYRIDINE.

PHENELZINE.

PHENETICILLIN.

PHENFORMIN.

PHENGLUTARIMIDE.

PHENINDIONE.

PHENIRAMINE except when included in Schedule 2 or 3.

PHENISATIN.

PHENOBARBITAL.

PHENOL in preparations for injection.

PHENOLPHTHALEIN for human therapeutic use.

PHENOXYBENZAMINE.

PHENOXYMETHYLPENICILLIN.

PHENSUXIMIDE.

# PHENTERMINE.

PHENTHIMENTONIUM.

PHENTOLAMINE.

PHENYLBUTAZONE.

PHENYLEPHRINE:

 (a) in preparations for injection; or

 (b) in preparations for human ophthalmic use containing 5% or more of phenylephrine.

PHENYLPIRACETAM.

PHENYLPROPANOLAMINE.

PHENYLTOLOXAMINE.

PHENYTOIN.

PHLEUM PRATENSE POLLEN EXTRACT (Timothygrass pollen extract).

PHOLCODINE:

 (a) in divided preparations containing 100 mg or less of pholcodine per dosage unit; or

 (b) in undivided preparations containing 2.5% or less of pholcodine;

except when included in Schedule 2.

PHOSPHODIESTERASE TYPE 5 INHIBITORS except:

 (a) when separately specified in these Schedules; or

 (b) when present as an unmodified, naturally occurring substance.

PHTHALYLSULFATHIAZOLE.

PHYSOSTIGMINE.

PIBRENTASVIR.

PICROTOXIN.

PILOCARPINE except in preparations containing 0.025% or less of pilocarpine.

PIMECROLIMUS.

PIMOBENDAN.

PIMOZIDE.

PINACIDIL.

PINDOLOL.

PIOGLITAZONE.

PIPECURONIUM.

PIPEMIDIC ACID.

PIPENZOLATE.

PIPER METHYSTICUM (kava) in preparations for human use except when included on the Register in preparations:

 (a) for oral use when present in tablet, capsule or teabag form that is labelled with a recommended maximum daily dose of 250 mg or less of kavalactones and:

 (i) the tablet or capsule form contains 125 mg or less of kavalactones per tablet or capsule; or

 (ii) the amount of dried whole or peeled rhizome and/or root in the teabag does not exceed 3 g;

  and, where containing more than 25 mg of kavalactones per dose, compliant with the requirements of the required advisory statements for medicine labels; or

 (b) in topical preparations for use on the rectum, vagina or throat containing dried whole or peeled rhizome and/or root or containing aqueous dispersions or aqueous extracts of whole or peeled rhizome and/or root; or

 (c) in dermal preparations.

PIPERACILLIN.

PIPERIDINE.

PIPERIDOLATE.

PIPOBROMAN.

PIPOTHIAZINE.

PIPRADROL.

PIRACETAM.

PIRBUTEROL.

PIRENOXINE (catalin).

PIRENZEPINE.

PIRETANIDE.

PIRFENIDONE.

PIROXICAM except in preparations for dermal use.

PIRPROFEN.

PITAVASTATIN.

PITUITARY HORMONES except when separately specified in these Schedules.

PIVAMPICILLIN.

PIZOTIFEN.

PLICAMYCIN.

PLITIDEPSIN.

PLERIXAFOR.

PNEUMOCOCCAL VACCINE.

PODOPHYLLOTOXIN for human use:

 (a) internally; or

 (b) in preparations for the treatment of anogenital warts; or

 (c) in other preparations except when included in Schedule 2 or 3.

PODOPHYLLUM EMODI (podophyllin) for human use:

 (a) internally; or

 (b) in preparations for the treatment of anogenital warts; or

 (c) in other preparations except when included in Schedule 2 or 3.

PODOPHYLLUM PELTATUM (podophyllin) for human use:

 (a) internally; or

 (b) in preparations for the treatment of anogenital warts; or

 (c) in other preparations except when included in Schedule 2 or 3.

POLIDEXIDE.

POLIOMYELITIS VACCINE.

POLYACRYLAMIDE in preparations for injection or implantation:

 (a) for tissue augmentation; or

 (b) for cosmetic use; or

 (c) for veterinary use.

POLYCAPROLACTONE in preparations for injection or implantation:

 (a) for tissue augmentation; or

 (b) for cosmetic use.

POLYESTRADIOL.

POLYLACTIC ACID in preparations for injection or implantation:

 (a) for tissue augmentation; or

 (b) for cosmetic use.

POLYMYXIN.

POLYSULFATED GLYCOSAMINOGLYCANS in preparations for injection, except when separately specified in these Schedules.

POLYTHIAZIDE.

POMALIDOMIDE.

PONATINIB.

PONESIMOD.

PORACTANT.

POSACONAZOLE.

POTASSIUM BROMIDE for therapeutic use.

POTASSIUM CHLORIDE in oral preparations for human therapeutic use except:

 (a) when containing less than 550 mg of potassium chloride per dosage unit; or

 (b) in preparations for oral rehydration therapy; or

 (c) in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures; or

 (d) in preparations for enteral feeding.

POTASSIUM PERCHLORATE for therapeutic use.

PRACTOLOL.

PRADOFLOXACIN.

PRALATREXATE.

PRALIDOXIME.

PRAMIPEXOLE.

PRAMIRACETAM.

PRAMOCAINE.

# PRALMORELIN (GROWTH HORMONE RELEASING PEPTIDE2 (GHRP2)).

PRALSETINIB.

PRAMPINE.

# PRASTERONE (dehydroepiandrosterone, dehydroisoandrosterone).

PRASUGREL.

PRAVASTATIN.

# PRAZEPAM.

PRAZIQUANTEL for human therapeutic use.

PRAZOSIN.

PREDNISOLONE.

PREDNISONE.

PREGABALIN.

PREGNENOLONE.

PRENALTEROL.

PRENYLAMINE.

PRILOCAINE except when included in Schedule 2.

PRIMAQUINE.

PRIMIDONE.

PROBENECID.

PROBUCOL.

PROCAINAMIDE.

PROCAINE.

PROCAINE BENZYLPENICILLIN.

PROCARBAZINE.

PROCHLORPERAZINE except when included in Schedule 3.

PROCYCLIDINE except when included in Schedule 2.

PROGESTERONE except when included in Schedule 5.

PROGESTOGENS except when separately specified in these Schedules.

PROGLUMIDE.

PROGUANIL.

PROLINTANE.

PROMAZINE.

PROMETHAZINE except when included in Schedule 2 or 3.

PROMOXOLANE.

PROPAFENONE.

PROPAMIDINE for therapeutic use except when included in Schedule 2.

PROPANIDID.

PROPANTHELINE.

PROPENTOFYLLINE.

# PROPETANDROL.

PROPIONIBACTERIUM ACNES for therapeutic use.

PROPOFOL.

PROPRANOLOL.

PROPYLHEXEDRINE.

PROPYLTHIOURACIL.

PROPYPHENAZONE.

PROQUAZONE.

PROSCILLARIDIN.

PROSTAGLANDINS except when separately specified in this Schedule.

PROSTIANOL.

PROTAMINE.

PROTHIONAMIDE.

PROTHIPENDYL.

PROTIRELIN.

PROTOVERATRINES.

PROTRIPTYLINE.

PROXYMETACAINE.

PRUCALOPRIDE.

PSEUDOEPHEDRINE except when included in Schedule 3.

PYRAZINAMIDE.

PYRIDINOLCARBAMATE.

PYRIDOSTIGMINE.

PYRIDOXINE, PYRIDOXAL OR PYRIDOXAMINE for human therapeutic use except:

 (a) in oral preparations containing 200 mg or less but more than 50 mg of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose when compliant with the requirements of the required advisory statements for medicine labels; or

 (b) in oral preparations containing 50 mg or less of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose.

PYRIMETHAMINE.

PYROVALERONE.

PYRVINIUM.

# QUAZEPAM.

QUETIAPINE.

QUINAGOLIDE.

QUINAPRIL.

# QUINBOLONE.

QUINETHAZONE.

QUINIDINE.

QUININE for human therapeutic use except when the maximum recommended daily dose is 50 mg or less of quinine.

QUINISOCAINE (dimethisoquin).

QUINUPRISTIN.

RABEPRAZOLE except when included in Schedule 2 or 3.

RABIES VACCINE.

RACETAMS except when separately specified in these Schedules.

RACTOPAMINE except when included in Schedule 5.

RALOXIFENE.

RALTEGRAVIR.

RALTITREXED.

RAMIPRIL.

RAMUCIRUMAB.

RANIBIZUMAB.

RANITIDINE except:

 (a) when included in Schedule 2; or

 (b) in divided preparations for oral use containing 150mg or less of ranitidine per dosage unit when supplied in the manufacturer’s original pack containing not more than 14 dosage units; or

 (c) in divided preparations for oral use containing 300mg or less of ranitidine per dosage unit in the manufacturer’s original pack containing not more than 7 dosage units.

RANOLAZINE.

RAPACURONIUM.

RASAGILINE.

RASBURICASE.

RAUWOLFIA SERPENTINA.

RAUWOLFIA VOMITORIA.

RAZOXANE.

REBOXETINE.

RED YEAST RICE for human therapeutic use.

REMDESIVIR.

REGDANVIMAB.

REGORAFENIB.

REMOXIPRIDE.

REPAGLINIDE.

RESERPINE.

RESLIZUMAB.

RETAPAMULIN.

RETEPLASE.

RETIGABINE.

RIBAVIRIN.

RIBOCICLIB.

RIDAFOROLIMUS.

RIFABUTIN.

RIFAMPICIN.

RIFAMYCIN.

RIFAPENTINE.

RIFAXIMIN.

RILPIVIRINE.

RILUZOLE.

RIMEGEPANT.

RIMEXOLONE.

RIMITEROL.

RIMONABANT.

# RIOCIGUAT.

RIPRETINIB.

RISANKIZUMAB.

RISDIPLAM.

RISEDRONIC ACID.

RISPERIDONE.

RITODRINE.

RITONAVIR.

RITUXIMAB.

RIVAROXABAN.

RIVASTIGMINE.

RIZATRIPTAN except when included in Schedule 3.

ROBENACOXIB.

ROCURONIUM.

ROFECOXIB.

ROFLUMILAST.

ROLITETRACYCLINE.

ROLZIRACETAM.

ROMIDEPSIN.

ROMIFIDINE.

ROMIPLOSTIM.

ROMOSOZUMAB.

RONIDAZOLE.

ROPINIROLE.

ROPIVACAINE.

ROSIGLITAZONE.

ROSOXACIN.

ROSUVASTATIN.

ROTIGOTINE.

# ROXIBOLONE.

ROXITHROMYCIN.

RUBELLA VACCINE.

RUBOXISTAURIN.

RUFINAMIDE.

RUPATADINE.

RUXOLITINIB.

SACITUZUMAB GOVITECAN.

SACUBITRIL.

SAFINAMIDE.

SALBUTAMOL except when included in Schedule 3.

SALICYLAMIDE when combined with aspirin, caffeine or paracetamol or any derivative of these substances.

SALINOMYCIN except:

 (a) when included in Schedule 6; or

 (b) in animal feeds containing 60 mg/kg or less of antibiotic substances.

SALMETEROL.

SAPROPTERIN.

SAQUINAVIR.

SARILUMAB.

SARSCOV2 (COVID19) VACCINE.

SAXAGLIPTIN.

SCHOENOCAULON OFFICINALE (sabadilla) except in preparations containing 10 mg/kg or 10 mg/L or less of total alkaloids of Schoenocaulon officinale.

SCOPOLIA CARNIOLICA for therapeutic use.

SEBELIPASE ALFA.

SECUKINUMAB.

# SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM).

SELEGILINE.

SELENIUM:

 (a) for human oral use with a recommended daily dose of more than 300 micrograms; or

 (b) for the treatment of animals except:

 (i) when included in Schedule 6 or 7; or

 (ii) in solid, slow release bolus preparations containing 300 mg or less of selenium per dosage unit; or

 (iii) in other divided preparations containing 30 micrograms or less of selenium per dosage unit; or

 (iv) as elemental selenium, in pellets containing 100 g/kg or less of selenium; or

 (v) in feeds containing 1 g/tonne or less of selenium.

SELETRACETAM.

SELEXIPAG.

SELINEXOR.

SELPERCATINIB.

SELUMETINIB.

SEMAGLUTIDE.

SERELAXIN.

SERMORELIN.

SERTINDOLE.

SERTRALINE.

SEVELAMER.

SEVOFLURANE.

SEX HORMONES and all substances having sex hormonal activity except when separately specified in these Schedules.

SIBUTRAMINE.

# SILANDRONE.

SILDENAFIL.

SILICONES for intraocular use.

SILODOSIN.

SILTUXIMAB.

SILVER SULFADIAZINE.

SIMEPREVIR.

SIMVASTATIN.

SIPONIMOD.

SIROLIMUS.

SISOMICIN (sisomycin).

SITAGLIPTIN.

# SITAXENTAN.

SODIUM BROMIDE for therapeutic use.

SODIUM CELLULOSE PHOSPHATE for human internal use.

SODIUM CROMOGLYCATE except when included in Schedule 2.

SODIUM GLYCEROPHOSPHATE HYDRATE.

SODIUM MORRHUATE in preparations for injection.

SODIUM NITROPRUSSIDE for human therapeutic use.

SODIUM PHENYLBUTYRATE.

SODIUM PHOSPHATE in preparations for oral laxative use.

SODIUM POLYSTYRENE SULPHONATE for human therapeutic use.

SODIUM SALICYLATE in preparations for internal use for the treatment of animals.

SODIUM TETRADECYLSULFATE in preparations for injection.

SODIUM ZIRCONIUM CYCLOSILICATE.

SOFOSBUVIR.

SOLASODINE.

SOLIFENACIN.

SOMAPACITAN.

SOMATOSTATIN.

SOMATOTROPIN EQUINE.

# SOMATROPIN (human growth hormone).

SONIDEGIB.

SONTOQUINE.

SORAFENIB.

SOTALOL.

SOTORASIB.

SOTROVIMAB.

SPARFLOXACIN.

SPARTEINE.

SPECTINOMYCIN.

SPESOLIMAB.

SPIRAMYCIN.

SPIRAPRIL.

SPIRONOLACTONE.

# STANOLONE.

# STANOZOLOL.

STAVUDINE.

# STENABOLIC (SR9009) and other synthetic REVERB agonists.

# STENBOLONE.

STEROID HORMONES except when separately specified in these Schedules.

STILBESTROL (diethylstilbestrol).

STIRIPENTOL.

STREPTODORNASE.

STREPTOKINASE.

STREPTOMYCIN.

STRONTIUM RANELATE.

STROPHANTHINS.

STROPHANTHUS spp.

STRYCHNINE in preparations containing 1.5% or less of strychnine for the treatment of animals.

STRYCHNOS spp. except in preparations containing 1 mg or less per litre or per kilogram of strychnine.

STYRAMATE.

SUCCIMER.

SUCROFERRIC OXYHYDROXIDE.

SUGAMMADEX.

SULBACTAM.

SULCONAZOLE except when included in Schedule 2.

SULFACETAMIDE except when included in Schedule 3 or 5.

SULFADIAZINE except when included in Schedule 5.

SULFADIMETHOXINE.

SULFADIMIDINE except when included in Schedule 5.

SULFADOXINE.

SULFAFURAZOLE.

SULFAGUANIDINE.

SULFAMERAZINE except when included in Schedule 5.

SULFAMETHIZOLE.

SULFAMETHOXAZOLE.

SULFAMETHOXYDIAZINE.

SULFAMETHOXYPYRIDAZINE.

SULFAMETROLE.

SULFAMONOMETHOXINE.

SULFAMOXOLE.

SULFAPHENAZOLE.

SULFAPYRIDINE.

SULFAQUINOXALINE.

SULFASALAZINE.

SULFATHIAZOLE except when included in Schedule 5.

SULFATROXAZOLE.

SULFINPYRAZONE.

SULFOMYXIN.

SULFONAMIDES except:

 (a) when separately specified in this Schedule; or

 (b) when included in Schedule 3, 5 or 6; or

 (c) when packed and labelled solely for use as a herbicide.

SULFONMETHANE (sulfonal) and alkyl sulfonals.

SULINDAC.

SULTAMICILLIN.

SULTHIAME.

SUMATRIPTAN except when included in Schedule 3.

SUNIFIRAM.

SUNITINIB.

SUPROFEN.

SUTILAINS.

SUXAMETHONIUM.

SUXETHONIUM.

SUVOREXANT.

TACRINE.

TACROLIMUS.

TADALAFIL.

TAFAMIDIS.

TAFASITAMAB.

TAFENOQUINE SUCCINATE.

TAFLUPROST.

TAGRAXOFUSP.

TALAZOPARIB.

TALIGLUCERASE ALFA.

TALIMOGENE LAHERPAREPVEC.

TAMOXIFEN.

TAMSULOSIN.

TANACETUM VULGARE except in preparations containing 0.8% or less of oil of tansy.

TASONERMIN.

TAZAROTENE.

TAZOBACTAM.

# TB500.

TCELL RECEPTOR ANTIBODY.

TECLISTAMAB.

TEDUGLUTIDE.

TEGAFUR.

TEGASEROD.

TELAPREVIR.

TELITHROMYCIN.

TEICOPLANIN.

TELBIVUDINE.

TELMISARTAN.

TELOTRISTAT ETHYL.

# TEMAZEPAM.

TEMOZOLOMIDE.

TEMSIROLIMUS.

TENECTEPLASE.

TENIPOSIDE.

TENOFOVIR.

TENOXICAM.

TEPOTINIB.

TEPOXALIN.

TERAZOSIN.

TERBINAFINE except:

 (a) when included in Schedule 2; or

 (b) in preparations for dermal use for the treatment of tinea pedis.

TERBUTALINE except when included in Schedule 3.

TERFENADINE.

TERIFLUNOMIDE.

# TERIPARATIDE.

TERLIPRESSIN.

TERODILINE.

TEROPTERIN.

# TESTOLACTONE.

# TESTOSTERONE except when included in Schedule 6.

TETANUS ANTITOXIN except when used for shortterm protection or treatment of tetanus in animals.

TETANUS TOXOID for human use.

TETRABENAZINE.

TETRACAINE except:

 (a) when included in Schedule 2; or

 (b) in dermal preparations containing 2% or less of total local anaesthetic substances.

TETRACOSACTIDE.

TETRACYCLINE except when included in Schedule 5.

TETRAETHYLAMMONIUM.

TETROXOPRIM.

TEZACAFTOR.

# THALIDOMIDE.

THENYLDIAMINE.

THEOPHYLLINE except when included in Schedule 3.

THEVETIA PERUVIANA.

THEVETIN.

THIACETARSAMIDE in preparations for the prevention or treatment of heartworm in dogs.

THIAMBUTOSINE.

THIAZOSULFONE.

THIETHYLPERAZINE.

THIOACETAZONE.

THIOCARLIDE.

# THIOMESTERONE (tiomesterone).

THIOPENTAL.

THIOPROPAZATE.

THIOPROPERAZINE.

THIORIDAZINE.

THIOSTREPTON.

THIOTEPA.

THIOTHIXENE.

THIOURACIL.

THIOUREA for therapeutic use except in preparations containing 0.1% or less of thiourea.

# THYMOSIN BETA 4 (THYMOSIN β4).

THYMOXAMINE (includes thymoxamine hydrochloride).

THYROID except when separately specified in this Schedule.

THYROTROPHIN.

THYROXINE (includes thyroxine sodium).

TIAGABINE.

TIAMULIN.

# TIANEPTINE.

TIAPROFENIC ACID.

TIARAMIDE.

TIBOLONE.

TICAGRELOR.

TICARCILLIN.

TICLOPIDINE.

TIEMONIUM.

TIENILIC ACID.

TIGECYCLINE.

TIGILANOL TIGLATE.

TIGLOIDINE.

TILDIPIROSIN.

TILETAMINE.

TILMANOCEPT.

TILMICOSIN.

TILUDRONIC ACID (includes disodium tiludronate).

TIMOLOL.

TINIDAZOLE.

TINZAPARIN (includes tinzaparin sodium).

TIOCONAZOLE except:

 (a) when included in Schedule 2 or 3; or

 (b) in preparations for dermal use for the treatment of tinea pedis.

TIOGUANINE.

TIOTROPIUM.

TIPEPIDINE.

TIPIRACIL.

TIPRANAVIR.

TIRBANIBULIN.

TIRILAZAD.

TIROFIBAN.

TIRZEPATIDE.

TIXAGEVIMAB.

TOBRAMYCIN.

TOCAINIDE.

TOCERANIB.

TOCILIZUMAB.

TOFACITINIB.

TOLAZAMIDE.

TOLAZOLINE.

TOLBUTAMIDE.

TOLCAPONE.

TOLFENAMIC ACID.

TOLMETIN.

TOLONIUM.

TOLPROPAMINE.

TOLRESTAT.

TOLTERODINE.

TOLVAPTAN.

TOPIRAMATE.

TOPOTECAN.

TORASEMIDE.

TOREMIFENE.

TOXOIDS for human parenteral use except when separately specified in these Schedules.

TRABECTEDIN.

TRAMADOL.

TRANDOLAPRIL.

TRAMETINIB DIMETHYL SULFOXIDE.

TRANEXAMIC ACID except in preparations containing 3% or less of cetyl tranexamate hydrochloride for dermal cosmetic use.

TRANYLCYPROMINE.

TRASTUZUMAB.

TRASTUZUMAB DERUXTECAN.

TRASTUZUMAB EMTANSINE.

TRAVOPROST.

TRAZODONE.

# TRENBOLONE (trienbolone, trienolone) except when included in Schedule 5.

TREOSULPHAN.

TREPROSTINIL.

# TRESTOLONE.

TRETAMINE.

# TRETINOIN except the ester hydroxypinacolone retinoate in preparations for dermal use containing 0.5% or less of hydroxypinacolone retinoate.

TRIACETYLOLEANDOMYCIN.

TRIAMCINOLONE except when included in Schedule 2 or 3.

TRIAMTERENE.

TRIAZIQUONE.

# TRIAZOLAM.

TRICHLORMETHIAZIDE.

TRICHLOROACETIC ACID for human dermal use except when in preparations containing 12.5% or less of trichloroacetic acid for the treatment of warts other than anogenital warts.

TRICHLOROETHYLENE for therapeutic use.

TRICLOFOS.

TRICYCLAMOL.

TRIDIHEXETHYL.

TRIENTINE.

TRIFAROTENE.

TRIFLUOPERAZINE.

TRIFLUPERIDOL.

TRIFLUPROMAZINE.

TRIFLURIDINE.

TRIHEXYPHENIDYL.

TRILOSTANE.

TRIMETAPHAN.

TRIMETHOPRIM.

TRIMIPRAMINE.

TRIMUSTINE.

TRINITROPHENOL (excluding its derivatives) in preparations for human therapeutic use.

TRIOXYSALEN.

TRIPELENNAMINE.

TRIPROLIDINE except when included in Schedule 2 or 3.

TRIPTORELIN.

TROGLITAZONE.

TROLAMINE when in preparations for tattoo removal.

TROMETAMOL in preparations for injection except in preparations containing 3% or less of trometamol.

TROPICAMIDE.

TROPISETRON.

TROVAFLOXACIN.

TROXIDONE.

TRYPTOPHAN for human therapeutic use except in preparations labelled with a recommended daily dose of 100 mg or less of tryptophan.

TUBERCULIN.

TUBOCURARINE.

TUCATINIB.

TULATHROMYCIN.

TULOBUTEROL.

TYLOSIN.

TYPHOID VACCINE.

ULIPRISTAL except when included in Schedule 3.

UMECLIDINIUM.

UNIFIRAM.

UNOPROSTONE.

UPADACITINIB.

URACIL.

URAPIDIL.

URETHANE (excluding its derivatives) for therapeutic use.

# UROFOLLITROPIN.

UROKINASE.

URSODEOXYCHOLIC ACID.

USTEKINUMAB.

VACCINES for human therapeutic use except when separately specified in this Schedule.

VACCINES for veterinary live virus except:

 (a) poultry vaccines; or

 (b) pigeon pox vaccine; or

 (c) scabby mouth vaccine; or

 (d) bovine ephemeral fever vaccine; or

 (e) bovine herpesvirus1 vaccine.

VACCINES – PLASMID DNA for animal use except when separately specified in these Schedules.

VACCINIA VIRUS VACCINE.

# VADADUSTAT.

VALACICLOVIR.

VALDECOXIB.

VALGANCICLOVIR.

VALNOCTAMIDE.

VALPROIC ACID.

VALSARTAN.

VANCOMYCIN.

VANDETANIB.

VARDENAFIL.

VARENICLINE.

VARICELLA VACCINE.

RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN.

VASOPRESSIN.

VECURONIUM.

VEDAPROFEN.

VEDOLIZUMAB.

VELAGLIFLOZIN.

VELAGLUCERASE ALFA.

VELPATASVIR.

VEMURAFENIB.

VENETOCLAX.

VENLAFAXINE.

VERAPAMIL.

VERATRUM spp. except when separately specified in this Schedule.

VERICIGUAT.

VERNAKALANT.

VERTEPORFIN.

VIDARABINE.

VIGABATRIN.

VILANTEROL.

VILDAGLIPTIN.

VILOXAZINE.

VINBLASTINE.

VINCAMINE.

VINCRISTINE.

VINDESINE.

VINFLUNINE.

VINORELBINE.

VINYL ETHER for therapeutic use.

VIRGINIAMYCIN except when included in Schedule 5.

VISMODEGIB.

VISNADINE.

VITAMIN A for human therapeutic or cosmetic use except:

 (a) in preparations for topical use containing 1% or less of Vitamin A; or

 (b) in preparations for internal use containing 3000 micrograms retinol equivalents or less of Vitamin A per daily dose; or

 (c) in preparations for parenteral nutrition replacement.

VITAMIN D for human internal therapeutic use except:

 (a) in preparations containing 25 micrograms or less of vitamin D per recommended daily dose ; or

 (b) when included in Schedule 3.

VORAPAXAR.

VORETIGENE NEPARVOVEC.

VORICONAZOLE.

VORINOSTAT.

VORTIOXETINE.

VOSORITIDE.

VOXILAPREVIR.

WARFARIN for therapeutic use.

XAMOTEROL.

XANTHINOL NICOTINATE.

XIMELAGATRAN.

XIPAMIDE.

XYLAZINE.

YOHIMBINE.

ZAFIRLUKAST.

ZALCITABINE.

ZALEPLON.

ZANAMIVIR.

ZANUBRUTINIB.

ZERANOL except when included in Schedule 6.

ZIDOVUDINE.

ZILPATEROL.

ZIMELDINE.

ZINC COMPOUNDS for human internal use except:

 (a) in preparations with a recommended daily dose of 25 mg or less of zinc; or

 (b) in preparations with a recommended daily dose of more than 25 mg but not more than 50 mg of zinc when compliant with the requirements of the required advisory statements for medicine labels.

ZIPRASIDONE.

ZOLAZEPAM.

ZOLEDRONIC ACID.

ZOLMITRIPTAN except when included in Schedule 3.

ZOLPIDEM.

ZONISAMIDE.

ZOPICLONE.

ZOXAZOLAMINE.

ZUCLOPENTHIXOL.

Schedule 5Caution

 

 

Note: See paragraph (e) of the definition of designated solvent in section 6, paragraph 7(j), sections 16 and 25, subsection 26(2) and sections 42, 46, 47, 49, 55 and 61.

ABAMECTIN

 (a) in preparations, for internal use for the treatment of animals, containing 1% or less of abamectin; or

 (b) in gel formulations containing 0.05% or less of abamectin in applicators containing 50 mg or less of abamectin.

ABSCISIC ACID.

ACEQUINOCYL.

ACETIC ACID (excluding its salts and derivatives) in preparations containing more than 30% of acetic acid (CH3COOH) except:

 (a) when included in Schedule 2 or 6; or

 (b) for therapeutic use.

ACETONE except in preparations containing 25% or less of designated solvents.

ACRIFLAVINIUM CHLORIDE in preparations for veterinary use containing 2.5% or less of acriflavinium chloride.

AFOXOLANER in oral divided preparations each containing 150 mg or less of afoxolaner per dosage unit

 (a) for the treatment and prevention of flea infestations and control of ticks in dogs; or

 (b) for the treatment and prevention of flea infestations, control of ticks, gastrointestinal nematodes and heartworm in dogs, when combined with milbemycin oxime.

AKLOMIDE.

ALBENDAZOLE for the treatment of animals, in preparations containing 12.5% or less of albendazole except in intraruminal implants each containing 3.85 g or less of albendazole.

ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination:

 (a) in solid orthodontic device cleaning preparations, the pH of which as an “inuse” aqueous solution is more than 11.5; or

 (b) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 11.5 but less than or equal to 12.5; or

 (c) in other solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or

 (d) in liquid or semisolid preparations, the pH of which is more than 11.5, unless:

 (i) in food additive preparations for domestic use; or

 (ii) in automatic dish washing preparations for domestic use with a pH of more than 12.5;

except when separately specified in these Schedules.

ALKOXYLATED FATTY ALKYLAMINE POLYMER in preparations containing 50% or less of alkoxylated fatty alkylamine polymer except in preparations containing 20% or less of alkoxylated fatty alkylamine polymer.

ALLETHRIN in preparations containing 10% or less of allethrin except:

 (a) in insecticidal mats; or

 (b) in other preparations containing 1% or less of allethrin.

ALLOXYDIM.

ALPHACYPERMETHRIN:

 (a) in aqueous preparations containing 3% or less of alphacypermethrin; or

 (b) in other preparations containing 1.5% or less of alphacypermethrin.

AMETRYN.

AMINES for use as curing agents for epoxy resins except when separately specified in these Schedules.

AMINOACRIDINE in preparations for veterinary use containing 2.5% or less of aminoacridine.

AMINOCYCLOPYRACHLOR except in preparations containing 25% or less of aminocyclopyrachlor.

AMINOPYRALID in preparations containing 22% or less of aminopyralid.

AMISULBROM.

AMITROLE.

AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) in preparations containing 5% or less of ammonia except:

 (a) in preparations for human internal therapeutic use; or

 (b) in preparations for inhalation when absorbed in an inert solid material; or

 (c) in preparations containing 0.5% or less of free ammonia.

AMMONIUM THIOCYANATE except in preparations containing 10% or less of ammonium thiocyanate.

ANHYDRIDES, ORGANIC ACID for use as curing agents for epoxy resins except when separately specified in these Schedules.

ANISE OIL except:

 (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

 (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:

  KEEP OUT OF REACH OF CHILDREN; or

 (c) in preparations containing 50% or less of anise oil.

ASPIRIN for the treatment of animals, that is in divided preparations, when:

 (a) packed in blister or strip packaging; or

 (b) in a container with a child-resistant closure.

ATRAZINE.

AZADIRACHTA INDICA EXTRACTS (neem extracts), extracted from neem seed kernels using water, methanol or ethanol, in preparations containing 5% or less of total limonoids, for agricultural use.

AZOXYSTROBIN.

BACILLUS THURINGIENSIS DELTA ENDOTOXIN encapsulated in killed Pseudomonas fluorescens.

BARIUM SILICOFLUORIDE when coated on paper in an amount not exceeding 8 mg of barium silicofluoride per sq. cm.

BASIL OIL except:

 (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

 (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:

  KEEP OUT OF REACH OF CHILDREN; or

 (c) in preparations containing 5% or less of methyl chavicol.

BEAUVERIA BASSIANA in preparations containing 1 x 108 Colony Forming Units (CFU)/mL or less of Beauveria bassiana.

BENALAXYL.

BENDIOCARB in preparations containing 2% or less of bendiocarb.

BENTAZONE.

BENZALKONIUM CHLORIDE in preparations containing 10% or less of benzalkonium chloride except in preparations containing 5% or less of benzalkonium chloride.

BENZOFENAP.

BENZOYL PEROXIDE except:

 (a) when included in Schedule 2 or 4; or

 (b) in preparations containing 5% or less of benzoyl peroxide.

BERGAMOT OIL except:

 (a) when steam distilled or rectified; or

 (b) in preparations for internal use; or

 (c) in preparations containing 0.4% or less of bergamot oil; or

 (d) in soaps or bath or shower gels that are washed off the skin; or

 (e) in medicines for human therapeutic use when compliant with the requirements of the required advisory statements for medicine labels; or

 (f) in other preparations when packed in containers labelled with the statement:

   Application to the skin may increase sensitivity to sunlight.

BETACYFLUTHRIN:

 (a) in aqueous preparations containing 2.5% or less of betacyfluthrin; or

 (b) in solid preparations containing 8% or less of betacyfluthrin in a plastic matrix.

BICYCLOPYRONE in preparations containing 20% or less of bicyclopyrone.

BIFLUORIDES (including ammonium, potassium and sodium salts), in preparations containing 0.3% or less of total bifluorides.

BIOALLETHRIN in preparations containing 10% or less of bioallethrin except in preparations containing 1% or less of bioallethrin.

BIORESMETHRIN except in preparations containing 10% or less of bioresmethrin.

BISPYRIBAC except in preparations containing 10% or less of bispyribac.

BIXAFEN.

BORIC ACID except:

 (a) when included in Schedule 4; or

 (b) in cosmetic hand cleaning preparations when labelled with a warning to the following effect:

  NOT TO BE USED FOR CHILDREN UNDER 3 YEARS OF AGE; and

  if the concentration of free soluble borates exceeds 1.5% (as boric acid), with the words:

  NOT TO BE USED ON PEELING OR IRRITATED SKIN; or

 (c) in cosmetic talc preparations containing 5% or less calculated as boric acid when labelled with a warning to the following effect:

  NOT TO BE USED FOR CHILDREN UNDER 3 YEARS OF AGE; and

  if the concentration of free soluble borates exceeds 1.5% (as boric acid), with the words:

  NOT TO BE USED ON PEELING OR IRRITATED SKIN; or

 (d) in cosmetic oral hygiene preparations containing 0.1% or less calculated as boric acid when labelled with a warning to the following effect:

  NOT TO BE SWALLOWED. NOT TO BE USED FOR CHILDREN UNDER 3 YEARS OF AGE; or

 (e) in other cosmetic preparations containing 3% or less calculated as boric acid when labelled with a warning to the following effect:

  NOT TO BE USED FOR CHILDREN UNDER 3 YEARS OF AGE; and

  if the concentration of free soluble borates exceeds 1.5% (as boric acid), with the words:

  NOT TO BE USED ON PEELING OR IRRITATED SKIN; or

 (f) in preparations, other than insect baits, containing 6% or less calculated as boric acid.

BORON TRIFLUORIDE in preparations containing 0.1% or less of boron trifluoride (BF3).

BROFLANILIDE in preparations containing 0.3% or less of broflanilide.

BROMUCONAZOLE in preparations containing 20% or less of bromuconazole.

BUPIVACAINE in aqueous gel preparations containing 0.5% or less of bupivacaine, for the dermal sprayon administration to the wounds of animals.

BUPROFEZIN except in preparations containing 40% or less of buprofezin.

BUTHIDAZOLE.

BUTOXYCARBOXIM in solid preparations containing 10% or less of butoxycarboxim.

BUTRALIN.

BUTROXYDIM.

nBUTYL ALCOHOL in preparations containing 10% or less of nbutyl alcohol except:

 (a) in preparations containing 5% or less of nbutyl alcohol; or

 (b) in preparations for cosmetic or therapeutic use other than spray form.

CAMPHOR as a natural component in essential oils containing 10% or less of camphor except:

 (a) in medicines for human therapeutic use, in essential oils when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

 (b) in preparations other than medicines for human therapeutic use, in essential oils when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warnings:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) NOT TO BE TAKEN; or

 (c) in rosemary oil, sage oil (Spanish), or lavandin oils; or

 (d) in preparations containing 2.5% or less of camphor.

CARBAMIDE PEROXIDE in preparations containing 18% or less of carbamide peroxide except in preparations containing 9% or less of carbamide peroxide.

CARBARYL:

 (a) in preparations containing 10% or less of carbaryl except when included in Schedule 4; or

 (b) when impregnated into plastic resin material containing 20% or less of carbaryl.

CASSIA OIL except:

 (a) in food additives; or

 (b) in preparations for dermal use as a rubefacient containing 5% or less of cassia oil; or

 (c) in other preparations containing 2% or less of cassia oil.

CHLORFENAC.

CHLORFENAPYR. in preparations containing 0.5% or less of chlorfenapyr.

CHLORFENSON.

CHLORHEXIDINE in preparations containing 3% or less of chlorhexidine except:

 (a) in preparations containing 1% or less of chlorhexidine; or

 (b) when in solid preparations.

CHLORINATING COMPOUNDS containing 20% or less of available chlorine, except:

 (a) when separately specified in these Schedules; or

 (b) sodium hypochlorite preparations with a pH of less than 11.5; or

 (c) liquid preparations containing not less than 2% but not more than 4% of available chlorine when labelled with the statements:

  WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products; or

 (d) liquid preparations containing less than 2% of available chlorine; or

 (e) other preparations containing 4% or less of available chlorine.

CHLORNIDINE.

CHLOROCRESOL except in preparations containing 3% or less of chlorocresol.

CHLORPROPHAM.

CHLORPYRIFOS:

 (a) in aqueous preparations containing 20% or less of microencapsulated chlorpyrifos; or

 (b) in controlled release granular preparations containing 10% or less of chlorpyrifos; or

 (c) in other preparations containing 5% or less of chlorpyrifos;

 except in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre.

CHLORSULFURON.

CHLORTETRACYCLINE in preparations:

 (a) for topical application to animals for ocular use only; or

 (b) containing 40% or less of chlortetracycline, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

CHLORTHALDIMETHYL.

CINMETHYLIN.

CINNAMON BARK OIL except:

 (a) in food additives; or

 (b) in preparations containing 2% or less of cinnamon bark oil.

CISJASMONE when prepared and packaged as an agricultural chemical except when present as a fragrance.

CLETHODIM.

CLIMBAZOLE in preparations containing 40% or less of climbazole except:

 (a) in leaveon hair, face and foot cosmetic preparations containing 0.5% or less of climbazole; or

 (b) in other preparations (that are not leaveon cosmetic preparations) containing 2% or less of climbazole.

CLOFENTEZINE.

CLOPYRALID.

CLOQUINTOCET.

CLORSULON.

CLOTHIANIDIN in preparations containing 20% or less of clothianidin except in gel preparations dispensed in sealed cartridges containing 1% or less of clothianidin.

CLOVE OIL for topical use in the mouth in a pack containing 5 mL or less of clove oil except in preparations containing 25% or less of clove oil.

COPPER ACETATE in preparations containing 20% or less of copper acetate except in preparations containing 5% or less of copper acetate.

COPPER COMPOUNDS in animal feed additives containing 5% or less of copper except in preparations containing 1% or less of copper.

COPPER HYDROXIDE in preparations containing 50% or less of copper hydroxide except in preparations containing 12.5% or less of copper hydroxide.

COPPER OXIDES in preparations containing 25% or less of copper oxides except:

 (a) in preparations for internal use; or

 (b) in marine paints; or

 (c) in other preparations containing 5% or less of copper oxides.

COPPER OXYCHLORIDE in preparations containing 50% or less of copper oxychloride except in preparations containing 12.5% or less of copper oxychloride.

COPPER SULFATE in preparations containing 15% or less of copper sulfate except:

 (a) in preparations for internal use; or

 (b) in other preparations containing 5% or less of copper sulfate.

COUMATETRALYL in rodenticides containing 0.05% or less of coumatetralyl.

4CPA.

CYANATRYN.

CYANOACRYLATE ESTERS in contact adhesives except:

 (a) when labelled with the warning:

  KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water. Do not use solvents near eyes or open wounds. In case of eye contact immediately flush with water; or

 (b) when packed in sealed measure packs each containing 0.5 g or less of cyanoacrylate esters:

 (i) labelled with the approved name or trade name of the poison, the quantity and the warning:

  Can cause eye injury. Instantly bonds skin; and

  enclosed in a primary pack labelled with the warning:

  KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water. Do not use solvents near eyes or open wounds. In case of eye contact immediately flush with water.

CYANTRANILIPROLE.

CYANURIC ACID (excluding its salts and derivatives).

CYAZOFAMID.

CYCLOHEXANONE PEROXIDE.

CYCLOPROTHRIN except in preparations containing 10% or less of cycloprothrin.

CYCLOXYDIM.

CYFLUFENAMID.

CYFLUMETOFEN.

CYFLUTHRIN:

 (a) in wettable powders containing 10% or less of cyfluthrin; or

 (b) in emulsifiable concentrates containing 2% or less of cyfluthrin; or

 (c) in emulsions containing 5% or less of cyfluthrin.

CYHALOFOPBUTYL.

CYMIAZOLE.

CYPERMETHRIN in preparations containing 10% or less of cypermethrin.

CYPHENOTHRIN in preparations containing 10% or less of cyphenothrin.

CYPROCONAZOLE except in preparations containing 10% or less of cyproconazole.

CYPRODINIL.

CYTHIOATE for the treatment of animals:

 (a) in divided preparations containing 30 mg or less of cythioate per dosage unit when packed in blister or strip packaging or in a container with a childresistant closure; or

 (b) in undivided preparations containing 5% or less of cythioate.

2,4D in preparations containing 20% or less of 2,4D.

DAMINOZIDE.

2,4DB.

DECOQUINATE:

DELTAMETHRIN:

 (a) when impregnated in plastic resin strip material containing 4% or less of deltamethrin; or

 (b) in aqueous preparations containing 5% or less of deltamethrin when no organic solvent other than a glycol is present; or

 (c) in wettable granular preparations containing 25% or less of deltamethrin when packed in childresistant packaging each containing 3 g or less of the formulation; or

 (d) in waterdispersible tablets each containing 500 mg or less of deltamethrin in childresistant packaging; or

 (e) in other preparations containing 0.5% or less of deltamethrin;

 except:

 (f) in factory prepared mosquito nets containing 1% or less deltamethrin; or

 (g) in preparations containing 0.1% or less of deltamethrin.

DEMBREXINE in oral preparations for the treatment of animals.

2,4DES.

DIAFENTHIURON.

N,NDIALLYLDICHLOROACETAMIDE except in preparations containing 10% or less of N,Ndiallyldichloroacetamide.

DIAZINON in dust preparations containing 2% or less of diazinon.

DICAMBA (including its salts and derivatives) in preparations containing 20% or less of dicamba.

DICHLONE.

pDICHLOROBENZENE.

DICHLOROISOCYANURIC ACID containing 40% or less of available chlorine, except in:

 (a) liquid preparations containing not less than 2% but not more than 4% of available chlorine when labelled with the statements:

  WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products; or

 (b) liquid preparations containing less than 2% of available chlorine; or

 (c) other preparations containing 4% or less of available chlorine.

DICHLOROMETHANE (methylene chloride) except:

 (a) in preparations in pressurised spray packs labelled as degreasers, decarbonisers or paint strippers and containing 10% or less of dichloromethane; or

 (b) in other preparations in pressurised spray packs; or

 (c) in paints and tinters containing 5% or less of dichloromethane; or

 (d) in preparations for human therapeutic use.

DICHLOROPHEN for the treatment of animals.

DICHLORVOS:

 (a) when impregnated in plastic resin strip material containing 20% or less of dichlorvos; or

 (b) in sustained release resin pellets containing 20% or less of dichlorvos for the treatment of animals; or

 (c) in pressurised spray packs containing 10 g or less of dichlorvos.

DICLOBUTRAZOL.

DICLORAN.

DICOFOL.

DIETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20% or less of diethanolamine except in preparations containing 5% or less of diethanolamine.

DIETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not less than 10 mg/kg of denatonium benzoate as a bittering agent except:

 (a) in paints or paint tinters; or

 (b) in toothpastes or mouthwashes containing more than 0.25% of diethylene glycol; or

 (c) in other preparations containing 2.5% or less of diethylene glycol.

DIETHYLENE GLYCOL MONOBUTYL ETHER except in preparations containing 10% or less of diethylene glycol monobutyl ether.

DIETHYLTOLUAMIDE (DEET) except:

 (a) in medicines for human therapeutic use containing 20% or less of diethyltoluamide, when compliant with the requirements of the required advisory statements for medicine labels; or

 (b) in preparations for human use, other than medicines, containing 20% or less of diethyltoluamide, when labelled with the warning statement:

  WARNING: May be dangerous, particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you keep using it for a long time; or

 (c) in preparations other than for human use containing 20% or less of diethyltoluamide.

DIFENOCONAZOLE.

DIFLUBENZURON.

DIMETHICODIETHYLBENZALMALONATE except when included in preparations containing 10% or less of dimethicodiethylbenzalmalonate.

DIMETHIRIMOL.

DIMETHOMORPH except in preparations containing 10% or less of dimethomorph.

DIMETHYLACETAMIDE in preparations containing 20% or less of dimethylacetamide.

DIMETHYLFORMAMIDE in preparations containing 10% or less of dimethylformamide except in silicone rubber mastic containing 2% or less of dimethylformamide.

3,7DIMETHYL2,6OCTADIENAL and its isomers in cosmetic and household cleaning preparations except in preparations containing 5% or less of 3,7dimethyl2,6,octadienal isomers.

DIMPROPYRIDAZ in preparations containing 13% or less of dimpropyridaz.

DINICONAZOLE.

DINOTEFURAN except in preparations containing 1% or less of dinotefuran.

DInPROPYL ISOCINCHOMERONATE except in preparations containing 25% or less of dinpropyl isocinchomeronate.

DIPHENAMID.

DIRECT RED 254 in preparations containing 30% or less of Direct Red 254 calculated as free acid.

DITHIOPYR.

N(NDODECYL)2PYRROLIDONE in preparations containing 50% or less of N(Ndodecyl)2pyrrolidone or preparations containing 50% or less of a mixture of any two or more of N(Ndodecyl)2pyrrolidone, Nmethyl2pyrrolidone or N(Noctyl)2pyrrolidone except in preparations containing 25% or less of designated solvents.

DORAMECTIN for internal use for the treatment of animals, in preparations containing 2% or less of doramectin.

EMAMECTIN in preparations containing 2% or less of emamectin.

EMODEPSIDE in preparations:

 (a) containing 2.5% or less of emodepside for the external treatment of animals; or

 (b) containing 30 mg or less of emodepside per dosage unit for the oral treatment of animals.

EPOXICONAZOLE.

EPOXY RESINS, LIQUID.

EPRINOMECTIN in preparations containing 0.5% or less of eprinomectin.

ESBIOTHRIN in preparations containing 10% or less of esbiothrin except in pressurised spray packs containing 1% or less of esbiothrin.

ESFENVALERATE in preparations containing 0.1% or less of esfenvalerate.

ESTRADIOL in implant preparations for growth promotion in animals.

1,2ETHANEDIAMINE POLYMERWITH (CHLOROMETHYL) OXIRANE AND NMETHYLMETHANAMINE.

ETHER in preparations containing more than 10% of ether for use in internal combustion engines.

ETHOFUMESATE.

ETHOXYQUIN except in preparations containing 10% or less of ethoxyquin.

ETHOXYSULFURON.

ETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not less than 10 mg/kg of denatonium benzoate as a bittering agent except:

 (a) in paints or paint tinters; or

 (b) in toothpastes or mouthwashes containing more than 0.25% of ethylene glycol; or

 (c) in other preparations containing 2.5% or less of ethylene glycol.

ETHYL METHACRYLATE (excluding its derivatives) for cosmetic use except in preparations containing 1% or less of ethyl methacrylate as residual monomer in a polymer.

ETRIDIAZOLE.

EUGENOL for topical use in the mouth in a pack containing 5 mL or less of eugenol except in preparations containing 25% or less of eugenol.

EXTRACT OF LEMON EUCALYPTUS, being acid modified oil of lemon eucalyptus (Corymbia citriodora), except in preparations containing 40% or less of extract of lemon eucalyptus.

FENARIMOL.

FENBENDAZOLE for the treatment of animals.

FENBUCONAZOLE.

FENCHLORAZOLEETHYL.

FENNEL OIL except:

 (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of an instrument made under subsection 3(5A) of the Act relating to medicine advisory statements; or

 (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:

  KEEP OUT OF REACH OF CHILDREN; or

 (c) in preparations containing 5% or less of methyl chavicol.

FENOPROP.

FENOXAPROPETHYL.

FENOXAPROPpETHYL.

FENPYRAZAMINE except in preparations containing 40% or less of fenpyrazamine.

FENSON.

FENTHION:

 (a) in preparations containing 25% or less of fenthion when packed in singleuse containers having a capacity of 2 mL or less; or

 (b) in preparations containing 10% or less of fenthion.

FIPRONIL in preparations containing 10% or less of fipronil except in preparations containing 0.05% or less of fipronil.

FLAMPROPMETHYL.

FLAMPROPMMETHYL.

FLAZASULFURON.

FLORASULAM.

FLUAZAINDOLIZINE in preparations containing 50% or less fluazaindolizine.

FLUAZURON.

FLUBENDAZOLE for the treatment of animals.

FLUBENDIAMIDE.

FLUCHLORALIN.

FLUDIOXONIL except in preparations containing 10% or less of fludioxonil.

FLUMETHRIN:

 (a) when impregnated in plastic resin strip material containing 3% or less of flumethrin; or

 (b) in oil based preparations containing 1% or less of flumethrin.

FLUMICLORAC PENTYL.

FLUOPYRAM except in preparations containing 50% or less of fluopyram.

FLUORIDES in preparations containing 3% or less of fluoride ion except:

 (a) in preparations for human use; or

 (b) in preparations containing 15 mg/kg or less of fluoride ion.

FLURALANER except when included in Schedule 4.

FLUVALINATE in aqueous preparations containing 25% or less of fluvalinate.

FLUXAPYROXAD.

FORAMSULFURON.

FORMIC ACID (excluding its salts and derivatives) except in preparations containing 0.5% or less of formic acid.

FOSPIRATE when impregnated in plastic resin strip material containing 20% or less of fospirate.

FURALAXYL.

FURATHIOCARB in microencapsulated suspensions containing 50% or less of furathiocarb.

GAMMACYHALOTHRIN in aqueous preparations containing 15% or less of microencapsulated gammacyhalothrin.

GLUFOSINATEAMMONIUM.

GLUTARAL in preparations containing 5% or less of glutaral except:

 (a) when included in Schedule 2; or

 (b) in preparations containing 0.5% or less of glutaral when labelled with the statements:

 (A) IRRITANT; and

 (B) Avoid contact with eyes.

GLYPHOSATE.

HALOSULFURONMETHYL.

HEXACONAZOLE except in preparations containing 5% or less of hexaconazole.

HEXAZINONE in preparations containing 25% or less of hexazinone.

HYDRAMETHYLNON in solid baits containing 2% or less of hydramethylnon in welded plastic labyrinths.

HYDROCARBONS, LIQUID, including kerosene, diesel (distillate), mineral turpentine, white petroleum spirit, toluene, xylene and light mineral and paraffin oils (but excluding their derivatives), except:

 (a) toluene and xylene when included in Schedule 6; or

 (b) benzene and liquid aromatic hydrocarbons when included in Schedule 7; or

 (c) food grade and pharmaceutical grade white mineral oils; or

 (d) in solid or semisolid preparations; or

 (e) in preparations containing 25% or less of designated solvents; or

 (f) in preparations packed in pressurised spray packs; or

 (g) in adhesives packed in containers each containing 50 g or less of adhesive; or

 (h) in writing correction fluids and thinners for writing correction fluids packed in containers having a capacity of 20 mL or less; or

 (i) in other preparations when packed in containers with a capacity of 2 mL or less.

HYDROCHLORIC ACID (excluding its salts and derivatives) in preparations containing 10% or less of hydrochloric acid (HCl) except:

 (a) in preparations containing 0.5% or less of hydrochloric acid (HCl); or

 (b) for therapeutic use.

HYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 0.1% or less of hydrogen fluoride.

HYDROGEN PEROXIDE (excluding its salts and derivatives):

 (a) in hair dye preparations containing 12% or less of hydrogen peroxide except in hair dyes containing 6% or less of hydrogen peroxide; or

 (b) in other preparations containing 6% (20 volume) or less of hydrogen peroxide except in preparations containing 3% (10 volume) or less of hydrogen peroxide.

HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 0.1% or less of hydrosilicofluoric acid (H2SiF6).

2HYDROXYETHYL METHACRYLATE except:

 (a) when included in dental restorative preparations for therapeutic use; or

 (b) in nail preparations when labelled “Avoid contact with skin”; or

 (c) in other preparations containing 0.1% or less of 2hydroxyethyl methacrylate when labelled “Avoid contact with skin”.

2HYDROXYPROPYL METHACRYLATE in nail preparations except when labelled “Avoid contact with skin”.

IMAZALIL.

IMAZAMOX except in preparations containing 25% or less of imazamox.

IMAZAPIC except in preparations containing 25% or less of imazapic.

IMAZAPYR except in preparations containing 25% or less of imazapyr.

IMAZETHAPYR except in preparations containing 25% or less of imazethapyr.

IMIDACLOPRID in preparations containing 20% or less of imidacloprid except in preparations containing 5% or less of imidacloprid.

IMIPROTHRIN in preparations containing 50% or less of imiprothrin except in preparations containing 10% or less of imiprothrin.

INDOXACARB (includes the R and S enantiomers) in preparations containing 1% or less of indoxacarb.

3IODO2PROPYNYL BUTYL CARBAMATE (Iodocarb) in preparations containing 10% or less of 3iodo2propynyl butyl carbamate except:

 (a) in aqueous preparations not for cosmetic use containing 10% or less 3iodo2propynyl butyl carbamate; or

 (b) in cosmetic preparations (other than aerosolised preparations) containing 0.1% or less of 3iodo2propynyl butyl carbamate.

IODOSULFURONMETHYLSODIUM.

IPCONAZOLE in preparations containing 2% or less of ipconazole.

IRON COMPOUNDS:

 (a) for the treatment of animals (excluding up to 1% of iron oxides when present as an excipient):

 (i) in preparations for injection containing 20% or less of iron except in preparations containing 0.1% or less of iron; or

 (ii) in other preparations containing 4% or less of iron except:

 (A) in liquid or gel preparations containing 0.1% or less of iron; or

 (B) in animal feeds or feed premixes; or

 (b) for use as agricultural chemicals except in preparations containing 4% or less of iron.

ISOEUGENOL in preparations not intended for skin contact containing 25% or less of isoeugenol except in preparations containing 10% or less of isoeugenol.

ISOPHORONE.

ISOXABEN.

ISOXAFLUTOLE.

IVERMECTIN for use in animals:

 (a) in preparations for the prophylaxis of heartworm in cats and dogs; or

 (b) in intraruminal implants containing 160 mg or less of ivermectin; or

 (c) in preparations containing 3.5% or less of ivermectin when packed in childresistant packaging or in packaging approved by the relevant registration authority; or

 (d) in other preparations containing 2% or less of ivermectin.

KITASAMYCIN in animal feed premixes for growth promotion containing 2% or less of antibiotic substances.

LAMBDACYHALOTHRIN:

 (a) in aqueous preparations containing 1% or less of lambda cyhalothrin; or

 (b) in aqueous preparations containing 10% or less of microencapsulated lambdacyhalothrin.

LASIODIPLODIA PSEUDOTHEOBROMAE except when used as a herbicide in capsule preparations at a concentration of 16 CFU or less per capsule.

LEMON OIL except:

 (a) when steam distilled or rectified; or

 (b) in preparations for internal use; or

 (c) in preparations containing 0.05% or less of lemon oil; or

 (d) in soaps or bath or shower gels that are washed off the skin; or

 (e) in medicines for human therapeutic use, when compliant with the requirements of the required advisory statements for medicine labels; or

 (f) in other preparations when packed in containers labelled with the statement:

  Application to the skin may increase sensitivity to sunlight.

LEMONGRASS OIL in cosmetic and household cleaning preparations except in preparations containing 5% or less of 3,7dimethyl2,6octadienal.

LEVAMISOLE in preparations containing 15% or less of levamisole for the treatment of animals except:

 (a) when included in Schedule 4; or

 (b) in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole.

LIDOCAINE:

 (a) in aqueous gel preparations containing 4.5% or less of lidocaine, for the dermal sprayon administration to the wounds of animals; or

 (b) in injectable preparations containing 2% or less of lidocaine when packaged in a container with a tamper resistant cartridge which can only be dispensed through a rubber ring applicator for tail docking and castration of lambs; or castration of calves.

LIME OIL except:

 (a) when steam distilled or rectified; or

 (b) in preparations for internal use; or

 (c) in preparations containing 0.5% or less of lime oil; or

 (d) in soaps or bath or shower gels that are washed off the skin; or

 (e) in medicines for human therapeutic use, when compliant with the requirements of the required advisory statements for medicine labels; or

 (f) in other preparations when packed in containers labelled with the statement:

  Application to the skin may increase sensitivity to sunlight.

LINDANE in preparations containing 10% or less of lindane except when included in Schedule 2 or 4.

LOTILANER.

LUFENURON except:

 (a) in divided preparations each containing 500 mg or less of lufenuron for the treatment of animals; or

 (b) in single use syringes each containing 500 mg or less of lufenuron for the treatment of animals.

MACROPHOMINA PHASEOLINA except when used as a herbicide in capsule preparations at a concentration of 16 CFU or less per capsule.

MADURAMICIN in animal feed premixes containing 1% or less of antibiotic substances.

MAGNESIUM CHLORATE except in preparations containing 10% or less of magnesium chlorate.

MALACHITE GREEN in preparations for veterinary use containing 10% or less of malachite green.

MALATHION in preparations containing 10% or less of malathion except:

 (a) for human therapeutic use; or

 (b) in dust preparations containing 2% or less of malathion.

MANCOZEB.

MANDESTROBIN except in preparations containing 25% or less of mandestrobin.

MANDIPROPAMID.

MARJORAM OIL except:

 (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

 (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:

  KEEP OUT OF REACH OF CHILDREN; or

 (c) in preparations containing 50% or less of marjoram oil.

MCPA:

 (a) in preparations containing 25% or less of MCPA (acid); or

 (b) in preparations containing 50% or less of the salts and esters of MCPA.

MEBENDAZOLE for the treatment of animals:

 (a) in divided preparations each containing 300 mg or less of mebendazole per dosage unit; or

 (b) in undivided preparations containing 25% or less of mebendazole.

MECLOFENAMIC ACID for the treatment of animals.

MECOPROP in preparations containing 2% or less of mecoprop.

MEFENPYRDIETHYL.

MEFENTRIFLUCONAZOLE except in preparations containing 7.5% or less of mefentrifluconazole.

MEPIQUAT.

MERCAPTAMINE in cosmetic preparations containing 6% or less of mercaptamine except in preparations containing 1% or less of mercaptamine.

MERCAPTOACETIC ACID and its salts, but excluding its derivatives, in cosmetic preparations containing 20% or less of mercaptoacetic acid or its salts (as mercapturic acid), except in preparations containing 5% or less of mercaptoacetic acid or its salts (as mercapturic acid)

MESOTRIONE.

METAFLUMIZONE.

METALAXYL in preparations containing 35% or less of metalaxyl.

METALDEHYDE in preparations containing 2% or less of metaldehyde.

METAZACHLOR.

METHABENZTHIAZURON.

METHANOL (excluding its derivatives) in preparations containing 10 % or less of methanol except:

 (a) when included in Schedule 10; or

 (b) in preparations containing 2% or less of methanol; or

 (c) when methanol is present only as a denaturant of ethanol.

METHENAMINE in cosmetic preparations, except in preparations containing 0.15% or less of methenamine.

METHIOCARB in pelleted preparations containing 2% or less of methiocarb.

METHIOZOLIN.

METHOXYCHLOR.

METHYLATED SPIRIT(S) (being ethanol denatured with denatonium benzoate, methyl isobutyl ketone and fluorescein) except:

 (a) when included in preparations or admixtures; or

 (b) when packed in containers having a capacity of more than 5 L.

METHYLATED SPIRIT(S) when packed and labelled as a “biofuel” suitable for use in “spirit burners”.

METHYLENE BLUE in preparations for veterinary use containing 50% or less of methylene blue.

METHYL ETHYL KETONE except in preparations containing 25% or less of designated solvents.

METHYL ETHYL KETONE PEROXIDE.

METHYL ISOAMYL KETONE except in preparations containing 25% or less of designated solvents.

METHYL ISOBUTYL KETONE except in preparations containing 25% or less of designated solvents.

NMETHYL2PYRROLIDONE:

 (a) when packed in single use containers having a capacity of 2 mL or less; or

 (b) in preparations containing 50% or less of Nmethyl2pyrrolidone or preparations containing 50% or less of a mixture of any two or more of Nmethyl2pyrrolidone, N(Noctyl)2pyrrolidone or N(Ndodecyl)2pyrrolidone except in preparations containing 25% or less of designated solvents.

METHYL SALICYLATE in preparations containing 25% or less of methyl salicylate except:

 (a) in preparations for therapeutic use; or

 (b) in preparations containing 5% or less of methyl salicylate.

2METHYLTHIO4(2METHYLPROP2YL) AMINO6CYCLOPROPYLAMINO5 TRIAZINE.

METIRAM.

METOBROMURON except in preparations containing 50% or less of metobromuron.

METOFLUTHRIN:

 (a) in impregnated fabric mosquito repellent preparations for use in a vaporiser containing 15 mg or less of metofluthrin per disk; or

 (b) when impregnated into a polyethylene slow release matrix containing 250 mg or less of metofluthrin.

METOLACHLOR.

METRAFENONE in preparations containing 50% or less of metrafenone.

MILBEMECTIN in preparations containing 1% or less of milbemectin.

MILBEMYCIN OXIME

 (a) for the prophylaxis of heartworm in dogs and cats; or

 (b) for the treatment and prevention of flea infestations, control of ticks, gastrointestinal nematodes and heartworm in dogs, when combined with afoxolaner, in oral divided preparations each containing 150 mg or less of afoxolaner per dosage unit.

MONENSIN in intraruminal implants for cattle, each containing 35 g or less of monensin.

MONEPANTEL.

MONOETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20% or less of monoethanolamine except:

 (a) when included in Schedule 4; or

 (b) in preparations containing 5% or less of monoethanolamine.

MORANTEL in preparations containing 25% or less of morantel except in preparations containing 10% or less of morantel.

MOXIDECTIN:

 (a) in preparations for external use for the treatment of animals other than cats and dogs, containing 0.5% or less of moxidectin; or

 (b) in preparations for external use for the treatment of cats and dogs, containing 2.5% or less of moxidectin packed in single dose tubes with a volume of 1 mL or less; or

 (c) for internal use for the treatment of animals:

 (i) in divided preparations for dogs, containing 250 micrograms or less of moxidectin per dosage unit in a pack containing six or less dosage units; or

 (ii) in other preparations containing 2% or less of moxidectin.

MYCLOBUTANIL.

NAA except in preparations containing 25% or less of NAA.

NALED when impregnated in plastic resin strip material containing 20% or less of naled.

NAPTALAM.

NEOSCYTALIDIUM NOVAEHOLLANDIAE except when used as a herbicide in capsule preparations at a concentration of 16 CFU or less per capsule.

NETOBIMIN for the treatment of animals, in preparations containing 12.5% or less of netobimin.

NITRIC ACID (excluding its salts and derivatives) in preparations containing 10% or less of nitric acid (HNO3) except in preparations containing 0.5% or less of nitric acid.

NITROSCANATE for the treatment of animals.

NONANOIC ACID:

 (a) when used in a pesticide; or

 (b) in other preparations except in preparations containing 10% or less of nonanoic acid.

NONOXINOL 9 in preparations containing 25% or less of nonoxinol 9 except:

 (a) when labelled with the statements:

 (i) IRRITANT; and

 (ii) Avoid contact with eyes; or

 (b) in preparations containing 12.5% or less of nonoxinol 9; or

 (c) in preparations for human use.

NORBORMIDE.

NUTMEG OIL except:

 (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

 (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:

  KEEP OUT OF REACH OF CHILDREN; or

 (c) in preparations containing 50% or less of nutmeg oil.

NOCTYL BICYCLOHEPTENE DICARBOXIMIDE except in preparations containing 10% or less of Noctyl bicycloheptene dicarboximide.

N(NOCTYL)2PYRROLIDONE in preparations containing 50% or less of:

 (a) N(Noctyl)2pyrrolidone or preparations containing 50% or less of a mixture of any two or more of N(Noctyl)2pyrrolidone, Nmethyl2pyrrolidone; or

 (b) N(Ndodecyl)2pyrrolidone except in preparations containing 25% or less of designated solvents.

OLEANDOMYCIN in animal feed premixes for growth promotion.

OMETHOATE in pressurised spray packs containing 0.2% or less of omethoate.

ORANGE OIL (BITTER) except:

 (a) when steam distilled or rectified; or

 (b) in preparations for internal use; or

 (c) in preparations containing 1.4% or less of orange oil (bitter); or

 (d) in soaps or bath or shower gels that are washed off the skin; or

 (e) in medicines for human therapeutic use, when compliant with the requirements of the required advisory statements for medicine labels; or

 (f) in other preparations when packed in containers labelled with the statement:

  Application to the skin may increase sensitivity to sunlight.

OXADIARGYL.

OXADIXYL.

OXANTEL EMBONATE for the treatment of animals.

OXFENDAZOLE for the treatment of animals.

OXIBENDAZOLE for the treatment of animals.

OXYCARBOXIN.

OXYTETRACYCLINE in preparations:

 (a) for topical application to animals for ocular use only; or

 (b) containing 40% or less of oxytetracycline per dose, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

OXYTHIOQUINOX.

PACLOBUTRAZOL.

PENCONAZOLE.

PENDIMETHALIN.

PENFLUFEN.

PENTHIOPYRAD except in preparations containing 20% or less of penthiopyrad.

PERACETIC ACID in concentrations of 10% or less of peracetic acid.

PERMETHRIN (excluding preparations for human therapeutic use):

 (a) in preparations containing 25% or less of permethrin; or

 (b) in preparations for external use, for the treatment of dogs, containing 50% or less of permethrin when packed in single use containers having a capacity of 4 mL or less;

 except in preparations containing 2% or less of permethrin.

PETROL except preparations containing 25% or less of petrol.

PHENAZONE for the external treatment of animals.

PHENISOPHAM.

PHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, when in animal feed additives containing 15% or less of such substances, except in preparations containing 1% or less of phenol and in preparations containing 3% or less of cresols and xylenols and other homologues of phenol.

PHENYL METHYL KETONE except in preparations containing 25% or less of designated solvents.

oPHENYLPHENOL except in preparations containing 5% or less of ophenylphenol.

PHOSPHONIC ACID (excluding its salts and derivatives) except in preparations containing 10% or less of phosphonic acid (H3PO3).

PHOSPHORIC ACID (excluding its salts and derivatives) in preparations containing 35% or less of phosphoric acid (H3PO4) except:

 (a) in preparations containing 15% or less of phosphoric acid (H3PO4); or

 (b) in solid or semisolid preparations; or

 (c) in professional dental kits.

oPHTHALALDEHYDE in preparations containing 1% or less of ophthalaldehyde.

PICARIDIN except in preparations containing 20% or less of picaridin.

PINE OILS in preparations containing 25% or less of pine oils when packed and labelled as a herbicide.

PINOXADEN in preparations containing 10% or less of pinoxaden.

PIPERAZINE for animal use.

PIRIMICARB in preparations containing 0.5% or less of pirimicarb.

POLIXETONIUM SALTS in preparations containing 60% or less of polixetonium salts except in preparations containing 1% or less of polixetonium salts.

POLYETHANOXY (15) TALLOW AMINE.

POLYOXIN D ZINC SALT.

POLY(OXY1,2ETHANEDIYL), α [2[(2HYDROXYETHYL)AMINO]2OXOETHYL] α HYDROXY,MONOC1315ALKYL ETHERS.

POTASSIUM CHLORATE except:

 (a) when included in Schedule 2; or

 (b) in preparations containing 10% or less of potassium chlorate.

POTASSIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5% or less of potassium hydroxide being:

 (a) solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or

 (b) liquid or semisolid preparations, the pH of which is more than 11.5 except in food additive preparations for domestic use.

POTASSIUM METABISULPHITE when packed for domestic use except in preparations containing 10% or less of potassium metabisulphite.

POTASSIUM NITRITE in preparations containing 1% or less of potassium nitrite except:

 (a) in preparations containing 0.5% or less of potassium nitrite;

 (b) when present as an excipient in preparations for therapeutic use; or

 (c) in aerosols.

POTASSIUM PEROXOMONOSULFATE TRIPLE SALT in preparations containing 5% or less of potassium peroxomonosulfate triple salt being:

 (a) solid preparations, the pH of which in a 10 g/L aqueous solution is less than 2.5; or

 (b) liquid or semisolid preparations, the pH of which is less than 2.5.

POTASSIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of potassium sulfide.

PRALLETHRIN (cis:trans=20:80) in preparations containing 10% or less of prallethrin except in insecticidal mats containing 1% or less of prallethrin.

PROFOXYDIM except in preparations containing 20% or less of profoxydim.

PROGESTERONE:

 (a) in implant preparations or controlled release pessaries for synchronisation of oestrus in cattle, sheep or goats; or

 (b) in implant preparations for growth promotion in cattle.

PROHEXADIONE CALCIUM.

PROMETRYN.

PROPAMOCARB.

PROPANIL.

PROPAQUIZAFOP.

PROPICONAZOLE in preparations containing 20% or less of propiconazole.

PROPIONIC ACID (excluding its salts and derivatives) in preparations containing 80% or less of propionic acid, except:

 (a) in preparations containing 30% or less of propionic acid; or

 (b) for therapeutic use.

PROPOXUR:

 (a) when impregnated in plastic resin strip material containing 10% or less of propoxur; or

 (b) in dust preparations containing 3% or less of propoxur; or

 (c) in granular sugarbased fly baits containing 1% or less of propoxur, a dark colouring agent and a separate bittering agent; or

 (d) in pressurised spray packs containing 2% or less of propoxur; or

 (e) in printed paper sheets for pest control containing 0.5% or less of propoxur and in any case not more than 100 mg of propoxur per sheet.

nPROPYL ALCOHOL in preparations containing 10% or less of npropyl alcohol except:

 (a) in preparations containing 5% or less of npropyl alcohol; or

 (b) in preparations for cosmetic or therapeutic use other than in spray form.

PROPYZAMIDE.

PROTHIOCONAZOLEDESCHLORO except in preparations containing 0.5% or less of prothioconazoledeschloro.

PROTHIOCONAZOLETRIAZOLIDINETHIONE except in preparations containing 0.5% or less of prothioconazoletriazolidinethione.

PYMETROZINE.

PYRACLOSTROBIN.

PYRAFLUFENETHYL.

PYRASULFOTOLE.

PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids except:

 (a) in preparations for human therapeutic use; or

 (b) in preparations containing 10% or less of such substances.

PYRIDABEN in preparations containing 25% or less of pyridaben.

PYRIFENOX.

PYRITHIOBAC SODIUM.

PYRITHIONE ZINC in paints containing 0.5% or less of pyrithione zinc calculated on the nonvolatile content of the paint except in paints containing 0.1% or less of pyrithione zinc calculated on the nonvolatile content of the paint.

PYRIOFENONE in preparations containing 30% or less of pyriofenone.

QUATERNARY AMMONIUM COMPOUNDS in preparations containing 20% or less of quaternary ammonium compounds except:

 (a) when separately specified in these Schedules; or

 (b) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C16/C18) sources; or

 (c) in preparations containing 5% or less of such quaternary ammonium compounds.

QUINCLORAC.

QUININE in preparations for veterinary use containing 1% or less of quinine.

QUINTOZENE.

QUIZALOFOPpETHYL in aqueous preparations containing 40% or less of
quizalofoppethyl.

RACTOPAMINE in animal feed premixes containing 10% or less of ractopamine.

RESMETHRIN in preparations containing 10% or less of resmethrin.

RIMSULFURON.

ROBENIDINE except in preparations containing 20% or less of robenidine.

ROSIN when packaged for use as a soldering flux or in fluxcored solder.

SAFLUFENACIL in water dispersible granules or a waterbased suspension concentrate.

SALICYLANILIDE.

SAROLANER for veterinary use in divided preparations each containing 120 mg or less of sarolaner per dosage unit.

SEDAXANE.

SELAMECTIN except in preparations containing 12% or less of selamectin.

SETHOXYDIM.

SIDURON.

SILICOFLUORIDES in preparations containing 3% or less of fluoride ion except:

 (a) barium silicofluoride when separately specified in this Schedule; or

 (b) in preparations containing 15 mg/kg or less of fluoride ion.

SINBIOALLETHRIN in preparations containing 10% or less of sinbioallethrin except in preparations containing 1% or less of sinbioallethrin.

SODIUM BROMIDE except when included in Schedule 4.

SODIUM CHLORATE except in preparations containing 10% or less of sodium chlorate.

SODIUM DIACETATE except in preparations containing 60% or less of sodium diacetate.

SODIUM DODECYLBENZENE SULFONATE except in preparations containing 30% or less of sodium dodecylbenzene sulfonate.

SODIUM HYDROGEN SULFATE except in preparations containing 10% or less of sodium hydrogen sulfate.

SODIUM HYDROSULFITE when packed for domestic use except in preparations containing 10% or less of sodium hydrosulfite.

SODIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5% or less of sodium hydroxide being:

 (a) solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or

 (b) liquid or semisolid preparations, the pH of which is more than 11.5 except in food additive preparations for domestic use.

SODIUM LAURETH6 CARBOXYLATE except in preparations containing 1% or less of sodium laureth6 carboxylate.

SODIUM METABISULPHITE when packed for domestic use except in preparations containing 10% or less of sodium metabisulphite.

SODIUM NITRITE in preparations containing 1% or less of sodium nitrite except:

 (a) in preparations containing 0.5% or less of sodium nitrite; or

 (b) when present as an excipient in preparations for therapeutic use; or

 (c) in aerosols.

SODIUM PERCARBONATE (CAS No. 15630894) in preparations containing 35% or less of sodium percarbonate except in preparations containing 15% or less of sodium percarbonate.

SODIUM POLYSTYRENE SULPHONATE in preparations for cosmetic use except in preparations containing 10% or less of sodium polystyrene sulphonate.

SODIUM STANNATE except in preparations for cosmetic use containing 1% or less of sodium stannate.

SODIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of sodium sulfide.

SPINETORAM.

SPINOSAD except in aqueous suspensions containing 25% or less of spinosad.

SPIROMESIFEN for agricultural use.

STAR ANISE OIL except:

 (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

 (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:

  KEEP OUT OF REACH OF CHILDREN; or

 (c) in preparations containing 50% or less of star anise oil.

STYRENE (excluding its derivatives).

SULFACETAMIDE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

SULFADIAZINE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

SULFADIMIDINE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

SULFAMERAZINE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

SULFAMIC ACID (excluding its salts and derivatives) in preparations containing 10% or less of sulfamic acid (H3NO3S).

SULFATHIAZOLE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

SULFOMETURONMETHYL.

SULFOXAFLOR in preparations containing 25% or less of sulfoxaflor.

SYMPHYTUM spp. (Comfrey) for dermal therapeutic or dermal cosmetic use.

2,3,6TBA.

TDE (1,1dichloro2,2bis[4chlorophenyl]ethane) in preparations containing 10% or less of TDE.

TEBUCONAZOLE.

TEBUFENOZIDE.

TEFLUTHRIN in preparations containing 2% or less of tefluthrin.

TEMEPHOS:

 (a) in liquid preparations containing 10% or less of temephos; or

 (b) in powders containing 2% or less of temephos; or

 (c) in preparations containing 40% or less of temephos when packed in single use containers having a capacity of 2 mL or less.

TEPRALOXYDIM.

TERBUTRYN.

TETRACHLOROETHYLENE in preparations containing 5% or less of tetrachloroethylene except:

 (a) when included in Schedule 2; or

 (b) in preparations for the treatment of animals; or

 (c) when absorbed into an inert solid.

TETRACHLORVINPHOS except in animal feeds containing 0.2% or less of tetrachlorvinphos.

TETRACONAZOLE in preparations containing 20% or less of tetraconazole.

TETRACYCLINE in preparations:

 (a) for topical application to animals for ocular use only; or

 (b) containing 40% or less of tetracycline when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

TETRAMETHRIN [(R, cis): (R, trans) = 20:80] except in pressurised spray packs.

TETRANILIPROLE except in preparations containing 20% or less tetraniliprole.

THIABENDAZOLE:

 (a) for the treatment of animals; or

 (b) when packed and labelled for use as a fungicide except in preparations containing 50% or less of thiabendazole.

THIAMETHOXAM in preparations containing 60% or less of thiamethoxam.

THIAZOPYR.

THIFENSULFURON.

THIOBENCARB.

THIODICARB in pelleted preparations containing 1.5% or less of thiodicarb.

THIOPHANATEMETHYL in preparations containing 25% or less of thiophanatemethyl.

THYME OIL except:

 (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

 (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:

  KEEP OUT OF REACH OF CHILDREN; or

 (c) in preparations containing 50% or less of thyme oil.

TIGOLANER in preparations containing 10% or less of tigolaner.

TIOCARBAZIL.

TOLCLOFOSMETHYL.

TOLTRAZURIL.

TOPRAMEZONE

TRALKOXYDIM.

TRENBOLONE in implant preparations for growth promotion in animals.

TRIADIMEFON in wettable powders containing 25% or less of triadimefon.

TRIADIMENOL.

TRIALLATE.

TRIBENURONMETHYL.

TRICHLOROACETIC ACID, alkali salts of.

1,1,1TRICHLOROETHANE except:

 (a) in preparations packed in pressurised spray packs; or

 (b) in preparations containing 25% or less of designated solvents; or

 (c) in preparations, other than writing correction fluids or thinners for writing correction fluids in containers having a capacity of 50 mL or less; or

 (d) in writing correction fluids or thinners for writing correction fluids, in containers having a capacity of 50 mL or less labelled with:

 (i) the word “Trichloroethane” written in letters not less than 1 mm in height and in distinct contrast to the background; and

 (ii) the expression:

  WARNING – DO NOT DELIBERATELY SNIFF THIS PRODUCT. SNIFFING MIGHT HARM OR KILL YOU;

  written in bold face sans serif capital letters not less than 1 mm in height and in distinct contrast to the background.

TRIDIPHANE.

TRIETAZINE.

TRIFLOXYSTROBIN.

TRIFLUDIMOXAZIN except in preparations containing 12.5% or less.

TRIFLUMIZOLE.

TRIFLUMURON.

TRIISOPROPANOLAMINE LAURYL ETHER SULFATE except in preparations containing 30% or less of triisopropanolamine lauryl ether sulfate when labelled with the statements:

 (a) Avoid contact with eyes and skin; and

 (b) Wash hands after handling.

TRINEXAPACETHYL except:

 (a) when packed in a sealed watersoluble measure pack; or

 (b) in solid preparations containing 25% or less of trinexapacethyl in packs of 50 g or less.

3,6,9TRIOXAUNDECANEDIOIC ACID except in preparations containing 5% or less of 3,6,9trioxaundecanedioic acid, the pH of which is 3.5 or greater.

TRITICONAZOLE.

TROLAMINE (excluding its salts and derivatives) except:

 (a) when in Schedule 4; or

 (b) in preparations containing 5% or less of trolamine.

TURPENTINE OIL except in preparations containing 25% or less of turpentine oil.

VIRGINIAMYCIN in animal feed additives containing 1% or less of virginiamycin for the prevention of laminitis in horses when in a pack of 5 kg or less.

VERNOLATE.

WARFARIN in rodent baits containing 0.1% or less of warfarin.

ZINEB.

Schedule 6Poisons

 

 

Note: See section 16, subsection 46(2), section 49, subsection 54(3) and sections 55 and 61.

ABAMECTIN:

 (a) in preparations for pesticidal use containing 4% or less of abamectin except when included in Schedule 5; or

 (b) in slowrelease plastic matrix ear tags for livestock use containing 1 g or less of abamectin.

ACEPHATE.

ACETAMIPRID except in preparations containing 1% or less of acetamiprid.

ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80% of acetic acid (CH3COOH) except when included in Schedule 2.

ACETIC ANHYDRIDE excluding its derivatives.

ACIFLUORFEN.

ACINITRAZOLE except in preparations containing 20% or less of acinitrazole.

ACLONIFEN.

ALBENDAZOLE for the treatment of animals except:

 (a) when included in Schedule 5; or

 (b) in intraruminal implants each containing 3.85 g or less of albendazole.

ALDRIN.

ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for nondomestic use:

 (a) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or

 (b) in liquid or semisolid automatic dishwashing preparations, the pH of which is more than 12.5.

ALKOXYLATED FATTY ALKYLAMINE POLYMER except:

 (a) when included in Schedule 5; or

 (b) in preparations containing 20% or less of alkoxylated fatty alkylamine polymer.

ALLETHRIN except:

 (a) when included in Schedule 5; or

 (b) in insecticidal mats containing 20% or less of allethrin; or

 (c) in other preparations containing 1% or less of allethrin.

ALLYL ESTERS (excluding derivatives) being:

 (a) ALLYL CYCLOHEXANEACETATE (CAS No. 4728829); or

 (b) ALLYL CYCLOHEXANEPROPIONATE (CAS No. 2705875); or

 (c) ALLYL HEPTANOATE/ALLYL HEPTYLATE (CAS No. 142198); or

 (d) ALLYL HEXANOATE (CAS No. 123682); or

 (e) ALLYL ISOVALERATE (CAS No. 2835394); or

 (f) ALLYL NONANOATE (CAS No. 7493723); or

 (g) ALLYL OCTANOATE (CAS No. 4230971); or

 (h) ALLYL PHENYLACETATE (CAS No. 1797746); or

 (i) ALLYL TRIMETHYLHEXANOATE (CAS No. 68132809);

 in preparations containing 0.1% or less of free allyl alcohol by weight of allyl ester except in preparations containing 5% or less of allyl esters with 0.1% or less of free allyl alcohol by weight of allyl esters.

ALPHACYPERMETHRIN:

 (a) in aqueous preparations containing 30% or less of alphacypermethrin; or

 (b) in other preparations containing 10% or less of alphacypermethrin;

 except when included in Schedule 5.

AMICARBAZONE.

AMIDITHION.

AMIDOPROPYL BETAINES except:

 (a) in cosmetic washoff preparations containing 30% or less of amidopropyl betaines and, if containing more than 5% of amidopropyl betaines when labelled with a warning to the following effect:

  IF IN EYES WASH OUT IMMEDIATELY WITH WATER;

  in cosmetic leaveon preparations containing 1.5% or less of amidopropyl betaines; or

 (b) in other preparations containing 30% or less of amidopropyl betaines and, if containing more than 5% of amidopropyl betaines, when labelled with warnings to the following effect:

 (i) IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and

 (ii) IF SKIN OR HAIR CONTACT OCCURS, REMOVE CONTAMINATED CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER.

2AMINO6CHLORO4NITROPHENOL in hair dye and eyebrow/eyelash colouring preparations, except:

 (a) in preparations containing 2% or less of 2amino6chloro4nitrophenol when applied directly to the hair, or containing 2% or less of 2amino6chloro4nitrophenol after mixing and when the immediate container and primary pack are labelled with the following statements:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

 (b) in eyelash and eyebrow tinting products containing 1.5% or less of 2amino6chloro4nitrophenol after mixing for use when the immediate container and primary pack are labelled with the following statement:

  WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals, and when used for eyelash or eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use;

  written in letters not less than 1.5mm in height.

4AMINOmCRESOL in hair dyes and eyebrow/eyelash colouring preparations except:

 (a) in hair dye preparations containing 1.5% or less of 4aminomcresol after mixing for use when the immediate container and primary pack are labelled with the following statements:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

  written in letters not less than 1.5mm in height; or

 (b) in eyelash and eyebrow tinting products containing 1.5% or less of 4aminomcresol after mixing for use when the immediate container and primary pack are labelled with the following statement:

  WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals, and when used for eyelash or eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use;

  written in letters not less than 1.5mm in height.

2AMINO5ETHYLPHENOL in hair dye preparations except in preparations containing 1% or less of 2amino5ethylphenol when the immediate container and primary pack are labelled with the following statements:

 (a) KEEP OUT OF REACH OF CHILDREN; and

 (b) WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes and eyebrows; to do so may be injurious to the eye;

 written in letters not less than 1.5 mm in height.

4AMINO2HYDROXYTOLUENE in hair dyes and eyebrow/eyelash colouring products except:

 (a) in hair dye preparations containing 1.5% or less of 4amino2hydroxytoluene after mixing for use when the immediate container and primary pack are labelled with the following statements:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

  written in letters not less than 1.5mm in height; or

 (b) in eyelash and eyebrow tinting products containing 1.5% or less of 4amino2hydroxytoluene after mixing for use when the immediate container and primary pack are labelled with the following statement:

  WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals, and when used for eyelash or eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use;

  written in letters not less than 1.5mm in height.

AMINOCARB in preparations containing 25% or less of aminocarb.

AMINOETHOXYVINYLGLYCINE except in preparations containing 15% or less of aminoethoxyvinylglycine.

1AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE.

4AMINO3NITROPHENOL except:

 (a) in nonoxidative hair dye preparations and eyebrow/eyelash colouring products containing 1% or less of 4amino3nitrophenol when the immediate container and primary pack are labelled with the following statements:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

  written in letters not less than 1.5 mm in height; or

 (b) in oxidative hair dye preparations and eyebrow/eyelash colouring products containing 1% or less of 4amino3nitrophenol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

  written in letters not less than 1.5 mm in height.

2,2'[(4AMINO3NITROPHENYL)IMINO]BISETHANOL (including its salts) except:

 (a) in nonoxidative hair dye preparations containing 2.5% or less of 2,2'[(4amino3nitrophenyl)imino]bisethanol after mixing when the immediate container and primary pack are labelled with the following statements:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

  written in letters not less than 1.5 mm in height; or

 (b) in oxidative hair dye preparations containing 1.25% or less of 2,2'[(4amino3nitrophenyl)imino]bisethanol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

  written in letters not less than 1.5 mm in height.

mAMINOPHENOL except when used in hair dye and eyebrow/eyelash preparations at a concentration of 1.2% or less of maminophenol after mixing for use when the immediate container and primary pack are labelled with the following statements:

 (a) KEEP OUT OF REACH OF CHILDREN; and

 (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

 written in letters not less than 1.5 mm in height.

p AMINOPHENOL except when used in hair dye and eyebrow/eyelash colouring products at a concentration of 1% or less of paminophenol after mixing for use when the immediate container and primary pack are labelled with the following statements:

 (a) KEEP OUT OF REACH OF CHILDREN; and

 (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

 written in letters not less than 1.5 mm in height.

AMINOPYRALID except when included in Schedule 5.

AMITRAZ.

AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) except:

 (a) when included in Schedule 5; or

 (b) in preparations for human internal therapeutic use; or

 (c) in preparations for inhalation when absorbed in an inert solid material; or

 (d) in preparations containing 0.5% or less of ammonia.

AMMONIUM COCOYL ISETHIONATE, except in cosmetic rinseoff preparations containing 30% or less of ammonium cocoyl isethionate and, if containing more than 5% of ammonium cocoyl isethionate, when labelled with a warning to the following effect:

  IF IN EYES WASH OUT IMMEDIATELY WITH WATER.

AMMONIUM PERSULFATE in hair preparations.

ANILINE (excluding its salts and derivatives) except in preparations containing 1% or less of aniline.

ANTIMONY COMPOUNDS except:

 (a) when included in Schedule 4; or

 (b) antimony chloride in polishes; or

 (c) antimony titanate pigments in paint; or

 (d) in paints or tinters containing 5% or less of antimony calculated on the nonvolatile content of the paint or tinter.

ARBUTIN (ALPHA) except:

 (a) in preparations for application to the face containing 2% or less alphaarbutin with hydroquinone levels of 10mg/kg or less; or

 (b) in preparations for application to the body containing 0.5% or less alphaarbutin with hydroquinone levels of 10mg/kg or less.

ARBUTIN (BETA) except:

 (a) when included in Schedule 4; or

 (b) oral herbal preparations containing 500 mg or less betaarbutin per recommended daily dose; or

 (c) in preparations for application to the face containing 7% or less betaarbutin with hydroquinone levels of 10mg/kg or less.

ARBUTIN (DEOXY OR OTHER DERIVATIVES).

ARSENIC:

 (a) in ant poisons containing 0.4% or less of arsenic; or

 (b) in animal feed premixes containing 4% or less of arsenic; or

 (c) in preparations for the treatment of animals except thiacetarsamide when included in Schedule 4,

 except when separately specified in this Schedule.

ASPIRIN for the treatment of animals except when included in Schedule 4 or 5.

AZACONAZOLE except in preparations containing 1% or less of azaconazole.

AZADIRACHTA INDICA (Neem) including its extracts and derivatives except:

 (a) when included in Schedule 5; or

 (b) in preparations for human internal use; or

 (c) debitterised neem seed oil; or

 (d) in preparations for human dermal therapeutic use containing cold pressed neem seed oil, when in a container fitted with a childresistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

 (e) in preparations for dermal use containing 1% or less of cold pressed neem seed oil.

AZAMETHIPHOS.

AZOBENZENE.

BAMBERMYCIN (flavophospholipol) in animal feed premixes for growth promotion containing 2% or less of antibiotic substances.

BARIUM SALTS except:

 (a) when included in Schedule 5; or

 (b) barium sulfate; or

 (c) in paints or tinters containing 5% or less of barium calculated on the nonvolatile content of the paint or tinter.

BASIC BLUE 26 (CAS No. 2580565) except when used as a colourant in cosmetics not intended to be in contact with mucous membranes.

BASIC ORANGE 31 (2[(4aminophenyl)azo]1,3dimethyl1Himidazolium chloride) except:

 (a) in preparations for skin colouration and dyeing of eyelashes or eyebrows; or

 (b) in hair dye preparations containing 1% or less of Basic Orange 31 when the immediate container and primary pack are labelled with the following statements:

 (i) KEEP OUT OF REACH OF CHILDREN;

 (ii) IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and

 (iii) WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

  written in letters not less than 1.5 mm in height.

BASIC RED 76 (CAS No. 68391300) in nonoxidative hair dye preparations and eyebrow/eyelash colouring products containing 2% or less of Basic Red 76 and 0.001% or less of free oanisidine.

BAY OIL except:

 (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

 (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a childresistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

 (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) NOT TO BE TAKEN; or

 (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a childresistant closure and labelled with the warnings:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) NOT TO BE TAKEN; or

 (e) in preparations containing 25% or less of bay oil.

BEAUVERIA BASSIANA except when included in Schedule 5.

BENDIOCARB:

 (a) in wettable powders containing 80% or less of bendiocarb when packed in containers or primary packs containing not less than 100 g of bendiocarb; or

 (b) in wettable powders containing 20% or less of bendiocarb and not less than 0.002% of denatonium benzoate when packed in containers or primary packs containing not less than 48 g of bendiocarb and labelled for use as a fly control preparation; or

 (c) in insoluble granular preparations containing 5% or less of bendiocarb; or

 (d) when impregnated in plastic resin strip material containing 10% or less of bendiocarb;

 except when included in Schedule 5.

BENQUINOX.

BENSULIDE.

BENZALKONIUM CHLORIDE except:

 (a) when included in Schedule 5; or

 (b) in preparations containing 5% or less of benzalkonium chloride.

1,2BENZENEDIOL.

BENZOVINDIFLUPYR.

6BENZYLADENINE except in preparations containing 10% or less of 6benzyladenine.

BERYLLIUM.

BETACYFLUTHRIN in preparations containing 12.5% or less of betacyfluthrin except when included in Schedule 5.

BETACYPERMETHRIN.

BHC (excluding lindane).

BICYCLOPYRONE except when included in Schedule 5.

BIFENTHRIN in preparations containing 25% or less of bifenthrin except in preparations containing 0.5% or less of bifenthrin.

BIFLUORIDES (including ammonium, potassium and sodium salts) in preparations containing 3% or less of total bifluorides except when included in Schedule 5.

BIOALLETHRIN except:

 (a) when included in Schedule 5; or

 (b) in preparations containing 1% or less of bioallethrin.

1,3BIS(2,4DIAMINOPHENOXY)PROPANE (including its salts) except when in hair dye preparations containing 1.2% or less of 1,3bis(2,4diaminophenoxy)propane after mixing when the immediate container and primary pack are labelled with the following statements:

 (a) KEEP OUT OF REACH OF CHILDREN; and

 (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

 written in letters not less than 1.5 mm in height.

BISISOBUTYL PEG/PPG20/35/AMODIMETICONE COPOLYMER except in rinseoff cosmetic products containing 1% or less of bisisobutyl PEG/PPG20/35/amodimeticone copolymer when labelled with a warning to the following effect:

  IF IN EYES, WASH OUT IMMEDIATELY WITH WATER.

N,NBIS(PHENYLMETHYLENE)BICYCLO(2.2.1)HEPTANE2,5DIMETHANAMINE except in preparations containing 1% or less of N,Nbis(phenylmethylene)bicyclo (2.2.1)heptane2,5dimethanamine, or a combination of N,Nbis(phenylmethylene)bicyclo(2.2.1)heptane2,5dimethanamine and N,Nbis(phenylmethylene)bicyclo(2.2.1)heptane2,6dimethanamine, when labelled with statements to the effect of:

 (a) IRRITANT; and

 (b) REPEATED EXPOSURE MAY CAUSE SENSITISATION; and

 (c) Avoid contact with eyes; and

 (d) Avoid contact with skin; and

 (e) Wear protective gloves when mixing or using; and

 (f) Ensure adequate ventilation when using.

N,NBIS(PHENYLMETHYLENE)BICYCLO(2.2.1)HEPTANE2,6DIMETHANAMINE except in preparations containing 1% or less of N,Nbis(phenylmethylene)bicyclo(2.2.1)heptane2,6dimethanamine, or a combination of N,Nbis(phenylmethylene)bicyclo(2.2.1)heptane2,5dimethanamine and N,Nbis(phenylmethylene)bicyclo(2.2.1)heptane2,6dimethanamine, when labelled with statements to the effect of:

 (a) IRRITANT; and

 (b) REPEATED EXPOSURE MAY CAUSE SENSITISATION; and

 (c) Avoid contact with eyes; and

 (d) Avoid contact with skin; and

 (e) Wear protective gloves when mixing or using; and

 (f) Ensure adequate ventilation when using.

BITHIONOL for the treatment of animals.

BORON TRIFLUORIDE in preparations containing 1% or less of boron trifluoride (BF3) except when included in Schedule 5.

BRODIFACOUM in preparations containing 0.25% or less of brodifacoum.

BROFLANILIDE except when included in Schedule 5.

BROMADIOLONE in preparations containing 0.25% or less of bromadiolone.

BROMETHALIN in rodent baits containing 0.01% or less of bromethalin.

BROMOFORM except when included in Schedule 4.

BROMOPHOS.

BROMOPHOSETHYL.

BROMOXYNIL.

BROMUCONAZOLE except when included in Schedule 5.

BROTIANIDE.

BUNAMIDINE.

BUTACARB.

BUTOXYCARBOXIM except when included in Schedule 5.

2BUTOXYETHANOL and its acetates except:

 (a) in plant growth regulator preparations containing 20% or less of such substances; or

 (b) in other preparations containing 10% or less of such substances.

2BUTOXY2'THIOCYANODIETHYL ETHER.

nBUTYL ALCOHOL except:

 (a) when included in Schedule 5; or

 (b) in preparations containing 5% or less of nbutyl alcohol; or

 (c) in preparations for cosmetic or therapeutic use other than in spray form.

BUTYRIC ACID in preparations for use as insect lures.

CACODYLIC ACID:

 (a) in animal feed premixes containing 4% or less of arsenic; or

 (b) in herbicide or defoliant preparations containing 10% or less of cacodylic acid.

CADMIUM COMPOUNDS except:

 (a) when included in Schedule 4; or

 (b) in paints or tinters containing 0.1% or less of cadmium calculated on the nonvolatile content of the paint or tinter.

CADUSAFOS in aqueous preparations containing 20% or less of microencapsulated cadusafos.

CAFFEINE except:

 (a) when included in Schedule 4; or

 (b) in divided preparations for internal human therapeutic use when labelled with a maximum recommended daily dose of no greater than 600 mg of total caffeine; or

 (c) in undivided preparations for internal human therapeutic use with a concentration of less than 5% of total caffeine and when labelled with a maximum recommended daily dose of no greater than 600 mg of total caffeine; or

 (d) in preparations for external use; or

 (e) in other preparations with a concentration of less than 5% of caffeine.

CAJUPUT OIL except:

 (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

 (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a childresistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

 (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) NOT TO BE TAKEN; or

 (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a childresistant closure and labelled with the warnings:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) NOT TO BE TAKEN; or

 (e) in preparations containing 25% or less of cajuput oil; or

 (f) in oils containing 25% or less of cajuput oil.

CALCIFEROL in rodent baits containing 0.1% or less of calciferol.

CAMBENDAZOLE.

CAMPHOR except:

 (a) when included in Schedule 4 or 5; or

 (b) when enclosed in an inhaler device which prevents ingestion of its contents; or

 (c) in solid or semisolid preparations containing 12.5% or less of camphor; or

 (d) in liquid preparations containing 2.5% or less of camphor; or

 (e) in essential oils when the camphor is present as a natural component of the oil:

 (i) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

 (ii) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a childresistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

 (iii) in essential oils other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

 (A) KEEP OUT OF REACH OF CHILDREN; and

 (B) NOT TO BE TAKEN; or

 (iv) in essential oils other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a childresistant closure and labelled with the warnings:

 (A) KEEP OUT OF REACH OF CHILDREN; and

 (B) NOT TO BE TAKEN; or

 (f) in rosemary oil, sage oil (Spanish), or lavandin oil as such.

CAPTAN.

CARBARYL except when included in Schedule 4 or 5.

CARBON DISULFIDE.

CARBAMIDE PEROXIDE except:

 (a) when included in Schedule 5; or

 (b) in other preparations containing 9% or less of carbamide peroxide.

CARBETAMIDE.

CASTOR OIL, MONOMALEATE (excluding its salts and derivatives) in preparations for cosmetic use except in washoff preparations containing 1% or less of castor oil, monomaleate.

CHLORALOSE (alphaCHLORALOSE) when packed and labelled for use as a pesticide.

CHLORDANE.

CHLORFENAPYR in preparations containing 36% or less of chlorfenapyr except when included in Schedule 5.

CHLORFENETHOL.

CHLORHEXIDINE in preparations containing 7% or less of chlorhexidine except:

 (a) when included in Schedule 5; or

 (b) in preparations containing 1% or less of chlorhexidine; or

 (c) when in solid preparations.

CHLORINATING COMPOUNDS except:

 (a) when included in Schedule 5; or

 (b) when separately specified in these Schedules; or

 (c) sodium hypochlorite preparations with a pH of less than 11.5; or

 (d) in liquid preparations containing not less than 2% but not more than 4% of available chlorine when labelled with the statements:

  WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products; or

 (e) in liquid preparations containing less than 2% of available chlorine; or

 (f) in other preparations containing 4% or less of available chlorine.

CHLORMEQUAT.

CHLOROACETAMIDE

 (a) in preparations for cosmetic use; or

 (b) in preparations for topical therapeutic use; or

 (c) in other preparations containing more than 0.3% of chloroacetamide.

2CHLORO6(ETHYLAMINO)4NITROPHENOL except:

 (a) in nonoxidative hair dye preparations containing 3% or less of 2chloro6(ethylamino)4nitrophenol after mixing for use when the immediate container and primary pack are labelled with the following statements:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

  written in letters not less than 1.5 mm in height; or

 (b) in oxidative hair dye preparations containing 1.5% or less of 2chloro6(ethylamino)4nitrophenol after mixing for use when the immediate container and primary pack are labelled with the following statements:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

  written in letters not less than 1.5 mm in height.

CHLOROFORM except:

 (a) when included in Schedule 2 or 4; or

 (b) in preparations containing 10% or less of chloroform.

ALPHACHLOROHYDRIN.

CHLOROPHACINONE.

(E)(S)1(4CHLOROPHENYL)4,4DIMETHYL2(1H1,2,4TRIAZOL1YL)PENT1EN3OL (uniconazolep) except in preparations containing 5% or less of (E)(S)1(4chlorophenyl)4,4dimethyl2(1H1,2,4triazol1yl)pent1en3ol.

CHLOROPICRIN in preparations containing 5% or less of chloropicrin.

CHLOROTHALONIL except in waterbased paint containing 0.5% or less of chlorothalonil.

2CHLORO6(TRICHLOROMETHYL)PYRIDINE.

CHLORPYRIFOS except:

 (a) when included in Schedule 5; or

 (b) in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre.

CHLORPYRIFOSMETHYL.

CHLORTHIAMID.

CHROMATES (including dichromates) except in paints or tinters containing 5% or less of chromium as the ammonium, barium, calcium, iron, potassium, sodium, strontium or zinc chromate calculated on the nonvolatile content of the paint or tinter.

CHROMIUM TRICHLORIDE HEXAHYDRATE except in preparations containing 0.5% or less chromium.

CHROMIUM TRIOXIDE (excluding its salts and derivatives).

CHRYSOIDINE BASE except when in Schedule 10.

CINEOLE except:

 (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

 (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a childresistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

 (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) NOT TO BE TAKEN; or

 (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a childresistant closure and labelled with the warnings:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) NOT TO BE TAKEN; or

 (e) in preparations containing 25% or less of cineole; or

 (f) in oils containing 25% or less of cineole; or

 (g) in rosemary oil or camphor oil (white).

CINNAMON LEAF OIL except:

 (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

 (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a childresistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

 (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) NOT TO BE TAKEN; or

 (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a childresistant closure and labelled with the warnings:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) NOT TO BE TAKEN; or

 (e) in preparations containing 25% or less of cinnamon leaf oil.

CLIMBAZOLE except:

 (a) when included in Schedule 5; or

 (b) in leaveon hair, face and foot cosmetic preparations containing 0.5% or less of climbazole; or

 (c) in other preparations (that are not leaveon cosmetic preparations) containing 2% or less of climbazole.

CLODINAFOPPROPARGYL.

CLOMAZONE.

CLOSANTEL.

CLOTHIANIDIN except

 (a) when included in Schedule 5; or

 (b) when in gel preparations dispensed in sealed cartridges containing 1% or less of clothianidin.

CLOTRIMAZOLE for the external treatment of animals.

CLOVE OIL except:

 (a) when included in Schedule 5; or

 (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

 (c) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a childresistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

 (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) NOT TO BE TAKEN;

 (e) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a childresistant closure and labelled with the warnings:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) NOT TO BE TAKEN; or

 (f) in preparations containing 25% or less of clove oil.

NCOCO1,3DIAMINOPROPANE.

COCOYL GLYCINATE in cosmetic preparations except:

 (a) in leaveon preparations containing 5% or less of cocoyl glycinate; or

 (b) in washoff preparations containing 30% or less of cocoyl glycinate and, when containing more than 5% of cocoyl glycinate labelled with a warning to the following effect:

  IF IN EYES WASH OUT IMMEDIATELY WITH WATER.

COPPER ACETATE except:

 (a) when included in Schedule 5; or

 (b) in preparations containing 5% or less of copper acetate.

COPPER COMPOUNDS except:

 (a) when separately specified in these Schedules; or

 (b) in preparations for human internal use containing 5 mg or less of copper per recommended daily dose; or

 (c) pigments where the solubility of the copper compound(s) in water is 1 g per litre or less; or

 (d) in feed additives containing 1% or less of copper; or

 (e) in other preparations containing 5% or less of copper compounds.

COPPER HYDROXIDE except:

 (a) when included in Schedule 5; or

 (b) in preparations containing 12.5% or less of copper hydroxide.

COPPER NITRATE in preparations containing copper chloride for the treatment of footrot in sheep.

COPPER OXIDES except:

 (a) when included in Schedule 5; or

 (b) in preparations for internal use; or

 (c) in marine paints; or

 (d) in other preparations containing 5% or less of copper oxides.

COPPER OXYCHLORIDE except:

 (a) when included in Schedule 5; or

 (b) in preparations containing 12.5% of less of copper oxychloride.

COPPER SULFATE except:

 (a) when included in Schedule 5; or

 (b) in preparations for internal use; or

 (c) in other preparations containing 5% or less of copper sulfate.

COUMAPHOS:

 (a) in slowrelease plastic matrix ear tags for livestock use containing 6 g or less of coumaphos; or

 (b) in other preparations containing 5% or less of coumaphos.

COUMATETRALYL in rodenticides containing 1% or less of coumatetralyl except when included in Schedule 5.

CREOSOTE derived from wood other than beechwood except:

 (a) when included in Schedule 2; or

 (b) in preparations for human therapeutic use containing 10% or less of creosote derived from wood other than beechwood; or

 (c) in other preparations containing 3% or less of phenols and homologues of phenol boiling below 220°C.

CROTOXYPHOS.

CRUFOMATE.

CYANAMIDE.

CYANAZINE.

CYCLANILIDE.

NCYCLOHEXYLDIAZENIUMDIOXYPOTASSIUM.

CYCLOSILAZANES, DIME, ME HYDROGEN, POLYMERS WITH DIME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3(TRIETHOXYSILYL)1PROPANAMINE (CAS 475645842) when presented in a wipe and when packaged in a container with a childresistant closure, with chemical resistant gloves and labelled with the following effect:

 (a) DO NOT USE WITHOUT PROTECTIVE GLOVES; and

 (b) KEEP OUT OF EYES.

CYFLUTHRIN except:

 (a) when included in Schedule 5; or

 (b) in pressurised spray packs containing 1% or less of cyfluthrin.

CYOMETRINIL.

CYPERMETHRIN except when included in Schedule 5.

CYPHENOTHRIN except when included in Schedule 5.

CYTHIOATE except when included in Schedule 5.

2,4D except when included in Schedule 5.

DAZOMET.

DELTAMETHRIN:

 (a) in aqueous preparations containing 25% or less of deltamethrin, when no organic solvent, other than 10% or less of a glycol, is present; or

 (b) in wettable granular preparations containing 25% or less of deltamethrin; or

 (c) in waterdispersible tablets each containing 500 mg or less of deltamethrin; or

 (d) in emulsifiable concentrates containing 11% or less of deltamethrin in a solvent containing 40% or less of acetophenone and 45% or less of liquid hydrocarbons; or

 (e) in other preparations containing 3% or less of deltamethrin;

 except:

 (f) when included in Schedule 5; or

 (g) in factory prepared mosquito nets containing 1% or less of deltamethrin; or

 (h) in preparations containing 0.1% or less of deltamethrin.

DERQUANTEL.

1DEOXY1(METHYLAMINO)dGLUCITOL NCOCO ACYL DERIVATIVES except:

 (a) in cosmetic rinseoff preparations containing 8% or less of 1deoxy1(methylamino)dglucitol Ncoco acyl derivatives when labelled with the following statement:

  IF IN EYES WASH OUT IMMEDIATELY WITH WATER, or

 (b) in household cleaning preparations, other than those intended to be sprayed, containing 10% or less of 1deoxy1(methylamino)dglucitol Ncoco acyl derivatives when labelled with the following statement:

  IF IN EYES WASH OUT IMMEDIATELY WITH WATER.

2,4DIAMINOPHENOXYETHANOL except when used in hair dye and eyebrow/eyelash preparations at concentrations of 2% or less of 2,4diaminophenoxyethanol after mixing for use when the immediate container and primary pack are labelled with the following statements:

 (a) KEEP OUT OF REACH OF CHILDREN; and

 (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

 written in letters not less than 1.5 mm in height.

DIAZINON except when included in Schedule 5.

DICAMBA (including its salts and derivatives) except when included in Schedule 5.

DICHLOBENIL.

DICHLOFENTHION.

DICHLOFLUANID.

oDICHLOROBENZENE.

DICHLOROETHYL ETHER.

DICHLOROISOCYANURIC ACID except:

 (a) when included in Schedule 5; or

 (b) in liquid preparations containing not less than 2% but not more than 4% of available chlorine when labelled with the statements:

  WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products; or

 (c) in liquid preparations containing less than 2% of available chlorine; or

 (d) in other preparations containing 4% or less of available chlorine.

4,5DICHLORO2NOCTYL3(2H)ISOTHIAZOLONE.

DICHLOROPHEN except:

 (a) when included in Schedule 4 or 5; or

 (b) in fabrics other than when:

 (i) for human therapeutic use; or

 (ii) as part of a registered pesticidal product.

1,2DICHLOROPROPANE.

2,4DICHLORPROP (including the R and S enantiomers).

DICHLORVOS in preparations containing 50% or less of dichlorvos except when included in Schedule 5.

DICLOFOPMETHYL.

DICYCLANIL except in preparations containing 6.5% or less of dicyclanil.

DIDECYLDIMETHYLAMMONIUM SALTS except in preparations containing 1% or less of didecyldimethylammonium salts labelled with the statement:

  Avoid contact with eyes.

DIELDRIN.

DIETHANOLAMINE (excluding its salts and derivatives) except:

 (a) when included in Schedule 5; or

 (b) in preparations containing 5% or less of diethanolamine.

DIETHYLENE GLYCOL (excluding its salts and derivatives) except:

 (a) when included in Schedule 5; or

 (b) in paints or paint tinters; or

 (c) in toothpastes or mouthwashes containing more than 0.25% of diethylene glycol; or

 (d) in other preparations containing 2.5% or less of diethylene glycol.

DIETHYLENE GLYCOL MONOMETHYL ETHER.

DIFENACOUM in preparations containing 0.25% or less of difenacoum.

DIFENZOQUAT.

DIFETHIALONE in rodent baits containing 0.0025% or less of difethialone.

5,6DIHYDROXYINDOLINE.

DIMETHENAMIDP.

DIMETHIPIN.

DIMETHOATE.

2,6DIMETHOXY3,5PYRIDINEDIAMINE except when used in hair dye and eyebrow/eyelash colouring products at a concentration of 0.25% or less of 2,6dimethoxy3,5pyridinediamine after mixing for use when the immediate container and primary pack are labelled with the following statements:

 (a) KEEP OUT OF REACH OF CHILDREN; and

 (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

 written in letters not less than 1.5 mm in height.

DIMETHYLACETAMIDE except when included in Schedule 5.

N,NDIMETHYLDECANAMIDE.

DIMETHYLFORMAMIDE except:

 (a) when included in Schedule 5; or

 (b) in silicone rubber mastic containing 2% or less of dimethylformamide.

4,4DIMETHYL1CYCLOHEXENE1PROPANAL except:

 (a) in leaveon cosmetic preparations containing 0.1% or less of 4,4dimethyl1cyclohexene1propanal; or

 (b) in rinseoff cosmetic preparations containing 0.5% or less of 4,4dimethyl1cyclohexene1propanal; or

 (c) in other preparations containing 1% or less of 4,4dimethyl1cyclohexene1propanal.

3,7DIMETHYL2,6OCTADIEN1OL and its isomers except in products containing 5% or less 3,7dimethyl2,6octadien1ol and its isomers.

N,NDIMETHYLOCTANAMIDE.

DIMETHYL SULFOXIDE (excluding dimethyl sulfone):

 (a) when not for therapeutic use; or

 (b) in cosmetic preparations; or

 (c) for the treatment of animals:

 (i) when combined with no other therapeutic substance(s); or

 (ii) in liquid preparations containing copper salicylate and 1% or less of methyl salicylate as the only other therapeutic substances; or

 (iii) in clay poultices containing 2% or less of dimethyl sulfoxide; or

 (d) in other preparations except when containing 10% or less of dimethyl sulfoxide.

DIMPROPYRIDAZ except when included in Schedule 5.

DINITROCRESOLS and their homologues in preparations containing 5% or less of such compounds except:

 (a) when included in Schedule 4; or

 (b) when separately specified in this Schedule.

DINITROPHENOLS and their homologues in preparations containing 5% or less of such compounds except:

 (a) when included in Schedule 4; or

 (b) when separately specified in this Schedule.

DIOXACARB.

DIOXANE.

DIPHACINONE.

DIQUAT in preparations containing 20% or less of diquat.

DIRECT RED 254 except when included in Schedule 5.

DISPERSE YELLOW 3 except when in Schedule 10.

DISULFIRAM except when included in Schedule 4.

DISULFOTON in granular preparations containing 5% or less of disulfoton.

DITHIANON.

DITHIAZANINE in preparations containing 2% or less of dithiazanine for the treatment of animals.

DIUREDOSAN.

N(NDODECYL)2PYRROLIDONE except:

 (a) when included in Schedule 5; or

 (b) in preparations containing 25% or less of designated solvents.

DODINE.

DORAMECTIN for external use for the treatment of animals, in preparations containing 2% or less of doramectin.

DSMA in herbicide or defoliant preparations containing 10% or less of DSMA.

ECONAZOLE for the external treatment of animals.

EMAMECTIN in preparations containing 5% or less of emamectin except when included in Schedule 5.

EMODEPSIDE for the treatment of animals except when included in Schedule 5.

ENDOSULFAN in aqueous preparations containing 33% or less of microencapsulated endosulfan.

ENDOTHAL in preparations containing 20% or less of endothal.

EPRINOMECTIN for internal use in preparations containing 5% or less of eprinomectin except when included in Schedule 5.

EPTC.

ESBIOTHRIN except:

 (a) when included in Schedule 5; or

 (b) in pressurised spray packs containing 1% or less of esbiothrin.

ESFENVALERATE except when included in Schedule 5.

ETHEPHON (excluding its salts and derivatives).

ETHER except:

 (a) when included in Schedule 2, 4 or 5; or

 (b) in preparations containing 10% or less of ether.

ETHIOFENCARB.

ETHOATEMETHYL.

ETHOPROPHOS in granular formulations containing 10% or less of ethoprophos and 2% of linseed oil.

ETHYL BROMIDE.

ETHYLENE CHLOROHYDRIN.

ETHYLENE DICHLORIDE.

ETHYLENE GLYCOL (excluding its salts and derivatives) except:

 (a) when included in Schedule 5; or

 (b) in paints or paint tinters; or

 (c) in toothpastes or mouthwashes containing more than 0.25% of ethylene glycol; or

 (d) in other preparations containing 2.5% or less of ethylene glycol.

ETHYLENE GLYCOL MONOALKYL ETHERS and their acetates, except:

 (a) when separately specified in these Schedules; or

 (b) in preparations containing 10% or less of such substances.

ETHYL FORMATE when packed and labelled for use as a fumigant.

ETHYLHEXANEDIOL except in preparations containing 5% or less of ethylhexanediol.

2ETHYLHEXANOIC ACID and its alkyl esters except in preparations containing 5% or less calculated as 2ethylhexanoic acid.

ETRIMFOS.

EUCALYPTUS OIL except:

 (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

 (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a childresistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

 (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) NOT TO BE TAKEN; or

 (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a childresistant closure and labelled with the warnings:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) NOT TO BE TAKEN; or

 (e) in preparations containing 25% or less of eucalyptus oil.

EUGENOL except:

 (a) when included in Schedule 5; or

 (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

 (c) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a childresistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

 (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) NOT TO BE TAKEN; or

 (e) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a childresistant closure and labelled with the warnings:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) NOT TO BE TAKEN; or

 (f) in preparations containing 25% or less of eugenol.

FAMOXADONE.

FAMPHUR in preparations containing 20% or less of famphur.

FEBANTEL except:

 (a) in divided preparations containing 1000 mg or less of febantel per dosage unit; or

 (b) in undivided preparations containing 10% or less of febantel.

FENAMIPHOS in granular preparations containing 5% or less of fenamiphos.

FENAZAFLOR.

FENBUTATIN OXIDE.

FENCHLORPHOS.

FENITROTHION.

FENOXACRIM in preparations for the treatment of carpets during manufacture.

FENPROPIDIN.

FENPYROXIMATE.

FENTHION in preparations containing 60% or less of fenthion except when included in Schedule 5.

FENVALERATE.

FIPRONIL except:

 (a) when included in Schedule 5; or

 (b) in preparations containing 0.05% or less of fipronil.

FLOCOUMAFEN in preparations containing 0.005% or less of flocoumafen.

FLONICAMID.

FLUAZAINDOLIZINE except when included in Schedule 5.

FLUAZIFOPBUTYL.

FLUAZIFOPpBUTYL.

FLUAZINAM.

FLUCOFURON in preparations for the treatment of carpets during manufacture.

FLUENSULFONE.

FLUMETHRIN except when included in Schedule 5.

FLUMIOXAZIN when contained in water soluble bags individually packed in sealed sachets.

FLUORIDES except:

 (a) when included in Schedule 5; or

 (b) in preparations for human use; or

 (c) in preparations containing 15 mg/kg or less of fluoride ion.

FLUPROPANATE.

FLUPYRADIFURONE.

FLUQUINCONAZOLE.

FLUSILAZOL.

FLUTRIAFOL except in fertilisers containing 0.5% or less of flutriafol.

FLUVALINATE except when included in Schedule 5.

FOMESAFEN SODIUM.

FORMALDEHYDE (excluding its derivatives) in preparations containing 0.05% or more of free formaldehyde except:

 (a) for human therapeutic use; or

 (b) in oral hygiene preparations; or

 (c) in nail hardener cosmetic preparations containing 5% or more of free formaldehyde; or

 (d) in nail hardener cosmetic preparations containing 0.2% or less of free formaldehyde when labelled with the statement:

  PROTECT CUTICLES WITH GREASE OR OIL;

 (e) in all other cosmetic preparations; or

 (f) in other preparations containing 0.2% or less of free formaldehyde when labelled with the warning statement:

  CONTAINS FORMALDEHYDE.

FORMOTHION.

FOSPIRATE except when included in Schedule 5.

FUMAGILLIN.

FURFURAL except in preparations containing 0.1% or less of furfural.

GLUTARAL except:

 (a) when included in Schedule 2 or 5; or

 (b) in preparations containing 0.5% or less of glutaral when labelled with the statements:

  IRRITANT; and

  Avoid contact with eyes.

GLYCERYL THIOGLYCOLLATE in hair waving preparations except when labelled with directions for use that include the statement:

  Wear protective gloves when using. Keep out of eyes.

GLYCOLIC ACID (including its salts and esters) in cosmetic products or when packed and labelled for use as an agricultural chemical except:

 (a) in cosmetic preparations for salon use only, when labelled in accordance with requirements under applicable jurisdictional Work Health and Safety laws, as amended from time to time; or

 (b) in preparations containing 5% or less of glycolic acid; or

 (c) in preparations containing 20% or less of glycolic acid with a pH of 3.5 or greater.

GUANIDINE except:

 (a) when included in Schedule 4; or

 (b) in preparations containing 1% or less of guanidine.

GUAZATINE.

HALOXON.

HALOXYFOP.

HC VIOLET 1 except:

 (a) in nonoxidative hair dye preparations containing 0.28% or less of HC Violet 1 after mixing when the immediate container and primary pack are labelled with the following statements:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

  written in letters not less than 1.5 mm in height; or

 (b) in oxidative hair dye preparations containing 0.25% or less of HC Violet 1 after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

  written in letters not less than 1.5 mm in height.

HEPTACHLOR.

HEXACHLOROPHENE:

 (a) in preparations for the treatment of animals; or

 (b) for cosmetic use.

HEXAZINONE except when included in Schedule 5.

HEXYLOXYETHANOL except in preparations containing 10% or less of hexyloxyethanol.

HYDRAMETHYLNON except when included in Schedule 5.

HYDRAZINE.

HYDROCHLORIC ACID (excluding its salts and derivatives) except:

 (a) when included in Schedule 5; or

 (b) in preparations for therapeutic use; or

 (c) in preparations containing 0.5% or less of hydrochloric acid (HCl).

HYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 1% or less of hydrogen fluoride except when included in Schedule 5.

HYDROGEN PEROXIDE (excluding its salts and derivatives) except:

 (a) when included in Schedule 5; or

 (b) in hair dye preparations containing 6% (20 volume) or less of hydrogen peroxide; or

 (c) in other preparations containing 3% (10 volume) or less of hydrogen peroxide.

HYDROQUINONE except:

 (a) when included in Schedule 2 or 4; or

 (b) in preparations containing 10% or less of hydroquinone.

HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 1% or less of hydrosilicofluoric acid (H2SiF6) except when included in Schedule 5.

HYDROXYETHYL3,4METHYLENEDIOXYANILINE (including its salts) except in oxidative hair dye preparations containing 1.5% or less of hydroxyethyl3,4methylenedioxyaniline after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:

 (a) KEEP OUT OF REACH OF CHILDREN; and

 (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

 written in letters not less than 1.5 mm in height.

IMIDACLOPRID except:

 (a) when included in Schedule 5; or

 (b) in preparations containing 5% or less of imidacloprid.

IMIDOCARB.

IMINOCTADINE TRIALBESILATE.

IMIPROTHRIN except:

 (a) when included in Schedule 5; or

 (b) in preparations containing 10% or less of imiprothrin.

INDAZIFLAM.

INDOXACARB (includes the R and S enantiomers) except when included in Schedule 5.

INPYRFLUXAM.

IODINE (excluding its salts, derivatives and iodophors) except:

 (a) when included in Schedule 2; or

 (b) in solid or semisolid preparations containing 2.5% or less of available iodine.

IODOPHORS except in preparations containing 1.5% or less of available iodine.

3IODO2PROPYNYL BUTYL CARBAMATE (Iodocarb) except:

 (a) when included in Schedule 5; or

 (b) in aqueous preparations not for cosmetic use containing 10% or less of 3iodo2propynyl butyl carbamate (Iodocarb); or

 (c) in cosmetic preparations (other than aerosolised preparations) containing 0.1% or less of 3iodo2propynyl butyl carbamate.

IOXYNIL.

IPCONAZOLE except when included in Schedule 5.

IRON COMPOUNDS (excluding up to 1% of iron oxides when present as an excipient) for the treatment of animals except:

 (a) when included in Schedule 5; or

 (b) in liquid or gel preparations containing 0.1% or less of iron; or

 (c) in animal feeds or feed premixes.

ISOCONAZOLE for the external treatment of animals.

ISOCYANATES, free organic, boiling below 300° C, except in:

 (a) viscous polyurethane adhesives; or

 (b) viscous polyurethane sealants;

 containing not more than 0.7% of free organic isocyanates boiling below 300°C.

ISOCYCLOSERAM.

ISOEUGENOL except:

 (a) when included in Schedule 5; or

 (b) in preparations not intended for skin contact containing 10% or less of isoeugenol; or

 (c) in preparations intended for skin contact containing 0.02% or less of isoeugenol.

ISOPYRAZAM.

ISOTIANIL.

LAMBDACYHALOTHRIN:

 (a) in aqueous preparations containing 25% or less of microencapsulated lambdacyhalothrin; or

 (b) in emulsifiable granule formulations containing 25% or less lambdacyhalothrin; or

 (c) in other preparations containing 1.6% or less of lambdacyhalothrin;

 except when included in Schedule 5.

LASALOCID except in animal feeds containing 100 mg/kg or less of antibiotic substances.

LAURETH CARBOXYLIC ACIDS (excluding their salts and derivatives) except:

 (a) in leaveon preparations containing 1.5% or less of laureth carboxylic acids; or

 (b) in washoff preparations containing 30% or less of laureth carboxylic acids and, if containing more than 5% of laureth carboxylic acids, when labelled with a warning to the following effect:

  IF IN EYES WASH OUT IMMEDIATELY WITH WATER; or

 (c) in other preparations containing 30% or less of laureth carboxylic acids and, if containing more than 5% of laureth carboxylic acids, when labelled with warnings to the following effect:

 (i) IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and

 (ii) IF SKIN OR HAIR CONTACT OCCURS, REMOVE CONTAMINATED CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER.

LAURYL ISOQUINOLINIUM BROMIDE.

LAURYL SULFATE SALTS (excluding their derivatives) except:

 (a) in washoff preparations containing 30% or less of lauryl sulfates and, if containing more than 5% of lauryl sulfates, when labelled with a warning to the following effect:

  IF IN EYES WASH OUT IMMEDIATELY WITH WATER; or

 (b) in leaveon preparations containing 1.5% or less of lauryl sulfates; or

 (c) in toothpaste and oral hygiene preparations containing 5% or less of lauryl sulfates; or

 (d) in other preparations for animal use containing 2% or less of lauryl sulfates; or

 (e) in other preparations containing 30% or less of lauryl sulfates and, if containing more than 5% of lauryl sulfates, when labelled with warnings to the following effect:

 (i) IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and

 (ii) IF SKIN OR HAIR CONTACT OCCURS, REMOVE CONTAMINATED CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER.

LEAD COMPOUNDS except:

 (a) when included in Schedule 4; or

 (b) in paints, tinters, inks or ink additives; or

 (c) in preparations for cosmetic use containing 100 mg/kg or less of lead; or

 (d) in pencil cores, finger colours, showcard colours, pastels, crayons, poster paints/colours or coloured chalks containing 100 mg/kg or less of lead; or

 (e) in ceramic glazes when labelled with the warning statement:

  CAUTION – Harmful if swallowed. Do not use on surfaces which contact food or drink;

  written in letters not less than 1.5 mm in height.

LEPTOSPERMUM SCOPARIUM OIL (manuka oil) except:

 (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

 (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a childresistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

 (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) NOT TO BE TAKEN; or

 (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a childresistant closure and labelled with the warnings;

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) NOT TO BE TAKEN; or

 (e) in preparations containing 25% or less of Leptospermum scoparium oil.

LEVAMISOLE for the treatment of animals except:

 (a) when included in Schedule 4 or 5; or

 (b) in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole.

LINDANE except when included in Schedule 2, 4 or 5.

MAFENIDE when packed and labelled for the treatment of ornamental fish only.

MALATHION except:

 (a) when included in Schedule 5; or

 (b) for human therapeutic use; or

 (c) in dust preparations containing 2% or less of malathion.

MCPA except when included in Schedule 5.

MCPB.

MEBENDAZOLE for the treatment of animals except when included in Schedule 5.

MECOPROP except when included in Schedule 5.

MECOPROPP.

MEFLUIDIDE.

MELALEUCA OIL (tea tree oil) except:

 (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

 (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a childresistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

 (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) NOT TO BE TAKEN; or

 (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a childresistant closure and labelled with the warnings:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) NOT TO BE TAKEN; or

 (e) in preparations containing 25% or less of melaleuca oil.

MELENGESTROL ACETATE when used as an animal feed additive.

MELOXICAM in oral transmucosal preparations containing 1% or less meloxicam for presurgical treatment and pain management in livestock during routine animal husbandry procedures.

MENAZON.

MERCAPTAMINE for cosmetic use except:

 (a) when included in Schedule 5; or

 (b) in preparations containing 1% or less of mercaptamine.

MERCAPTOACETIC ACID and its salts, but excluding its derivatives, in cosmetic preparations except:

 (a) when included in Schedule 5; or

 (b) in preparations containing 5% or less of mercaptoacetic acid or its salts (as mercapturic acid).

2MERCAPTOETHANOL in preparations for use as insect lures.

MERCURIC OXIDE for the treatment of animals, in preparations for ocular use.

MERCUROCHROME for the treatment of animals, in preparations for topical use.

METACRESOLSULPHONIC ACID AND FORMALDEHYDE CONDENSATION PRODUCT for the treatment of animals.

METALAXYL except when included in Schedule 5.

METALDEHYDE except when included in Schedule 5.

METHACRIFOS in preparations containing 60% or less of methacrifos.

METHAM.

METAMITRON.

METHANOL (excluding its derivatives) except:

 (a) when included in Schedule 5; or

 (b) when included in Schedule 10; or

 (c) in preparations containing 2% or less of methanol.

METHIOCARB in preparations containing 20% or less of methiocarb except when included in Schedule 5.

METHOMYL in flybaits containing 1% or less of methomyl and not less than 0.002% of denatonium benzoate as a bittering agent.

6METHOXYN2METHYL2,3PYRIDINEDIAMINE except when used in oxidative or non oxidative hair dyes at a concentration of 1% or less when the immediate container and primary pack are labelled with the following statements:

 (a) KEEP OUT OF REACH OF CHILDREN; and

 (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.

 written in letters not less than 1.5 mm in height.

2METHOXY5NITROPHENOL.

METHYLCHLOROISOTHIAZOLINONE except:

 (a) in rinseoff cosmetic preparations or therapeutic goods intended for topical rinseoff application containing 0.0015% or less of methylchloroisothiazolinone and methylisothiazolinone in total; or

 (b) in other preparations that are not intended for direct application to the skin containing 0.1% or less of methylchloroisothiazolinone and methylisothiazolinone in total.

METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL in preparations containing 10% or less of methylcyclopentadienyl manganese tricarbonyl when fitted with a childresistant closure.

METHYLDIBROMO GLUTARONITRILE except when in Schedule 10.

METHYLENE BISTHIOCYANATE except in preparations containing 1% or less of methylene bisthiocyanate.

METHYLEUGENOL except in preparations containing 1% or less of methyleugenol.

METHYL ETHYL KETONE OXIME except:

 (a) in viscous silicone adhesives or viscous silicone sealants containing 2.5% or less of methyl ethyl ketone oxime; or

 (b) in other preparations containing 1% or less of methyl ethyl ketone oxime.

pMETHYLAMINOPHENOL except when used in hair dye and eyebrow/eyelash colouring products at a concentration of 1% or less of pmethylaminophenol after mixing for use when the immediate container and primary pack are labelled with the following statements:

 (a) KEEP OUT OF REACH OF CHILDREN; and

 (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

 written in letters not less than 1.5 mm in height.

METHYL ISOTHIOCYANATE.

METHYL METHACRYLATE (excluding its derivatives) except:

 (a) for cosmetic use; or

 (b) in preparations containing 1% or less of methyl methacrylate as residual monomer in a polymer.

METHYL NEODECANAMIDE except in liquid preparations containing 2% or less of methyl neodecanamide.

METHYLISOTHIAZOLINONE except:

 (a) in rinseoff cosmetic preparations or therapeutic goods intended for topical rinseoff application containing 0.0015% or less of methylisothiazolinone; or

 (b) in other preparations that are not intended for direct application to the skin containing 0.1% or less of methylisothiazolinone

METHYLNORBORNYLPYRIDINE.

NMETHYL2PYRROLIDONE except:

 (a) when included in Schedule 5; or

 (b) in preparations containing 25% or less of designated solvents.

2METHYLRESORCINOL except:

 (a) in nonoxidative hair dye preparations containing 1.8% or less of 2methylresorcinol when the immediate container and primary pack are labelled with the following statements:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) WARNING – This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

  written in letters not less than 1.5 mm in height; or

 (b) in oxidative hair dye preparations containing 1.8% or less of 2methylresorcinol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) WARNING – This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

  written in letter not less than 1.5 mm in height.

METHYLROSANILINIUM CHLORIDE (formerly known as crystal violet CAS No. 548629) and the following TRIARYLMETHANE DYES:

 (a) Acid Violet 49 (CAS No. 1694093);

 (b) Ethyl Violet (CAS No. 2390592);

 (c) Basic Blue 7 (CAS No. 2390605);

 (d) Methylium, 4(dimethylamino)phenylbis4(ethylamino)3methylphenyl, acetate (CAS No. 72102557);

 except when included in Schedule 4 or Schedule 10.

METHYL SALICYLATE except:

 (a) when included in Schedule 5; or

 (b) in preparations for therapeutic use; or

 (c) in preparations containing 5% or less of methyl salicylate.

METOFLUTHRIN except when included in Schedule 5.

METOSULAM.

METRAFENONE except when included in Schedule 5.

METRIBUZIN.

MICONAZOLE for the external treatment of animals.

MILBEMECTIN except when included in Schedule 5.

MOMFLUOROTHRIN except in preparations containing 0.2% or less of momfluorothrin.

MONENSIN:

 (a) in animal feed premixes containing 12.5% or less of antibiotic substances; or

 (b) in stockfeed supplements, blocks or licks containing 0.75% or less of antibiotic substances.

MONOETHANOLAMINE (excluding its salts and derivatives) except:

 (a) when included in Schedule 4 or 5; or

 (b) in preparations containing 5% or less of monoethanolamine.

MORANTEL except:

 (a) when included in Schedule 5; or

 (b) in preparations containing 10% or less of morantel.

MOXIDECTIN:

 (a) in preparations for external use containing 2.5% or less of moxidectin when packed in single dose tubes for the treatment of cats and dogs; or

 (b) in preparations for external use containing 2% or less of moxidectin for the treatment of animals; or

 (c) in preparations for internal use containing 10% or less of moxidectin for the treatment of sheep or cattle;

 except when included in Schedule 5.

MSMA in herbicide or defoliant preparations containing 10% or less of MSMA.

NALED except when included in Schedule 5.

NAPHTHALENE (excluding its derivatives) except in liquid hydrocarbons.

1,5NAPHTHALENEDIOL except:

 (a) in nonoxidative hair dye preparations containing 1% or less of 1,5naphthalenediol when the immediate container and primary pack are labelled with the following statements:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

  written in letters not less than 1.5 mm in height; or

 (b) in oxidative hair dye preparations containing 1% or less of 1,5naphthalenediol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

  written in letters not less than 1.5 mm in height.

2,7NAPHTHALENEDIOL except:

 (a) in nonoxidative hair dye preparations containing 1% or less of 2,7naphthalenediol when the immediate container and primary pack are labelled with the following statements:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

  written in letters not less than 1.5 mm in height; or

 (b) in oxidative hair dye preparations containing 1% or less of 2,7naphthalenediol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

  written in letters not less than 1.5 mm in height.

1NAPHTHOL except in hair dye preparations containing 1% or less of 1naphthol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

 written in letters not less than 1.5 mm in height.

NAPHTHALOPHOS in preparations containing 80% or less of naphthalophos.

NARASIN in animal feed premixes containing 12% or less of narasin.

NETOBIMIN for the treatment of animals except when included in Schedule 5.

NICKEL SULFATE.

NIMIDANE in preparations containing 25% or less of nimidane.

NITENPYRAM except in divided preparations containing 100 mg or less of nitenpyram.

NITRIC ACID (excluding its salts and derivatives) except:

 (a) when included in Schedule 5; or

 (b) in preparations containing 0.5% or less of nitric acid (HNO3).

NITROBENZENE except:

 (a) in solid or semisolid polishes; or

 (b) in soaps containing 1% or less of nitrobenzene; or

 (c) in other preparations containing 0.1% or less of nitrobenzene.

3NITROpHYDROXYETHYLAMINOPHENOL except

 (a) in nonoxidative hair dye preparations containing 1.85% or less of 3nitrophydroxyethylaminophenol after mixing when the immediate container and primary pack are labelled with the following statements:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

  written in letters not less than 1.5 mm in height; or

 (b) in oxidative hair dye preparations containing 3% or less of 3nitrophydroxyethylaminophenol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

  written in letters not less than 1.5 mm in height.

NITROPHENOLS, ortho, meta and para, except when separately specified in these Schedules.

NITROPRUSSIDES in preparations containing 2.5% or less of nitroprussides except when included in Schedule 4.

NITROUS OXIDE except when included in Schedule 4.

NITROXYNIL.

NONOXINOL 9 except:

 (a) when included in Schedule 5; or

 (b) in preparations containing 25% or less of nonoxinol 9 when labelled with the statements:

 (i) IRRITANT; and

 (ii) Avoid contact with eyes; or

 (c) in preparations containing 12.5% or less of nonoxinol 9; or

 (d) in preparations for human use.

1OCTEN3OL except in preparations containing 5% or less of 1octen3ol.

OCTHILINONE except in paints, jointing compounds and sealants containing 1% or less of octhilinone calculated on the nonvolatile content.

N(NOCTYL)2PYRROLIDONE except:

 (a) when included in Schedule 5; or

 (b) in preparations containing 25% or less of designated solvents.

OLAQUINDOX except in preparations containing 10% or less of olaquindox.

NOLEYL1,3DIAMINOPROPANE.

OMETHOATE in preparations containing 30% or less of omethoate except when included in Schedule 5.

OXADIAZON.

OXALIC ACID except

 (a) in dental care preparations, including mouthwashes, containing 3% or less of soluble salts of oxalic acid; or

 (b) its insoluble salts.

OXYCLOZANIDE.

PAECILOMYCES LILACINUS STRAIN 251.

PARAFORMALDEHYDE (excluding its derivatives) in preparations containing 0.05% or more of free formaldehyde except:

 (a) for human therapeutic use; or

 (b) in oral hygiene preparations; or

 (c) in nail hardener cosmetic preparations containing 5% or more of free formaldehyde; or

 (d) in nail hardener cosmetic preparations containing 0.2% or less of free formaldehyde when labelled with the statement:

  PROTECT CUTICLES WITH GREASE OR OIL; or

 (e) in all other cosmetic preparations; or

 (f) in other preparations containing 0.2% or less of free formaldehyde when labelled with the warning statement:

  CONTAINS FORMALDEHYDE.

PARATHIONMETHYL in aqueous preparations containing 45% or less of microencapsulated parathionmethyl.

PARBENDAZOLE.

PEBULATE.

PENNYROYAL OIL except:

 (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a childresistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

 (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a childresistant closure and labelled with the warnings:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) NOT TO BE TAKEN; or

 (c) in preparations containing 4% or less of dpulegone.

PENTACHLOROPHENOL in preparations containing 1.5% or less of pentachlorophenol.

PERACETIC ACID except when included in Schedule 5.

PERFLUIDONE.

PERMANGANATES except potassium permanganate in aqueous solutions containing 1% or less of potassium permanganate.

PERMETHRIN except:

 (a) when included in Schedule 4 or 5; or

 (b) in preparations for human therapeutic use containing 5% or less of permethrin; or

 (c) in preparations containing 2% or less of permethrin.

2PHENOXYETHANOL except:

 (a) in cosmetic preparations containing 1% or less of 2phenoxyethanol; or

 (b) in other preparations containing 15% or less of 2phenoxyethanol.

PHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, except:

 (a) when separately specified in these Schedules; or

 (b) in preparations containing 1% or less of phenols, and in preparations containing 3% or less of cresols and xylenols and other homologues of phenol.

PHENOTHIAZINE (excluding its derivatives) except in preparations containing 10% or less of phenothiazine.

PHENOXYMETHYL OXIRANE.

PHENYLENEDIAMINES including alkylated, arylated, halogenated and nitro derivatives not elsewhere specified in these Schedules:

 (a) in preparations packed and labelled for photographic purposes; or

 (b) in preparations packed and labelled for testing water except tablets containing 10 mg or less of diethylparaphenylenediamine or dimethylparaphenylenediamine in opaque strip packaging provided the directions for use include the statement, “Do not discard testing solutions into the pool”; or

 (c) in hair dye preparations except when the immediate container and primary pack are labelled with the following statements:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) WARNING ‒ This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

  written in letters not less than 1.5 mm in height; or

 (d) in eyelash and eyebrow tinting products when the immediate container and primary pack are labelled with the following statement:

  WARNING ‒ This product contains ingredients which may cause skin irritation to certain individuals, and when used for eyelash and eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use;

  written in letters not less than 1.5 mm in height.

PHENYL METHYL PYRAZOLONE except when used in hair dye and eyebrow/eyelash preparations at a concentration of 0.25% or less after mixing for use when the immediate container and primary pack are labelled with warning statements to the following effect:

 (a) KEEP OUT OF REACH OF CHILDREN; and

 (b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use.

 written in letters not less than 1.5 mm in height.

PHOSALONE.

PHOSMET.

PHOSPHORIC ACID (excluding its salts and derivatives) except:

 (a) when included in Schedule 5; or

 (b) in preparations containing 15% or less of phosphoric acid (H3PO4); or

 (c) in solid or semisolid preparations; or

 (d) in professional dental kits.

PHOXIM.

oPHTHALALDEHYDE except when included in Schedule 5.

PICRAMIC ACID including its salts (excluding other derivatives) except when used in hair dye products at a concentration of 0.6% or less of picramic acid after mixing for use when the immediate container and primary pack are labelled with the following statements:

 (a) KEEP OUT OF REACH OF CHILDREN; and

 (b) WARNING ‒ This product contains ingredients which may cause skin allergy to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

 written in letters not less than 1.5 mm in height.

PINDONE.

PINE OILs when packed and labelled as a herbicide except when included in Schedule 5.

PINOXADEN except when included in Schedule 5.

PIPEROPHOS.

PIRIMICARB except when included in Schedule 5.

PIRIMIPHOSETHYL.

PIRIMIPHOSMETHYL.

POLIHEXANIDE except:

 (a) in cosmetic preparations containing 0.3% or less of polihexanide; or

 (b) when packed and labelled for therapeutic use; or

 (c) in other preparations containing 5% or less of polihexanide.

POLIXETONIUM SALTS except:

 (a) when included in Schedule 5; or

 (b) in preparations containing 1% or less of polixetonium salts.

POTASSIUM AZELOYL DIGLYCINATE except in preparations for cosmetic use containing 1% or less of potassium azeloyl diglycinate.

POTASSIUM BROMATE except in preparations containing 0.5% or less of potassium bromate.

POTASSIUM CYANATE.

POTASSIUM HYDROXIDE (excluding its salts and derivatives) except:

 (a) when included in Schedule 5 or Schedule 10; or

 (b) in preparations containing 5% or less of potassium hydroxide being:

 (i) solid preparations, the pH of which in a 10 g/L aqueous solution is 11.5 or less; or

 (ii) liquid or semisolid preparations, the pH of which is 11.5 or less.

POTASSIUM NITRITE in preparations containing 40% or less of potassium nitrite except:

 (a) when included in Schedule 5; or

 (b) in preparations containing 0.5% or less of potassium nitrite; or

 (c) when present as an excipient in preparations for therapeutic use; or

 (d) in aerosols containing 2% or less of potassium nitrite.

POTASSIUM PEROXOMONOSULFATE TRIPLE SALT except:

 (a) when included in Schedule 5; or

 (b) in solid orthodontic device cleaning preparations, the pH of which as an “inuse” aqueous solution is 2.5 or more, but not more than 11.5; or

 (c) in preparations containing 5% or less of potassium peroxomonosulfate triple salt being:

 (i) solid preparations, the pH of which in a 10 g/L aqueous solution is 2.5 or more; or

 (ii) liquid or semisolid preparations, the pH of which is 2.5 or more.

POTASSIUM PERSULFATE in hair preparations.

PRALLETHRIN (cis:trans=20:80) except:

 (a) when included in Schedule 5; or

 (b) in insecticidal mats containing 1% or less of prallethrin.

PROCHLORAZ.

PROFENOFOS.

PROMACYL.

PROPACHLOR.

PROPARGITE.

PROPETAMPHOS.

PROPICONAZOLE except when included in Schedule 5.

PROPINEB.

PROPIONIC ACID (excluding its salts and derivatives) except:

 (a) when included in Schedule 5; or

 (b) in preparations containing 30% or less of propionic acid; or

 (c) for therapeutic use.

PROPOXUR except when included in Schedule 5.

nPROPYL ALCOHOL except:

 (a) when included in Schedule 5; or

 (b) in preparations containing 5% or less of npropyl alcohol; or

 (c) in preparations for cosmetic or therapeutic use other than in spray form.

PROQUINAZID.

PROSULFOCARB.

PROSULFURON.

PROTHIOFOS.

dPULEGONE except in preparations containing 4% or less of dpulegone.

PYRACLOFOS.

PYRAZOPHOS.

PYRIDABEN except when included in Schedule 5.

PYRIDALYL.

PYRIDATE.

PYRIPROLE.

PYRITHIONE COPPER.

PYRITHIONE ZINC except:

 (a) when included in Schedule 2 or 5; or

 (b) for human use in preparations for the treatment of the scalp containing 2% or less of pyrithione zinc when compliant with the requirements of the required advisory statements for medicine labels; or

 (c) in semisolid hair preparations for animal use; or

 (d) in shampoos for animal use containing 2% or less of pyrithione zinc when labelled with the statements “Keep out of eyes” and “If in eyes rinse well with water”; or

 (e) when immobilised in solid preparations containing 0.5% or less of pyrithione zinc; or

 (f) in paints, jointing materials or sealants containing 0.1% or less of pyrithione zinc calculated on the nonvolatile content.

PYRIOFENONE except when included in Schedule 5.

PYROXASULFONE.

PYROXSULAM.

QUATERNARY AMMONIUM COMPOUNDS except:

 (a) when separately specified in these Schedules; or

 (b) when included in Schedule 5; or

 (c) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C16/C18) sources; or

 (d) in preparations containing 5% or less of such quaternary ammonium compounds.

QUININE in cosmetic preparations except:

 (a) in rinseoff hair preparations containing 0.5% or less of quinine calculated as free base; or

 (b) in leaveon hair preparations containing 0.2% or less of quinine calculated as free base.

QUINOLINE and its salts (excluding other derivatives).

QUIZALOFOP ETHYL.

QUIZALOFOPpETHYL except when included in Schedule 5.

QUIZALOFOPpTEFURYL.

RESCALURE for agricultural use except when enclosed in a vapour releasing device which in normal use prevents access to its contents.

RESMETHRIN except when included in Schedule 5.

RESORCINOL except:

 (a) in preparations for human therapeutic use; or

 (b) in oxidative hair dye preparations containing 1.25% or less of resorcinol after mixing for use when the immediate container and primary pack are labelled with the following statements:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

  written in letters not less than 1.5 mm in height; or

 (c) in oxidative eyelash and eyebrow dye preparations containing 1.25% or less of resorcinol after mixing for use when the immediate container and primary pack are labelled with the following statements:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

  written in letters not less than 1.5 mm in height; or

 (d) in hair lotions/shampoo products containing 0.5% or less of resorcinol when the immediate container and primary pack are labelled with the following statement:

  WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals;

  written in letters not less than 1.5 mm in height.

ROTENONE except in solid or semisolid preparations containing 2% or less of rotenone.

SAFROLE except:

 (a) for internal use; or

 (b) in other preparations containing 1% or less of safrole.

SAGE OIL (Dalmatian) except:

 (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a childresistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

 (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a childresistant closure and labelled with the warnings:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) NOT TO BE TAKEN; or

 (c) in preparations containing 4% or less of thujone.

SALINOMYCIN in animal feed premixes containing 12% or less of antibiotic substances.

SAROLANER except when included in Schedule 5.

SASSAFRAS OIL except:

 (a) for internal use; or

 (b) in other preparations containing 1% or less of safrole.

SELENIUM:

 (a) in preparations containing 2.5% or less of selenium when packed and labelled:

 (i) for the blueing of gun barrels; or

 (ii) for photographic purposes; or

 (iii) for the colouring of lead or lead alloys; or

 b) in coated granules containing 1% or less of selenium for application to pasture except in fertilisers containing 200 g/tonne or less of selenium; or

 (c) for the treatment of animals:

 (i) in a drench, injection, paste, stocklick, vaccine or horse feed supplement containing 0.5% or less of selenium; or

 (ii) in animal feed premixes containing 2% or less of selenium for the preparation of feeds containing 1 g/tonne or less of selenium; or

 (iii) in controlled release bolus preparations containing 25 mg or less of selenium with a release rate not greater than 0.25 mg/day; or

 (iv) as barium selenate in preparations for injection containing 5% or less of selenium.

SEMDURAMICIN in animal feed premixes for coccidiosis prevention containing 5% or less of antibiotic substances.

SILICOFLUORIDES except:

 (a) when included in Schedule 5; or

 (b) in preparations containing 15 mg/kg or less of fluoride ion.

SILVER NITRATE except:

 (a) when included in or expressly excluded from Schedule 2; or

 (b) in preparations containing 1% or less of silver.

SINBIOALLETHRIN except:

 (a) when included in Schedule 5; or

 (b) in preparations containing 1% or less of sinbioallethrin.

SODIUM ALUMINATE (excluding its salts and derivatives) except:

 (a) in solid preparations, the pH of which in a 10 g/L aqueous solution is 11.5 or less; or

 (b) in liquid preparations, the pH of which is 11.5 or less.

SODIUM BROMATE except in preparations containing 0.5% or less of sodium bromate.

SODIUM HYDROXIDE (excluding its salts and derivatives) except:

 (a) when included in Schedule 5 or Schedule 10; or

 (b) in preparations containing 5% or less of sodium hydroxide being:

 (i) solid preparations, the pH of which in a 10 g/L aqueous solution is 11.5 or less; or

 (ii) liquid or semisolid preparations, the pH of which is 11.5 or less.

SODIUM NITRITE:

 (a) in preparations containing 15% or less of sodium nitrite except:

 (i) when included in Schedule 2 or 5; or

 (ii) in preparations containing 0.5% or less of sodium nitrite; or

 (iii) when present as an excipient in preparations for therapeutic use; or

 (iv) in aerosols containing 2% or less of sodium nitrite; or

 (b) for use in closedloop water treatment systems (products).

SODIUM PERCARBONATE (CAS No. 15630894) except:

 (a) when included in Schedule 5; or

 (b) in preparations containing 15% or less of sodium percarbonate.

SODIUM PERSULFATE:

 (a) in hair preparations; or

 (b) in products for the treatment of water for swimming pools and spas.

SODIUM SULFIDE in preparations for use as insect lures.

SPIROPIDION.

SPIROTETRAMAT.

SPIROXAMINE.

SULCOFURON in preparations for the treatment of carpets during manufacture.

SULFAMIC ACID (excluding its salts and derivatives) except when included in Schedule 5.

SULFLURAMID.

SULFOXAFLOR except when included in Schedule 5.

SULFURIC ACID (excluding its salts and derivatives) except:

 (a) in fire extinguishers; or

 (b) in preparations containing 0.5% or less of sulfuric acid (H2SO4).

SULFURYL FLUORIDE.

SULPROFOS.

2,4,5T.

NTALLOW ALKYL1,3PROPANEDIAMINE DIACETATE and TALLOW ALKYLAMINE ACETATES.

TAR ACIDS distilling within the range 230290°C inclusive.

TCMTB (2[thiocyanomethylthio]benzothiazole).

TDE (1,1dichloro2,2bis[4chlorophenyl]ethane) except when included in Schedule 5.

TEBUFENPYRAD.

TEBUTHIURON.

TEMEPHOS except when in Schedule 5.

TERBUTHYLAZINE except in preparations containing 5% or less of terbuthylazine.

TERPENES, CHLORINATED.

TESTOSTERONE in implant preparations for use in animals.

TETRACHLOROETHYLENE except:

 (a) when included in Schedule 2 or 5; or

 (b) in preparations containing 6% or less of tetrachloroethylene when absorbed into an inert solid; or

 (c) in preparations for the treatment of animals.

TETRACONAZOLE except when included in Schedule 5.

TETRADIFON.

TETRAHYDROFURFURYL ALCOHOL (excluding its derivatives).

2,2',6,6'TETRAISOPROPYLDIPHENYLCARBODIIMIDE in amitraz formulations containing 2% or less of 2,2',6,6'tetraisopropyldiphenylcarbodiimide.

TETRAMISOLE in preparations for the treatment of animals.

THIACLOPRID.

THIAMETHOXAM except when included in Schedule 5.

THIAZAFLURON.

THIODICARB except when included in Schedule 5.

THIOMETON.

THIOPHANATEMETHYL except when included in Schedule 5.

THIOUREA AND ALKYL THIOUREAS except:

 (a) when separately specified in these Schedules; or

 (b) for therapeutic use.

THIRAM except in paint containing 0.5% or less of thiram.

THUJONE except in preparations containing 4% or less of thujone.

THYMOL when packed and labelled for use as a pesticide.

TIGOLANER except when in Schedule 5.

TOLUENE (excluding its derivatives) except in preparations containing 50% or less of toluene or toluene and xylene.

TOLUENEDIAMINES not elsewhere specified in these Schedules:

 (a) in hair dye preparations except when the immediate container and primary pack are labelled with the following statements:

 (i) KEEP OUT OF REACH OF CHILDREN; and

 (ii) WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

  written in letters not less than 1.5 mm in height; or

 (b) in eyelash and eyebrow tinting products when the immediate container and primary pack are labelled with the following statement:

  WARNING – This product contains ingredients which may cause skin irritation to certain individuals, and when used for eyelash and eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use;

  written in letters not less than 1.5 mm in height; or

 (c) in nail polish preparations containing 2,5toluenediamine except when labelled “avoid contact with skin”.

TOLYLFLUANID.

TRANSFLUTHRIN except:

 (a) in preparations containing 1% or less of transfluthrin; or

 (b) in a cartridge for vaporiser use containing 600 mg or less of transfluthrin per cartridge.

TRIADIMEFON except:

 (a) when included in Schedule 5; or

 (b) in fertilisers containing 5 g/kg or less of triadimefon.

TRICHLORFON except metrifonate included in Schedule 4.

TRICHLOROACETIC ACID except:

 (a) when included in Schedule 4 or 5; or

 (b) in human dermal preparations containing 12.5% or less of trichloroacetic acid for the treatment of warts other than anogenital warts.

TRICHLOROETHYLENE except when included in Schedule 4.

TRICHLOROPHENOL.

TRICLABENDAZOLE except in preparations containing 20% or less of triclabendazole.

TRICLOPYR.

TRICLOSAN in cosmetic preparations for human use containing more than 0.3% of triclosan.

TRIDEMORPH.

TRIETHYL PHOSPHATE.

TRIFLUOROMETHANESULFONIC ACID.

TRINITROPHENOL (excluding its derivatives) except:

 (a) in preparations for human therapeutic use; or

 (b) in preparations containing 5% or less of trinitrophenol.

TRISODIUM NITRILOTRIACETATE except in preparations containing 20% or less of trisodium nitrilotriacetate.

VAMIDOTHION.

VINYL ACETATE MONOMER (excluding its derivatives) except:

 (a) in preparations for therapeutic use; or

 (b) in cosmetic preparations containing 0.01% or less of vinyl acetate as residual monomer in a polymer; or

 (c) in other preparations containing 1% or less of vinyl acetate.

WARFARIN except when included in Schedule 4 or 5.

XYLENE (excluding its derivatives) except in preparations containing 50% or less of xylene or xylene and toluene.

ZERANOL in ear implants for use as a growth promotant in steer cattle.

ZETACYPERMETHRIN in preparations containing 10% or less of zetacypermethrin.

ZINC BORATE (excluding its derivatives) for use as an agricultural chemical.

ZINC CHLORIDE except:

 (a) when included in Schedule 2; or

 (b) in preparations containing 5% or less of zinc chloride.

ZINC paraPHENOLSULFONATE except in preparations containing 5% or less of zinc paraphenolsulfonate.

ZINC LACTATE in toothpaste except in toothpaste preparations containing 2.5% or less of zinc lactate and labelled with the statement:

  Not recommended for children under twelve years of age.

ZINC SULFATE except:

 (a) when included in or expressly excluded from Schedule 4; or

 (b) in other preparations containing 5% or less of zinc sulfate.

ZIRAM in granular preparations.

Schedule 7Dangerous poisons

 

 

Note: See section 16, subsection 54(4) and sections 55, 56, 62 and 65.

ABAMECTIN except when included in Schedule 5 or 6.

ACIBENZOLARSMETHYL.

ACRIFLAVINIUM CHLORIDE for veterinary use except when in Schedule 5.

ACROLEIN.

ACRYLONITRILE.

ALACHLOR.

ALDICARB.

ALDOXYCARB.

ALLYL ALCOHOL except:

 (a) in preparations containing 5% or less of allyl esters with 0.1% or less of free allyl alcohol by weight of allyl ester; or

 (b) when separately specified in these Schedules.

ALPHACYPERMETHRIN except when included in Schedule 5 or 6.

AMINOACRIDINE for veterinary use except when included in Schedule 5.

AMINOCARB except when included in Schedule 6.

2AMINO5METHYLPHENOL except when included in Schedule 10.

4AMINOPROPIOPHENONE.

4AMINOPYRIDINE except when included in Schedule 4.

AMITON.

ARPRINOCID.

ARSENIC except:

 (a) when separately specified in this Schedule; or

 (b) when included in Schedule 4 or 6; or

 (c) as selenium arsenide in photocopier drums; or

 (d) as 10,10'oxydiphenoxarsine in silicone rubber mastic containing 120 mg/kg or less of arsenic; or

 (e) as 10,10'oxydiphenoxarsine contained in polyvinyl chloride and polyurethane extruded and moulded articles containing 160 mg/kg or less of arsenic other than when included in articles:

 (i) in contact with foodstuffs, animal feeds or potable water; or

 (ii) of clothing and footwear in contact with the skin; or

 (iii) used as infant wear; or

 (iv) intended for use as packaging materials; or

 (f) in animal feeds containing 75 g/tonne or less of arsenic; or

 (g) in paints containing 0.1% or less of arsenic calculated on the nonvolatile content of the paint.

AZAFENIDIN.

AZINPHOSETHYL.

AZINPHOSMETHYL.

AZOCYCLOTIN.

AZO DYES that are derivatives by diazotisation of any of the following substances:

 (a) paminoazobenzene (CAS No. 60093);

 (b) oaminoazotoluene (CAS No. 97563);

 (c) oanisidine (CAS No. 90040);

 (d) pchloroaniline (CAS No. 106478);

 (e) 4chlorootoluidine (CAS No. 95692);

 (f) 2,4diaminoanisole (CAS No. 615054);

 (g) 6methoxymtoluidine (pcresidine) (CAS No. 120718);

 (h) 4,4methylenedianiline (CAS No. 101779);

 (i) 2naphthylamine (CAS No. 91598);

 (j) 5nitrootoluidine (CAS No. 99558);

 (k) 2,4toluenediamine (CAS No. 95807);

 (l) otoluidine (CAS No. 95534);

 (m) 2,4,5trimethylaniline (CAS No. 137177);

 except for BASIC RED 76 (CAS No. 68391300) when included in Schedule 6.

BENDIOCARB except when included in Schedule 5 or 6.

BENOMYL except in paints containing 0.5% or less of benomyl.

BENZENE (excluding its derivatives) except:

 (a) preparations containing 15 mL/L or less of benzene; or

 (b) petrol containing 50 mL/L or less of benzene.

BENZIDINEBASED AZO DYES being:

 (a) 2,2'[[1,1'biphenyl]4,4'diylbis(azo)]bis[N(4chlorophenyl)3oxobutanamide] (CAS No. 94249033); or

 (b) Acid Red 85 (Acid Fast Red A): 1,3Naphthalenedisulfonic acid, 7hydroxy8[[4'[[4[[(4methylphenyl)sulfonyl]oxy]phenyl]azo][1,1'biphenyl]4yl]azo], disodium salt (CAS No. 3567655); or

 (c) C.I Acid Black 29: (CAS No. 12217140); or

 (d) C.I. Direct Orange 1: (CAS No. 54579281); or

 (e) Direct Black 38: 2,7Naphthalenedisulfonic acid, 4amino3[[4'[(2,4diaminophenyl)azo][1,1'biphenyl]4yl]azo]5hydroxy6(phenylazo), disodium salt (CAS No. 1937377); or

 (f) Direct Blue 2: 2,7Naphthalenedisulfonic acid, 5amino3[[4'[(7amino1hydroxy3sulfo2naphthalenyl)azo][1,1'biphenyl]4yl]azo]4hydroxy, trisodium salt (CAS No. 2429734); or

 (g) Direct Blue 6: 2,7Naphthalenedisulfonic acid, 3,3'[[1,1'biphenyl]4,4'diylbis(azo)]bis[5amino4hydroxy, tetrasodium salt (CAS No. 2602462); or

 (h) Direct Brown 2: 5[[4'[(7amino1hydroxy3sulfo2naphthalenyl)azo][1,1'biphenyl]4yl]azo]2hydroxy benzoic acid disodium salt (CAS No. 2429825); or

 (i) Direct Brown 95: Cuprate(2), [5[[4'[[2,6dihydroxy3[(2hydroxy5sulfophenyl)azo]phenyl]azo][1,1'biphenyl]4yl]azo]2hydroxybenzoato(4)], disodium salt (CAS No. 16071866); or

 (j) Direct Green 1: 2,7Naphthalenedisulfonic acid, 4amino5hydroxy3[[4'[(4hydroxyphenyl)azo][1,1'biphenyl]4yl]azo]6(phenylazo), disodium salt (CAS No. 3626286); or

 (k) Direct Green 6: 2,7Naphthalenedisulfonic acid, 4amino5hydroxy6[[4'[(4hydroxyphenyl)azo][1,1'biphenyl]4yl]azo]3[(4nitrophenyl)azo], disodium salt (CAS No. 4335095); or

 (l) Direct Red 28 (Congo Red): 1Naphthalenesulfonic acid, 3,3'[[1,1'biphenyl]4,4'diylbis(azo)]bis[4amino, disodium salt (CAS No. 573580); or

 (m) Direct Red 37: 1,3Naphthalenedisulfonic acid, 8[[4'[(4ethoxyphenyl)azo][1,1'biphenyl]4yl]azo]7hydroxy, disodium salt (CAS No. 3530196).

BENZIDINECONGENER (3,3'disubstituted) AZO DYES.

BETACYFLUTHRIN except when included in Schedule 5 or 6.

BIFENTHRIN except:

 (a) when included in Schedule 6; or

 (b) in preparations containing 0.5% or less of bifenthrin.

BIFLUORIDES (including ammonium, potassium and sodium salts) except when included in Schedule 5 or 6.

BORON TRIFLUORIDE except when included in Schedule 5 or 6.

BRODIFACOUM except when included in Schedule 6.

BROMADIOLONE except when included in Schedule 6.

BROMETHALIN except when included in Schedule 6.

BROMINE (excluding its salts and derivatives).

BRUCINE except in alcohol containing 0.02% or less of brucine as a denaturant.

CACODYLIC ACID except:

 (a) when included in Schedule 6; or

 (b) in animal feeds containing 75 g/tonne or less of arsenic.

CADUSAFOS except when included in Schedule 6.

CALCIFEROL for use as a rodenticide except when included in Schedule 6.

CAPTAFOL.

CARBADOX.

CARBENDAZIM except in paints, jointing compounds and sealants containing 0.1% or less of carbendazim.

CARBOFURAN.

CARBON TETRACHLORIDE except in chlorinated rubber based paint containing 1% or less of carbon tetrachloride.

CARBONYL SULFIDE when packed and labelled for use as a fumigant.

CARBOPHENOTHION.

CARBOSULFAN.

CHLORDECONE.

CHLORDIMEFORM.

CHLORFENAPYR except when included in Schedule 5 or 6.

CHLORFENVINPHOS.

CHLORINE (excluding its salts and derivatives).

CHLORHEXIDINE except:

 (a) when included in Schedule 5 or 6; or

 (b) in preparations containing 1% or less of chlorhexidine; or

 (c) in solid preparations.

CHLOROMETHIURON.

5CHLORO3METHYL4NITROPYRAZOLE.

4CHLOROoTOLUIDINE.

CHLOROPICRIN except when included in Schedule 6.

CHLORTHIOPHOS.

COLECALCIFEROL for use as a rodenticide.

COUMAPHOS except when included in Schedule 6.

COUMATETRALYL except when included in Schedule 5 or 6.

CREOSOTE derived from coal.

CREOSOTE derived from beechwood.

CYANIDES, metallic except:

 (a) ferricyanides; or

 (b) ferrocyanides; or

 (c) when separately specified in these Schedules.

CYANOGEN.

CYCLOSILAZANES, DIME, ME HYDROGEN, POLYMERS WITH DIME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3(TRIETHOXYSILYL)1PROPANAMINE (CAS 475645842) except when included in Schedule 6.

CYHALOTHRIN (aRS,1R,cis,Z):(aRS,1S,cis,Z) = 50:50.

CYHEXATIN.

DELTAMETHRIN except:

 (a) when included in Schedule 5 or 6; or

 (b) in factory prepared mosquito nets containing 1% or less of deltamethrin; or

 (c) in preparations containing 0.1% or less of deltamethrin.

DEMETON.

DEMETONOMETHYL.

DEMETONSMETHYL.

DIALIFOS.

4,4DIAMINODIPHENYLMETHANE (Methylene dianiline).

1,2DIBROMO3CHLOROPROPANE.

1,3DICHLOROPROPENE except in biocidal preparations containing 0.3% or less of 1,3dichloropropene.

DICHLORVOS except when included in Schedule 5 or 6.

DICROTOPHOS.

DIFENACOUM except when included in Schedule 6.

DIFETHIALONE except when included in Schedule 6.

DIMEFOX.

4DIMETHYLAMINOAZOBENZENE (N,Ndimethyl4[phenylazo]benzenamine).

DIMETHYL SULFATE.

DIMETILAN.

DINITROCRESOLS except when included in Schedule 4 or 6.

DINITROPHENOLS except when included in Schedule 4, 6 or 10.

DINOCAP.

DINOSEB.

DIQUAT except when included in Schedule 6.

DISULFOTON except when included in Schedule 6.

DORAMECTIN except when included in Schedule 5 or 6.

DSMA except when included in Schedule 6.

EMAMECTIN except when included in Schedule 5 or 6.

ENDOSULFAN except when included in Schedule 6.

ENDOTHAL except when included in Schedule 6.

ENDRIN.

EPICHLOROHYDRIN.

EPIDERMAL GROWTH FACTOR except in preparations for human therapeutic use.

EPRINOMECTIN except when included in Schedule 5 or 6.

ETACONAZOLE.

ETHALFLURALIN.

ETHION.

ETHOPROPHOS except when included in Schedule 6.

2ETHOXYETHANOL and its acetates except in preparations containing 0.5% or less of 2ethoxyethanol.

ETHYLENE DIBROMIDE.

ETHYLENE OXIDE.

FAMPHUR except when included in Schedule 6.

FENAMIPHOS except when included in Schedule 6.

FENOXACRIM except:

 (a) when included in Schedule 6; or

 (b) in treated carpets.

FENSULFOTHION.

FENTHION except when included in Schedule 5 or 6.

FENTHIONETHYL.

FLOCOUMAFEN except when included in Schedule 6.

FLUCOFURON except:

 (a) when included in Schedule 6; or

 (b) in treated carpets.

FLUCYTHRINATE.

FLUMIOXAZIN except when included in Schedule 6.

FLUOROACETAMIDE.

FLUOROACETIC ACID.

FOLPET.

FORMETANATE.

FOSTHIAZATE.

FURATHIOCARB except when included in Schedule 5.

GAMMACYHALOTHRIN except when included in Schedule 5.

HALOFUGINONE except when included in Schedule 4.

HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS.

HCB.

HYDROCARBONS LIQUID AROMATIC (including aromatic extract oils), any fraction of which boils above 350°C except:

 (a) when in solid polymers; or

 (b) when containing 1% or less of total polycyclic aromatic compounds as measured by IP 346; or

 (c) when having a Mutagenicity Index of zero as measured by ASTM E168795.

HYDROCYANIC ACID except:

 (a) when included in Schedule 4; or

 (b) its salts and derivatives other than cyanides separately specified in this Schedule.

HYDROFLUORIC ACID (excluding its salts and derivatives) except when included in Schedule 5 or 6.

HYDROGEN SULFIDE.

HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) except when included in Schedule 5 or 6.

IODOMETHANE.

ISOCARBOPHOS.

ISOFENPHOS.

ISOPROTURON.

IVERMECTIN except when included in Schedule 4 or 5.

LAMBDACYHALOTHRIN except when included in Schedule 5 or 6.

LEPTOPHOS.

LITHIUM PERFLUOROOCTANE SULFONATE except in sealed bait stations containing 1% or less of lithium perfluorooctane sulfonate.

MADURAMICIN except:

 (a) when included in Schedule 5; or

 (b) in animal feeds containing 5 mg/kg or less of antibiotic substances.

MALACHITE GREEN for veterinary use except when included in Schedule 5.

MAZIDOX.

MECARBAM.

2METHOXYETHANOL and its acetates except in preparations containing 0.5% or less of 2methoxyethanol.

MERCURIC CHLORIDE when prepared for use for agricultural, industrial, pastoral or horticultural purposes.

MERCURY except:

 (a) when separately specified in this Schedule; or

 (b) when included in Schedule 2, 4 or 6; or

 (c) in preparations containing 0.01% or less of mercury in organic form as a preservative; or

 (d) mercury (metallic) in scientific instruments; or

 (e) dental amalgams; or

 (f) in a sealed device, for therapeutic use, which prevents access to the mercury.

METHACRIFOS except when included in Schedule 6.

METHAMIDOPHOS.

METHAPYRILENE.

METHAZOLE.

METHIDATHION.

METHIOCARB except when included in Schedule 5 or 6.

METHOMYL except when included in Schedule 6.

METHOXYETHYLMERCURIC ACETATE.

METHOXYETHYLMERCURIC CHLORIDE.

METHYL BROMIDE.

METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL except:

 (a) when included in Schedule 6; or

 (b) when used in laboratory analysis; or

 (c) when packed for industrial use in containers with a nominal capacity of 100 L or more.

4,4'METHYLENEBIS[2CHLOROANILINE] (MOCA).

METHYLENE BLUE for veterinary use except when included in Schedules 4 or 5.

MEVINPHOS.

MIPAFOX.

MIREX.

MOLINATE.

MONOCROTOPHOS.

MOXIDECTIN except when included in Schedule 4, 5 or 6.

MSMA except when included in Schedule 6.

NAPHTHALOPHOS except when included in Schedule 6.

NICOTINE except:

 (a) when included in Schedule 4; or

 (b) in preparations for oromucosal or transdermal administration for human therapeutic use as an aid in withdrawal from tobacco smoking; or

 (c) in tobacco prepared and packed for smoking.

NIMIDANE except when included in Schedule 6.

NITROFEN.

NITROPRUSSIDES except when included in Schedule 4 or 6.

2NITROTOLUENE.

OMETHOATE except when included in Schedule 5 or 6.

OXAMYL.

OXYDEMETON METHYL.

PARAQUAT.

PARATHION.

PARATHIONMETHYL except when included in Schedule 6.

PENTACHLOROPHENOL except when included in Schedule 6.

PHENYLMERCURIC ACETATE except in preparations containing 0.01% or less of mercury as a preservative.

PHORATE.

PHOSFOLAN.

PHOSPHIDES, METALLIC.

PHOSPHINE.

PHOSPHORUS, YELLOW (excluding its salts and derivatives).

POTASSIUM NITRITE except:

 (a) when included in Schedule 5 or 6; or

 (b) in preparations containing 0.5% or less of potassium nitrite; or

 (c) when present as an excipient in preparations for therapeutic use; or

 (d) in aerosols containing 2% or less of potassium nitrite.

PROCYMIDONE.

PROPYLENE OXIDE.

PYRINURON.

QUININE for veterinary use except when included in Schedule 5.

SAFLUFENACIL except when included in Schedule 5.

SCHRADAN.

SELENIUM except:

 (a) when included in Schedule 6; or

 (b) as selenium arsenide in photocopier drums; or

 (c) in preparations for therapeutic use other than:

 (i) drench concentrates containing 2.5% or less of selenium; or

 (ii) pouron preparations containing 0.5% or less of selenium; or

 (d) in paints or tinters containing 0.1% or less of selenium calculated on the nonvolatile content of the paint or tinter; or

 (e) in fertilisers containing 200 g/tonne or less of selenium.

SEMDURAMICIN except:

 (a) when included in Schedule 6; or

 (b) in animal feeds containing 25 mg/kg or less of antibiotic substances.

SODIUM NITRITE except:

 (a) when included in Schedule 2, 5 or 6; or

 (b) in preparations containing 0.5% or less of sodium nitrite; or

 (c) when present as an excipient in preparations for therapeutic use; or

 (d) in aerosols containing 2% or less of sodium nitrite.

STRYCHNINE except when included in Schedule 4.

SULCOFURON except:

 (a) when included in Schedule 6; or

 (b) in treated carpets.

SULFENTRAZONE.

SULFOTEP.

TEFLUTHRIN except when included in Schedule 5.

TEPP.

TERBUFOS.

TETRACHLOROETHANE.

2,2',6,6'TETRAISOPROPYLDIPHENYLCARBODIIMIDE except when included in Schedule 6.

THALLIUM.

THIOFANOX.

TIN ORGANIC COMPOUNDS, being dialkyl, trialkyl and triphenyl tin compounds where the alkyl group is methyl, ethyl, propyl or butyl except:

 (a) when separately specified in this Schedule; or

 (b) in plastics; or

 (c) in semisolid sealants, adhesives or elastomers containing 1% or less of the dialkyl, trialkyl or triphenyl tin component; or

 (d) in paint containing 1% or less of such compounds calculated as tin in the nonvolatile content of the paint.

oTOLIDINE except in solidstate diagnostic therapeutic reagents.

TRIAMIPHOS.

TRIAZBUTIL.

TRIBUFOS (S,S,Stributylphosphorotrithioate).

VINCLOZOLIN.

VINYL CHLORIDE.

ZETACYPERMETHRIN except when included in Schedule 6.

ZIRAM except when included in Schedule 6.

Schedule 8Controlled drugs

 

 

Note 1: See paragraph 7(b), sections 16, 17, 28, 31, 50 and subsection 57(1).

Note 2: Substances marked # are listed in Appendix D.

ACETYLDIHYDROCODEINE.

ACETYLMETHADOL.

ACETYLMORPHINES.

ALFENTANIL.

ALPHACETYLMETHADOL.

ALPHAPRODINE.

# ALPRAZOLAM.

AMFETAMINE.

AMOBARBITAL except when included in Schedule 4.

ANILERIDINE.

BENZYLMORPHINE.

BEZITRAMIDE.

BUPRENORPHINE.

BUTOBARBITAL.

BUTORPHANOL.

# CANNABIS (including seeds, extracts, resins and the plant, and any part of the plant) when prepared or packed for human therapeutic use, when:

 (a) cultivated or produced, or in products manufactured[1], in accordance with the Narcotic Drugs Act 1967; and/or

 (b) for use in products manufactured in accordance with the Narcotic Drugs Act 1967; and/or

 (c) imported as therapeutic goods, or for use in therapeutic goods, for supply, in accordance with the Act; and/or

 (d) in therapeutic goods supplied in accordance with the Act;

 except:

 (e) when it is in a product to which item 4, 8, 10, 11 or 12 of Schedule 5A to the Therapeutic Goods Regulations 1990 applies; or

 (f) when separately specified in the NABIXIMOLS entry in this Schedule; or

 (g) when captured by the CANNABIDIOL entry in Schedule 4 or Schedule 3; or

 (h) hemp seed oil containing 75 mg/kg or less of cannabidiol and 10 mg/kg or less of tetrahydrocannabinols.

CARFENTANYL.

COCAINE.

CODEINE except when included in Schedule 4.

CODEINENOXIDE.

CONCENTRATE OF POPPY STRAW (the material arising when poppy straw has entered into a process for concentration of its alkaloids).

4CYANO1METHYL4PHENYLPIPERIDINE (Pethidine intermediate A).

CYCLOBARBITAL.

DEXAMFETAMINE.

DEXTROMORAMIDE.

# DEXTROPROPOXYPHENE except when included in Schedule 4.

DIFENOXIN except when included in Schedule 4.

DIHYDROCODEINE except when included in Schedule 3 or 4.

DIHYDROMORPHINE.

# N, α DIMETHYL3,4(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA) in preparations for human therapeutic use for the treatment of post-traumatic stress disorder.

DIPHENOXYLATE except when included in Schedule 3 or 4.

DIPIPANONE.

# DRONABINOL (delta9tetrahydrocannabinol) when prepared and packed for therapeutic use.

DROTEBANOL.

ESKETAMINE.

ETHYLAMFETAMINE.

ETHYLMORPHINE except when included in Schedule 2 or 4.

FENTANYL.

# FLUNITRAZEPAM.

HYDROCODONE.

HYDROMORPHINOL.

HYDROMORPHONE.

KETAMINE.

LEVAMFETAMINE.

LEVOMETHAMFETAMINE.

LEVOMORAMIDE.

LEVORPHANOL (excluding its stereoisomers).

LISDEXAMFETAMINE.

METHADONE.

METAMFETAMINE.

METHYLDIHYDROMORPHINE.

METHYLPHENIDATE.

1METHYL4PHENYLPIPERIDINE4CARBOXYLIC ACID (Pethidine intermediate C).

MORPHINE.

MORPHINE METHOBROMIDE.

MORPHINENOXIDE.

NABILONE.

# NABIXIMOLS (botanical extract of Cannabis sativa which includes the following cannabinoids: tetrahydrocannabinols, cannabidiol, cannabinol, cannabigerol, cannabichromene, cannabidiolic acid, tetrahydrocannabinolic acids, tetrahydrocannabivarol, and cannabidivarol, where tetrahydrocannabinols and cannabidiol (in approximately equal proportions) comprise not less than 90% of the total cannabinoid content) in a buccal spray for human therapeutic use.

NORCODEINE.

NORMETHADONE.

OPIUM except the alkaloids noscapine in Schedule 2 and papaverine when included in Schedule 2 or 4.

OXYCODONE.

OXYMORPHONE.

PENTAZOCINE.

# PENTOBARBITAL except when included in Schedule 4.

PETHIDINE.

PHENDIMETRAZINE.

PHENMETRAZINE.

PHENOPERIDINE.

4PHENYLPIPERIDINE4CARBOXYLIC ACID ETHYL ESTER (Pethidine intermediate B).

PHOLCODINE except when included in Schedule 2 or 4.

PIRITRAMIDE.

PROPIRAM.

# PSILOCYBINE in preparations for human therapeutic use for the treatment of treatmentresistant depression.

RACEMORAMIDE.

REMIFENTANIL.

SECBUTOBARBITAL.

SECOBARBITAL.

# SODIUM OXYBATE for human therapeutic use.

SUFENTANIL.

TAPENTADOL.

# TETRAHYDROCANNABINOLS when extracted from cannabis for human therapeutic use, when:

 (a) included in products manufactured in accordance with the Narcotic Drugs Act 1967; and/or

 (b) imported as therapeutic goods, or for use in therapeutic goods, for supply, in accordance with the Act; and/or

 (c) in therapeutic goods supplied in accordance with the Act;

 except when:

 (d) it is in a product to which item 4, 8, 10, 11 or 12 of Schedule 5A to the Therapeutic Goods Regulations 1990 applies; or

 (e) separately specified in the NABIXIMOLS entry in this Schedule; or

 (f) captured by the CANNABIDIOL entry in Schedule 4 or Schedule 3; or

 (g) in hemp seed oil at a concentration of 10 mg/kg or less.

THEBACON.

THEBAINE.

TILIDINE.

Schedule 9Prohibited substances

 

 

Note 1: See paragraph 7(b) and subsection 57(2).

Note 2: Trivial or unofficial names are marked *.

ACETORPHINE.

ACETYLALPHAMETHYLFENTANYL.

ALKOXYAMFETAMINES and substituted alkoxyamfetamines except when separately specified in these Schedules.

ALKOXYPHENYLETHYLAMINES and substituted alkoxyphenylethylamines except when separately specified in these Schedules.

ALKYLTHIOAMFETAMINES and substituted alkylthioamfetamines except when separately specified in these Schedules.

ALLYLPRODINE.

ALPHAMEPRODINE.

ALPHAMETHYLFENTANYL.

ALPHAMETHYLTHIOFENTANYL.

ALPHAMETHADOL.

ALPHAPYRROLIDINOVALEROPHENONE *(ALPHAPVP).

2AMINO1(2,5DIMETHOXY4METHYL)PHENYLPROPANE *(STP or DOM).

5(2AMINOPROPYL)INDAN and substituted 5(2aminopropyl)indans except when separately specified in these Schedules.

BENZETHIDINE.

BENZOYLINDOLES except when separately specified in these Schedules.

BENZYLPIPERAZINE *(BZP).

BETACETYLMETHADOL.

BETAHYDROXYFENTANYL.

BETAHYDROXY3METHYLFENTANYL.

BETAMEPRODINE.

BETAMETHADOL.

BETAPRODINE.

1(8BROMOBENZO[1,2B;4,5B]DIFURAN4YL)2AMINOPROPANE *(BromoDragonfly).

4BROMO2,5DIMETHOXYPHENETHYLAMINE *(BDMPEA).

BUFOTENINE.

BUTONITAZENE.

CANNABIS (including seeds, extracts, resins, and the plant and any part of the plant when packed or prepared), except:

 (a) when separately specified in these Schedules; or

 (b) processed hemp fibre containing 0.1% or less of tetrahydrocannabinols and hemp fibre products manufactured from such fibre; or

 (c) hemp seed oil containing 75 mg/kg or less of cannabidiol and 10 mg/kg or less of tetrahydrocannabinols.

CATHINONES except when separately specified in these Schedules.

CLONAZOLAM.

CLONITAZENE.

COCA LEAF.

CODOXIME.

4CYANO2DIMETHYLAMINO4,4'DIPHENYLBUTANE.

CYCLOHEXYLPHENOLS except:

 (a) when separately specified in these Schedules; or

 (b) in preparations containing 0.5% or less of cyclohexylphenols.

DESCHLOROETIZOLAM.

DESOMORPHINE.

N,NDIALKYLAMINOCYCLOHEXYL ALKYL BENZAMIDES except when separately specified in these Schedules.

N,NDIALKYLAMINOCYCLOHEXYLMETHYL ALKYL BENZAMIDES except when separately specified in these Schedules.

DIAMPROMIDE.

DIBENZOPYRANS except when separately specified in these Schedules.

3,4DICHLORON[(1R,2R)2(DIMETHYLAMINO)CYCLOHEXYL]NMETHYLBENZAMIDE (U47700).

3,4DICHLORON{[1 (DIMETHYLAMINO)CYCLOHEXYL]METHYL}BENZAMIDE *(AH7921).

DICLAZEPAM.

DIETHYLTHIAMBUTENE.

N,NDIETHYLTRYPTAMINE *(DET).

2,5DIHYDRO2(1METHYL1PHENYLETHYL)5PENTYL1HPYRIDO[4,3B]INDOL1ONE (SGT151).

DIMENOXADOL.

DIMEPHEPTANOL.

2,5DIMETHOXYAMFETAMINE *(DMA).

2,5DIMETHOXY4BROMOAMFETAMINE *(DOB).

2,5DIMETHOXY4ETHYLaAMFETAMINE *(DOET).

2,5DIMETHOXY4ETHYLTHIOPHENETHYLAMINE *(2CT2).

2,5DIMETHOXY4IODOPHENETHYLAMINE *(2CI).

2,5DIMETHOXY4(N)PROPYLTHIOPHENETHYLAMINE *(2CT7).

3(2DIMETHYLAMINOETHYL)4HYDROXYINDOLE *(PSILOCINE or PSILOTSIN).

3(1,2DIMETHYLHEPTYL)1HYDROXY7,8,9,10TETRAHYDRO6,6,9 TRIMETHYL6HDIBENZO (b,d) PYRAN *(DMHP).

N, α DIMETHYL3,4(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA) except when included in Schedule 8.

N,NDIMETHYLAMFETAMINE (Dimetamfetamine).

DIMETHYLTHIAMBUTENE.

N,NDIMETHYLTRYPTAMINE *(DMT).

DIOXAPHETYL BUTYRATE.

ECGONINE.

NETHYLαMETHYL3,4(METHYLENEDIOXY)PHENETHYLAMINE *(NETHYL MDA).

ETHYLMETHYLTHIAMBUTENE.

ETICYCLIDINE *(PCE).

ETODESNITAZENE.

ETONITAZENE.

ETONITAZEPIPNE.

ETONITAZEPYNE.

ETORPHINE.

ETOXERIDINE.

FENETYLLINE.

4FLUORONMETHYLAMFETAMINE.

FLUBROMAZEPAM.

FLUBROMAZOLAM.

FLUNITAZENE.

1(5FLUOROPENTYL)3(2IODOBENZOYL)INDOLE *(AM694).

FURETHIDINE.

HARMALA ALKALOIDS except in herbs, or preparations, for therapeutic use:

 (a) containing 0.1% or less of harmala alkaloids; or

 (b) in divided preparations containing 2 mg or less of harmala alkaloids per recommended daily dose.

HEROIN.

3HEXYL1HYDROXY7,8,9,10TETRAHYDRO6,6,9TRIMETHYL6HDIBENZO (b,d) PYRAN *(PARAHEXYL).

4HYDROXYBUTANOIC ACID and its salts except for sodium oxybate when in Schedule 8. *(GAMMA HYDROXYBUTYRATE (GHB)).

2[(1R,3S)3HYDROXYCYCLOHEXYL]5(2METHYLNONAN2YL)PHENOL *(Cannabicyclohexanol or CP 47,497 C8 homologue).

2[(1R,3S)3HYDROXYCYCLOHEXYL]5(2METHYLOCTAN2YL)PHENOL *(CP 47,497).

HYDROXYPETHIDINE.

ISOMETHADONE.

ISOTONITAZENE.

KETOBEMIDONE.

LEVOMETHORPHAN (excluding its stereoisomers).

LEVOPHENACYLMORPHAN.

LYSERGIC ACID.

LYSERGIDE.

MECLONAZEPAM.

MECLOQUALONE.

METAZOCINE.

METHAQUALONE.

METHCATHINONE.

5METHOXY α –METHYLTRYPTAMINE *(5MeOAMT).

5METHOXY3,4METHYLENEDIOXYAMFETAMINE *(MMDA).

4METHOXY α –METHYLPHENYLETHYLAMINE *(PMA).

2(2METHOXYPHENYL)1(1PENTYLINDOL3YL)ETHANONE *(JWH250).

METHYL (2S, 4aR, 6aR, 7R, 9S, 10aS, 10bR)9ACETOXY6a,10bDIMETHYL4,10DIOXODODECAHYDRO2(3FURYL)2HNAPHTHO[2,1c]PYRAN7CARBOXYLATE *(SALVINORIN A).

4METHYLAMINOREX.

METHYLDESORPHINE.

3,4METHYLENEDIOXYAMFETAMINE *(MDA).

3,4METHYLENEDIOXYPYROVALERONE *(MDPV).

3METHYLFENTANYL.

4METHYLMETHCATHINONE *(MEPHEDRONE).

N α [METHYL3,4(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE *(NHYDROXY MDA).

NMETHYL1(3,4METHYLENEDIOXYPHENYL)2BUTANAMINE *(MBDB).

2METHYL3MORPHOLINO1, 1DIPHENYLPROPANE CARBOXYLIC ACID (Moramide intermediate).

METHYLONE *(MDMC).

1METHYL4PHENYL4PIPERIDINOL PROPIONATE *(MPPP).

4METHYLTHIOAMFETAMINE.

3METHYLTHIOFENTANYL.

METODESNITAZENE.

METONITAZENE.

METOPON.

MITRAGYNA SPECIOSA.

MITRAGYNINE.

MORPHERIDINE.

(1(2MORPHOLIN4YLETHYL)INDOL3YL)NAPTHALEN1YLMETHANONE *(JWH200).

MUSCIMOL.

MYROPHINE.

NAPHTHOYLINDOLES except when separately specified in these Schedules.

NAPHTHYLMETHYLINDOLES except when separately specified in these Schedules.

NAPHTHOYLPYRROLES except when separately specified in these Schedules.

NAPHTHYLMETHYLINDENES except when separately specified in these Schedules.

NAPHTHALEN1YL(1BUTYLINDOL3YL)METHANONE *(JWH073).

NICOCODINE.

NICODICODINE.

NICOMORPHINE.

NIFOXIPAM.

NORACYMETHADOL.

NORLEVORPHANOL.

NORMORPHINE.

NORPIPANONE.

PARAFLUOROFENTANYL.

1PENTYL3(4METHYL1NAPTHOYL)INDOLE. *(JWH122).

1PENTYL3(1NAPHTHOYL)INDOLE *(JWH018).

PHENADOXONE.

PHENAMPROMIDE.

PHENAZOCINE.

PHENCYCLIDINE *(PCP).

PHENIBUT.

NPHENETHYL4PIPERIDONE.

PHENOMORPHAN.

PHENYLACETYLINDOLES except when separately specified in these Schedules.

1PHENYLETHYL4PHENYL4PIPERIDINOL ACETATE *(PEPAP).

PIMINODINE.

PROHEPTAZINE.

PROPERIDINE.

PROTONITAZENE.

PSILOCYBINE except when included in Schedule 8.

PYRAZOLAM.

RACEMETHORPHAN.

RACEMORPHAN.

ROLICYCLIDINE *(PHP or PCPY).

SALVIA DIVINORUM.

SYNTHETIC CANNABINOMIMETICS except when separately specified in these Schedules.

TENOCYCLIDINE *(TCP).

TETRAHYDROCANNABINOLS and their alkyl homologues, except:

 (a) when included in Schedule 4 or Schedule 8; or

 (b) processed hemp fibre containing 0.1% or less of tetrahydrocannabinols, and hemp fibre products manufactured from such fibre; or

 (c) in hemp seed oil at a concentration of 10 mg/kg or less.

THIOFENTANYL.

1(3TRIFLUOROMETHYLPHENYL)PIPERAZINE *(TFMPP).

TRIMEPERIDINE.

3,4,5TRIMETHOXY α –METHYLPHENYLETHYLAMINE *(TMA).

3,4,5TRIMETHOXYPHENETHYLAMINE (mescaline) and other substances structurally derived from methoxyphenylethylamine except:

 (a) methoxyphenamine; or

 (b) when separately specified in this Schedule.

1(3,4,5TRIMETHOXYPHENYL)2AMINOBUTANE.

Schedule 10Substances of such danger to health as to warrant prohibition of supply and use

 

 

Note 1: See subsection 57(2) and section 63.

Note 2: Schedule 10 contains substances previously included in Appendix C.

ABRUS PRECATORIUS (Jequirity) seed or root for therapeutic use.

ACORUS CALAMUS (calamus) for human therapeutic use.

ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for domestic use:

 (a) in liquid or semisolid food additive preparations, the pH of which is more than 11.5; or

 (b) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or

 (c) in liquid or semisolid automatic dishwashing preparations, the pH of which is more than 12.5.

ALKYLAMINES WITH STIMULANT PROPERTIES except when separately specified in these schedules.

2AMINO5METHYLPHENOL in preparations for cosmetic use.

AMINOPHENAZONE (amidopyrine) and its derivatives for human therapeutic use.

AMYGDALIN for therapeutic use.

ANCHUSA OFFICINALIS for therapeutic use.

oANISIDINE (excluding derivatives) in preparations for skin colouration (including tattooing) and dyeing of hair, eyelashes or eyebrows except in preparations containing 0.001% or less of oanisidine.

APRONAL for therapeutic use.

ARISTOLOCHIA spp. for therapeutic use.

ARISTOLOCHIC ACID(S) for human therapeutic use.

ASARUM spp. containing aristolochic acid(s) for human therapeutic use.

AZADIRACHTA INDICA (neem) including its extracts and derivatives, in preparations for human internal use except “debitterised neem seed oil”.

BASIC ORANGE 31 (2[(4aminophenyl)azo]1,3dimethyl1Himidazolium chloride) in preparations for skin colouration and dyeing of eyelashes or eyebrows.

1,2BENZENEDIAMINE in preparations for cosmetic use and skin colouration (including tattooing).

1,3BENZENEDIAMINE in preparations for cosmetic use and skin colouration (including tattooing).

BITHIONOL for human therapeutic use.

BORAGO OFFICINALIS (Borage) for therapeutic use except the fixed oil derived from the seeds of Borago officinalis.

BRAGANTIA spp. containing aristolochic acid(s) for human therapeutic use.

BUCLOSAMIDE for therapeutic use.

BUNIODYL SODIUM for therapeutic use.

1,4BUTANEDIOL (excluding its derivatives) in nonpolymerised form in preparations for domestic use.

BUTYL BENZYL PHTHALATE for cosmetic use.

CACALIA spp. for therapeutic use.

CARBAMIDE PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations containing more than 18% of carbamide peroxide except in preparations manufactured for, and supplied solely by, registered dental practitioners as part of their dental practice.

CARDARINE.

CHRYSOIDINE BASE in preparations for use in hair dyes.

CINCHOPHEN and its derivatives for therapeutic use.

CLIOQUINOL and other halogenated derivatives of oxyquinoline for human internal use except or when being used solely for experimental purposes in humans and where such use:

 (a) is in accordance with:

 (i) an approval granted under paragraph 19(1)(b) of the Act, including any conditions specified in the notice of approval; and

 (ii) any conditions specified in the Therapeutic Goods Regulations 1990 for the purposes of subsection 19(1A) of the Act; and

 (iii) any conditions specified in the Therapeutic Goods Regulations 1990 for the purposes of subsection 19(4A) of the Act; or

 (b) is in accordance with the requirements of item 3 of Schedule 5A to the Therapeutic Goods Regulations 1990.

COAL TAR for cosmetic use other than in therapeutic goods.

CONIUM MACULATUM (coniine) for therapeutic use.

COTARNINE for therapeutic use.

CROTALARIA spp. for therapeutic use.

CROTON TIGLIUM for therapeutic use.

CYNOGLOSSUM spp. for therapeutic use.

DIBUTYL PHTHALATE for cosmetic use.

DICOPHANE (DDT) for therapeutic use.

DIETHYLENE GLYCOL for use in toothpastes or mouthwashes except in preparations containing 0.25% or less of diethylene glycol.

DIETHYLENE GLYCOL MONOMETHYL ETHER for cosmetic use.

DIETHYLHEXYL PHTHALATE for cosmetic use.

DIETHYLPHTHALATE in sunscreens, personal insect repellents or body lotion preparations for human use except in preparations containing 0.5% or less of diethylphthalate.

5,6DIHYDROXYINDOLINE for cosmetic use in preparations containing more than 2% of 5,6dihydroxyindoline.

DIIODOHYDROXYQUINOLINE (iodoquinol) for human internal use.

DIISOBUTYL PHTHALATE for cosmetic use.

1,3DIMETHYLAMYLAMINE (DMAA).

1,3DIMETHYLBUTYLAMINE (DMBA) except when separately specified in these schedules.

1(1,1DIMETHYLETHYL)2METHOXY4METHYL3,5DINITROBENZENE (musk ambrette).

1,5DIMETHYLHEXYLAMINE (DMHA) except when separately specified in these schedules.

1,4DIMETHYLPENTYLAMINE (DMPA).

DIMETHYLPHTHALATE in sunscreens, personal insect repellents or body lotion preparations for human use except in preparations containing 0.5% or less of dimethylphthalate.

DI(METHYLOXYETHYL) PHTHALATE for cosmetic use.

2,4DINITROPHENOL for human use.

DISPERSE YELLOW 3 for use in hair dyes.

DULCIN for therapeutic use.

ETHYLENE GLYCOL for use in toothpastes or mouthwashes except in preparations containing 0.25% or less of ethylene glycol.

EUPATORIUM CANNABINUM (Hemp Agrimony) for therapeutic use.

FARFUGIUM JAPONICUM for therapeutic use.

FORMALDEHYDE (excluding its derivatives):

 (a) in oral hygiene preparations containing more than 0.1% of free formaldehyde; or

 (b) in aerosol sprays for cosmetic use containing 0.005% or more of free formaldehyde; or

 (c) in nail hardener cosmetic preparations containing 5% or more of free formaldehyde; or

 (d) in all other cosmetic preparations containing 0.05% or more of free formaldehyde except in preparations containing 0.2% or less of free formaldehyde when labelled with the warning statement:

  CONTAINS FORMALDEHYDE.

GAMMA BUTYROLACTONE (excluding its derivatives) in nonpolymerised form in preparations for domestic and cosmetic use.

HELIOTROPIUM spp. for therapeutic use.

HYDROGEN PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations containing more than 6% (20 volume) of hydrogen peroxide except in preparations manufactured for, and supplied solely by, registered dental practitioners as part of their dental practice.

ISOPROPYL NITRITE.

JUNIPERUS SABINE [savin(e)] for therapeutic use.

KAMBO.

LEAD COMPOUNDS:

 (a) in antifouling paints except in preparations containing 0.1% or less of lead calculated on the nonvolatile content of the paint; or

 (b) in paints (other than antifouling paints), tinters, inks or ink additives except in preparations containing 0.009% or less of lead calculated on the nonvolatile content of the paint, tinter, ink or ink additive.

LIGULARIA DENTATA for therapeutic use.

MELIA AZEDARACH including its extracts and derivatives.

METHANOL in hand sanitiser preparations containing more than 5% methanol.

METHYLDIBROMO GLUTARONITRILE in preparations intended to be in contact with the skin, including cosmetic use.

METHYL METHACRYLATE for cosmetic use except in preparations containing 1% or less of methyl methacrylate as residual monomer in a polymer.

METHYLROSANILINIUM CHLORIDE (formerly known as crystal violet) and the following TRIARYLMETHANE DYES – for use in hair dyes:

 (a) Acid Violet 49; or

 (b) Ethyl Violet; or

 (c) Basic Blue 7; or

 (d) Basic Blue 26 (CI 44045).

NAPHTHALENE (excluding derivatives) in preparations in block, ball, disc, pellet or flake form for domestic use except when enclosed in a device which, in normal use, prevents removal or ingestion of its contents.

OXYPHENISATIN for therapeutic use.

PARAFORMALDEHYDE (excluding its derivatives):

 (a) in oral hygiene preparations containing more than 0.1% of free formaldehyde; or

 (b) in aerosol sprays for cosmetic use containing 0.005% or more of free formaldehyde; or

 (c) in nail hardener cosmetic preparations containing 5% or more of free formaldehyde; or

 (d) in all other cosmetic preparations containing 0.05% or more of free formaldehyde except in preparations containing 0.2% or less of free formaldehyde when labelled with the warning statement:

  CONTAINS FORMALDEHYDE.

PETASITES spp. for therapeutic use.

PHENPROMETHAMINE.

PHENYLENEDIAMINES, including alkylated, arylated, halogenated and nitro derivatives, in preparations for skin colouration, tattooing and dyeing of eyelashes or eyebrows except when included in Schedule 6.

POTASSIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semisolid food additive preparations, for domestic use, the pH of which is more than 11.5.

nPROPYL NITRITE.

PTERIDIUM spp. for therapeutic use.

PULMONARIA spp. for therapeutic use.

SAFROLE for internal therapeutic use except in preparations containing 0.1% or less of safrole.

SANGUINARIA CANADENSIS (bloodroot) in preparations for human use except in preparations containing 0.01% or less of SANGUINARINE.

SENECIO spp. for therapeutic use.

SILICONES for injection or implantation except when included in Schedule 4.

SODIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semisolid food additive preparations, for domestic use, the pH of which is more than 11.5.

SYMPHYTUM spp. (Comfrey) in preparations for human or animal use except when in Schedule 5.

2,4TOLUENEDIAMINE in preparations for skin colouration (including tattooing) and dyeing of hair, eyelashes or eyebrows.

TOLUENEDIAMINES in preparations for skin colouration (including tattooing) and dyeing of eyelashes or eyebrows except when included in Schedule 6.

oTOLUIDINE (excluding derivatives) in preparations for skin colouration (including tattooing) and dyeing of hair, eyelashes or eyebrows except in preparations containing 0.001% or less of otoluidine.

1,1,1TRICHLOROETHANE in pressurised spray packs for therapeutic use.

TRICHODESMA AFRICANA for therapeutic use.

TRIPARANOL for therapeutic use.

TUSSILAGO FARFARA for therapeutic use.

Appendix AGeneral exemptions

 

 

Note: See paragraph 11(a).

1  Exempt preparations and products

  The following table specifies preparations and products for the purposes of paragraph 11(a).

 

Exempt preparations and products

Item

Column 1
Preparation or product

1

ALGICIDES, BACTERIOCIDES OR SLIMICIDES for industrial use that are not agricultural chemical products or veterinary chemical products

2

BACTERIAL CULTURE MEDIA containing antibiotics

3

CERAMICS

4

CHEMISTRY SETS for toy and educational use, when complying with the requirements of Australian Standard AS 8124.42003, Safety of toys, Part 4: Experimental sets for chemistry and related activities

5

COPPER COMPOUNDS in paints

6

DEXTRANS, GELATIN SUCCINYLATED & ETHERIFIED STARCHES used as plasma substitutes/blood volume expanders

7

ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS or LAMPS

8

ELECTRONIC COMPONENTS

9

ENHANCING AGENTS for use in ultrasonic and magnetic resonance imaging

10

EXPLOSIVES

11

FOOD except:

(a) food additives before incorporation into food; or

(b) when used as a means of administering a poison for therapeutic use

12

FRITTED GLAZING OR ENAMELLING PREPARATIONS in which the poison is confined as a nonmigratory component of glassy solid flakes or granules

13

GLASS (including CRYSTAL WARE)

14

GLAZED POTTERY

15

HUMAN BLOOD PRODUCTS including:

(a) whole blood;

(b) blood components including red cells, white cells, platelets and plasma (including cryoprecipitate); and

(c) the following plasmaderived therapeutic proteins; and their equivalent recombinant alternatives:

(i) albumin;

(ii) anticoagulation complex;

(iii) C1 esterase inhibitors;

(iv) clotting factors;

(v) fibrinogen;

(vi) protein C;

(vii) prothrombin complex concentrate (PCC);

(viii) thrombin

16

IN VITRO DIAGNOSTIC AND ANALYTICAL PREPARATIONS containing 0.001% or less of a poison included in Schedules 1 to 8

17

INTRAOCULAR VISCOELASTIC PRODUCTS

18

LUBRICANTS in preparations that provide a lubricating action between machinery parts, except soluble oils and solventdeposited lubricating agents

19

MATCHES

20

MEDICAL AND VETERINARY ADHESIVES, GLUES AND CEMENTS

21

MEDICAL DEVICES classified as Class III by the classification rules set out in Schedule 2 to the Therapeutic Goods (Medical Devices) Regulation 2002, except the following:

(a) injectable tissue reconstructive, augmentation and restoration materials, including collagen;

(b) medical devices which include anticoagulants;

(c) artificial tears;

(d) urinary catheters;

(e) intraarticular fluids

22

MOTOR, HEATING or FURNACE FUELS except the following:

(a) when the contrary intention appears in any Schedule;

(b) when containing methanol;

(c) toy or hobby fuels; or

(d) petrol or kerosene when packed in containers having a capacity of 20 L or less

23

NUTRITION REPLACEMENT PREPARATIONS FOR PARENTERAL ADMINISTRATION

24

PAPER except:

(a) when prepared for pesticidal use; or

(b) when containing a poison included in Schedule 8 or 9

25

PHOTOGRAPHIC PAPER or FILM

26

PIGMENTS when immobilised in a polymer

27

PORCELAIN

28

PRINTING INKS or INK ADDITIVES except:

(a) when containing a pesticide; or

(b) preparations containing more than 0.1% of lead calculated on the nonvolatile content of the ink or ink additive

29

RADIOGRAPHIC CONTRAST MEDIA (radiopaques) for therapeutic use

30

RADIOISOTOPES for therapeutic use

31

SEEDS treated with seed protectants

32

SINGLEUSE TUBES for the estimation of alcohol content of breath

33

TERMITE BARRIERS consisting of an active ingredient, other than arsenic, approved by the relevant registration authority, and laminated between impervious sheeting

34

TIMBER or WALLBOARD

35

TREATMENT LAYERS OF COATED METAL ARTICLES except articles intended for use in the collection of drinking water when not compliant with the health and safety requirements of the Australian Standard AS 4020:2018, Testing of products for use in contact with drinking water

36

VITREOUS ENAMELS

37

WRITING CORRECTION PENS which do not allow ingestion of the contents and which contain no scheduled poison other than designated solvents included in Schedule 5

Appendix BSubstances considered not to require control by scheduling

 

 

Note: See paragraph 11(b).

1  Reasons for including substances in the table in clause 3

  For the purposes of the table in clause 3, the letter specified in column 1 of an item of the following table represents the reason specified in column 2 of the item.

 

Reasons for including substances in the table in clause 3

Item

Column 1
Letter

Column 2
Reason

1

a

Low Toxicity

2

b

Use pattern restricts hazard

3

c

Presentation/packaging restricts hazard

4

d

Industrial use only

2  Areas of use in relation to substances included in the table in clause 3

  For the purposes of the table in clause 3, the number specified in column 1 of an item of the following table represents the area, subarea or subsubarea of use specified in column 2, 3 or 4 (as applicable) of the item.

 

Areas of use in relation to substances included in the table in clause 3

Item

Column 1
Number

Column 2
Area

Column 3
Subarea

Column 4
Subsubarea

1

1

Agriculture

 

 

2

1.1

 

Herbicide

 

3

1.2

 

Insecticide

 

4

1.2.1

 

 

Insecticide for codling moth

5

1.2.2

 

 

Termiticide

6

1.3

 

Fungicide

 

7

1.3.1

 

 

On seed fungicide

8

1.4

 

Bird Repellent

 

9

1.5

 

Fertiliser

 

10

1.6

 

Plant Growth Regulator

 

11

1.7

 

Insect Pheromone

 

12

1.8

 

Mushroom Bactericide

 

13

1.9

 

Acaricide

 

14

1.10

 

Biological control agent

 

15

1.11

 

Adjuvant in agricultural products

 

16

2

Veterinary

 

 

17

2.1

 

For animal use

 

18

2.2

 

Treatment of mastitis in cows

 

19

2.3

 

Coccidiostat

 

20

2.4

 

Feed additive

 

21

2.5

 

Antiseptic

 

22

2.6

 

Scabicide

 

23

2.7

 

Anthelmintic

 

24

2.8

 

Vitamin/Mineral

 

25

2.9

 

Growth Promotant

 

26

2.10

 

Ectoparasiticide

 

27

3

Domestic

 

 

28

3.1

 

Aromatherapy

 

29

3.2

 

Food additive

 

30

3.3

 

Cosmetic

 

31

3.4

 

Human use

 

32

3.5

 

Miticide

 

33

4

Industrial

 

 

34

4.1

 

Water treatment

 

35

4.2

 

Biological control agent

 

36

5

Environmental

 

 

37

5.1

 

Mosquito control

 

38

6

Human therapeutic use

 

 

39

6.1

 

Diagnostic agent

 

40

6.2

 

Medical device

 

41

6.3

 

Antiseptic

 

42

6.4

 

Sunscreen

 

43

6.5

 

External use

 

44

6.6

 

Laxative

 

45

6.7

 

Antiseborrheic

 

46

6.8

 

Cytoprotective

 

47

6.9

 

Vitamin/Mineral

 

48

6.10

 

Eye Drops

 

49

7

General

 

 

50

7.1

 

Any use

 

51

7.2

 

Excipient

 

52

7.3

 

Synergist

 

53

7.4

 

Flux

 

54

7.5

 

Pesticide

 

55

7.6

 

Insect repellent

 

56

7.7

 

Solvent

 

57

7.8

 

Disinfectant

 

58

7.9

 

Preservative

 

59

7.10

 

Antioxidant

 

60

7.11

 

Resin activator/accelerant

 

61

7.12

 

Sweetener artificial

 

62

7.13

 

Food additive

 

3  Substances exempt in certain uses

  For the purposes of paragraph 11(b), the following table specifies:

 (a) substances; and

 (b) areas, subareas and subsubareas of use in relation to those substances.

Note: Columns 3 and 4 of the table are included for information only.

 

Substances exempt in certain uses

Item

Column 1
Substance

Column 2
Area, subarea or subsubarea of use

Column 3
Reason for inclusion

Column 4
Date of inclusion

1

4[4(ACETYLOXY)PHENYL]2BUTANONE

1.7

b

Feb 2005

2

AFIDOPYROPEN

1.2

b

Jun 2018

3

ALCOHOL, DEHYDRATED

6

b

Aug 2000

4

ALUM

7.1

a

May 1997

5

ALUMINIUM AMMONIUM SULFATE

7.1

a

May 1997

6

ALUMINIUM POTASSIUM SULFATE

7.1

a

May 1997

7

ALUMINIUM SILICATE

7.1

a

Nov 1974

8

ALUMINIUM tris (ETHYLPHOSPHONATE)

1

a

Aug 1986

9

AMETOCTRADIN

1.3

a

May 2012

10

AMMONIUM PHOSPHATE

7.1

a

Nov 1974

11

AMMONIUM THIOSULPHATE

7.1

a

Nov 1974

12

AMPROLIUM

2.3

a

Jun 1969

13

AMYL ACETATE

7.1

a

Nov 1974

14

α AMYLASE derived from Aspergillus niger

2.4

a

Feb 2005

15

AMYL CINNAMALDEHYDE

3.3

a, b

Feb 2017

16

ANDROSTENEDIONE ALBUMEN CONJUGATE WITH DEA DEXTRAN ADJUNCT

2.1

a

Jun 2004

17

ASPARTIC ACID

6

a

18

ASULAM

1

a

May 1986

19

AUREOBASIDIUM PULLULANS (strains DSM14940 and DSM14941)

1.3

a

Oct 2017

20

AZIMSULFURON

1.1

a

Jun 2003

21

BACILLUS AMYLOLIQUEFACIENS

1.3

a

Jun 2018

22

BACILLUS SPHAERICUS, STRAIN 2362

5.1

a

Feb 2003

23

BACILLUS THURINGIENSIS

5.1

a

May 1992

24

BACILLUS THURINGIENSIS (excluding endotoxin)

2.10

a

Jun 2003

25

BACILLUS TOYOI

2.9

a

Aug 1980

26

BACULOVIRUS CYDIA POMONELLA

1.2

a

Jun 2006

27

BENFLURALIN

1.1

a

28

BENSULFURONMETHYL

1

a

Aug 1987

29

BENTONITE

7.1

a

Jun 2002

30

BENZYL BENZOATE

1.2

a

Aug 1989

31

BETAINE HYDROCHLORIDE

7.1

a

Nov 1974

32

BIFENAZATE

1.9

a

Oct 2002

33

BISMUTH SUBNITRATE

2.1

b, c

Nov 1999

34

BISTRIFLURON

1.2.2

a

Feb 2014

35

BIURET

2.4

a

Nov 1974

36

BIXLOZONE

1.1

a

Feb 2020

37

BLAD (banda de Lupinus albus doce)

1.3

a

Feb 2016

38

BOSCALID

1.3

a

June 2003

39

BOVINE SOMATOTROPHIN

2

a

May 1992

40

BROMACIL

1

a

Aug 1987

41

BROMOPROPYLATE

1

a

Nov 1994

42

BUPIRIMATE

1

a

Nov 1990

43

BUTAFENACIL

1

a

May 2000

44

BUTOXYPOLYPROPYLENE GLYCOL

7.7

a

Nov 1974

45

nBUTYL BUTYRATE

7.1

a

46

nBUTYL LACTATE

7.1

a

47

CARBOXIN

1

a

Aug 1987

48

CARFENTRAZONEETHYL

1

a

Aug 1998

49

CELLULASE derived from Aspergillus niger

2.4

a

Feb 2005

50

CETYL ALCOHOL

7.1

a

Nov 1974

51

CHAMOMILE OIL

3.1

a

Feb 2000

52

CHINA CLAY

1.2

a

Sep 2008

53

CHLORANTRANILIPROLE

1.2

a

Sep 2008

54

CHLORFLUAZURON

1.2.2

a

Oct 2005

55

CHLORFLURENOL

1.6

a

Feb 1974

56

CHLORIDAZON

1

a

May 1988

57

CHLOROXYLENOLS

7.8

a

Feb 1975

58

CITRONELLA OIL

7.1

a

Feb 2000

59

CLARY SAGE OIL

7.1

a

Feb 2000

60

CLITORIA TERNATEA EXTRACT

1.2

a

Feb 2016

61

CLOPIDOL

2.3

d

Nov 1974

62

COBALT NAPHTHENATE

7.1

d

63

CROSPOVIDONE

2

a

Aug 1996

64

CULICINOMYCES CLAVOSPORUS

5.1

a

Nov 1982

65

CYCLAMIC ACID

7.1

a

Nov 1971

66

CYCLANILIPROLE

1.2

a

Oct 2016

67

CYCLOBUTRIFLURAM

1.3, 1.3.1

a

Oct 2022

68

CYCLOHEXANE

7.7

a

Nov 1974

69

CYCLOHEXANOL ACETATE

7.7

a

70

CYPRINID HERPESVIRUS3

1.10

a

Oct 2018

71

CYROMAZINE

2

a

Nov 1980

72

DICLAZURIL

2.3

a

Nov 2001

73

DIETHYL CARBONATE

7.1

a

74

DIFLUFENICAN

1

a

Feb 1987

75

DIKEGULACSODIUM

1.6

a

Mar 1980

76

DIMETHYL ETHER

4

d

Nov 1988

77

DIMETICONE

7.1

a

78

DIPHENYLAMINE

1

a

Feb 1988

79

DIPROPYLENE GLYCOL MONOMETHYL ETHER

4

a

Nov 1987

80

DISODIUM MANGANESE EDTA

2.1

a

Feb 2022

81

DIURON

1

a

Nov 1987

82

DOCUSATE SODIUM (DIOCTYL SODIUM SULFOSUCCINATE)

7.1

a

Feb 1970

83

2,2DPA

1

a

Nov 1989

84

DROMETRIZOLE TRISILOXANE

6.4

a

Oct 2003

85

DUDDINGTONIA FLAGRANS, STRAIN IAH 1297

2.7

a

Feb 2018

86

EPSIPRANTEL

2

a

Nov 1991

87

ETHAMETSULFURONMETHYL

1.1

a

Nov 2000

88

ETHOPABATE

2.3

d

Jun 1969

89

ETHYL ACETATE

7.1

a

Nov 1974

90

ETHYL ALCOHOL

7.1

a

Nov 1974

91

ETHYLBUTYLACETYL AMINOPROPRIONATE

3.4

a

Aug 2000

92

ETHYL BUTYRATE

7.1

a

93

ETHYL LACTATE

7.1

a

94

ETOFENPROX

1.2

a

Jun 2018

95

ETOXAZOLE

1.2

a

Oct 2003

96

EUBACTERIUM sp. strain DSM11798

2.4

a

Sep 2013

97

FENFURAM

1.3.1

a

May 1977

98

FENHEXAMID

1

a

Feb 1999

99

FENOXYCARB

1

a

Feb 1988

100

FLORPYRAUXIFENBENZYL

1, 1.1

a

Feb 2018

101

FLORYLPICOXAMID

1.3

a

Feb 2021

102

FLUFENOXURON

1

a

Feb 1997

103

FLUMETSULAM

1

a

Feb 1992

104

FLUOMETURON

1

a

Aug 1989

105

FLUOPICOLIDE

1.3

a

Oct 2016

106

FLUOXAPIPROLIN

1.3

a

Feb 2022

107

FLUTOLANIL

1.3

a

Nov 2001

108

FLUROXYPYR

1

a, c

May 1986

109

FORCHLORFENURON

1.6

a

Feb 2005

110

FULLERS EARTH

7.1

a

Nov 1974

111

FUNGAL PROTEASE derived from Aspergillus niger

2.4

a

Feb 2005

112

GERANIUM OIL

7.1

a

Feb 2000

113

GIBBERELLIC ACID

1.6

a

Nov 1974

114

αGLUCANASE derived from Aspergillus niger

2.4

a

Feb 2005

115

HALAUXIFEN METHYL

1, 1.1

a

Oct 2014

116

HELIONAL

7

a

Feb 2023

117

HEXAFLURON

1

a

Nov 1988

118

HEXYL ACETATE

7.7

a

119

HEXYL CINNAMALDEHYDE

3.3

a, b

Feb 2017

120

HEXYTHIAZOX

1

a

Feb 1988

121

HUMAN OSTEOGENIC PROTEIN1 (OP1)

6.2

b

Aug 2001

122

HYDROPRENE

1

a

Feb 1988

123

HYDROXYPROPYL CELLULOSE

7.1

a

Nov 1982

124

ICODEXTRIN

6

b

Nov 2000

125

INDOLE3ACETIC ACID

1.6

b

Feb 1985

126

IPFLUFENOQUIN

1.3, 1.3.1

a

Sep 2022

127

ISOPRENE ALCOHOL

7.1

a

128

IPRODIONE

1

a

Feb 1997

129

ISETHIONATE, as mixed ammonium and ethanolamine salts of 2hydroxyethanesulfonic acid

1.11

a, b

Jun 2016

130

ISOFETAMID

1.3

a

Feb 2018

131

ISOSTEARYL ALCOHOL ETHOXYLATE

5.1

a

Nov 1999

132

KAOLIN

7.1

a

Nov 1974

133

KINETIN

1.6

a

Feb 2022

134

KRESOXIMMETHYL

1

a

Aug 1999

135

KUNZEA OIL

7.1

a

Feb 2000

136

LAURIC ACID

7.1

a

Oct 2005

137

LAURYL ALCOHOL (1DODECANOL)

7.1

a

Nov 1974

138

LAVANDIN OIL

7.1

a

Feb 2000

139

LAVENDER OIL

7.1

a

Feb 2000

140

LEAD METALLIC

7.1

a

141

LEPIDOPTEROUS SEX PHEROMONES

1

a

Nov 1990

142

LIMONENE (DIPENTENE)

7.1

a

Jun 2002

143

LINOLEIC ACID

7.1

a

Oct 2005

144

LINSEED FATTY ACIDS

2.1

a

Aug 1990

145

LINURON

1

a

Feb 1990

146

LIQUORICE, DEGLYCYRRHISINISED

7.1

a

May 1999

147

MAGNESIUM HYDROXIDE

7.1

a

Jun 2021

148

MALEIC HYDRAZIDE

1

a

Nov 1992

149

MANGANESE DIOXIDE

1

b

May 1999

150

MEGASPHAERA ELSDENII strain 41125

2.4

a

Sep 2013

151

MESOSULFURONMETHYL

1.1

a

Feb 2002

152

METARHIZIUM ANISOPLIAE

4.2

b

Feb 2000

153

METARHIZIUM ANISOPLIAE

1.10

a

Jun 2003

154

METCAMIFEN

1.1

a

Feb 2020

155

METHOPRENE

1

a

Aug 1987

156

METHOXYFENOZIDE

1

a

Nov 2000

157

METHYL ACETATE

7.7

a

158

METHYL BENZOQUATE

2.3

d

Nov 1974

159

1METHYLCYCLOPROPENE

1.6

a

Jun 2003

160

METHYL pHYDROXYBENZOATE

7.9

a

Nov 1974

161

METSULFURONMETHYL

1.1

a

Nov 1985

162

MYRISTIC ACID

7.1

a

Oct 2005

163

NAPROPAMIDE

1

a

Aug 1987

164

NAPTHYL ACETAMIDE

1.6

a

Nov 1974

165

NEROLI OIL

7.1

a

Feb 2000

166

NICARBAZIN

2.3

d

Jun 1969

167

NISIN

3.2

a

Jun 2003

168

NORFLURAZON

1.1

a

Nov 1983

169

NOVALURON

1

a

Nov 2000

170

NUCLEAR POLYHEDROSIS VIRUS of Helicoverpa armigera occlusion bodies

1.2

a

Feb 2004

171

OCTYL ALCOHOLS

7.1

a

Nov 1974

172

OLEIC ACID

7.1

a

Oct 2005

173

ORANGE OIL, SWEET

7.1

a

Aug 2000

174

OXABETRINIL

1

a

Feb 1987

175

OXATHIAPIPROLIN

1.3

a

Jun 2016

176

OXYFLUORFEN

1

a

May 2001

177

PALMAROSA OIL

7.1

a

Feb 2000

178

PALMITIC ACID

7.1

a

Oct 2005

179

PATCHOULI OIL

7.1

a

Feb 2000

180

PECTINASE derived from Aspergillus niger

2.4

a

Feb 2005

181

PEGBOVIGRASTIM

2.1

a

Jun 2017

182

PENCYCURON

1

a

Aug 1994

183

PENTADECANOIC ACID

7.1

a

Oct 2005

184

PEPPERMINT OIL

7.1

a

Feb 2000

185

PHENMEDIPHAM

1.1

a

May 1989

186

DPHENOTHRIN

7.5, 1.2

a

Feb 1982

187

PHYTASE

2.4

a

Feb 1996

188

PICLORAM

1

a

Aug 1987

189

PICOLINAFEN

1

a

May 2000

190

PIMELIC ACID

7.1

a

Oct 2005

191

PIPERONYL BUTOXIDE

7.5

a

Aug 1991

192

POLOXALENE

7.1

a

Nov 1974

193

POLY DIALLYL DIMETHYL AMMONIUM CHLORIDE (PolyDADMAC)

4.1

a

Nov 1997

194

POLYHEDROSIS VIRUS of Helico zea occlusion bodies

1

a

Nov 1996

195

POLY (GNRF) OVALBUMIN

2

a

Feb 1990

196

POLYSORBATE 20

1

a

May 2001

197

PORCINE SOMATOTROPHIN

2

c

Nov 1991

198

POTASSIUM SORBATE

1.3

a

Oct 2004

199

POTASSIUM BICARBONATE

1

a

Jun 2004

200

PROPYL ACETATES

7.1

a

201

PROPYLENE GLYCOL

7.1

a

Nov 1974

202

2PROPYLENE GLYCOL 1MONOMETHYL ETHER

4

a

Nov 1987

203

PROTHIOCONAZOLE

1.3.1

a

Jun 2005

204

PSEUDOMONAS FLUORESCENS

1.8

a

May 1985

205

PYDIFLUMETOFEN

1.3

a

Feb 2018

206

PYRIMETHANIL

1

a

Feb 1996

207

PYRIPROXYFEN

1

a

Aug 1994

208

QUASSIA

6, 2.1

d

Nov 1974

209

QUINOXYFEN

1.3

a

Nov 2001

210

RHIZOBIUM RHIZOGENES

1

b

Nov 1989

211

ROSEMARY OIL

7.1

a

Feb 2000

212

SAGE OIL (Spanish)

7.1

a

Feb 2000

213

SANDALWOOD OIL

7.1

a

Feb 2000

214

SEAWEED & UNFRACTIONED SEAWEED EXTRACTS

1.5

d

Feb 1985

215

SILVER OXIDE

7.14

b

Jun 2018

216

SIMAZINE

1.1

a

Nov 1987

217

SODIUM BICARBONATE

1

a

Jun 2004

218

SODIUM PROPIONATE

1.3

a

Oct 2004

219

STERIC ACID

7.1

a

Oct 2005

220

STREPTOMYCES LYDICUS WYEC 108

1.3

a

Oct 2016

221

SUCRALFATE

6.8

a

Aug 1982

222

SULESOMAB

6.1

b

Jun 2002

223

SULFOSULFURON

1

a

Feb 1998

224

SULPHATED POLYSACCHARIDES

7.1

a

225

TANNIC ACID

7.1

a

Dec 1965

226

TANNIC ACID/BENZYL ALCOHOL PRODUCT

7.1

a

Nov 1993

227

TERBACIL

1

a

Aug 1987

228

THAUMATIN

3.2

a

Nov 1990

229

THIDIAZURON

1

a

Nov 1989

230

TIAFENACIL

1

a

June 2019

231

TRIASULFURON

1

a

Feb 1988

232

TRICHODERMA HARZIANUM

1

a

May 1996

233

(Z)9TRICOSENE

1

a

Aug 1991

234

TRIETHYLENE GLYCOL

7.1

a

Nov 1974

235

TRIFLOXYSULFURON

1.1

a

Feb 2002

236

TRIFLURALIN

1

a

Aug 1990

237

TRIFORINE

1

a

Aug 1987

238

ULOCLADIUM OUDEMANSII

1.10

a

Oct 2003

239

UREA

7.1

a

Nov 1974

240

13CUREA

6.1

a

May 2001

241

VETIVER OIL

7.1

a

Feb 2000

242

VINYL ETHER

6

b

Nov 1987

243

VITAMIN K

6.9, 2.8

a

Jul 1963

244

XANTHOPHYLL (lutein)

7.1

a

Nov 1974

245

XYLANASE derived from Aspergillus niger

2.4

a

Feb 2005

246

YLANG YLANG OIL

7.1

a

Feb 2000

247

ZINC NAPHTHENATE

1.3

a

 

Appendix CBlank

 

   

Note 1: Appendix C is intentionally blank.

Note 2: Appendix C previously included poisons now included in Schedule 10.

Appendix DAdditional controls on possession or supply of poisons included in Schedule 4 or 8

 

 

Note: See section 64.

1  Poisons available for human use only from or on the prescription or order of an authorised medical practitioner

  A poison specified in the following table may be supplied for human use only by, on the prescription or order of, an authorised medical practitioner.

 

Item

Poison

1

CANNABIS for human use

2

CLOMIFENE for human use

3

CLOZAPINE for human use

4

CORIFOLLITROPIN ALFA (recombinant follicle stimulant) for human use

5

CYCLOFENIL for human use

6

DINOPROST for human use

7

DINOPROSTONE for human use

8

FOLLITROPIN ALFA (recombinant human folliclestimulating hormone) for human use

9

FOLLITROPIN BETA (recombinant human folliclestimulating hormone) for human use

10

FOLLITROPIN DELTA (recombinant human folliclestimulating hormone) for human use

11

LUTEINISING HORMONE for human use

12

NABIXIMOLS for human use

13

SODIUM OXYBATE for human use

14

TETRAHYDROCANNABINOLS for human use

15

TERIPARATIDE for human use

16

UROFOLLITROPIN (human folliclestimulating hormone) for human use

2  Poisons available for human use only from or on the prescription or order of a specialist physician or a dermatologist

  A poison specified in the following table may be supplied for human use:

 (a) only by, or on the prescription or order of, a specialist physician or a dermatologist; and

 (b) if the person to whom the poison is to be supplied is a woman of childbearing age—only if the specialist physician or dermatologist has:

 (i) ensured that the possibility of pregnancy has been excluded prior to commencement of treatment; and

 (ii) if the poison is acitretin or etretinate—advised the patient to avoid becoming pregnant during or for a period of 36 months after completion of treatment; and

 (iii) if the poison is bexarotene, isotretinoin or thalidomide—advised the patient to avoid becoming pregnant during or for a period of 1 month after completion of treatment.

 

Item

Poison

1

ACITRETIN for human use

2

BEXAROTENE for human use

3

ETRETINATE for human use

4

ISOTRETINOIN for human oral use

5

THALIDOMIDE for human use

3  Poisons available only from or on the prescription or order of a medical practitioner approved or authorised under section 19 of the Act

  A poison specified in the following table may be supplied only by, or on the prescription or order of, a medical practitioner for whom an approval or authority under section 19 of the Act that covers the poison is in force.

 

Item

Poison

1

DRONABINOL (delta9tetrahydrocannabinol)

4  Poisons available only from or on the order of a specialist physician

  A poison specified in the following table may be supplied:

 (a) only by, or on the prescription or order of, a specialist physician; and

 (b) if the person to whom the poison is to be supplied is a woman of childbearing age—only if the specialist physician has:

 (i) ensured that the possibility of pregnancy has been excluded prior to commencement of treatment; and

 (ii) advised the patient to avoid becoming pregnant during or for a period of 1 month after completion of treatment.

 

Item

Poison

1

LENALIDOMIDE

2

POMALIDOMIDE

3

RIOCIGUAT for human use

4

TRETINOIN for human oral use

5  Poisons for which possession without authority is illegal

  The following table specifies poisons that must not be possessed by a person without authority (for example, possession other than in accordance with a legal prescription).

 

Item

Poison

1

ANABOLIC STEROIDAL AGENTS, including those separately specified in Schedule 4

2

ANDROGENIC STEROIDAL AGENTS, including those separately specified in Schedule 4

3

AOD9604 (CAS No. 221231103)

4

BENZODIAZEPINE DERIVATIVES, including those separately specified in Schedule 4 and Schedule 8

5

CJC1295 (CAS No. 863288340)

6

DARBEPOETIN

7

DEXTROPROPOXYPHENE

8

N, α -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA)

9

EPHEDRINE

10

EPOETINS

11

ERYTHROPOIETIN

12

ERYTHROPOIETINS except when separately specified in this Appendix

13

FIBROBLAST GROWTH FACTORS

14

FOLLISTATIN

15

GLUTETHIMIDE

16

GROWTH HORMONE RELEASING HORMONES (GHRHs) including those separately specified in Schedule 4

17

GROWTH HORMONE RELEASING PEPTIDES (GHRPs) including those separately specified in Schedule 4

18

GROWTH HORMONE RELEASING PEPTIDE6 (GHRP6)

19

GROWTH HORMONE SECRETAGOGUES including those separately specified in Schedule 4

20

HEXARELIN

21

IBUTAMOREN

22

INSULINLIKE GROWTH FACTORS

23

IPAMORELIN

24

NICOTINE

25

PERAMPANEL for human use

26

PHENTERMINE

27

PRALMORELIN ((GROWTH HORMONE RELEASING PEPTIDE2) (GHRP2))

28

PSILOCYBINE

29

SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM), including those separately specified in Schedule 4

30

SOMATROPIN (human growth hormone)

31

STENABOLIC (SR9009) and other synthetic REVERB agonists

32

TB500

33

THYMOSIN BETA 4 (THYMOSIN β4)

34

TIANEPTINE

35

VADADUSTAT

6  Poisons available for human use only from or on the prescription or order of a specialist physician

  A poison specified in the following table may be supplied for human use:

 (a) only by, or on the prescription or order of, a specialist physician; and

 (b) if the person to whom the poison is to be supplied is a woman of childbearing age—only if the specialist physician has:

 (i) ensured that the possibility of pregnancy has been excluded prior to commencement of treatment; and

 (ii) advised the patient to avoid becoming pregnant during and for a period of 3 months after completion of treatment.

 

Item

Poison

1

AMBRISENTAN for human use

2

BOSENTAN for human use

3

ENZALUTAMIDE for human use

4

MACITENTAN for human use

5

SITAXENTAN for human use

7  Poisons available for human use only from or on the prescription or order of a dermatologist

  A poison specified in the following table may be supplied for human use only by, or on the prescription or order of, a dermatologist.

 

Item

Poison

1

ALEFACEPT for human use

8  Poisons available for initial treatment of a patient only if authorised by certain health practitioners

  HYDROXYCHLOROQUINE may be supplied, for human use, for the initial treatment of a patient only if that treatment is authorised by:

 (a) a medical practitioner registered under State or Territory legislation that forms part of the Health Practitioner Regulation National Law as a specialist in any of the following specialties or fields of specialty practice:

 (i) dermatology;

 (ii) emergency medicine;

 (iii) intensive care medicine;

 (iv) paediatrics and child health;

 (v) physician; or

 (b) a dental practitioner registered under State or Territory legislation that forms part of the Health Practitioner Regulation National Law as a specialist in the specialty of oral medicine.

9  Poisons which must be stored in a locked container to prevent unauthorised access

  The following table specifies poisons that must be stored in a locked container to prevent unauthorised access.

 

Item

Poison

1

PENTOBARBITAL in injectable preparations

10  Poisons available only when prescribed or authorised in certain circumstances

  N, α -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA) in preparations for human use may be supplied only for the treatment of post-traumatic stress disorder:

 (a) if MDMA is prescribed, or its supply is authorised, by a medical practitioner:

 (i) registered under State or Territory legislation that forms part of the Health Practitioner Regulation National Law as a specialist psychiatrist; and

 (ii) for whom an authority under subsection 19(5) of the Act that covers MDMA is in force; or

 (b) for use in a clinical trial that is approved by, or notified to, the Secretary under the Act.

 

  PSILOCYBINE in preparations for human use may be supplied only for the treatment of treatment-resistant depression:

 (a) if psilocybine is prescribed, or its supply is authorised, by a medical practitioner:

 (i) registered under State or Territory legislation that forms part of the Health Practitioner Regulation National Law as a specialist psychiatrist; and

 (ii) for whom an authority under subsection 19(5) of the Act that covers psilocybine is in force; or

 (b) for use in a clinical trial that is approved by, or notified to, the Secretary under the Act.

Appendix EFirst aid instructions for poisons

 

 

Note: See section 31.

1  Standard statements for first aid instructions

  For the purposes of the table in clause 3, the statement code specified in column 2 of an item of the following table represents:

 (a) the statement specified in column 3 of the item; or

 (b) a different statement that has the same intent as the statement specified in column 3 of the item.

 

Standard statements for first aid instructions

Item

Column 1
Category

Column 2
Statement code

Column 3
Statement

1

Basic

A

For advice, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor (at once).

2

Basic

Z

First aid is not generally required. If in doubt, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.

3

General

G1

Urgent hospital treatment is likely to be needed.

(Note the words “at once” to be added to instruction A).

4

General

G2

If swallowed, give activated charcoal if instructed.

(Note the words “at once” to be added to instruction A).

5

General

G3

If swallowed, do NOT induce vomiting.

6

General

G4

Immediately give a glass of water.

7

General

G5

Avoid giving milk or oils.

8

General

G6

If sprayed in mouth, rinse mouth with water.

9

Eyes

E1

If in eyes wash out immediately with water.

10

Eyes

E2

If in eyes, hold eyelids apart and flush the eye continuously with running water. Continue flushing until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor, or for at least 15 minutes.

11

Respiratory system

R1

If inhaled, remove from contaminated area. Apply artificial respiration if not breathing.

12

Respiratory system

R2

If swallowed or inhaled, remove from contaminated area. Apply artificial respiration if not breathing. Do not give direct mouthtomouth resuscitation. To protect rescuer, use airviva, oxyviva or oneway mask. Resuscitate in a wellventilated area.

13

Skin

S1

If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water.

14

Skin

S2

If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water. Continue flushing with water until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.

15

Skin

S3

If on skin, remove any contaminated clothing, wash skin thoroughly with soap and water, then methylated spirit if available. Contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.

16

Skin

S4

If on skin, immediately remove any contaminated clothing, wash skin with methylated spirit or PEG (polyethylene glycol) 300 or 400 if available, then flush under running water until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.

17

Skin

S5

If skin contact occurs, immediately remove contaminated clothing. Flush skin under running water for 15 minutes. Then apply calcium gluconate gel. Contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766).

18

Special Purpose

SP1

If swallowed, splashed on skin or in eyes, or inhaled, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor at once. Remove any contaminated clothing and wash skin thoroughly. If swallowed, activated charcoal may be advised. Give atropine if instructed.

2  Poisons information centre contact information in statements

  A statement required for a poison that includes a reference to a Poisons Information Centre must include:

 (a) the telephone number that is appropriate to the country or countries in which the poison is to be supplied; and

 (b) immediately following the reference to a Poisons Information Centre:

 (i) the national telephone number for the Poisons Information Centre in Australia (13 11 26); or

 (ii) the telephone number for another poisons information centre:

 (A) that is attended by adequately trained staff for 24 hour emergency poisons information; and

 (B) calls to which are logged and submitted for incorporation into the official collection of poisoning data.

Note: For subparagraph (b)(ii), in 2022 the Poisons Information Centre telephone number in New Zealand was 0800 764 766.

3  First aid instructions for poisons

 (1) For the purposes of subsection 31(1), and subject to subclause (2), the statement represented by each statement code specified in column 2 of an item of the following table is required for the poison specified in column 1 of the item.

 (2) A statement required for a poison must:

 (a) be modified for its use in relation to that poison as appropriate for the poison (for example if the poison is combined with other substances (whether toxic or nontoxic) or is in a particular physical form or presentation); and

 (b) if the statement refers to a Poisons Information Centre—comply with clause 2.

 

Poisons that must be labelled with first aid instructions

Item

Column 1
Poison

Column 2
Statement code

1

ACETIC ACID

A, G3, E2, S1

2

ACETIC ANHYDRIDE

A, G3, E2, S1

3

ACETONE

A, G3

4

ACROLEIN

A, G1, G2, G3, E2, R2, S2

5

ALKALINE SALTS

A, G3, E2, S1

6

ALKYL NITRITES

A

7

AMIDOPROPYL BETAINES—in cosmetic washoff preparations when included in Schedule 6

E1

8

AMIDOPROPYL BETAINES—in other preparations when included in Schedule 6

E1, S1

9

AMINES for use as curing agents

A, G3, E1, S1

10

2AMINO6CHLORO4NITROPHENOL

A, E1

11

4AMINOmCRESOL

A, E1

12

2AMINO5ETHYLPHENOL

A

13

4AMINO2HYDROXYTOLUENE

A, E1

14

4AMINO3NITROPHENOL

A

15

2,2'[(4AMINO3NITROPHENYL)IMINO]BISETHANOL

E1

16

mAMINOPHENOL

A, S1

17

pAMINOPHENOL

A, S1

18

4AMINOPYRIDINE

A, G1, G2, E1, S1

19

AMMONIA—5% or less

A

20

AMMONIA—above 5%

A, G3, E1, R1, S1

21

AMMONIUM COCOYL ISETHIONATE

E1

22

AMMONIUM PERSULFATE

A, G3, E2

23

AMMONIUM THIOCYANATE

A

24

AMYL NITRITE

A

25

ANHYDRIDES, organic acid, for use as curing agents for epoxy resins

A, G3, E1, S1

26

ANILINE

A, E2, R1, S1

27

ANISE OIL

A, G3

28

ANITMONY CHLORIDE

A, E2, S2

29

ANTIMONY COMPOUNDS, except antimony chloride

A

30

ARBUTIN when included in Schedule 6

A, G2, G3, E2, R2, S1

31

AZADIRACHTA INDICA (neem) including its extracts and derivatives when included in Schedule 6

A, E1

32

AZO DYES (derivatives by diazotisation)

A

33

BARIUM SALTS, except barium sulfate

A

34

BASIC RED 76

A

35

BASIL OIL

A, G3

36

BAY OIL

A, G3

37

BENZALKONIUM CHLORIDE—when included in Schedule 5

A, G3, E2

38

BENZALKONIUM CHLORIDE—when included in Schedule 6

A, G3, E2, S1

39

BENZENE

A, G3, E1, R1, S1

40

1,2BENZENEDIOL (Catechol)

A, E1, S1

41

BENZOYL PEROXIDE—above 20%

A, E2, S1

42

BENZOYL PEROXIDE—above 10% up to 20%

A, E1

43

BENZOYL PEROXIDE—10% or less

A

44

BERGAMOT OIL

A, G3

45

BIFLUORIDES (including ammonium, potassium and sodium salts)—when included in Schedule 5

A

46

BIFLUORIDES (including ammonium, potassium and sodium salts)—when included in Schedule 6 or 7

A, G3, E2, S5

47

1,3BIS(2,4DIAMINOPHENOXY)PROPANE

E1, S1

48

BISISOBUTYL PEG/PPG20/35/AMODIMETICONE COPOLYMER

A, E1

49

BORAX

A

50

BORIC ACID

A

51

BORON TRIFLUORIDE—when included in Schedule 5

A

52

BORON TRIFLUORIDE—when included in Schedule 6 or 7

A, G3, E2, S5

53

BROMOFORM

A, G3, E2, R1, S2

54

BRUCINE

A, G1, G2, G3, R2

55

2BUTOXYETHANOL and its acetates

A, E2, S1

56

nBUTYL ALCOHOL

A, E1, S1

57

BUTYL NITRITE

A

58

CADMIUM COMPOUNDS

A

59

CAJUPUT OIL

A, G3

60

CAMPHOR

A, G1, G3, G5

61

CARBAMIDE PEROXIDE—more than 9% up to 60%

A, G3, E2, S1

62

CARBAMIDE PEROXIDE—more than 60%

A, G1, G3, G4, E2, S1

63

CARBON DISULFIDE

A, G3, E2, R1, S2

64

CARBON TETRACHLORIDE

A, G3, E1, R1, S1

65

CASSIA OIL

A, G3

66

CHLORINATING COMPOUNDS, except when separately specified—containing above 4% and below 10% of available chlorine

A, G3, E1, S1

67

CHLORINATING COMPOUNDS, except when separately specified—containing 10% or more of available chlorine

A, G3, E2, S1

68

CHLORIDE (gas)

A, E1, R1

69

CHLOROACETAMIDE

A

70

CHLOROCRESOL

A, G3, E2, S2

71

2CHLORO6(ETHYLAMINO)4NITROPHENOL

A, S1

72

CHLOROFORM

A, G3, E1, R1, S1

73

CHROMATES

A, G3, E2, S1

74

CHROMIUM TRIOXIDE

A, G3, E2, S1

75

CHRYSOIDINE BASE

A, S1, E1

76

CINEOLE

A, G1, G3

77

CINNAMON BARK OIL

A, G3

78

CINNAMON LEAF OIL

A, G3

79

CLIMBAZOLE

A

80

CLOVE OIL

A, G1, G3, E2

81

COCOYL GLYCINATE

E1

82

COPPER SULFATE

A, G3, E2, S1

83

CREOSOTE

A, G3, E2, S1

84

CRESOLS

A, G3, E2, S3

85

CRESOLS in pressurised spray packs

A, G6, E1, S1

86

CYANIDES

A, G1, E1, R2

87

CYANOACRYLIC ACID ESTERS

A

88

CYANURIC ACID

A

89

CYCLOHEXANONE PEROXIDE

A, G3, E2, S1

90

CYCLOSILAZANES, DIME, ME HYDROGEN, POLYMERS WITH DIME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3(TRIETHOXYSILYL)1PROPANAMINE (CAS 475645842)

A, E2, S1

91

CYCTEAMINE

E1

92

1DEOXY1(METHYLAMINO)dGLUCITOL NCOCO ACYL DERIVATIVES

E1

93

2,4DIAMINOPHENOXYETHANOL

A, E2, S1

94

oDICHLOROBENZENE

A, G3, E1, S1

95

paraDICHLOROBENZENE (PDB)

A

96

DICHLOROETHYL ETHER

A, G3, E1, R1, S1

97

DICHLOROISOCYANURATES

A, G3, E1, S1

98

DICHLOROMETHANE (methylene chloride)

A, G3, G5, E1, R1, S1

99

DICHLOROMETHANE (methylene chloride)—in pressurised spray packs

A, G6, S1

100

DICHROMATES

A, G1, G3, E2, S1

101

DIDECYLDIMETHYLAMMONIUM SALTS

A, G3

102

DIESEL (distillate)

A, G3

103

DIETHANOLAMINE—when included in Schedule 5

A, G3

104

DIETHANOLAMINE—when included in Schedule 6

A, G3, E2, S1

105

DIETHYLENE GLYCOL MONOBUTYL ETHER

A, E1, S1

106

5,6DIHYDROXYINDOLINE

E1

107

DIMETHYLFORMAMIDE—less than 75%

A

108

DIMETHYLFORMAMIDE—75% or more

A, E1, R1, S1

109

4,4DIMETHYL1CYCLOHEXENE1PROPANAL

A, E2

110

3,7DIMETHYL2,6OCTADIEN1OL

A, E1, S1

111

DIMETHYL SULFOXIDE

A, G3, E1, S1

112

DINITROCRESOLS

A, G1, E1, S1

113

DINITROPHENOLS

A, G1, E1, S1

114

DIOXANE

A, G3, E1, R1, S1

115

DISPERSE YELLOW 3

A, S1

116

DISTILLATE

A, G3

117

N(NDODECYL)2PYRROLIDONE—when included in Schedule 5

A, G3, E1

118

N(NDODECYL)2PYRROLIDONE—when included in Schedule 6

A, G3, E2, S1

119

EPOXY RESINS liquid

A, G3, E2, S1

120

Essential oils containing CAMPHOR as natural component unless otherwise specified

A, G3

121

ETHER

A, G3, E1, R1

122

ETHYL BROMIDE

A, E2, S1, R1

123

ETHYLENE GLYCOL

A

124

ETHYLENE GLYCOL MONOALKYL ETHERS and their acetates, except when separately specified

A, G3, E2, S1

125

ETHYLENE OXIDE

A, E2, R1

126

ETHYLHEXANEDIOL

A, E2

127

2ETHYLHEXANOIC ACID

A

128

EUCALYPTUS OIL

A, G1, G3

129

EUGENOL

A, G1, G3, E2

130

FENNEL OIL

A, G3

131

FLUORIDES except when separately specified—when included in Schedule 5

A

132

FLUORIDES except when separately specified—when included in Schedule 6

A, G1, G3, E2, S1

133

FORMALDEHYDE (see also paraformaldehyde)

A, G3, E2, R1, S1

134

FORMIC ACID

A, G3, E2, S1

135

FURFURAL

A, E1, S1

136

GLUTARAL—below 5%

A, G3, E1

137

GLUTARAL—5% or more

A, G3, E2, S1

138

GLYCOLIC ACID

A, G3, E2

139

GUANIDINE when included in Schedule 6

A, G3, E2, S1

140

HC VIOLET 1

E1

141

HEXACHLOROPHENE when included in Schedule 6

A

142

HEXYLOXYETHANOL

A, G3, E2, S1

143

HYDRAZINE

A, G1, G3, E2, R1, S1

144

HYDROCARBONS, liquid

A, G3

145

HYDROCHLORIC ACID

A, G3, E2, S1

146

HYDROCHLORIC ACID—when included in Schedule 5

A, G3

147

HYDROFLUORIC ACID and admixtures that generate hydrofluoric acid—when included in Schedule 5

A

148

HYDROFLUORIC ACID and admixtures that generate hydrofluoric acid—when included in Schedule 6 or 7

A, G3, E2, S5

149

HYDROGEN PEROXIDE—more than 3% up to 20%

A, G3, E2, S1

150

HYDROGEN PEROXIDE—more than 20%

A, G1, G3, G4, E2, S1

151

HYDROQUINONE—when included in Schedule 2

A

152

HYDROQUINONE—when included in Schedule 4 or 6

A, G2, G3, E2, R2, S1

153

HYDROSILICOFLUORIC ACID—when included in Schedule 5

A

154

HYDROSILICOFLUORIC ACID—when included in Schedule 6 or 7

A, G3, E2, S5

155

2HYDROXYETHYL METHACRYLATE

A, E1, S1

156

HYDROXYETHYL3,4METHYLENEDIOXYANILINE

E1, S1

157

IODINE (excluding salts, derivatives and iodophors)—2.5% or more for human external use

A, E2

158

IODINE (excluding salts, derivatives and iodophors)—2.5% or more for other uses

A, E2, S1

159

IODINE (excluding salts, derivatives and iodophors)—below 2.5%

A

160

IODOPHORS

A

161

ISOAMYL NITRITE

A

162

ISOBUTYL NITRITE

A

163

ISOCYANATES, free organic

A, E2, S1

164

ISOEUGENOL

A, E1, S1

165

ISOPHORONE

A, G3, E2, S1

166

KEROSENE

A, G3

167

LAURETH CARBOXYLIC ACIDS—leaveon or washoff preparations above 5%

E1

168

LAURETH CARBOXYLIC ACIDS—other preparations above 5%

E1, S1

169

LAURYL ISOQUINOLINIUM BROMIDE

A, E1

170

LEAD COMPOUNDS—in hair cosmetics

A

171

LEAD COMPOUNDS—in other preparations

A, S1

172

LEMON OIL

A, G3

173

LEPTOSPERMUM SCOPARIUM OIL (manuka oil)

A, G1, G3

174

LIME OIL

A, G3

175

MAGNESIUM CHLORATE

A

176

MALATHION at 20% or less

A

177

MARJORAM OIL

A, G3

178

MELALEUCA OIL

A, G1, G3

179

MERCAPTOACETIC ACID

A, E1

180

MERCURIC CHLORIDE—for external therapeutic use

A

181

MERCURIC CHLORIDE—for other uses

A, G1, G3, E2, R2, S1

182

MERCURIC IODIDE

A, G1, G3, E2, R2, S1

183

MERCURIC NITRATE

A, G1, G3, E2, R2, S1

184

MERCURIC OXIDE

A, G1, G3

185

MERCURIC POTASSIUM IODIDE

A, G1, G3, E2, R2, S1

186

MERCURIC THIOCYANATE

A, G1, G3, E2, R2, S1

187

MERCUROCHROME

A

188

MERCUROUS CHLORIDE

A

189

MERCURY—metallic

A

190

MERCURY—organic compounds

A, S1

191

MERCURY—organic compounds in preparations for human external use

A

192

METALDEHYDE

A, E1, S1

193

METHANOL—above 10%

A, G3

194

METHANOL—10% or less

A

195

METHYLATED SPIRIT(S)

A, G3

196

METHYLATED SPIRIT(S)—when packed and labelled as a “biofuel” suitable for use in “spirit burners”

A, G3

197

METHYL ETHYL KETONE

A, G3

198

METHYL ETHYL KETONE OXIME

A, E1, S1

199

METHYL ETHYL KETONE PEROXIDE

A, G3, E2, S1

200

METHYLEUGENOL

A

201

METHYL ISOAMYL KETONE

A, G3

202

METHYL ISOBUTYL KETONE

A, G3

203

NMETHYL2PYRROLIDONE—when included in Schedule 5

A, G3, E1

204

NMETHYL2PYRROLIDONE—when included in Schedule 6

A, G3, E2

205

2METHYLRESORCINOL

A, E1

206

METHYL SALICYLATE LIQUID when included in Schedule 5 or 6

A, G3, E1

207

MONOETHANOLAMINE—when included in Schedule 5

A, G3, E1

208

MONOETHANOLAMINE—when included in Schedule 6

A, G3, E2, S1

209

1,5NAPHTHALENEDIOL

A, E1, S1

210

2,7NAPHTHALENEDIOL

A, E1, S1

211

NAPHTHALENE

A, G1, G3

212

1NAPHTHOL

A, E1, S1

213

NITRIC ACID

A, G3, E2, S1

214

NITROBENZENE

A, G3, E1, S1

215

3NITROpHYDROXYETHYLAMINOPHENOL

E1

216

NITROPHENOL

A, G3, E2, S1

217

NITROPRUSSIDES—in aerosols

A, G6, R1

218

NITROPRUSSIDES—in other preparations

A, G3

219

NITROUS OXIDE

A

220

NONOXINOL 9

A, E2

221

NUTMEG OIL

A, G3

222

OCTHILINONE

A, G3, E2, S1

223

OCTYL NITRITE

A

224

N(NOCTYL)2PYRROLIDONE—when included in Schedule 5

A, G3, E1

225

N(NOCTYL)2PYRROLIDONE—when included in Schedule 6

A, G3, E2

226

ORANGE OIL (bitter)

A, G3

227

OXALIC ACID

A, G3, E2, S1

228

PARAFORMALDEHYDE

A, G3, E2, R1, S1

229

PENNYROYAL OIL

A, G3

230

PERACETIC ACID—when included in Schedule 5

A, G3, E1, S1

231

PERACETIC ACID—when included in Schedule 6

A, G3, E2, S1

232

PETROL

A, G3, R1

233

2PHENOXYETHANOL

A, E1

234

PHENOL when included in Schedule 6

A, E1

235

PHENOLS—25% and less

A, G3, E2, S3

236

PHENOLS—above 25%

A, G3, E2, S4

237

PHENOLS—in pressurised spray packs

A, E1

238

PHENOXYMETHYL OXIRANE

A, E1

239

PHENYLENEDIAMINES including alkylated, arylated, halogenated and nitro derivatives—in hair dyes

A, E1

240

PHENYLENEDIAMINES including alkylated, arylated, halogenated and nitro derivatives—in preparations other than hair dyes

A, G1, G3, E1, S1

241

PHENYL METHYL KETONE as such, or in preparations of similar viscosity

A, G3, E1

242

PHENYL METHYL PYRAZOLONE

A, S1

243

N,NBIS(PHENYLMETHYLENE)BICYCLO(2.2.1)HEPTANE2,5DIMETHANAMINE

A, E2, S1

244

N,NBIS(PHENYLMETHYLENE)BICYCLO(2.2.1)HEPTANE2,6DIMETHANAMINE

A, E2, S1

245

oPHENYLPHENOL

A, G3, E2, S1

246

oPHENYLPHENOL—in pressurised spray packs

A, G6, E2, S1

247

PHOSPHONIC ACID

A, G3, E2, S1

248

PHOSPHONIC ACID—neutralised to pH 6 (approx)

A

249

PHOSPHONIC ACID—in spray packs

A, E2, S1

250

PHOSPHORIC ACID

A, G3, E2, S1

251

PHOSPHORUS, YELLOW

A, G1, G3, E2, R2, S2

252

oPHTHALALDEHYDE—when included in Schedule 5

A, E1

253

oPHTHALALDEHYDE—when included in Schedule 6

A, G3, E2, S1

254

PICRAMIC ACID including its salts (excluding other derivatives)

A, E1

255

PICRIC ACID

A, G1, G3, E2, R1, S1

256

POLIHEXANIDE

E1

257

POLYETHANOXY (15) TALLOW AMINE

A, E2, S1

258

POLY(OXY1,2ETHANEDIYL), Α [2[(2HYDROXYETHYL)AMINO]2OXOETHYL]
Α HYDROXY,MONOC1315ALKYL ETHERS

A, E1

259

POTASSIUM BROMATE

A

260

POTASSIUM CHLORATE

A

261

POTASSIUM CYANATE

A, E1, S1

262

POTASSIUM HYDROXIDE

A, G3, E2, S1

263

POTASSIUM METABISULPHITE

A

264

POTASSIUM NITRITE—when included in Schedule 7

A, G1, G3

265

POTASSIUM NITRITE—when included in Schedule 5 or 6

A, G3

266

POTASSIUM PEROXOMONOSULFATE TRIPLE SALT—when included in Schedule 5

A, G3, E1

267

POTASSIUM PEROXOMONOSULFATE TRIPLE SALT—when included in Schedule 6

A, G3, E2, S1

268

POTASSIUM PERSULFATE

A, G3, E2

269

POTASSIUM SULFIDE

A, G3, E2, S1

270

PROPIONIC ACID

A, G3, E1, S1

271

nPROPYL ALCOHOL

A, E1

272

DPULEGONE

A, G3

273

PYRITHIONE ZINC

A, E1

274

QUATERNARY AMMONIUM COMPOUNDS except when separately specified—above 20%

A, G3, E2

275

QUATERNARY AMMONIUM COMPOUNDS except when separately specified—20% and below

A, E2

276

QUATERNARY AMMONIUM COMPOUNDS except when separately specified—in pressurised spray packs

A, E2, G6

277

QUINOLINE

A, E1, S1

278

RESORCINOL

A, E2, S1

279

SAFROLE

A, G1, G3

280

SAGE OIL (Dalmatian)

A, G3

281

SASSAFRAS OIL

A, G1, G3

282

SELENIUM COMPOUNDS

A, G1, E1, S1

283

SILICOFLUORIDES—when included in Schedule 5

A

284

SILICOFLUORIDES—when included in Schedule 6

A, G1, G3, E2, S1

285

SILVER SALTS

A, E2

286

SODIUM ALUMINATE

A, G3, E2, S1

287

SODIUM BROMATE

A, G1

288

SODIUM CHLORATE

A

289

SODIUM DIACETATE

A, G3, E2, S1

290

SODIUM DICHLOROISOCYANURATE

A, G3, E1, S1

291

SODIUM DODECYLBENZENE SULFONATE

A, G3, E2, S1

292

SODIUM HYDROGEN SULFATE

A, G3, E1, S1

293

SODIUMHYDROSULFITE

A, G3, E2, S1

294

SODIUM HYDROXIDE

A, G3, E2, S1

295

SODIUM LAURETH6 CARBOXYLATE

A

296

LAURYL SULFATE SALTS—leaveon or washoff preparations above 5%

E1

297

LAURYL SULFATE SALTS—other preparations above 5%

E1, S1

298

SODIUM METABISULPHITE

A, G3

299

SODIUM NITRITE—when included in Schedule 7

A, G1, G3

300

SODIUM NITRITE—when included in Schedule 5 or 6

A, G3

301

SODIUM PERCARBONATE—when included in Schedule 5

A, G3, S1

302

SODIUM PERCARBONATE—when included in Schedule 6

A, G3, E2, S1

303

SODIUM PERSULFATE

A, G3, E2

304

SODIUM STANNATE

A, E1

305

SODIUM SULFIDE

A, G3, E2, S1

306

SODIUM TRICHLOROACETATE

A

307

STRYCHNINE

A, G1, G2, G3, R2

308

STYRENE

A, G3, S1, E1

309

SULCOFURON

A

310

SULFAMIC ACID

A, G3, E2, S1

311

SULFURIC ACID

A, G3, E2, S1

312

TERPENES, chlorinated

A, G3

313

TETRACHLOROETHANE

A, G3, E1, R1, S1

314

TETRACHLOROETHYLENE

A, G3, E2, R1, S1

315

THIOUREA

A

316

THUJONE

A, G3

317

THYME OIL

A, G3

318

oTOLIDINE

A

319

TOLUENE—above 75%

A, G3, E1, R1, S1

320

TOLUENE—75% and below

A, G3

321

TOLUENE—in pressurised spray packs

A

322

TOLUENEDIAMINES—in hair dyes

A, E1

323

TOLUENEDIAMINES—in other preparations

A, G1, G3, E1, S1

324

TRICHLOROACETIC ACID

A, G3, E2, S1

325

TRICHLOROACETIC ACID ALKALI SALTS

A

326

1,1,1TRICHLOROETHANE

A, G3, E1, R1, S1

327

TRICHLOROETHYLENE

A, G3, E1, R1, S1

328

TRICHLOROISOCYANURIC ACID

A, G3, E1, S1

329

TRIETHYL PHOSPHATE

A, E1

330

TRIFLUOROMETHANESULFONIC ACID

A, G3, E2

331

TRIISOPROPANOLAMINE LAURYL ETHER SULFATE

A, E1, S1

332

TROLAMINE

A, G3, E1, S1

333

TURPENTINE (mineral)

A, G3

334

TURPENTINE OIL (vegetable)

A, G3, E2

335

VINYL ACETATE MONOMER

A, R1

336

WHITE SPIRIT

A, G3

337

XYLENE—above 75%

A, G3, E1, R1, S1

338

XYLENE—75% and below

A, G3

339

XYLENE—in pressurised spray packs

A, G6, E1, S1

340

XYLENOLS in pressurised spray packs

A, E1

341

ZINC CHLORIDE

A, G3, E2, S1

342

ZINC SULFATE

A, G3, E2, S1

Appendix FWarning statements and general safety directions for poisons

 

 

Note: See sections 29 and 30, subsection 33(2) and section 42.

1  Warning statements

  For the purposes of the table in clause 4 of this Appendix and the table in clause 2 of Appendix L, the item number of an item of the following table represents the warning statement specified in column 1 of the item.

Note: See section 30.

 

Warning statements

Item

Column 1
Warning statement

1

Highly corrosive.

2

Corrosive.

3

Corrosive liquid.

4

Strongly alkaline.

5

Irritant.

6

May cause cancer.

7

WARNING – Causes birth defects.

8

WARNING – May be fatal to children.

9

Can be fatal to children if sucked or swallowed.

10

May produce severe burns.

11

WARNING – Vapour may be harmful.

12

Vapour is harmful to health on prolonged exposure.

13

May be fatal if inhaled, swallowed or absorbed through skin.

14

Dust will irritate and burn eyes, nose and skin.

15

Liquid will cause burns.

16

Forms dangerous gas near radiators or naked flames.

17

Contact with eyes even for short periods can cause blindness.

18

Product will irritate the eyes, nose, throat and skin.

19

WARNING – Skin contact may be dangerous. Take every precaution to avoid contact – wash off after spillage and after use.

20

May give off dangerous gas if mixed with other products.

21

WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.

22

Highly reactive oxidising chlorine compound.

23

May cause fire or explosion.

24

For external washing only. Rinse skin thoroughly after use.

25

Do not use on broken skin. Wash hands thoroughly after use.

26

(Powder) (and) (concentrated solutions) are dangerous if swallowed.

27

Not for therapeutic use.

28

(Over) (Repeated) exposure may cause sensitisation.

29

If congestion persists, consult your doctor or pharmacist.

30

WARNING – Do not use on face or on anal or genital areas.

31

WARNING – Do not use on face or on anal or genital areas except on doctor’s advice.

32

This preparation should be part of an overall treatment plan regularly assessed with your doctor.

33

Do not take for periods longer than four weeks except on medical advice.

34

WARNING – This medication may be dangerous when used in large amounts or for a long time (period).

35

CAUTION – This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged use without medical supervision could be harmful.

or

CAUTION – This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged or excessive use without medical supervision could be harmful.

36

For use under medical supervision only.

37

Consult a doctor before giving this medication to children or teenagers with chicken pox, influenza or fever.

38

CAUTION – Do not use for children under 2 years unless a doctor has told you to.

39

This medication may cause drowsiness. If affected do not drive a vehicle or operate machinery. Avoid alcohol.

40

This medication may cause drowsiness and may increase the effects of alcohol. If affected do not drive a motor vehicle or operate machinery.

41

Do not give to children under 12 years of age. Do not use beyond 48 hours or in pregnancy or lactation except on doctor’s advice.

42

WARNING – Overuse may stain the skin or mouth.

43

Use of this product is not necessary in areas supplied with fluoridated water.

44

WARNING – May be dangerous, particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you keep using it for a long time.

45

WARNING – If a pigmented spot or mole has recently become darker, changed colour, become enlarged or itchy, or bleeds, do not use this product, see your doctor immediately. Do not use on children. Do not use near the eyes. Mild irritation may occur; stop use if it becomes severe. If fading is not evident in three months, seek doctor’s advice.

46

WARNING – Contains (name of substance) which causes birth defects in laboratory animals. Women of child bearing age should avoid contact with (name of substance).

47

WARNING – This product contains (name of substance) which causes birth defects in certain laboratory animals. Women of child bearing age are advised not to mix, load or spray this product. They should keep out of crops being sprayed.

48

WARNING – This product forms cyhexatin which causes birth defects in certain laboratory animals. Women of child bearing age are advised not to mix, load or spray this product. They should keep out of crops being sprayed.

49

WARNING – Do not mix with other medication except on veterinarian’s advice.

50

Unless adequately fired, utensils glazed with this preparation must not be used as containers for food or beverages; to do so may cause lead poisoning.

51

Irritant to skin, eyes, mucous membranes and upper respiratory tract.

52

Breathing vapour or spray mist is harmful and may cause an asthmalike reaction.

53

CAUTION – (Name of substance) should not be used by pregnant women.

54

Seek medical advice before first course of treatment.

55

Keep from eyes, lips, mouth and sensitive areas of the neck. If excessive swelling, irritation, redness or peeling occurs, discontinue use. If these persist, consult a physician. Avoid excessive exposure to sunlight and other sources of ultra violet light.

56

WARNING – Can cause elevated blood pressure and interact adversely with other medication.

57

Not to be applied to infants under 12 months of age unless on doctor’s advice.

58

Highly reactive oxidising bromine and chlorine compound.

59

May cause allergy.

60

Do not mix with detergents or other chemicals.

61

WARNING Can react with other medicines. Ask your doctor or pharmacist before taking.

62

Do not use if pregnant.

63

See a doctor if you are pregnant or diabetic.

64

See a doctor (or) (dentist) if no better after (Insert number of days as per approved Product Information) days.

65

If getting better, keep using for (Insert number of days as per approved Product Information) days.

66

See a doctor if problem returns.

67

Do not use if pregnant or likely to become pregnant.

68

If symptoms persist beyond 5 days consult a doctor (or) (dentist).

69

If symptoms recur within two weeks of completing the course, consult a doctor.

70

Use only under medical supervision if you are taking other medicines.

71

Do not use during the last three months of pregnancy.

72

Do not use in the eyes.

73

Do not use for acne.

74

Do not use under waterproof bandages unless a doctor has told you to.

75

Do not use for more than 7 days unless a doctor has told you to.

76

Do not become pregnant during use or within (Insert number of months as per approved Product Information) month(s) of stopping treatment.

77

WARNING May cause birth defects.

78

Attacks skin and eyes.

79

Will irritate eyes.

80

WARNING: Do not attempt to refill burner while it is in use or still warm; it could lead to serious burn injury.

81

(Intentionally blank)

82

(Intentionally blank)

83

This paint is dangerous to health, even when dry.

For industrial use only.

Do not use on toys or furniture.

Do not use on, in or around the home.

84

Breathing the vapour is dangerous.

Provide adequate ventilation during application.

Do not use in the presence of a naked flame.

Do not smoke.

85

This paint contains lead and is dangerous to health, even when dry.

For industrial use only.

Do not use on toys or furniture.

Do not use for painting any building or fixed structure.

Do not use where contact with food or drinking water is possible.

86

This tinter contains lead.

Do not add to any paint which is for application to any toy, furniture, building (interior or exterior), fixed structure or to anything which may contact food or drinking water.

87

(Insert brand name) remains in the body for many months after treatment has stopped. Do not become pregnant or father a child before consulting your doctor.

88

This product is not recommended for dyeing eyelashes or eyebrows. To do so may be injurious to the eye.

89

Application to skin may increase sensitivity to sunlight.

90

This preparation is to aid sleep. Drowsiness may continue the following day. If affected do not drive or operate machinery. Avoid alcohol.

91

CAUTION – Total iodine intake may exceed recommended level when taking this preparation.

92

WARNING – Contains iodine do not take when pregnant except on physician’s advice.

93

Causes severe burns, which are not likely to be immediately painful or visible.

94

WARNING – Contains nitrite. Substitution for table or cooking salt may be dangerous, particularly for young children.

95

CAUTION – Do not use for children under 12 years unless a doctor has told you to.

96

CAUTION – This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. If symptoms persist or recur within two weeks, consult a doctor.

97

Adults: Keep to the recommended dose. Don’t take this medicine for longer than a few days at a time unless advised to by a doctor.

98

Children and adolescents: Keep to the recommended dose. Do not give this medicine for longer than 48 hours at a time unless advised to by a doctor.

99

If an overdose is taken or suspected, ring the Poisons Information Centre (Australia 13 11 26; New Zealand 0800 764 766) or go to a hospital straight away even if you feel well because of the risk of delayed, serious liver damage.

100

Do not take with other products containing paracetamol, unless advised to do so by a doctor or pharmacist.

101

Don’t use [this product/name of the product]:

If you have a stomach ulcer.

In the last 3 months of pregnancy. [This statement may be omitted in preparations used exclusively for the treatment of dysmenorrhoea.]

If you are allergic to (name of substance) or antiinflammatory medicines.

102

Unless a doctor has told you to, don’t use [this product/name of the product]:

For more than a few days at a time.

With other medicines containing aspirin or other antiinflammatory medicines.

If you have asthma.

In children under 12 years of age.

In children 1216 years of age with or recovering from chicken pox, influenza or fever.

If you are pregnant.

103

See a doctor before taking [this product/name of the product] for thinning the blood or for your heart. [This statement may be omitted in products for inhibition of platelet aggregation or with additional active ingredients.]

104

Unless a doctor has told you to, don’t use [this product/name of the product]:

For more than a few days at a time.

With other medicines containing (name of substance) or other antiinflammatory medicines.

If you have asthma.

If you are pregnant. [This statement may be omitted in preparations used exclusively for the treatment of dysmenorrhoea.]

105

Do not use on the bedding or clothing of infants or in the bedrooms of children 3 years of age or less.

106

Contains formaldehyde.

107

Not recommended for children under twelve years of age.

108

Breathing of solder fumes is harmful and may cause asthma or sensitisation.

109

See your healthcare provider if you consider that you may be at risk of a Sexually Transmitted Infection (STI).

110

See a doctor if you plan to become pregnant, or are breastfeeding or plan to breastfeed.

111

Do not use if breastfeeding or planning to breastfeed.

112

WARNING – May cause irreversible nerve damage if inhaled.

2  Safety directions—general

  For the purposes of the table in clause 4, the item number of an item of the following table represents the safety direction specified in column 1 of the item.

Note: See section 29.

 

Safety directions

Item

Column 1
Safety direction

1

Avoid contact with eyes.

2

Attacks eyes protect eyes when using.

3

Wear eye protection when mixing or using.

4

Avoid contact with skin.

5

Wear protective gloves when mixing or using.

6

Wash hands after use.

7

Wash hands thoroughly after use.

8

Avoid breathing dust (or) vapour (or) spray mist.

9

Use only in well ventilated area.

10

Ensure adequate ventilation when using.

11

No smoking.

12

Do not allow product to come into contact with other chemicals, especially acids.

13

Do not allow product to come into contact with combustible materials such as paper, fabric, sawdust or kerosene.

14

Do not allow to get damp.

15

Store under cover in a dry, clean, cool, well ventilated place away from sunlight.

16

Store and transport in an upright container.

17

Do not mix with other chemicals.

18

Do not mix with different types of chlorinating chemicals.

19

Use clean containers for dispensing.

20

Mix with water only.

21

Do not add water to product add product to water, but in case of fire drench with water.

22

In case of spillage flush with large quantities of water.

23

Keep away from heat, sparks and naked flames.

24

Avoid contact of the crystals or strong solutions with the eyes, mouth, nose and other mucous membranes.

25

Avoid contact with food.

26

Avoid contact with clothing.

27

Wear a positivepressure airsupplied fullface respirator whilst spraying and until spray mist has been effectively dispersed.

28

Do not mix with hot water.

29

Obtain a supply of calcium gluconate gel.

30

(Intentionally blank)

31

Do not use on broken skin.

32

Do not use under occlusive dressing.

33

Mix strictly according to instructions.

34

May cause fire if it comes into contact with other chemicals, paper or other flammable materials.

35

Wash gloves thoroughly, immediately after use.

36

Protect cuticles with grease or oil.

37

Avoid breathing solder fumes.

38

Do not intentionally inhale contents.

3  Poisons information centre contact information in statements

  A statement required for a poison that includes a reference to a Poisons Information Centre must include:

 (a) the telephone number that is appropriate to the country or countries in which the poison is to be supplied; and

 (b) immediately following the reference to a Poisons Information Centre:

 (i) the national telephone number for the Poisons Information Centre in Australia (13 11 26); or

 (ii) the telephone number for another poisons information centre:

 (A) that is attended by adequately trained staff for 24 hour emergency poisons information; and

 (B) calls to which are logged and submitted for incorporation into the official collection of poisoning data.

Note: For subparagraph (b)(ii), in 2022 the Poisons Information Centre telephone number in New Zealand was 0800 764 766.

4  Poisons that must be labelled with warning statements and safety directions

 (1) For the purposes of subsections 29(1) and 30(1), and subject to subclauses (2) and (3), the following are required for a poison specified in column 1 of an item of the following table:

 (a) the warning statement represented by each item number specified in column 2 of the item;

 (b) the safety direction represented by each item number specified in column 3 of the item.

 (2) A warning statement or safety direction required for a poison must:

 (a) be completed or modified for its use in relation to that poison if the statement or direction indicates that such completion is required or such modification is appropriate; and

 (b) if the statement includes a reference to a Poisons Information Centre—comply with clause 3.

Note: For paragraph (a), for example:

(a) a statement or direction may require completion by including the name of the poison; and

(b) a statement or direction may indicate that modification is appropriate by including different options for the text, or by stating that certain text is not needed in certain circumstances.

 (3) If more than one statement or direction is required for a poison, the statements and directions may be combined to form simple sentences (if appropriate).

Poisons that must be labelled with warning statements and safety directions

Item

Column 1
Poison

Column 2
Warning statement item number

Column 3
Safety direction item number

1

ACETIC ACID in concentrations of 80% or more except when included in Schedule 2

2

1, 4, 8

2

ACETIC ANHYDRIDE

2

1, 4, 8

3

ACETONE in concentrations greater than 75%

 

1, 4, 8

4

ACITRETIN—for oral use

7, 62, 76

 

5

ACITRETIN—for topical use

62, 77

 

6

ADAPALENE for topical use

62, 77

 

7

ALCLOMETASONE when included in Schedule 3

38, 72, 73, 74, 75

 

8

ALKALINE SALTS

4

1, 4

9

AMBRISENTAN

7, 62, 76

 

10

AMINES used as curing agents for epoxy resins

 

1, 3, 4, 5, 8

11

2AMINO6CHLORO4NITROPHENOL

28

 

12

4AMINOmCRESOL

28

 

13

2AMINO5ETHYLPHENOL

21

 

14

4AMINO2HYDROXYTOLUENE

28

 

15

4AMINO3NITROPHENOL

28

 

16

2,2'[(4AMINO3NITROPHENYL)IMINO]
BISETHANOL

28

 

17

mAMINOPHENOL

28

4, 8

18

pAMINOPHENOL

28

 

19

AMMONIA/AMMONIUM HYDROXIDE in concentrations greater than 20% ammonia except in smelling salts

4

1, 4, 8

20

AMMONIUM PERSULFATE

5, 21, 25

1, 5, 23, 33, 34

21

ANHYDRIDES, organic acid, for use as curing agents for epoxy resins

 

1, 3, 4, 5, 8

22

ANILINE

13

1, 4, 8

23

ANTIHISTAMINES not separately specified in this Appendix except the following:

(a) dermal, ocular, parenteral and paediatric preparations;

(b) oral preparations of astemizole, azelastine, bilastine, desloratadine, fexofenadine, loratadine, terfenadine or cetirizine;

(c) nasal preparations of azelastine;

(d) preparations for the treatment of animals

39 or 40

 

24

ARBUTIN when included in Schedule 6

45

1, 4

25

AROMATIC EXTRACT OILS

 

1, 3, 4, 5, 6

26

ASPIRIN—for inhibition of platelet aggregation

36

 

27

ASPIRIN—in sustained release preparations containing 650 mg or more of aspirin

36

 

28

ASPIRIN—in other preparations

101, 102, 103

 

29

ASTEMIZOLE

61

 

30

ASTODRIMER SODIUM—for the treatment and relief of bacterial vaginosis

63, 64, 69, 75, 109, 110

 

31

ASTODRIMER SODIUM—for the prevention of recurrent bacterial vaginosis

63, 75, 109, 110

 

32

AZADIRACHTA INDICA including its extracts and derivatives when included in Schedule 6

67

 

33

AZOCYCLOTIN

48

 

34

AZO DYES (derivatives by diazotisation)

6

5

35

BASIC RED 76

 

5

36

BENOMYL

46

 

37

BENZENE

12

1, 4, 9

38

1,2BENZENEDIOL (Catechol)

51, 59

1, 4, 8

39

BENZOYL PEROXIDE—when included in Schedule 2

55

 

40

BENZOYL PEROXIDE—when included in Schedule 5

 

1, 4, 8

41

BERGAMOT OIL

89

 

42

BERYLLIUM

 

1, 4, 8

43

BEXAROTENE—for human use

7, 62, 76

 

44

BEXAROTENE—for topical use

62, 77

 

45

BIFLUORIDES (including ammonium, potassium and sodium salts)—when included in Schedule 5

1, 4

 

46

BIFLUORIDES (including ammonium, potassium and sodium salts)—when included in Schedule 6 or 7

1, 17, 93

1, 3, 4, 5, 8, 29, 35

47

1,3BIS(2,4DIAMINOPHENOXY)PROPANE

28, 79

1

48

BISISOBUTYL PEG/PPG20/35/AMODIMETICONE COPOLYMER

 

1

49

BITHIONOL for the treatment of animals

 

1, 4, 8

50

BORIC ACID when used in Schedule 5

25, 26

 

51

BORON TRIFLUORIDE (including mixtures that generate boron trifluoride)—when included in Schedule 5

2

1, 4

52

BORON TRIFLUORIDE (including mixtures that generate boron trifluoride)—when included in Schedule 6 or 7

1, 17, 93

1, 3, 4, 5, 8, 29, 35

53

BOSENTAN

7, 62, 76

 

54

BROMOFORM

1, 4, 8

 

55

2BUTOXY2'THIOCYANODIETHYL ETHER

 

1, 4, 8

56

2BUTOXYETHANOL and its acetates

 

1, 4, 8

57

nBUTYL ALCOHOL

5

2, 4, 8

58

CAMPHOR—in block, ball, disc, pellet or flake form, enclosed in a device which, in normal use, prevents removal or ingestion of its contents

9

 

59

CAMPHOR—in other forms

9

1

60

CANNABIDIOL when included in Schedule 3

67, 111

 

61

CARBAMIDE PEROXIDE—more than 9% up to 30%

5

1

62

CARBAMIDE PEROXIDE—more than 30% up to 60%

5

2

63

CARBAMIDE PEROXIDE—more than 60%

2

2, 4

64

CARBON DISULFIDE

12

1, 4, 8, 9, 23

65

CARBON TETRACHLORIDE

12

1, 4, 8, 9

66

CASSIA OIL

 

4

67

CHLORINATING COMPOUNDS—in household cleaning or bleaching preparations

20

 

68

CHLORINATING COMPOUNDS—in preparations containing less than 10% of available chlorine

11

1, 4, 10

69

CHLORINATING COMPOUNDS—in liquid preparations containing 10% or more of available chlorine

3, 18

1, 4, 6, 8, 10, 15, 16, 17, 18, 19, 20, 22, 26

70

CHLORINATING COMPOUNDS—in dry preparations containing 10% or more of available chlorine

10, 18, 22, 23

1, 4, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 26

71

CHLORINATING COMPOUNDS—in dry preparations containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code

10, 18, 22

1, 4, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,

22, 26

72

CHLORINATING COMPOUNDS—in compressed block or tablets containing 10% or more of available chlorine except in preparations for use in toilet cisterns only, containing 15 g or less of trichloroisocyanuric acid

10, 22, 23

12, 13, 14, 15, 17, 18, 19, 21

73

CHLORINATING COMPOUNDS—in other compressed blocks or tablets containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code except in preparations for use in toilet cisterns only, containing 15 g or less of trichloroisocyanuric acid

10, 22

12, 13, 14, 15, 17, 18, 19, 21

74

CHLOROACETAMIDE

28

4

75

2CHLORO6(ETHYLAMINO)4NITROPHENOL

28

4

76

CHLOROFORM when included in Schedule 6

 

1, 4, 8

77

alphaCHLOROHYDRIN

13, 51

1, 4, 8, 9

78

CHROMATES (including dichromates) of alkali metals or ammonia

 

1, 4, 8

79

CHROMIUM TRIOXIDE

2, 14, 15, 23

1, 4, 8, 13

80

CIMETIDINE when included in Schedule 3

70, 96

 

81

CINNAMON BARK OIL

 

4

82

CLOBETASONE when included in Schedule 3

72, 73, 74, 75, 95

 

83

CLOTRIMAZOLE in vaginal preparations when included in Schedule 3

54, 63, 64, 66

 

84

CLOVE OIL

 

1

85

CYANIDES when included in Schedule 7

13

4, 8

86

CYANURIC ACID

 

1, 4, 8

87

CYCLOHEXANONE PEROXIDE

 

1, 4, 8

88

CYCLOSILAZANES, DIME, ME HYDROGEN, POLYMERS WITH DIME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3(TRIETHOXYSILYL)1PROPANAMINE (CAS 475645842)

2, 10, 78

1, 4, 5, 35

89

CYCTEAMINE

 

1

90

1DEOXY1(METHYLAMINO)dGLUCITOL NCOCO ACYL DERIVATIVES

79

1

91

4,4DIAMINODIPHENYLMETHANE (methylene dianiline)

 

1, 4, 8

92

2,4DIAMINOPHENOXYETHANOL

28, 79

1, 4

93

oDICHLOROBENZENE

 

1, 4, 8

94

paraDICHLOROBENZENE

 

1, 4

95

DICHLOROETHYLENE

 

1, 4, 8

96

DICHLOEOETHYL ETHER

 

1, 4, 8

97

DICHLOROISOCYANURATES—in household cleaning or bleaching preparations

20

 

98

DICHLOROISOCYANURATES—in preparations containing less than 10% of available chlorine

11

1, 4, 10

99

DICHLOROISOCYANURATES—in liquid preparations containing 10% or more of available chlorine

3, 18

1, 4, 6, 8, 10,

15, 16, 17, 18, 19, 20, 22, 26

100

DICHLOROISOCYANURATES—in dry preparations containing 10% or more of available chlorine

10, 18, 22, 23

1, 4, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 26

101

DICHLOROISOCYANURATES—in dry preparations containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code

10, 18, 22

1, 4, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 26

102

DICHLOROISOCYANURATES—in antibacterial tablets containing 2.5 g or less of sodium dichloroisocyanurate

60

 

103

DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine except in preparations containing 21 g or less of sodium dichloroisocyanurate for use in toilet cisterns only

10, 22, 23

12, 13, 14, 15, 17, 18, 19, 21

104

DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code except in preparations containing 21 g less of sodium dichloroisocyanurate for use in toilet cisterns only

10, 22

12, 13, 14, 15, 17, 18, 19, 21

105

DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine in preparations containing 5 g or less of sodium dichloroisocyanurate for use in toilet bowls only—during storage

10, 22, 23

12, 13, 14, 15, 17, 18, 21

106

DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine in preparations containing 5 g or less of sodium dichloroisocyanurate for use in toilet bowls only—during use

5

1, 4, 7, 12

107

DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code in preparations containing 5 g or less of sodium dichloroisocyanurate for use in toilet bowls only—during storage

10, 22

12, 13, 14, 15, 17, 18, 21

108

DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code in preparations containing 5 g or less of sodium dichloroisocyanurate for use in toilet bowls only—during use

5

1, 4, 7, 12

109

DICHLOROMETHANE (methylene chloride)—in paint or lacquer removers

12, 16

1, 4, 8, 11

110

DICHLOROMETHANE (methylene chloride)—other than in paint or lacquer removers

 

1, 4, 8, 25

111

DICLOFENAC

101, 104

 

112

DIENESTROL

67

 

113

DIETHANOLAMINE—when included in Schedule 5

5

1, 4

114

DIETHANOLAMINE—when included in Schedule 6

2, 11, 18

1, 4, 8

115

DIETHYLTOLUAMIDE for human use

44

 

116

DIETHYLENE GLYCOL MONOBUTYL ETHER

5

1, 4, 8, 9

117

5,6DIHYDROXYINDOLINE

21, 28

 

118

2,6DIMETHOXY3,5PYRIDINEDIAMINE

28

 

119

DIMETHYLFORMAMIDE

 

1, 4, 8

120

4,4DIMETHYL1CYCLOHEXENE1PROPANAL

5, 28

1, 2

121

3,7DIMETHYL2,6OCTADIEN1OL

5

1, 4

122

DIMETHYL SULFATE

2

1, 4, 8

123

DIMETHYL SULFOXIDE—when not packed and labelled for therapeutic use

27

1, 4, 5, 8

124

DIMETHYL SULFOXIDE—when packed and labelled for the treatment of animals

49

1, 4, 5, 8

125

DINITROCRESOLS (and their homologues) except when for therapeutic use

 

1, 4, 8

126

DINITROPHENOLS (and their homologues) except when for therapeutic use

 

1, 4, 8

127

DINOCAP

47

 

128

DIOXANE

 

1, 4, 8

129

DIPHENOXYLATE when included in Schedule 3

39 or 40, 41

 

130

DISPERSE YELLOW 3

28

4

131

ECONAZOLE in vaginal preparations when included in Schedule 3

54, 63, 64, 66

 

132

ENZALUTAMIDE

7, 67, 87

 

133

EPHEDRINE in nasal preparations for topical use

29

 

134

EPICHLOROHYDRIN

2

1, 4, 8

135

EPOXY RESINS, liquid

 

1, 3, 4, 5, 8

136

ETHER when included in Schedule 5 or 6

 

1, 4, 8

137

2ETHOXYETHANOL

77

1, 4, 8

138

ETHOXYETHYLMERCURIC CHLORIDE

 

1, 4

139

ETHYL BROMIDE

 

1, 4, 8

140

ETHYLENE CHLOROHYDRIN

 

1, 4, 8

141

ETHYLENE GLYCOL MONOALKYL ETHERS and their acetates except when separately specified

 

1, 4, 8

142

ETHYLENE OXIDE

 

1, 4, 8

143

ETHYLHEXANEDIOL

79

1

144

2ETHYLHEXANOIC ACID

53

 

145

ETHYLMERCURIC CHLORIDE

 

1, 4

146

ETHYL METHACRYLATE

28

4, 9, 23

147

ETRETINATE

7, 62, 76

 

148

EUGENOL

 

1

149

FAMOTIDINE when included in Schedule 2

96

 

150

FENTEROL in metered aerosols

32

 

151

FLUCONAZOLE in oral preparations when included in Schedule 3

64

 

152

FLUORIDES (including silicofluorides) when included in Schedule 5 or 6 except when separately specified

 

1, 4

153

FORMALDEHYDE—in nail hardener cosmetics

106

1, 4, 8, 36

154

FORMALDEHYDE—in other preparations

106

1, 4, 8

155

FORMIC ACID

 

1, 4, 8

156

FURFURAL

5

1, 4

157

Glazing preparations containing LEAD COMPOUNDS

50

 

158

GLUTARAL except when included in Schedule 2—25% or less

5, 59

1, 4, 5

159

GLUTARAL except when included in Schedule 2—more than 25%

3, 59

1, 4, 5, 8

160

GLYCOLIC ACID

79

1, 5, 6, 31

161

HC VIOLET 1

28

 

162

HEXACHLOROPHENE in preparations for skin cleansing purposes containing 3% or less of hexachlorophene

24

 

163

HEXYLOXYETHANOL

2

1, 4, 8

164

HYDRAZINE

 

1, 4, 8

165

HYDROCHLORIC ACID—30% or less of HCl

 

1, 4

166

HYDROCHLORIC ACID—more than 30% of HCl

 

1, 4, 8

167

HYDROCORTISONE—for dermal use when included in Schedule 2 or 3

38, 72, 73, 74, 75

 

168

HYDROCORTISONE—for topical rectal use when included in Schedule 2 or 3

38, 75

 

169

HYDROCYANIC ACID when included in Schedule 7

13

4, 8

170

HYDROFLUORIC ACID (including mixtures that generate hydrofluoric acid)—when included in Schedule 5

2

1, 4

171

HYDROFLUORIC ACID (including mixtures that generate hydrofluoric acid)—when included in Schedule 6 or 7

1, 17, 93

1, 3, 4, 5, 8, 29, 35

172

HYDROGEN PEROXIDE—more than 3% up to 10%

5

1

173

HYDROGEN PEROXIDE—more than 10% up to 20%

5

2

174

HYDROGEN PEROXIDE—more than 20%

2

2, 4

175

HYDROQUINONE—when included in Schedule 2

45

 

176

HYDROQUINONE—except when included in Schedule 2 or 4

 

1, 4

177

HYDROSILICOFLUORIC ACID (including mixtures that generate hydrosilicofluoric acid)—when included in Schedule 5

2

1, 4

178

HYDROSILICOFLUORIC ACID (including mixtures that generate hydrosilicofluoric acid)—when included in Schedule 6 or 7

1, 17, 93

1, 3, 4, 5, 8, 29, 35

179

2HYDROXYETHYL METHACRYLATE

28

4

180

HYDROXYETHYL3,4METHYLENEDIOXYANILINE

28

 

181

IBUPROFEN

101, 104

 

182

IODINE—more than 20%

 

1, 4, 8

183

IODINE—in preparations for human internal therapeutic use containing 300 micrograms or more of iodine per recommended daily dose

91, 92

 

184

IPRATROPIUM BROMIDE in metered aerosols

32

 

185

ISOCYANATES (free organic)—when in paint

28, 52

1, 5, 8, 10, 27

186

ISOCYANATES (free organic)—other than in paint

28, 52

1, 4, 8

187

ISOEUGENOL

19, 28, 79

1, 4

188

ISOPRENALINE in metered aerosols

32

 

189

ISOTRETINOIN—for human oral use

7, 62, 76

 

190

ISOTRETINOIN—for topical use

62, 77

 

191

LEAD COMPOUNDS—in hair cosmetics

25

 

192

LEAD COMPOUNDS—when included in Schedule 6

 

1, 4, 8

193

LEFLUNOMIDE

7, 62, 87

 

194

LEMON OIL

89

 

195

LENALIDOMIDE

7, 62, 76

 

196

LEVOCABASTINE—in eye or nasal preparations containing 0.5 mg/mL or less of levocabastine

62

 

197

LEVOCABASTINE—in other preparations

62 and either 39 or 40

 

198

LIME OIL

89

 

199

LOPERAMIDE when included in Schedule 2

41

 

200

MAGNESIUM CHLORATE

 

1, 4

201

MEFENAMIC ACID

101, 104

 

202

MERCAPTOACETIC ACID

5, 28

1, 31

203

MERCURIC THIOCYANATE

 

1, 4

204

METACRESOLSULPHONIC ACID and formaldehyde condensation product for the treatment of animals

 

1, 4

205

METHANOL except in methylated spirit

 

1, 4, 8

206

METHOXAMINE in nasal preparations for topical use

29

 

207

2METHOXYETHANOL

77

1, 4, 8

208

METHYLATED SPIRIT(S) when packed and labelled as a “biofuel” suitable for use in “spirit burners”

80

 

209

pMETHYLAMINOPHENOL

28

 

210

METHYL CHLORIDE

 

1, 4, 8

211

METHYL ETHYL KETONE

5

1, 4, 8

212

METHYL ETHYL KETONE OXIME

5, 28

1, 4

213

METHYL ETHYL KETONE PEROXIDE

2

2, 3, 4, 6

214

METHYL ISOAMYL KETONE

 

1, 4, 8

215

METHYL ISOBUTYL KETONE

 

1, 4, 8

216

METHYL ISOTHIOCYANATE

5, 12

1, 4, 8

217

METHYL METHACRYLATE

28

4, 9, 23

218

METHYLCHLOROISOTHIAZOLINONE

28

 

219

METHYLDIBROMO GLUTARONITRILE

28

1, 4, 7

220

METHYLENE BISTHIOCYANATE

 

1, 4

221

METHYLEUGENOL

 

1, 6

222

METHYLISOTHIAZOLINONE

28

 

223

METHYLNORBORNYLPYRIDINE

59

 

224

2METHYLRESORCINOL

 

1

225

1(BETAMETHYL SULPHONAMIDOETHYL) 2AMINO3N,NDIETHYLAMINOBENZENE

 

1, 4, 8

226

MICONAZOLE in vaginal preparations when included in Schedule 3

54, 63, 64, 66

 

227

MISOPROSTOL

53

 

228

MONOETHANOLAMINE when included in Schedule 5

5

1, 4

229

MONOETHANOLAMINE when included in Schedule 6

2, 11, 18

1, 4, 8

230

NAPHAZOLINE in nasal preparations for topical use

29

 

231

NAPHTHALENE—in block, ball, disc, pellet or flake form, enclosed in a device which, in normal use, prevents removal or ingestion of its contents

9, 105

 

232

NAPHTHALENE—in other forms

9, 105

1

233

1,5NAPHTHALENEDIOL

28

1

234

2,7NAPHTHALENEDIOL

28

1, 3

235

1NAPHTHOL

28

1

236

NAPROXEN

101, 104

 

237

NICOTINE except when in tobacco

 

1, 4

238

NITRIC ACID—75% or less HNO3

2

1, 4

239

NITRIC ACID—more than 75% HNO3

2

1, 4, 8

240

NITROBENZENE

 

1, 4, 8

241

3NITROpHYDROXYETHYLAMINOPHENOL

28

 

242

NITROPHENOLS

 

1, 4

243

NITROPRUSSIDES in aerosols

84

8

244

NITROUS OXIDE

112

38

245

NIZATIDINE when included in Schedule 2

96

 

246

NORADRENALINE in metered aerosols

32

 

247

NYSTATIN in vaginal preparations when included in Schedule 3

54, 63, 64, 65, 66

 

248

ORANGE OIL (bitter)

89

 

249

ORCIPRENALINE in metered aerosols

32

 

250

OXALATES, metallic

 

4, 8

251

OXALIC ACID

2

4, 8

252

OXYMETAZOLINE in nasal preparations for topical use

29

 

253

OXYQUINOLINE (including salts and derivatives) when prepared for internal use

33

 

254

PAINT—first group paints

83

 

255

PAINT—second group paints

84

 

256

PARACETAMOL

97 and/or 98, 99, 100

 

257

PENTACHLOROPHENOL

 

1, 4, 8

258

PERACETIC ACID

2

1, 4, 8

259

PERMANGANATES

2

24

260

2PHENOXYETHANOL

5

1

261

PHENOL and any other homologue of phenol

 

1, 4

262

PHENOL when included in Schedule 6

3, 51

2, 4, 8

263

PHENOLS

 

5

264

PHENOXYMETHYL OXIRANE

12, 28, 51

1, 3, 4, 5, 7, 8, 9

265

PHENYLENEDIAMINES including alkylated, arylated, halogenated and nitro derivatives—in hair dyes

21

 

266

PHENYLENEDIAMINES including alkylated, arylated, halogenated and nitro derivatives—in preparations other than hair dyes

28

1, 4, 8

267

PHENYL METHYL PYRAZOLONE

28

4

268

PHENYLEPHRINE in nasal preparations for topical use

29

 

269

POMALIDOMIDE

7, 62, 76

 

270

N,NBIS(PHENYLMETHYLENE)BICYCLO(2.2.1)HEPTANE2,5DIMETHANAMINE

5, 28

1, 4, 5, 10

271

oPHENYLPHENOL except when in antiseptics

 

1, 4

272

PHENYLPROPANOLAMINE

56

 

273

PHENYTOIN in pastes for the treatment of horses

9

 

274

PHOSPHONIC ACID

 

1, 4

275

PHOSPHORIC ACID

 

1, 4

276

PHOSPHORUS (yellow)

2

1, 4

277

oPHTHALALDEHYDE—when included in Schedule 5

51, 52, 59

1, 4, 5, 8, 10

278

oPHTHALALDEHYDE—when included in Schedule 6

51, 52, 59

2, 4, 5, 8, 10

279

PICRAMIC ACID including its salts (excluding other derivatives)

28

5

280

PICRIC ACID (more than 20%)

 

1, 4

281

PODOPHYLLIN—in preparations specifically for use on anal or genital area

36

 

282

PODOPHYLLIN—in other liquid preparations when included in Schedule 2 or 3

31

 

283

PODOPHYLLIN—in other solid or semisolid preparations when included in Schedule 2

30

 

284

PODOPHYLLOTOXIN—in preparations specifically for use on anal or genital area

36

 

285

PODOPHYLLOTOXIN—in other liquid preparations when included in Schedule 2 or 3

31

 

286

PODOPHYLLOTOXIN—in other solid or semisolid preparations when included in Schedule 2

30

 

287

POLIHEXANIDE

28

1, 4, 8

288

POLYETHANOXY (15) TALLOW AMINE

 

1, 4

289

POLY(OXY1,2ETHANEDIYL), Α [2[(2HYDROXYETHYL)AMINO] 2OXOETHYL] Α HYDROXY,MONOC1315 ALKYL ETHERS

5, 88

1, 5

290

POTASSIUM HYDROXIDE—in preparations containing 0.5% or less of potassium hydroxide

5

1, 4, 6

291

POTASSIUM HYDROXIDE—in solid preparations containing more than 0.5% of potassium hydroxide

2, 10, 78

3, 5, 28

292

POTASSIUM HYDROXIDE—in liquid preparations containing more than 0.5% of potassium hydroxide

2, 10, 78

3, 5

293

POTASSIUM PERSULFATE

5, 21, 25

1, 5, 23, 33, 34

294

POTASSIUM SULFIDE

2

1, 4

295

PROPIONIC ACID when included in Schedule 6

2

1, 4

296

nPROPYL ALCOHOL

5

1, 9

297

QUININE

28

 

298

QUINOLINE

79

1, 4

299

RANITIDINE when included in Schedule 2

96

 

300

RESORCINOL

19, 28, 79

1, 3, 4

301

ROSIN

108

37

302

SAFROLE—in preparations for therapeutic use

 

1

303

SAFROLE—other than for therapeutic use

 

1, 4

304

SALBUTAMOL in metered aerosols or in dry powder formulations

32

 

305

SALICYLAMIDE

34 or 35

 

306

SASSAFRAS OIL—in preparations for therapeutic use

 

1

307

SASSAFRAS OIL—other than for therapeutic use

 

1, 4

308

SELENIUM COMPOUNDS except when for therapeutic use (human or animal)

 

1, 4, 8

309

SILVER in smoking deterrents

42

 

310

SITAXENTAN

7, 62, 76

 

311

SODIUM ALUMINATE

2

1, 4

312

SODIUM CHLORATE

 

1, 4

313

SODIUM DODECYLBENZENE SULFONATE

79

1

314

SODIUM FLUORIDE in preparations for human ingestion when included in Schedule 2

43

 

315

SODIUM HYDROGEN SULFATE

 

1, 4, 8

316

SODIUM HYDROSULFITE (more than 50%)

5, 26

1, 4, 8

317

SODIUM HYDROXIDE—in preparations containing 0.5% or less of sodium hydroxide

5

1, 4, 6

318

SODIUM HYDROXIDE—in solid preparations containing more than 0.5% of sodium hydroxide

2, 10, 78

3, 5, 28

319

SODIUM HYDROXIDE—in liquid preparations containing more than 0.5% of sodium hydroxide

2, 10, 78

3, 5

320

SODIUM LAURETH6 CARBOXYLATE

79

1

321

SODIUM METABISULPHITE (more than 50%)

5, 26

1, 4

322

SODIUM NITRITE in pickling or curing salts

94

 

323

SODIUM PERSULFATE

5, 21, 25

1, 5, 23, 33, 34

324

SODIUM SULFIDE

2

1, 4

325

STYRENE

 

1, 4, 8

326

SULFAMIC ACID

2

1, 4

327

SULFURIC ACID

2

1, 4

328

SYMPHYTUM SPP. (Comfrey) when included in Schedule 5

 

31, 32

329

TAZAROTENE for topical use

77, 62

 

330

TERBUTALINE in metered aerosols or in dry powder formulations

32

 

331

TERFENADINE

 

61

332

TERIFLUNOMIDE

7, 62, 87

 

333

TERPENES, chlorinated

 

1, 4, 8

334

TETRACHLOROETHANE

12

8

335

TETRACHLOROETHYLENE when included in Schedule 5 or 6

12, 16

1, 4, 8, 11

336

TETRYZOLINE in nasal preparations for topical use

29

 

337

THALIDOMIDE

7, 62, 76

 

338

THIOUREA

 

1, 4

339

TOLUENE

 

1, 4, 8

340

TOLUENEDIAMINES—in hair dyes

21

 

341

TOLUENEDIAMINES—in preparations other than hair dyes

 

1, 4, 8

342

TRAMAZOLINE in nasal preparations for topical use

29

 

343

TRETINOIN—for human oral use

7, 62, 76

 

344

TRETINOIN—for topical use

62, 77

 

345

TRIAMCINOLONE when in topical preparations for the treatment of mouth ulcers

64 or 68

 

346

TRICHLOROACETIC ACID except when for therapeutic use

2

1, 4

347

1,1,1TRICHLOROETHANE

 

8, 9

348

TRICHLOROETHYLENE except when for therapeutic use

12

1, 4, 5, 8, 9

349

TRICHLOROPHENOL

 

1, 4, 8

350

TRIETHYL PHOSPHATE

 

1, 4, 8

351

TRIFLUOROMETHANESULFONIC ACID—more than 10%

1, 17

1, 4, 8

352

TRIFLUOROMETHANESULFONIC ACID—10% or less

 

1, 4, 8

353

TRIISOPROPANOLAMINE LAURYL ETHER SULFATE

 

1, 4, 6

354

3,6,9TRIOXAUNDECANEDIOIC ACID

5

1

355

TROLAMINE

5

1, 4

356

TYMAZOLINE in nasal preparations for topical use

29

 

357

VINCLOZOLIN

46

 

358

VINYL ACETATE MONOMER

11

8, 9

359

XYLENE

 

1, 4, 8

360

XYLOMETAZOLINE in nasal preparations for topical use

29

 

361

ZINC CHLORIDE

 

1, 4

362

ZINC LACTATE

107

 

363

ZINC SULFATE when included in Schedule 6

 

1, 4

 

Appendix GDilute preparations

 

 

Note: See paragraph 11(c).

1  Substances exempt at or below certain concentrations

  For the purposes of paragraph 11(c), the following table specifies:

 (a) substances; and

 (b) concentrations in relation to those substances.

 

Substances and concentrations

Item

Column 1
Substance

Column 2
Concentration (quantity per litre or kilogram)

1

ACETYLCHOLINE

1 mg

2

ALDOSTERONE

10 micrograms

3

ANTIMONY COMPOUNDS

1 mg

4

APOMORPHINE

1 mg

5

ARSENIC

1 mg

6

ATROPA BELLADONNA (belladonna)

300 micrograms

7

ATROPINE

300 micrograms

8

CANTHARIDIN

10 micrograms

9

CHLORINE

5 mg

10

CROTON TIGLIUM (croton oil)

1 mg

11

DIOXANE

100 mg

12

EPIDERMAL GROWTH FACTOR

2 mg

13

ERYSIMUM spp.

1 mg

14

ESTRADIOL

10 micrograms

15

ESTRONE

100 micrograms

16

FOLLICLESTIMULATING HORMONE

100 micrograms

17

GELSEMIUM SEMPERVIRENS

1 mg

18

GLUCAGON

100 micrograms

19

GLYCERYL TRINITRATE

100 micrograms

20

GROWTH HORMONE

10 micrograms

21

HALOPERIDOL

1 mg

22

HYDROCYANIC ACID

1 microgram

23

HYOSCINE

300 micrograms

24

HYOSCYAMINE

300 micrograms

25

HYOSCYAMUS NIGER

300 micrograms

26

HYPOTHALAMIC RELEASING FACTORS

10 micrograms

27

INDOMETACIN

1 mg

28

MERCURY

1 mg

29

METHYLMERCURY

300 micrograms

30

NAPHTHALENE

1 mg

31

NERIUM OLEANDER

1 mg

32

OXYTOCIN

1 microgram

33

PHOSPHORUS

1 mg

34

PODOPHYLLUM RESIN (podophyllin)

1 mg

35

PROGESTERONE

1 mg

36

PROPRANOLOL

1 mg

37

SELENIUM

100 micrograms

38

STROPHANTHUS spp.

1 mg

39

STRYCHNINE

1 mg

40

TESTOSTERONE

1 mg

41

THYROXINE

10 micrograms

 

Appendix HSchedule 3 medicines permitted to be advertised

 

 

Note: See paragraph 57(1)(a).

1  Schedule 3 medicines permitted to be advertised

  The following table specifies poisons for the purposes of paragraph 57(1)(a).

 

Schedule 3 medicines permitted to be advertised

Item

Column 1
Poison

1

ADAPALENE

2

ADRENALINE

3

ASTODRIMER SODIUM—for the treatment and relief of bacterial vaginosis and for the prevention of recurrent bacterial vaginosis

4

BILASTINE

5

BUTOCONAZOLE

6

CICLOPIROX

7

CLOBETASONE

8

CLOTRIMAZOLE

9

DICLOFENAC

10

DIMENHYDRINATE—for the prevention and relief of motion sickness

11

DIPHENOXYLATE

12

ECONAZOLE

13

ELETRIPTAN

14

ESOMEPRAZOLE

15

FAMCICLOVIR

16

FLUCONAZOLE

17

FLUORIDES

18

GLUCAGON

19

GLYCERYL TRINITRATE

20

HYDROCORTISONE

21

HYOSCINE BUTYLBROMIDE

22

IBUPROFEN

23

ISOCONAZOLE

24

KETOPROFEN

25

LANSOPRAZOLE

26

LEVONORGESTREL

27

MELATONIN

28

MICONAZOLE

29

NALOXONE

30

NAPROXEN

31

NYSTATIN

32

OMEPRAZOLE

33

OXICONAZOLE

34

PANTOPRAZOLE

35

PARACETAMOL

36

PODOPHYLLOTOXIN

37

PODOPHYLLUM EMODI (podophyllin)

38

PODOPHYLLUM PELTATUM (podophyllin)

39

RABEPRAZOLE

40

RIZATRIPTAN

41

SALICYLIC ACID

42

SUMATRIPTAN

43

TIOCONAZOLE

44

TRIAMCINOLONE

45

ULIPRISTAL—for emergency postcoital contraception

46

VITAMIN D

47

ZOLMITRIPTAN

Appendix IBlank

 

   

Note 1: Appendix I is intentionally blank.

Note 2: Appendix I previously included poisons now dealt with in Division 9 of Part 2.

Appendix JConditions for availability and use of certain poisons included in Schedule 7

 

 

Note: See subsection 62(6).

1  Conditions for supply of certain poisons included in Schedule 7

  For the purposes of subsection 62(6), a poison included in Schedule 7 that is specified in column 1 of an item of the following table may be supplied:

 (a) only to a person who is appropriately authorised or licensed under the law of the jurisdiction where the person will receive the poison; and

 (b) if “a” appears in column 2 of the item—only for analytical or research purposes; and

 (c) if “p” appears in column 2 of the item—only to a person who is authorised or licensed, under the law of the jurisdiction where the person will receive the poison, to possess and use the poison.

 

Conditions for supply of certain poisons included in Schedule 7

Item

Column 1
Poison

Column 2
Condition

1

ABAMECTIN

 

2

ACIBENZOLARSMETHYL

 

3

ACROLEIN

 

4

ACRYLONITRILE

 

5

ALACHLOR

a

6

ALLYL ALCOHOL

 

7

4AMINOPROPIOPHENONE

p

8

4AMINOPYRIDINE

 

9

ARPRINOCID

a

10

ARSENIC

p

11

AZOCYCLOTIN

a

12

BENZENE

 

13

BIFLUORIDE

 

14

BORON TRIFLUORIDE

 

15

BRODIFACOUM

 

16

BROMADIOLONE

 

17

BROMINE

 

18

BRUCINE

 

19

CALCIFEROL

 

20

CARBADOX

 

21

CARBON TETRACHLORIDE

 

22

CARBONYL SULFIDE

 

23

CHLORDECONE

a

24

CHLORDIMEFORM

a

25

CHLORINE

 

26

CHLOROMETHIURON

a

27

CHLOROPICRIN

 

28

4CHLOROoTOLUIDINE

a

29

COLECALCIFEROL

 

30

COUMATETRALYL

 

31

CYANOGEN

 

32

CYHEXATIN

a

33

4,4DIAMINODIPHENYLMETHANE

 

34

1,2DIBROMO3CHLOROPROPANE

a

35

1,3DICHLOROPROPENE

 

36

DIFENACOUM

 

37

4DIMETHYLAMINOAZOBENZENE

a

38

DINITROCRESOLS

a

39

DINITROPHENOLS

a

40

DINOSEB

a

41

EPICHLOROHYDRIN

 

42

EPIDERMAL GROWTH FACTOR

 

43

ETACONAZOLE

a

44

ETHYLENE DIBROMIDE

a

45

ETHYLENE OXIDE

 

46

FLUOROACETAMIDE

p

47

FLUOROACETIC ACID

p

48

FOLPET

 

49

HALOFUGINONE

 

50

HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS

a

51

HCB

a

52

HYDROCYANIC ACID AND CYANIDES

p

53

HYDROFLUORIC ACID

 

54

HYDROSILICOFLUORIC ACID

 

55

IODOMETHANE

 

56

MADURAMICIN

 

57

MERCURY

 

58

METHACRIFOS

 

59

METHOXYETHYLMERCURIC ACETATE

a

60

METHOXYETHYLMERCURIC CHLORIDE

 

61

METHYL BROMIDE

 

62

4,4'METHYLENEBIS[2CHLOROANILINE]

 

63

MIREX

a

64

MOLINATE

 

65

NICOTINE except when in tobacco

 

66

NITROFEN

a

67

PHENYLMERCURIC ACETATE

 

68

PHOSPHIDE, metallic

 

69

PHOSPHINE

 

70

PROPYLENE OXIDE

 

71

PYRINURON

a

72

STRYCHNINE

p

73

SULCOFURON

a

74

TETRACHLOROETHANE

 

75

2,2',6,6'TETRAISOPROPYLDIPHENYLCARBODIIMIDE

 

76

THALLIUM

p

77

oTOLIDINE

 

78

VINYL CHLORIDE

 

Appendix KHuman medicines required to be labelled with a sedation warning

 

 

Note: See subsection 33(2).

1  Human medicines required to be labelled with a sedation warning

  The following table specifies poisons for the purposes of subsection 33(2).

 

Human medicines required to be labelled with a sedation warning

Item

Column 1
Poison

1

ALIMEMAZINE

2

ALPRAZOLAM

3

AMISULPRIDE

4

AMITRIPTYLINE

5

AMOBARBITAL

6

ARIPIPRAZOLE

7

ASENAPINE

8

AZATADINE

9

BACLOFEN

10

BENZATROPINE

11

BREXPIPRAZOLE

12

BRIVARACETAM

13

BROMAZEPAM

14

BROMPHENIRAMINE

15

BUCLIZINE

16

BUPRENORPHINE

17

BUTOBARBITAL

18

CANNABIS except cannabidiol when included in Schedule 3 or 4

19

CETIRIZINE

20

CHLORAL HYDRATE

21

CHLORDIAZEPOXIDE

22

CHLORMETHIAZOLE

23

CHLORPHENAMINE

24

CHLORPROMAZINE

25

CLEMASTINE

26

CLOMIPRAMINE

27

CLONAZEPAM

28

CLONIDINE

29

CLORAZEPATE

30

CLOZAPINE

31

CODEINE.

32

CYCLIZINE

33

CYCLOBARBITAL

34

CYCLOSERINE

35

CYPROHEPTADINE

36

DANTROLENE

37

DESIPRAMINE

38

DEUTETRABENAZINE.

39

DEXCHLORPHENAMINE

40

DEXTROMORAMIDE

41

DEXTROPROPOXYPHENE

42

DIAZEPAM

43

DIFELIKEFALIN

44

DIFENOXIN

45

DIHYDROCODEINE

46

DIMENHYDRINATE

47

DIMETHINDENE

48

DIPHENHYDRAMINE

49

DIPHENOXYLATE

50

DIPHENYLPYRALINE

51

DOSULEPIN

52

DOXEPIN

53

DOXYLAMINE

54

DRONABINOL (delta9TETRAHYDROCANNABINOL)

55

DROPERIDOL

56

DULOXETINE

57

ESKETAMINE

58

ETHYLMORPHINE

59

FENFLURAMINE

60

FENTANYL

61

FLUNITRAZEPAM

62

FLUPENTIXOL

63

FLUPHENAZINE

64

FLURAZEPAM

65

GABAPENTIN

66

GEMCITABINE

67

GLUTETHIMIDE

68

GUANFACINE

69

HALOPERIDOL

70

HYDROCODONE

71

HYDROMORPHONE

72

HYDROXYZINE

73

IMIPRAMINE

74

LAMOTRIGINE

75

LEMBOREXANT.

76

LEVETIRACETAM

77

LEVOCABASTINE

78

LEVOCETIRIZINE

79

LORAZEPAM

80

LURASIDONE.

81

MAZINDOL

82

MEBHYDROLIN

83

MECLOZINE

84

MEDAZEPAM

85

MEPROBAMATE

86

MEPYRAMINE

87

MERCAPTAMINE

88

METHADONE

89

METHDILAZINE

90

METHOCARBAMOL

91

METHYLPHENOBARBITAL

92

MIANSERIN

93

MIDAZOLAM

94

MIRTAZAPINE

95

MORPHINE

96

NABIXIMOLS.

97

NALBUPHINE

98

NITRAZEPAM

99

NORMETHADONE

100

NORTRIPTYLINE

101

OLANZAPINE

102

OPIUM in any form except the alkaloids noscapine and papaverine

103

OXAZEPAM

104

OXYCODONE

105

PALIPERIDONE

106

PAPAVERETUM

107

PENTAZOCINE

108

PENTOBARBITAL

109

PERAMPANEL

110

PERICIAZINE

111

PERPHENAZINE

112

PETHIDINE

113

PHENELZINE

114

PHENIRAMINE

115

PHENOBARBITAL

116

PHENOPERIDINE

117

PHENYLTOLOXAMINE

118

PHOLCODINE

119

PIMOZIDE

120

PIZOTIFEN

121

PRAZEPAM

122

PREGABALIN

123

PROCHLORPERAZINE

124

PROMAZINE

125

PROMETHAZINE

126

PROTRIPTYLINE

127

QUETIAPINE

128

RETIGABINE

129

RISPERIDONE

130

ROTIGOTINE

131

RUFINAMIDE

132

RUPATADINE

133

SAFINAMIDE

134

SECBUTOBARBITAL

135

SECOBARBITAL

136

SELETRACETAM

137

SODIUM OXYBATE

138

STIRIPENTOL

139

SUVOREXANT

140

TAPENTADOL

141

TEMAZEPAM

142

TETRAHYDROCANNABINOLS except cannabidiol when included in Schedule 3 or 4

143

THENYLDIAMINE

144

THIETHYLPERAZINE

145

THIOPROPAZATE

146

THIORIDAZINE

147

THIOTHIXENE

148

TRABECTEDIN

149

TRAMADOL

150

TRANYLCYPROMINE

151

TRIFLUOPERAZINE

152

TRIMIPRAMINE

153

TRIPROLIDINE

154

ZIPRASIDONE

155

ZOLPIDEM

156

ZONISAMIDE

157

ZOPICLONE

Appendix LRequirements for dispensing labels for medicines

 

 

Note: See subsection 33(1) and paragraph 40(b).

1  General

 (1) This clause sets out requirements for the purposes of paragraph 40(b).

 (2) All details, words and other required information on a label on a container of a substance for therapeutic use must be in the English language in letters at least 1.5 mm in height.

 (3) All symbols, numbers and words on a label must be in durable characters.

 (4) The label on a container of a substance for therapeutic use must contain the following details:

 (a) the name, address and telephone number of the dispenser supplying the substance;

 (b) the approved name of the substance and/or its proprietary name (unless it is a preparation compounded in accordance with the dispenser’s own formula);

 (c) adequate directions for use;

 (d) the strength and form of the substance;

 (e) the total quantity of the goods in the container;

 (f) the words “KEEP OUT OF REACH OF CHILDREN” in red on a white background;

 (g) if the substance is intended for external use only, the word “POISON”, or the words “FOR EXTERNAL USE ONLY”, in red on a white background;

 (h) if the substance is a medicine for human use, the name of the person for whom it was dispensed; and

 (i) if the substance is a veterinary chemical, the species of animal, the name of the animal’s owner and the words “FOR ANIMAL TREATMENT ONLY”.

 (5) The label on a container of a medicine for human use, or a veterinary chemical, that is supplied on prescription must also include:

 (a) the prescription reference number; and

 (b) the date on which the prescription was supplied (unless that date is clear from the prescription reference number); and

 (c) the directions for use set out in the prescription.

2  Additional warning statements for certain human medicines

 (1) For the purposes of subsection 33(1), and subject to subclause (2), the warning statement represented by each item number specified in column 2 of an item of the following table is required for the poison specified in column 1 of the item.

Note: For the warning statements represented by the item numbers, see clause 1 of Appendix F.

 (2) If more than one statement or direction is required for a poison, the statements and directions may be combined to form simple sentences (if appropriate).

 

Additional warning statements for certain human medicines

Item

Column 1
Poison

Column 2
Warning statement item number

1

ACITRETIN—for oral use

7, 62, 76

2

ACITRETIN—for topical use

62, 77

3

ADAPALENE—for oral use

7, 62, 76

4

ADAPALENE—for topical use

62, 77

5

AMBRISENTAN

7, 62, 76

6

BELUMOSUDIL

62, 77

7

BEXAROTENE—for oral use

7, 62, 76

8

BEXAROTENE—for topical use

62, 77

9

BOSENTAN

7, 62, 76

10

DIENESTROL

67

11

ETRETINATE—for oral use

7, 62, 76

12

ETRETINATE—for topical use

62, 77

13

ENZALUTAMIDE

7, 67, 87

14

FARICIMAB

76

15

FINERENONE

67, 111

16

FINGOLIMOD

76

17

ISAVUCONAZOLE

53

18

ISOTRETINOIN—for oral use

7, 62, 76

19

ISOTRETINOIN—for topical use

62, 77

20

LEFLUNOMIDE

7, 62, 87

21

LENALIDOMIDE—for oral use

7, 62, 76

22

LENALIDOMIDE—for topical use

62, 77

23

LEVOCABASTINE

62

24

MACITENTAN

7, 62, 76

25

MISOPROSTOL

53

26

PLITIDEPSIN

7, 62, 63, 76, 87

27

POMALIDOMIDE

7, 62, 76

28

PONESIMOD

76

29

RIOCIGUAT

7, 62, 76

30

RUFINAMIDE

62, 76, 77

31

SAFINAMIDE

62, 76, 77

32

SELINEXOR

62 and 77

33

SELUMETINIB.

76

34

SITAXENTAN

7, 62, 76

35

TERIFLUOMIDE

7, 62, 87

36

THALIDOMIDE—for oral use

7, 62, 76

37

THALIDOMIDE—for topical use

62, 77

38

TIRZEPATIDE

67

39

TRASTUZUMAB DERUXTECAN

62, 77

40

TRETINOIN—for oral use

7, 62, 76

41

TRETINOIN—for topical use

62, 77

 

Appendix MAdditional controls or supply requirements for poisons included in Schedule 3 to allow them to be provided by a pharmacist

 

   

Note: Appendix M is intentionally blank. It is reserved for future use.

 

Index

 

 

A

ABACAVIR

Schedule 4

ABAMECTIN

Schedule 7
Schedule 6
Schedule 5
Appendix J, clause 1

ABATACEPT

Schedule 4

ABCIXIMAB

Schedule 4

ABEMACICLIB

Schedule 4

ABIRATERONE ACETATE

Schedule 4

ABRUS PRECATORIUS
cross reference: JEQUIRITY

Schedule 10

ABSCISIC ACID

Schedule 5

ACALABRUTINIB

Schedule 4

ACAMPROSATE CALCIUM

Schedule 4

ACARBOSE

Schedule 4

ACEBUTOLOL

Schedule 4

ACEPHATE

Schedule 6

ACEPROMAZINE

Schedule 4

ACEQUINOCYL

Schedule 5

ACETAMIPRID

Schedule 6

ACETANILIDE
cross reference: ALKYL ACETANILIDES

Schedule 4

ACETARSOL

Schedule 4

ACETAZOLAMIDE

Schedule 4

ACETIC ACID

Schedule 6
Schedule 5
Schedule 2
Appendix E, clause 3
Appendix F, clause 4

ACETIC ANHYDRIDE

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

ACETOHEXAMIDE

Schedule 4

ACETONE
cross reference: DESIGNATED SOLVENT

Schedule 5
Appendix E, clause 3
Appendix F, clause 4

ACETORPHINE

cross reference: CAS No. 25333-77-1

Schedule 9

ACETYLALPHAMETHYLFENTANYL

cross reference: CAS No. 101860-00-8

Schedule 9

ACETYLCARBROMAL

Schedule 4

ACETYLCHOLINE

Schedule 4
Appendix G, clause 1

ACETYLCYSTEINE

Schedule 4
Schedule 2

ACETYLDIGITOXIN

Schedule 4

ACETYLDIHYDROCODEINE

Schedule 8

ACETYL ISOVALERYLTYLOSIN

Schedule 4

ACETYLMETHADOL

Schedule 8

ACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE

Schedule 4

ACETYLMORPHINES

Schedule 8

4[4(ACETYLOXY)PHENYL]2BUTANONE

Appendix B, clause 3

ACETYLSTROPHANTHIDIN

Schedule 4

ACIBENZOLARSMETHYL

Schedule 7
Appendix J, clause 1

ACICLOVIR

Schedule 4

ACIFLUORFEN

Schedule 6

ACINITRAZOLE

Schedule 6

ACIPIMOX

Schedule 4

ACITRETIN

Schedule 4
Appendix D, clause 2
Appendix F, clause 4
Appendix L, clause 2

ACLIDINIUM BROMIDE

Schedule 4

ACLONIFEN

Schedule 6

ACOKANTHERA OUABAIO

Schedule 4

ACOKANTHERA SCHIMPERI

Schedule 4

ACONITUM spp.

Schedule 4
Schedule 2

ACORUS CALAMUS
cross reference: CALAMUS

Schedule 10

ACRIFLAVINE
cross reference: ACRIFLAVINIUM CHLORIDE

ACRIFLAVINUM CHLORIDE

Schedule 7
Schedule 5

ACRIVASTINE

Schedule 4

ACROLEIN

Schedule 7
Appendix E, clause 3
Appendix F, clause 4

ACRYLONITRILE

Schedule 7
Appendix J, clause 1

ADALIMUMAB

Schedule 4

ADAPALENE

Schedule 4
Schedule 3
Appendix F, clause 4
Appendix H, clause 1
Appendix L, clause 2

ADEFOVIR

Schedule 4

ADENOSINE

Schedule 4

ADIPHENINE

Schedule 4

ADONIS VERNALIS

Schedule 4

ADRAFINIL

Schedule 4

ADRENALINE

Schedule 4
Schedule 3

Appendix H, clause 1

ADRENOCORTICAL HORMONES

Schedule 4

AFAMELANOTIDE
cross reference: MELANOCYTE STIMULATING HORMONE, MELANOTAN I

Schedule 4

AFATINIB DIMALEATE

Schedule 4

AFIDOPYROPEN

Appendix B, clause 3

AFLIBERCEPT

Schedule 4

AFOXOLANER

Schedule 5

AGALSIDASE

Schedule 4

AGLEPRISTONE

Schedule 4

AGOMELATINE

Schedule 4

AKLOMIDE

Schedule 5

ALACHLOR

Schedule 7
Appendix J, clause 1

ALANYLGLUTAMINE

Schedule 4

ALATROFLOXACIN MESILATE
cross reference: ALATROFLOXACIN MESYLATE

Schedule 4

ALBENDAZOLE

Schedule 6
Schedule 5
Schedule 4

ALCLOFENAC

Schedule 4

ALCLOMETASONE

Schedule 4
Schedule 3
Appendix F, clause 4

ALCOHOL, DEHYDRATED

Appendix B, clause 3

ALCURONIUM

Schedule 4

ALDESLEUKIN

Schedule 4

ALDICARB

Schedule 7

ALDOSTERONE

Schedule 4
Appendix G, clause 1

ALDOXYCARB

Schedule 7

ALDRIN

Schedule 6

ALECTINIB

Schedule 4

ALEFACEPT

Schedule 4
Appendix D, clause 7

ALEMTUZUMAB

Schedule 4

ALENDRONIC ACID

Schedule 4

ALFACALCIDOL

Schedule 4

ALFENTANIL

Schedule 8

ALFUZOSIN

Schedule 4

ALGICIDES

Appendix A, clause 1

ALGLUCERASE

Schedule 4

ALGLUCOSIDASE

Schedule 4

ALIMEMAZINE
cross reference: TRIMEPRAZINE

Schedule 4
Schedule 3
Schedule 2
Appendix K, clause 1

ALIROCUMAB

Schedule 4

ALISKIREN

Schedule 4

ALKALINE SALTS
cross reference: LYE WATER, POTASSIUM CARBONATE. POTASSIUM PHOSPHATE, POTASSIUM SALTS, POTASSIUM SILICATE, SODIUM CARBONATE, SODIUM SALTS, SODIUM SILICATE(S)

Schedule 10
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

ALKOXYAMFETAMINES
cross reference: ALKOXYAMPHETAMINES

Schedule 9

ALKOXYLATED FATTY ALKYLAMINE POLYMER

Schedule 6
Schedule 5

ALKOXYPHENYLETHYLAMINES

Schedule 9

ALKYLAMINES WITH STIMULANT PROPERTIES
cross reference: 1,3DIMETHYLBUTYLAMINE, DMBA, OCTODRINE, 1AMINOISOHEPTANE, DMHA, 1,5DIMETHYLHEXYLAMINE, 4METHYLHEXANE2AMINE, 1,3DIMETHYLAMYLAMINE, DMAA, 4AMINO2METHYLPENTANE CITRATE (AMP CITRATE), 1,4DIMETHYLPENTYLAMINE, DMPA, 1,4DIMETHYLAMYLAMINE, DMAA.

Schedule 10

ALKYL NITRITES

Schedule 4
Appendix E, clause 3

ALKYLTHIOAMFETAMINES
cross reference: ALKYLTHIOAMPHETAMINES

Schedule 9

ALLERGENS

Schedule 4

ALLETHRIN

Schedule 6
Schedule 5

ALLOPURINOL

Schedule 4

ALLOXYDIM

Schedule 5

ALLYL ALCOHOL

Schedule 7
Appendix J, clause 1

ALLYL CYCLOHEXANEACETATE (CAS No. 4728829)

Schedule 6

ALLYL CYCLOHEXANEPROPIONATE (CAS No. 2705875)

Schedule 6

ALLYL ESTERS (excluding derivatives)

Schedule 6

ALLYLESTRENOL
cross reference: ALLYLOESTRENOL

Schedule 4

ALLYL HEPTANOATE/ALLYL HEPTYLATE (CAS No. 142198)

Schedule 6

ALLYL HEXANOATE (CAS No. 123682)

Schedule 6

ALLYL ISOVALERATE (CAS No. 2835394)

Schedule 6

ALLYL NONANOATE (CAS No. 7493723)

Schedule 6

ALLYL OCTANOATE (CAS No. 4230971)

Schedule 6

ALLYLOESTRENOL
cross reference: ALLYLESTRENOL

ALLYL PHENYLACETATE (CAS No. 1797746)

Schedule 6

ALLYLPRODINE

cross reference: CAS No. 25384-17-2

Schedule 9

ALLYL TRIMETHYLHEXANOATE (CAS No. 68132809)

Schedule 6

ALOGLIPTIN

Schedule 4

ALOSETRON

Schedule 4

ALOXIPRIN

Schedule 2

ALPELISIB

Schedule 4

ALPHACETYLMETHADOL

Schedule 8

ALPHACHLOROHYDRIN

Schedule 6
Appendix F, clause 4

ALPHACYPERMETHRIN

Schedule 7
Schedule 6
Schedule 5

ALPHADOLONE

Schedule 4

ALPHAMEPRODINE

cross reference: CAS No. 468-51-9

Schedule 9

ALPHAMETHADOL

cross reference: CAS No. 17199-54-1

Schedule 9

ALPHAMETHYLFENTANYL

cross reference: CAS No. 79704-88-4

Schedule 9

ALPHAMETHYLTHIOFENTANYL

cross reference: CAS No. 103963-66-2

Schedule 9

ALPHAPRODINE

Schedule 8

ALPHAPYRROLIDINOVALEROPHENONE *(ALPHAPVP).

cross reference: CAS No. 14530-33-7

Schedule 9

ALPHA1PROTEINASE INHIBITOR (HUMAN)

Schedule 4

ALPHAXALONE

Schedule 4

ALPRAZOLAM

Schedule 8
Appendix D, clause 5 (Benzodiazepine group entry)
Appendix K, clause 1

ALPRENOLOL

Schedule 4

ALPROSTADIL

Schedule 4

ALSEROXYLON

Schedule 4

ALTEPLASE

Schedule 4

ALTRENOGEST

Schedule 4

ALTRETAMINE
cross reference: HEXAMETHYLMELAMINE

Schedule 4

ALUM

Appendix B, clause 3

ALUMINIUM AMMONIUM SULFATE

Appendix B, clause 3

ALUMINIUM POTASSIUM SULFATE

Appendix B, clause 3

ALUMINIUM SILICATE

Appendix B, clause 3

ALUMINIUM tris (ETHYLPHOSPHONATE)

Appendix B, clause 3

AMANTADINE

Schedule 4

AMBENONIUM CHLORIDE

Schedule 4

AMBRISENTAN

Schedule 4
Appendix D, clause 6
Appendix F, clause 4
Appendix L, clause 2

AMBUCETAMIDE

Schedule 4

AMBUTONIUM BROMIDE

Schedule 4

AMCINONIDE

Schedule 4

AMETOCTRADIN

Appendix B, clause 3

AMETRYN

Schedule 5

AMICARBAZONE

Schedule 6

AMIDITHION

Schedule 6

AMIDOPROPYL BETAINES

Schedule 6
Appendix E, clause 3

AMIFAMPRIDINE

Schedule 4

AMIFOSTINE

Schedule 4

AMIKACIN

Schedule 4

AMILORIDE

Schedule 4

AMINACRINE
cross reference: AMINOACRIDINE

AMINES
cross reference: CURING AGENTS FOR EPOXY RESINS

Schedule 5
Appendix E, clause 3
Appendix F, clause 4

AMINOACRIDINE
cross reference: AMINACRINE

Schedule 7
Schedule 5

AMINOCAPROIC ACID

Schedule 4

AMINOCARB

Schedule 7
Schedule 6

2AMINO6CHLORO4NITROPHENOL

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

4AMINOmCRESOL

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

5AMINOoCRESOL
cross reference: 4AMINO2HYDROXYTOLUENE

AMINOCYCLOPYRACHLOR

Schedule 5

2AMINO1(2,5DIMETHOXY4METHYL)PHENYLPROPANE
cross reference: DOM, STP (CAS No. 15588-95-1), DOM HYDROCHLORIDE (CAS No. 15589-00-1)

Schedule 9

AMINOETHOXYVINYLGLYCINE

Schedule 6

2AMINO5ETHYLPHENOL

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

AMINOGLUTETHIMIDE

Schedule 4

4AMINO2HYDROXYTOLUENE

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

5AMINOLEVULINIC ACID

Schedule 4

1AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE

Schedule 6

2[(4AMINO2METHYL5NITROPHENYL)AMINO]ETHANOL
cross reference: HC VIOLET 1

2AMINO5METHYLPHENOL

cross reference: CAS No. 2835-98-5

Schedule 10
Schedule 7

AMINOMETRADINE

Schedule 4

4AMINO3NITROPHENOL

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

2,2'[(4AMINO3NITROPHENYL)IMINO]BISETHANOL
cross reference: HC RED 13

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

AMINOPHENAZONE
cross reference: AMIDOPYRINE (CAS No. 58-15-1), AMINOPHENAZONE HYDROCHLORIDE (CAS No. 6170-29-2)

Schedule 10
Schedule 4

mAMINOPHENOL

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

pAMINOPHENOL

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

AMINOPHYLLINE

Schedule 4
Schedule 3

4AMINOPROPIOPHENONE
cross reference: PARAAMINOPROPIOPHENONE (PAPP)

Schedule 7
Appendix J, clause 1

5(2AMINOPROPYL)INDAN

cross reference: CAS No. 13396-94-6

Schedule 9

AMINOPTERIN

Schedule 4

AMINOPYRALID

Schedule 6
Schedule 5

4AMINOPYRIDINE
cross reference: FAMPRIDINE

Schedule 7
Schedule 4
Appendix E, clause 3
Appendix J, clause 1

AMINOREX

Schedule 4

AMINOSALICYLIC ACID

Schedule 4

AMIODARONE

Schedule 4

AMIPHENAZOLE

Schedule 4

AMISOMETRADINE

Schedule 4

AMISULBROM

Schedule 5

AMISULPRIDE

Schedule 4
Appendix K, clause 1

AMITON

Schedule 7

AMITRAZ

Schedule 6

AMITRIPTYLINE

Schedule 4
Appendix K, clause 1

AMITROLE

Schedule 5

AMLODIPINE

Schedule 4

AMMI VISNAGA

Schedule 4

AMMONIA
cross reference: AMMONIUM HYDROXIDE, CHROMATES

Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

AMMONIUM BROMIDE

Schedule 4

AMMONIUM COCOYL ISETHIONATE

Schedule 6
Appendix E, clause 3

AMMONIUM PERSULFATE

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

AMMONIUM PHOSPHATE

Appendix B, clause 3

AMMONIUM THIOCYANATE

Schedule 5
Appendix E, clause 3

AMMONIUM THIOSULPHATE

Appendix B, clause 3

AMOBARBITAL

Schedule 8
Schedule 4
Appendix K, clause 1

AMODIAQUINE

Schedule 4

AMOROLFINE

Schedule 4
Schedule 2

AMOXAPINE

Schedule 4

AMOXICILLIN

Schedule 4

AMOXYCILLIN
cross reference: AMOXICILLIN

AMFETAMINE
cross reference: AMPHETAMINE

Schedule 8

AMPHOMYCIN

Schedule 4

AMPHOTERICIN
cross reference: AMPHOTERICIN B

AMPHOTERICIN B

Schedule 4

AMPICILLIN

Schedule 4

AMPRENAVIR

Schedule 4

AMPROLIUM

Appendix B, clause 3

AMRINONE

Schedule 4

AMSACRINE

Schedule 4

AMYGDALIN
cross reference: CAS No. 29883-15-6, APRICOT KERNELS

Schedule 10

AMYL ACETATE

Appendix B, clause 3

AMYL NITRITE

Schedule 4
Schedule 3
Appendix E, clause 3

αAMYLASE derived from Aspergillus niger

Appendix B, clause 3

AMYL CINNAMALDEHYDE

Appendix B, clause 3

AMYLOBARBITAL
cross reference: AMOBARBITAL

AMYLOBARBITONE
cross reference: AMOBARBITAL

AMYLOCAINE

Schedule 4

ANABOLIC STEROIDAL AGENTS
cross reference: ANDROSTERONE, STEROIDAL AGENTS

Schedule 4
Appendix D, clause 5

ANAGRELIDE

Schedule 4

ANAKINRA

Schedule 4

ANASTROZOLE

Schedule 4

ANCESTIM

Schedule 4

ANCHUSA OFFICINALIS

Schedule 10

ANCROD

Schedule 4

ANDEXANET ALFA

Schedule 4

ANDROGENIC STEROIDAL AGENTS
cross reference: STEROIDAL AGENTS

Schedule 4
Appendix D, clause 5

ANDROISOXAZOLE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

ANDROSTANOLONE

Schedule 4

ANDROSTENEDIOL

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

ANDROSTENEDIONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

ANDROSTENEDIONE ALBUMEN

Appendix B, clause 3

ANECORTAVE

Schedule 4

ANGIOTENSIN AMIDE

Schedule 4

ANHYDRIDES, ORGANIC ACID
cross reference: CURING AGENTS FOR EPOXY RESINS

Schedule 5
Appendix E, clause 3
Appendix F, clause 4

ANIDULAFUNGIN

Schedule 4

ANILERIDINE

Schedule 8

ANILINE

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

ANIRACETAM
cross reference: RACETAMS

Schedule 4

ANISE OIL

Schedule 5
Appendix E, clause 3, Part 4

oANISIDINE

cross reference: CAS No. 90-04-0, o-ANISIDINE HYDROCHLORIDE (CAS No. 134-29-2)

Schedule 10

ANISTREPLASE

Schedule 4

ANTAZOLINE

Schedule 4
Schedule 2

ANTIBIOTIC SUBSTANCES
cross reference: NISIN

Schedule 4

ANTIGENS

Schedule 4

ANTIHISTAMINES
cross reference: ASTEMIZOLE, AZELASTINE, BILASTINE, DESLORATADINE, FEXOFENADINE, LORATADINE, TERFENADINE, CETIRIZINE

Schedule 4
Appendix F, clause 4

ANTIMONY
cross reference: ANTIMONY COMPOUNDS, ANTIMONY CHLORIDE, ANTIMONY TITANATE

Schedule 6
Schedule 4
Appendix E, clause 3
Appendix G, clause 1

ANTISERA
cross reference: IMMUNOSERA

Schedule 4

AOD9604 (CAS No. 221231103)

Schedule 4
Appendix D, clause 5

APALUTAMIDE

Schedule 4

APIXABAN

Schedule 4

APOCYNUM spp.

Schedule 4

APOMORPHINE

Schedule 4
Appendix G, clause 1

APRACLONIDINE

Schedule 4

APRAMYCIN

Schedule 4

APREMILAST

Schedule 4

APREPITANT

Schedule 4

APRICOT KERNELS

cross reference: AMYGDALIN, HYDROCYANIC ACID

APRONAL

cross reference: ALLYLISOPROPYLACETYLUREA (CAS No. 528-92-7)

Schedule 10

APROTININ

Schedule 4

ARBUTIN (ALPHA)

cross reference: ARBUTIN (BETA); ARBUTIN (DEOXY OR OTHER DERIVATIVES)

Schedule 6

Appendix E, clause 3

Appendix F, clause 4

ARBUTIN (BETA)

cross reference: ARBUTIN (ALPHA); ARBUTIN (DEOXY OR OTHER DERIVATIVES)

Schedule 6

Schedule 4

Appendix E, clause 3

Appendix F, clause 4

ARBUTIN (DEOXY OR OTHER DERIVATIVES)

cross reference: ARBUTIN (ALPHA); ARBUTIN (BETA)

Schedule 6

Appendix E, clause 3

Appendix F, clause 4

ARECOLINE

Schedule 4

ARIPIPRAZOLE

Schedule 4
Appendix K, clause 1

ARISTOLOCHIA spp.

Schedule 10

ARISTOLOCHIC ACID(S)
cross reference: ASARUM spp, BRAGANTIA (CAS No. 313-67-7)

Schedule 10

ARPRINOCID

Schedule 7
Appendix J, clause 1

ARMODAFINIL

Schedule 4

ARSENIC
cross reference: ARSENIC TRIOXIDE, CACODYLIC ACID, TERMITE BARRIERS, COPPERCHROMEARSENIC, SELENIUM ARSENIDE, THIACETARSAMIDE

Schedule 7
Schedule 6
Schedule 4
Appendix G, clause 1
Appendix J, clause 1

ARTEMETHER

Schedule 4

ARTICAINE

Schedule 4

ASARUM spp

Schedule 10

ASCIMINIB

Schedule 4

ASENAPINE

Schedule 4
Appendix K, clause 1

ASFOTASE ALFA

Schedule 4

ASPARAGINASE

Schedule 4

ASPARTIC ACID

Appendix B, clause 3

ASPIRIN
cross reference: CAFFEINE, PARACETAMOL, SALICYLAMIDE

Schedule 6
Schedule 5
Schedule 4
Schedule 2
Appendix F, clause 4

ASTEMIZOLE

Schedule 4
Appendix F, clause 4

ASTODRIMER SODIUM

Schedule 3

Appendix F, clause 4

Appendix H, clause 1

ASULAM

Appendix B, clause 3

ASUNAPREVIR

Schedule 4

ATAMESTANE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

ATAZANAVIR

Schedule 4

ATENOLOL

Schedule 4

ATEZOLIZUMAB

Schedule 4

ATIPAMEZOLE

Schedule 4

ATOMOXETINE

Schedule 4

ATORVASTATIN

Schedule 4

ATOSIBAN

Schedule 4

ATOVAQUONE

Schedule 4

ATRACURIUM BESILATE
cross reference: ATRACURIUM BESYLATE

Schedule 4

ATRAZINE

Schedule 5

ATROPA BELLADONNA
cross reference: BELLADONNA

Schedule 4
Schedule 2
Appendix G, clause 1

ATROPINE

Schedule 4
Schedule 2
Appendix G, clause 1

ATROPINE METHONITRATE

Schedule 4

AURANOFIN

Schedule 4

AUREOBASIDIUM PULLULANS (Strains DSM14940 and DSM14941)

Appendix B

AUROTHIOMALATE SODIUM

Schedule 4

AVACOPAN

Schedule 4

AVATROMBOPAG

Schedule 4

AVELUMAB

Schedule 4

AVILAMYCIN

Schedule 4

AVIPTADIL

Schedule 4

AVOPARCIN

Schedule 4

AXITINIB

Schedule 4

AZACITIDINE

Schedule 4

AZACONAZOLE

Schedule 6

AZACYCLONOL

Schedule 4

AZADIRACHTA INDICA
cross reference: DEBITTERISED NEEM SEED OIL, NEEM

Schedule 10
Schedule 6

Schedule 5
Appendix E, clause 3
Appendix F, clause 4

AZADIRACHTA INDICA EXTRACTS

Schedule 5

AZAFENIDIN

Schedule 7

AZAMETHIPHOS

Schedule 6

AZAPERONE

Schedule 4

AZAPROPAZONE

Schedule 4

AZARIBINE

Schedule 4

AZATADINE

Appendix K, clause 1

AZATADINE

Schedule 4
Schedule 3

AZATHIOPRINE

Schedule 4

AZELAIC ACID

Schedule 4
Schedule 2

AZELASTINE

Schedule 4
Schedule 2

AZIMSULFURON

Appendix B, clause 3

AZINPHOSETHYL

Schedule 7

AZINPHOSMETHYL

Schedule 7

AZITHROMYCIN

Schedule 4

AZLOCILLIN

Schedule 4

AZOBENZENE

Schedule 6

AZOCYCLOTIN

Schedule 7
Appendix F, clause 4
Appendix J, clause 1

AZO DYES (derivatives by diazotisation)

Schedule 7
Appendix E, clause 3
Appendix F, clause 4

AZOXYSTROBIN

Schedule 5

AZTREONAM

Schedule 4

B

BACAMPICILLIN

Schedule 4

BACILLUS AMYLOLIQUEFACIENS
cross reference: BACILLUS SUBTILIS, STRAIN QST 713; BACILLUS AMYLOLIQUEFACIENS, STRAIN QST 713; BACILLUS AMYLOLIQUEFACIENS, STRAIN MBI 600

Appendix B, clause 3

BACILLUS SPHAERICUS, STRAIN 2362

Appendix B, clause 3

BACILLUS SUBTILIS, STRAIN QST 713
cross reference: BACILLUS AMYLOLIQUEFACIENS, STRAIN QST 713

BACILLUS THURINGIENSIS
cross reference: ENDOTOXIN

Appendix B, clause 3

BACILLUS THURINGIENSIS DELTA ENDOTOXIN

Schedule 5

BACILLUS TOYOI

Appendix B, clause 3

BACITRACIN

Schedule 4

BACLOFEN

Schedule 4
Appendix K, clause 1

BACTERIAL CULTURE MEDIA
cross reference: ANTIBIOTIC SUBSTANCES

Appendix A, clause 1

BACTERICIDES

Appendix A, clause 1

BACULOVIRUS CYDIA POMONELLA

Appendix B, clause 3

BALOXAVIR MARBOXIL

Schedule 4

BALSALAZIDE

Schedule 4

BAMBERMYCIN
cross reference: FLAVOPHOSPHOLIPOL

Schedule 6
Schedule 4

BAMBUTEROL

Schedule 4

BAMETHAN

Schedule 4

BAMIPINE

Schedule 4

BARBITURATES

Schedule 4

BARICITINIB

Schedule 4

BARIUM SALTS
cross reference: BARIUM METABORATE, BARIUM SULFATE

Schedule 6
Appendix E, clause 3

BARIUM SILICOFLUORIDE

Schedule 5

BASIC BLUE 26

Schedule 10
Schedule 6

BASIC ORANGE 31
cross reference: 2[(4AMINOPHENYL)AZO]1,3DIMETHYL1HIMIDAZOLIUM, CHLORIDE (CAS No. 97404-02-9)

Schedule 10
Schedule 6

BASIC RED 76 (CAS No. 68391300)
cross reference: [7HYDROXY8[(2 METHOXYPHENYL)AZO]2NAPHTHYL]TRIMETHYLAMMONIUM CHLORIDE (CAS No. 68391300)

Schedule 7
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

BASIL OIL
cross reference: METHYL CHAVICOL

Schedule 5
Appendix E, clause 3

BASILIXIMAB

Schedule 4

BATTERIES

Appendix A, clause 1

BAY OIL

Schedule 6
Appendix E, clause 3

BAZEDOXIFENE

Schedule 4

BEAUVERIA BASSIANA

Schedule 6
Schedule 5

BECAPLERMIN

Schedule 4

BECLAMIDE

Schedule 4

BECLOMETASONE
cross reference: BECLOMETHASONE

Schedule 4
Schedule 2

BECLOMETHASONE
cross reference: BECLOMETASONE

BELATACEPT

Schedule 4

BELIMUMAB

Schedule 4

BELUMOSUDIL

Schedule 4

Appendix L, clause 2

BELZUTIFAN

Schedule 4

BEMEGRIDE

Schedule 4

BENACTYZINE

Schedule 4

BENALAXYL

Schedule 5

BENAZEPRIL

Schedule 4

BENDAMUSTINE

Schedule 4

BENDIOCARB
cross reference: DENATONIUM BENZOATE

Schedule 7
Schedule 6
Schedule 5

BENDROFLUAZIDE

Schedule 4

BENETHAMINE PENICILLIN

Schedule 4

BENFLURALIN

Appendix B, clause 3

BENOMYL

Schedule 7
Appendix F, clause 4

BENORYLATE

Schedule 4

BENOXAPROFEN

Schedule 4

BENPERIDOL

Schedule 4

BENQUINOX

Schedule 6

BENRALIZUMAB

Schedule 4

BENSERAZIDE

Schedule 4

BENSULFURONMETHYL

Appendix B, clause 3

BENSULIDE

Schedule 6

BENTAZONE

Schedule 5

BENTONITE

Appendix B, clause 3

BENZALKONIUM CHLORIDE

Schedule 6
Schedule 5
Appendix E, clause 3

BENZATHINE PENICILLIN

Schedule 4

BENZENE

Schedule 7
Appendix E, clause 3
Appendix F, clause 4
Appendix J, clause 1

1,2BENZENEDIAMINE

cross reference: CAS No. 95-54-5, 1,2-BENZENEDIAMINE DIHYDROCHLORIDE (CAS No. 615-28-1)

Schedule 10

1,3BENZENEDIAMINE

cross reference: CAS No. 108-45-2

Schedule 10

1,2BENZENEDIOL
cross reference: CATECHOL

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

BENZETHIDINE

cross reference: CAS No. 3691-78-9

Schedule 9

BENZHEXOL
cross reference: TRIHEXYPHENIDYL

BENZIDINECONGENER (3,3'disubstituted) AZO DYES

Schedule 7

BENZIDINEBASED AZO DYES

Schedule 7

BENZILONIUM

Schedule 4

BENZOCAINE

Schedule 4
Schedule 2

BENZODIAZEPINE DERIVATIVES

Schedule 4
Appendix D, clause 5

BENZOFENAP

Schedule 5

BENZOVINDIFLUPYR

Schedule 6

BENZOYL PEROXIDE

Schedule 5
Schedule 4
Schedule 2
Appendix E, clause 3
Appendix F, clause 4

BENZOYLINDOLES

Schedule 9

BENZPHETAMINE

Schedule 4

BENZTHIAZIDE

Schedule 4

BENZATROPINE
cross reference: BENZITROPINE

Schedule 4
Appendix K, clause 1

BENZYDAMINE

Schedule 4
Schedule 2

6BENZYLADENINE

Schedule 6

BENZYL BENZOATE

Appendix B, clause 3

BENZYLMORPHINE

Schedule 8

BENZYLPENICILLIN

Schedule 4

BENZYLPIPERAZINE
cross reference: BZP (CAS No. 2759-28-6), BENZYLPIPERAZINE TARTRATE (CAS No. 10510-56-2), BENZYLPIPERAZINE DIHYDROCHLORIDE (CAS No. 5321-63-1)

Schedule 9

BEPHENIUM SALTS

Schedule 2

BEPRIDIL

Schedule 4

BERACTANT

Schedule 4

BERGAMOT OIL

Schedule 5
Appendix E, clause 3
Appendix F, clause 4

BERYLLIUM

Schedule 6
Appendix F, clause 4

BESIFLOXACIN

Schedule 4

BETACETYLMETHADOL

cross reference: CAS No. 17199-59-6

Schedule 9

BETACYFLUTHRIN

Schedule 7
Schedule 6
Schedule 5

BETACYPERMETHRIN

Schedule 6

BETAPHENYLGAMMAAMINOBUTYRIC ACID
cross reference: PHENIBUT

BETAHISTINE

Schedule 4

BETAHYDROXY3METHYLFENTANYL

cross reference: CAS No. 78995-14-9

Schedule 9

BETAHYDROXYFENTANYL

cross reference: CAS No. 78995-10-5

Schedule 9

BETAINE HYDROCHLORIDE

Appendix B, clause 3

BETAMEPRODINE

cross reference: CAS No. 468-50-8

Schedule 9

BETAMETHADOL

cross reference: CAS No. 17199-55-2

Schedule 9

BETAMETHASONE

Schedule 4

1(BETAMETHYL SULPHONAMIDOETHYL) 2AMINO3

Appendix F, clause 4

BETAPRODINE

cross reference: CAS No. 468-59-7

Schedule 9

BETAXOLOL

Schedule 4

BETHANECHOL CHLORIDE

Schedule 4

BETHANIDINE

Schedule 4

BEVACIZUMAB

Schedule 4

BEVANTOLOL

Schedule 4

BEXAROTENE

Schedule 4
Appendix D, clause 2
Appendix F, clause 4
Appendix L, clause 2

BEZAFIBRATE

Schedule 4

BEZITRAMIDE

Schedule 8

BEZLOTOXUMAB

Schedule 4

BHC

Schedule 6

BICALUTAMIDE

Schedule 4

BICTEGRAVIR

Schedule 4

BICYCLOPYRONE

Schedule 6
Schedule 5

BIFENAZATE

Appendix B, clause 3

BIFENTHRIN

Schedule 7
Schedule 6

BIFLUORIDES
cross reference: AMMONIUM BIFLUORIDE, AMMONIUM SALTS, POTASSIUM SALTS, SODIUM SALTS

Schedule 7
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4
Appendix J, clause 1

BIFONAZOLE

Schedule 4
Schedule 2

BILASTINE

Schedule 4
Schedule 3
Appendix H, clause 1

BIMATOPROST

Schedule 4

BINIMETINIB

Schedule 4

BIOALLETHRIN

Schedule 6
Schedule 5

BIORESMETHRIN

Schedule 5

BIPERIDEN

Schedule 4

1,3BIS(2,4DIAMINOPHENOXY)PROPANE

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

BISISOBUTYL PEG/PPG20/35/AMODIMETICONE COPOLYMER

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

BISMUTH COMPOUNDS
cross reference: BISMUTH CITRATE, BISMUTH FORMIC IODIDE, BISMUTH OXYCHLORIDE, BISMUTH SUBIODIDE

Schedule 4

BISMUTH SUBNITRATE

Appendix B, clause 3

BISOPROLOL

Schedule 4

N,NBIS(PHENYLMETHYLENE)BICYCLO(2.2.1)HEPTANE2,5DIMETHANAMINE
cross reference: N,NBIS(PHENYLMETHYLENE)BICYCLO(2.2.1)HEPTANE2,6DIMETHANAMINE

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

N,NBIS(PHENYLMETHYLENE)BICYCLO(2.2.1)HEPTANE2,6DIMETHANAMINE
cross reference: N,NbIS(PHENYLMETHYLENE)BICYCLO(2.2.1)HEPTANE2,6DIMETHANAMINE

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

BISPYRIBAC

Schedule 5

BISTRIFLURON

Appendix B, clause 3

BITHIONOL

cross reference: CAS No. 97-18-7

Schedule 10
Schedule 6
Appendix F, clause 4

BIURET

Appendix B, clause 3

BIVALIRUDIN

Schedule 4

BIXAFEN

Schedule 5

BIXLOZONE

Appendix B, clause 3

BLAD (banda de Lupinus albus doce)

Appendix B, clause 3

BLEOMYCIN

Schedule 4

BLINATUMOMAB

Schedule 4

BOCEPREVIR

Schedule 4

BOLANDIOL

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

BOLASTERONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

BOLAZINE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

BOLDENONE
cross reference: DEHYDROTESTOSTERONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

BOLENOL

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

BOLMANTALATE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

BORAGO OFFICINALIS
cross reference: BORAGE

Schedule 10

BORIC ACID
cross reference: BORAX, SODIUM BORATE, POTASSIUM BORATE, MEABORATE, MIPABORATE

Schedule 5

Schedule 4
Appendix E, clause 3
Appendix F, clause 4

BORON
cross reference: BORATES, BORAX, BORIC ACID, BORON COMPOUNDS

Schedule 4

BORON TRIFLUORIDE

Schedule 7
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4
Appendix J, clause 1

BORTEZOMIB

Schedule 4

BOSCALID

Appendix B, clause 3

BOSENTAN

Schedule 4
Appendix D, clause 6
Appendix F, clause 4
Appendix L, clause 2

BOSUTINIB

Schedule 4

BOTULINUM TOXINS

Schedule 4

BOVINE SOMATOTROPHIN

Appendix B, clause 3

BRAGANTIA spp

Schedule 10

BRENTUXIMAB VEDOTIN

Schedule 4

BRETYLIUM TOSILATE

Schedule 4

BRETYLIUM TOSYLATE

cross reference: BRETYLIUM TOSILATE

BREXPIPRAZOLE

Schedule 4
Appendix K, clause 1

BRIGATINIB

Schedule 4

BRIMONIDINE

Schedule 4
Schedule 2

BRINZOLAMIDE

Schedule 4

BRIVARACETAM

cross reference: RACETAMS

Schedule 4
Appendix K, clause 1

BRODIFACOUM

Schedule 7
Schedule 6
Appendix J, clause 1

BROFLANILIDE

Schedule 6
Schedule 5

BROMACIL

Appendix B, clause 3

BROMADIOLONE

Schedule 7
Schedule 6

Appendix J, clause 1

BROMAZEPAM

Schedule 4
Appendix D, clause 5 (benzodiazepine derivatives)
Appendix K, clause 1

BROMETHALIN

Schedule 7
Schedule 6

BROMHEXINE

Schedule 2

BROMIDES

Schedule 4

BROMINE

Schedule 7
Appendix J, clause 1

1(8BROMOBENZO[1,2B;4,5B]DIFURAN4YL)2AMINOPROPANE
cross reference: BROMODRAGONFLY (CAS No. 502759-67-3)

Schedule 9

BROMOCRIPTINE

Schedule 4

4BROMO2,5DIMETHOXYPHENETHYLAMINE 
cross reference: BDMPEA (CAS No. 66142-81-2)

Schedule 9

BROMOFORM

Schedule 6
Schedule 4
Appendix E, clause 3
Appendix F, clause 4

BROMOPHOS

Schedule 6

BROMOPHOSETHYL

Schedule 6

BROMOPROPYLATE

Appendix B, clause 3

BROMOXYNIL

Schedule 6

BROMPHENIRAMINE

Schedule 4
Schedule 3
Schedule 2
Appendix K, clause 1

BROMUCONAZOLE

Schedule 6

Schedule 5

BROMVALETONE

Schedule 4

BROTIANIDE

Schedule 6

BRUCINE

Schedule 7
Appendix E, clause 3
Appendix J, clause 1

BRUGMANSIA spp.

Schedule 4

BUCLIZINE

Schedule 4
Schedule 3

Appendix K, clause 1

BUCLOSAMIDE

cross reference: CAS No. 575-74-6

Schedule 10

BUDESONIDE

Schedule 4
Schedule 2

BUFEXAMAC

Schedule 4

BUFOTENINE

cross reference: CAS No. 487-93-4

Schedule 9

BUMETANIDE

Schedule 4

BUNAMIDINE

Schedule 6

BUNIODYL SODIUM

cross reference: CAS No. 1923-76-8, BUNIODYL BASE (CAS No. 1233-53-0)

Schedule 10

BUPHENINE

Schedule 4

BUPIRIMATE

Appendix B, clause 3

BUPIVACAINE

Schedule 5
Schedule 4

BUPRENORPHINE

Schedule 8
Appendix K, clause 1

BUPROFEZIN

Schedule 5

BUPROPION
cross reference: AMFEBUTAMONE

Schedule 4

BUSERELIN

Schedule 4

BUSPIRONE

Schedule 4

BUSULPHAN

Schedule 4

BUTACAINE

Schedule 4

BUTACARB

Schedule 6

BUTAFENACIL

Appendix B, clause 3

BUTAMBEN
cross reference: BUTYL AMINOBENZOATE

Schedule 4

1,4BUTANEDIOL

cross reference: CAS No. 110-63-4

Schedule 10

BUTHIDAZOLE

Schedule 5

BUTOBARBITAL

Schedule 8
Appendix K, clause 1

BUTOBARBITONE
cross reference: BUTOBARBITAL

BUTOCONAZOLE

Schedule 4
Schedule 3
Appendix H, clause 1

BUTONITAZENE

cross reference: CAS No. 95810-54-1

Schedule 9

BUTORPHANOL

Schedule 8

BUTOXYCARBOXIM

Schedule 6
Schedule 5

2BUTOXYETHANOL

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

BUTOXYPOLYPROPYLENE GLYCOL

Appendix B, clause 3

2BUTOXY2'THIOCYANODIETHYL ETHER

Schedule 6
Appendix F, clause 4

BUTRACONAZOLE

Schedule 4

BUTRALIN

Schedule 5

BUTROXYDIM

Schedule 5

nBUTYL ALCOHOL

Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

BUTYL AMINOBENZOATE
cross reference BUTAMBEN

BUTYL BENZYL PHTHALATE

cross reference: CAS No. 85-68-7

Schedule 10

nBUTYL BUTYRATE

Appendix B, clause 3

nBUTYL LACTATE

Appendix B, clause 3

BUTYL NITRITE

Schedule 4
Appendix E, clause 3

BUTYLCHLORAL HYDRATE

Schedule 4

BUTYRIC ACID

Schedule 6

C

CABAZITAXEL

Schedule 4

CABERGOLINE

Schedule 4

CABOTEGRAVIR

Schedule 4

CABOZANTINIB

Schedule 4

CACALIA spp.

Schedule 10

CACODYLIC ACID

Schedule 7
Schedule 6

CADMIUM COMPOUNDS
cross reference: CADMIUM, CADMIUM ACETATE, CADMIUM CHLORIDE, CADMIUM NITRATE

Schedule 6
Schedule 4
Appendix E, clause 3

CADUSAFOS

Schedule 7
Schedule 6

CAFFEINE
cross reference: PARACETAMOL, ASPIRIN, SALICYLAMIDE

Schedule 6
Schedule 4

CAJUPUT OIL

Schedule 6
Appendix E, clause 3

CALCIFEDIOL

Schedule 4

CALCIFEROL

Schedule 7
Schedule 6
Appendix J, clause 1

CALCIPOTRIOL

Schedule 4

CALCITONIN SALMON

Schedule 4

CALCITRIOL

Schedule 4

CALCIUM CARBIMIDE

Schedule 4

CALCIUM HYDROXYLAPATITE

Schedule 4

CALCIUM POLYSTYRENE SULPHONATE

Schedule 4

CALOTROPIS GIGANTEA

Schedule 4

CALOTROPIS PROCERA

Schedule 4

CALUSTERONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

CAMBENDAZOLE

Schedule 6

CAMPHOR
cross reference: ESSENTIAL OILS, LAVANDIN OIL, ROSEMARY OIL, SHUI OIL

Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

CAMPHORATED OIL

Schedule 4

CAMPHOTAMIDE

Schedule 4

CANAGLIFLOZIN

Schedule 4

CANAKINUMAB

Schedule 4

CANDESARTAN CILEXETIL

Schedule 4

CANDICIDIN

Schedule 4

CANINE TICK ANTISERUM

Schedule 4

CANNABICHROMENE
cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS

CANNABIDIOL
cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS

Schedule 4
Schedule 3
Appendix F, clause 4

CANNABIDIOLIC ACID
cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS

CANNABIDIVAROL
cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS

CANNABIGEROL
cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS

CANNABINOIDS
cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS

CANNABINOL
cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS

CANNABIS
cross reference: CANNABIS SATIVA, HEMP, HEMP SEED OIL, TETRAHYDROCANNABINOLS

Schedule 9
Schedule 8
Appendix D, clause 1
Appendix K, clause 1

CANTHARIDIN

Schedule 4
Appendix G, clause 1

CAPECITABINE

Schedule 4

CAPREOMYCIN

Schedule 4

CAPTAFOL

Schedule 7
Appendix J, clause 1

CAPTAN

Schedule 6

CAPTODIAME

Schedule 4

CAPTOPRIL

Schedule 4

CAPURIDE

Schedule 4

CARAMIPHEN

Schedule 4

CARBACHOL

Schedule 4

CARBADOX

Schedule 7
Appendix J, clause 1

CARBAMAZEPINE

Schedule 4

CARBAMIDE PEROXIDE

cross reference: CAS No. 124-43-6

Schedule 10
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

CARBARYL

Schedule 6
Schedule 5
Schedule 4

CARBAZOCHROME

Schedule 4

CARBENDAZIM

Schedule 7

CARBENICILLIN

Schedule 4

CARBENOXOLONE

Schedule 4

CARBETAMIDE

Schedule 6

CARBETAPENTANE

Schedule 2

CARBETOCIN

Schedule 4

CARBIDOPA

Schedule 4

CARBIMAZOLE

Schedule 4

CARBOCISTEINE

Schedule 2

CARBOCROMEN

Schedule 4

CARBOFURAN

Schedule 7

CARBON DISULFIDE

Schedule 6
Appendix E, clause 3

CARBON TETRACHLORIDE

Schedule 7
Appendix E, clause 3
Appendix F, clause 4
Appendix J, clause 1

CARBONYL SULFIDE

Schedule 7

Appendix J, clause 1

CARBOPHENOTHION

Schedule 7

CARBOPLATIN

Schedule 4

CARBOPROST

Schedule 4

CARBOSULFAN

Schedule 7

CARBOXIN

Appendix B, clause 3

CARBROMAL

Schedule 4

CARBUTAMIDE

Schedule 4

CARBUTEROL

Schedule 4

CARDARINE

cross reference: CAS No. 317318-70-0

Schedule 10

CARFENTANYL

Schedule 8

CARFENTRAZONEETHYL

Appendix B, clause 3

CARFILZOMIB.

Schedule 4

CARGLUMIC ACID

Schedule 4

CARINDACILLIN

Schedule 4

CARIPRAZINE

Schedule 4

CARISOPRODOL

Schedule 4

CARMUSTINE

Schedule 4

CARNIDAZOLE

Schedule 4

CARPROFEN

Schedule 4

CARVEDILOL

Schedule 4

CASIRIVIMAB

Schedule 4

CASPOFUNGIN

Schedule 4

CASSIA OIL

Schedule 5
Appendix E, clause 3
Appendix F, clause 4

CASTOR OIL, MONOMALEATE

Schedule 6

CATHINE

Schedule 4

CATHINONES
cross reference: SYNTHETIC CATHINONES

Schedule 9

CATUMAXOMAB

Schedule 4

CEDAZURIDINE

Schedule 4

CEFACETRILE
cross reference: CEPHACETRILE

Schedule 4

CEFACLOR

Schedule 4

CEFADROXIL

Schedule 4

CEFALEXIN
cross reference: CEPHALEXIN

Schedule 4

CEFALORIDINE
cross reference: CEPHALORIDINE

Schedule 4

CEFALOTIN
cross reference: CEPHALOTHIN, CEFALOTHIN

Schedule 4

CEFAMANDOLE
cross reference: CEPHAMANDOLE

Schedule 4

CEFAPIRIN
cross reference: CEPHAPIRIN

Schedule 4

CEFAZOLIN
cross reference: CEPHAZOLIN

Schedule 4

CEFEPIME

Schedule 4

CEFETAMET

Schedule 4

CEFIXIME

Schedule 4

CEFODIZIME

Schedule 4

CEFONICID

Schedule 4

CEFOPERAZONE

Schedule 4

CEFOTAXIME

Schedule 4

CEFOTETAN

Schedule 4

CEFOTIAM

Schedule 4

CEFOVECIN

Schedule 4

CEFOXITIN

Schedule 4

CEFPIROME

Schedule 4

CEFPODOXIME

Schedule 4

CEFQUINOME

Schedule 4

CEFSULODIN

Schedule 4

CEFTAROLINE FOSAMIL

Schedule 4

CEFTAZIDIME

Schedule 4

CEFTIBUTEN

Schedule 4

CEFTIOFUR

Schedule 4

CEFTRIAXONE

Schedule 4

CEFUROXIME

Schedule 4

CELECOXIB

Schedule 4

CELIPROLOL

Schedule 4

CELLULASE derived from Aspergillus niger

Appendix B, clause 3

CENEGERMIN

Schedule 4

CEPHAELIS ACUMINATA
cross reference: IPECACUANHA, CARAPICHEA IPECACUANHA

Schedule 4

CEPHAELIS IPECACUANHA
cross reference: IPECACUANHA, CARAPICHEA IPECACUANHA

Schedule 4

CEPHALEXIN
cross reference: CEFALEXIN

CEPHALONIUM

Schedule 4

CEPHALOTHIN
cross reference: CEFALOTIN

CEPHRADINE

Schedule 4

CERAMICS

Appendix A, clause 1

CERITINIB

Schedule 4

CERIVASTATIN

Schedule 4

CERLIPONASE ALFA

Schedule 4

CERTOLIZUMAB PEGOL

Schedule 4

CERULETIDE

Schedule 4

CETIRIZINE

Schedule 4
Schedule 2
Appendix K, clause 1

CETRORELIX

Schedule 4

CETUXIMAB

Schedule 4

CETYL ALCOHOL

Appendix B, clause 3

CHAMOMILE OIL

Appendix B, clause 3

CHEMISTRY SETS

Appendix A, clause 1

CHENODEOXYCHOLIC ACID

Schedule 4

CHINA CLAY

Appendix B, clause 3

CHLOPHEDIANOL

Schedule 2

CHLORAL FORMAMIDE

Schedule 4

CHLORAL HYDRATE

Schedule 4
Appendix K, clause 1

CHLORALOSE
cross reference: ALPHACHLORALOSE

Schedule 6
Schedule 4

CHLORAMBUCIL

Schedule 4

CHLORAMPHENICOL

Schedule 4
Schedule 3

CHLORANDROSTENOLONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

CHLORANTRANILIPROLE

Appendix B, clause 3

CHLORAZANIL

Schedule 4

CHLORBUTANOL

Schedule 3
Schedule 2

CHLORBUTOL
cross reference: CHLOROBUTANOL

CHLORCYCLIZINE

Schedule 4

CHLORDANE

Schedule 6

CHLORDECONE

Schedule 7
Appendix J, clause 1

CHLORDIAZEPOXIDE

Schedule 4
Appendix D, clause 5 (benzodiazepine derivative)
Appendix K, clause 1

CHLORDIMEFORM

Schedule 7
Appendix J, clause 1

CHLORFENAC

Schedule 5

CHLORFENAPYR

Schedule 7
Schedule 6
Schedule 5

CHLORFENETHOL

Schedule 6

CHLORFENSON

Schedule 5

CHLORFENVINPHOS

Schedule 7

CHLORFLUAZURON

Appendix B, clause 3

CHLORFLURENOL

Appendix B, clause 3

CHLORHEXIDINE

Schedule 7
Schedule 6
Schedule 5

CHLORIDAZON

Appendix B, clause 3

CHLORIDE

Appendix E, clause 3

CHLORINATING COMPOUNDS
cross reference: BLEACHES, BROMOCHLORODIMETHYLHYDANTOIN, TRICHLOROISOCYANURIC ACID, CALCIUM HYPOCHLORITE, CHLORINE, DICHLOROETHYL ETHER, SODIUM HYPOCHLORITE

Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4
Appendix J, clause 1

CHLORINE
cross reference: CHLORINATING COMPOUNDS, DICHLOROISOCYANURATES, DICHLOROISOCYANURIC ACID

Schedule 7
Appendix G, clause 1
Appendix J, clause 1

CHLORMEQUAT

Schedule 6

CHLORMERODRIN

Schedule 4

CHLORMETHIAZOLE

Schedule 4
Appendix K, clause 1

CHLORMEZANONE

Schedule 4

CHLORNIDINE

Schedule 5

CHLOROACETAMIDE

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

CHLOROCRESOL

Schedule 5
Appendix E, clause 3

2CHLORO6(ETHYLAMINO)4NITROPHENOL

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

CHLOROFORM

Schedule 6
Schedule 4
Schedule 2
Appendix E, clause 3
Appendix F, clause 4

4CHLOROMETHANDIENONE

Schedule 4
Appendix D, clause D (Anabolic and/or androgenic steroidal agents)

CHLOROMETHIURON

Schedule 7
Appendix J, clause 1

5CHLORO3METHYL4NITROPYRAZOLE

Schedule 7

2CHLORO5NITRONHYDROXYETHYLpPHENYLENEDIAMINE
cross reference: PHENYLENEDIAMINES

CHLOROPHACINONE

Schedule 6

2(4CHLOROPHENYL)(1,2,4)TRIAZOLO[5,1A]ISOQUINOLINE

Schedule 4

CHLOROPICRIN

Schedule 7
Schedule 6

CHLOROPICRIN

Appendix J, clause 1

CHLOROQUINE

Schedule 4

CHLOROTHALONIL

Schedule 6

CHLOROTHIAZIDE

Schedule 4

4CHLOROoTOLUIDINE

Schedule 7
Appendix J, clause 1

CHLOROTRIANISENE

Schedule 4

2CHLORO6(TRICHLOROMETHYL)PYRIDINE

Schedule 6

CHLOROXYDIENONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

CHLOROXYLENOLS

Appendix B, clause 3

CHLORPHENAMINE
cross reference: CHLORPHENIRAMINE

Schedule 4
Schedule 3
Schedule 2
Appendix K, clause 1

CHLORPHENIRAMINE
cross reference: CHLORPHENAMINE

CHLORPHENTERMINE

Schedule 4

CHLORPROMAZINE

Schedule 4
Appendix K, clause 1

CHLORPROPAMIDE

Schedule 4

CHLORPROPHAM

Schedule 5

CHLORPROTHIXENE

Schedule 4

CHLORPYRIFOS

Schedule 6
Schedule 5

CHLORPYRIFOSMETHYL

Schedule 6

CHLORQUINALDOL

Schedule 4

CHLORSULFURON

Schedule 5

CHLORTALIDONE

Schedule 4

CHLORTETRACYCLINE

Schedule 5
Schedule 4

CHLORTHALDIMETHYL

Schedule 5

CHLORTHALIDONE
cross reference: CHLORTALIDONE

CHLORTHIAMID

Schedule 6

CHLORTHIOPHOS

Schedule 7

CHLORZOXAZONE

Schedule 4

CHOLECALCIFEROL
cross reference: COLECALCIFEROL

Schedule 7
Appendix J, clause 1

CHOLERA VACCINE

Schedule 4

CHOLESTYRAMINE
cross reference: COLESTYRAMINE

CHOLIC ACID

Schedule 4

CHOLINE SALICYLATE

Schedule 2

CHROMATES
cross reference: AMMONIUM CHROMATE, BARIUM CHROMATE, CHROMIUM, COPPERCHROMEARSENIC, DICHROMATES, POTASSIUM CHROMATE, ZINC CHROMATE SODIUM CHROMATE, STRONTIUM CHROMATE

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

CHROMIUM TRICHLORIDE HEXAHYDRATE

Schedule 6

CHROMIUM TRIOXIDE
cross reference: CHROMIC ACID

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

CHRYSOIDINE BASE

cross reference: CAS No. 495-54-5

Schedule 10
Schedule 6
Appendix E, clause 3

CHYMOPAPAIN

Schedule 4

CICLACILLIN

Schedule 4

CICLESONIDE

Schedule 4

CICLOPIROX

Schedule 4
Schedule 3
Schedule 2
Appendix H, clause 1

CICLOSPORIN

Schedule 4

CIDOFOVIR

Schedule 4

CILASTATIN

Schedule 4

CILAZAPRIL

Schedule 4

CILGAVIMAB

Schedule 4

CILOSTAZOL

Schedule 4

CIMETIDINE

Schedule 4
Schedule 3
Appendix F, clause 4

CIMICOXIB

Schedule 4

CINACALCET

Schedule 4

CINCHOCAINE

Schedule 4
Schedule 2

CINCHOPHEN

cross reference: CAS No. 132-60-5, CINCHOPHEN HYDROCHLORIDE (CAS No. 132-58-1), CINCHOPHEN SODIUM (CAS No. 5949-18-8)

Schedule 10

CINEOLE
cross reference: CAMPHOR OIL (white), ROSEMARY OIL

Schedule 7
Appendix E, clause 3

CINMETHYLIN

Schedule 5

CINNAMEDRINE

Schedule 2

CINNAMON BARK OIL

Schedule 5
Appendix E, clause 3
Appendix F, clause 4

CINNAMON LEAF OIL

Schedule 6
Appendix E, clause 3

CINNARIZINE

Schedule 4

CINOXACIN

Schedule 4

CIPROFLOXACIN

Schedule 4

CISAPRIDE

Schedule 4

CISATRACURIUM BESILATE
cross reference: CISATRACURIUM BESYLATE

Schedule 4

CISJASMONE
cross reference: (Z)JASMONE

Schedule 5

CISPLATIN

Schedule 4

CITALOPRAM

Schedule 4

CITRONELLA OIL

Appendix B, clause 3

CJC1295 (CAS No. 863288340)

Schedule 4
Appendix D, clause 5

CLADRIBINE

Schedule 4

CLANOBUTIN

Schedule 4

CLARITHROMYCIN

Schedule 4

CLARY SAGE OIL

Appendix B, clause 3

CLAVULANIC ACID

Schedule 4

CLEMASTINE

Schedule 4
Schedule 3
Appendix K, clause 1

CLEMIZOLE

Schedule 4

CLENBUTEROL

Schedule 4

CLETHODIM

Schedule 5

CLEVIDIPINE

Schedule 4

CLIDINIUM BROMIDE

Schedule 4

CLIMBAZOLE

Schedule 6
Schedule 5
Appendix E, clause 3

CLINDAMYCIN

Schedule 4

CLIOQUINOL
cross reference: OXYQUINOLINE, CHLORQUINALDOL, HALQUINOL (CAS No. 130-26-7)

Schedule 10
Schedule 4

CLITORIA TERNATEA EXTRACT

Appendix B, clause 3

CLOBAZAM

Schedule 4

CLOBETASOL

Schedule 4

CLOBETASONE

Schedule 4
Schedule 3
Appendix F, clause 4

Appendix H, clause 1

CLOCORTOLONE

Schedule 4

CLODINAFOPPROPARGYL

Schedule 6

CLODRONIC ACID
cross reference: SODIUM CLODRONATE

Schedule 4

CLOFARABINE

Schedule 4

CLOFAZIMINE

Schedule 4

CLOFENAMIDE

Schedule 4

CLOFENTEZINE

Schedule 5

CLOFIBRATE

Schedule 4

CLOMAZONE

Schedule 6

CLOMIFENE
cross reference: CLOMIPHENE

Schedule 4
Appendix D, clause 1

CLOMIPHENE
cross reference: CLOMIFENE

CLOMIPRAMINE

Schedule 4
Appendix K, clause 1

CLOMOCYCLINE

Schedule 4

CLONAZEPAM

Schedule 4
Appendix D, clause 5 (benzodiazepine derivatives)
Appendix K, clause 1

CLONAZOLAM

cross reference: CAS No. 33887-02-4

Schedule 9

CLONIDINE

Schedule 4
Appendix K, clause 1

CLONITAZENE

cross reference: CAS No. 3861-76-5

Schedule 9

CLOPAMIDE

Schedule 4

CLOPIDOGREL

Schedule 4

CLOPIDOL

Appendix B, clause 3

CLOPROSTENOL

Schedule 4

CLOPYRALID

Schedule 5

CLOQUINTOCET

Schedule 5

CLORAZEPATE

Schedule 4
Appendix D, clause 5 (benzodiazepine derivatives)
Appendix K, clause 1

CLOREXOLONE

Schedule 4

CLORPRENALINE

Schedule 4

CLORSULON

Schedule 5

CLOSANTEL

Schedule 6

CLOSTEBOL
cross reference: 4CHLOROTESTOSTERONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

CLOTHIANIDIN

Schedule 6
Schedule 5

CLOTRIMAZOLE

Schedule 6
Schedule 4
Schedule 3
Schedule 2
Appendix F, clause 4
Appendix H, clause 1

CLOVE OIL

Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

CLOXACILLIN

Schedule 4

CLOZAPINE

Schedule 4
Appendix D, clause 1
Appendix K, clause 1

COAL TAR

Schedule 10

COBALT
cross reference: DICOBALT EDETATE

Schedule 4

COBALT NAPHTHENATE

Appendix B, clause 3

COBICISTAT

Schedule 4

COBIMETINIB

Schedule 4

COCA LEAF

Schedule 9

COCAINE

Schedule 8

NCOCO1,3DIAMINOPROPANE

Schedule 6

COCOYL GLYCINATE

Schedule 6
Appendix E, clause 3

COCOYL METHYL GLUCAMAIDE
cross reference: 1DEOXY1(METHYLAMINO)DGLUCITOL NCOCO ACYL DERIVATIVES

CODEINE

Schedule 8
Schedule 4
Appendix K, clause 1

CODEINENOXIDE

Schedule 8

CODERGOCRINE

Schedule 4

CODOXIME

cross reference: CAS No. 7125-76-0

Schedule 9

COLASPASE
cross reference: ASPARAGINASE

COLCHICINE

Schedule 4

COLCHICUM AUTUMNALE

Schedule 4

COLECALCIFEROL
cross reference: CHOLECALCIFEROL

Schedule 7
Appendix J, clause 1

COLESTIPOL

Schedule 4

COLESTYRAMINE

Schedule 4

COLFOSCERIL PALMITATE

Schedule 4

COLISTIN

Schedule 4

COLLAGEN

Schedule 4

COLLAGENASE CLOSTRIDIUM HISTOLYTICUM

Schedule 4

COLURACETAM
cross reference: RACETAMS

Schedule 4

CONCENTRATE OF POPPY STRAW

Schedule 8

CONCIZUMAB

Schedule 4

CONIUM MACULATUM
cross reference: CONIINE (CAS No. 3238-60-6), CONIINE R-ISOMER (CAS No. 5985-99-9), CONIINE S-ISOMER (CAS No. 458-88-8)

Schedule 10

CONVALLARIA KEISKI

Schedule 4

CONVALLARIA MAJALIS

Schedule 4

COPPER ACETATE

Schedule 6
Schedule 5

COPPER COMPOUNDS
cross reference: COPPER

Schedule 6
Schedule 5
Schedule 4
Appendix A, clause 1

COPPER HYDROXIDE

Schedule 6
Schedule 5

COPPER NITRATE
cross reference: COPPER CHLORIDE

Schedule 6

COPPER OXIDES

Schedule 6
Schedule 5

COPPER OXYCHLORIDE

Schedule 6
Schedule 5

COPPER SULFATE

Schedule 6
Schedule 5
Appendix E, clause 3

CORIFOLLITROPIN ALFA
cross reference: FOLLICLE STIMULANT, RECOMBINANT

Schedule 4
Appendix D, clause 1

CORONILLA spp.

Schedule 4

CORTICOSTERONE

Schedule 4

CORTICOTROPHIN

Schedule 4

CORTISONE

Schedule 4

COTARNINE

cross reference: CAS No. 82-54-2, COTARNINE HYDROCHLORIDE (CAS No. 36647-02-6), COTARNINE CHLORIDE (CAS No. 10018-19-6)

Schedule 10

COTRIMOXAZOLE

Schedule 4

COUMAPHOS

Schedule 7
Schedule 6

COUMARIN

Schedule 4

COUMATETRALYL

Schedule 7
Schedule 6
Schedule 5
Appendix J, clause 1

4CPA

Schedule 5

CREOSOTE
cross reference: BEECHWOOD, PHENOL, WOOD

Schedule 7
Schedule 6
Schedule 2
Appendix E, clause 3

CRESOLS

Appendix E, clause 3

CRISABOROLE

Schedule 4

CRIZOTINIB

Schedule 4

CROFELEMER

Schedule 4

CROSPOVIDONE

Appendix B, clause 3

CROTALARIA spp.

Schedule 10

CROTON TIGLIUM
cross reference: CROTON OIL

Schedule 10
Appendix G, clause 1

CROTOXYPHOS

Schedule 6

CRUFOMATE

Schedule 6

CRYSTAL VIOLET
cross reference: METHYLROSANILINIUM CHLORIDE, GENTIAN VIOLET

CULICINOMYCES CLAVOSPORUS

Appendix B, clause 3

CUPRIMYXIN

Schedule 4

CURARE

Schedule 4

13CUREA

Appendix B, clause 3

CYANAMIDE

Schedule 6

CYANATRYN

Schedule 5

CYANAZINE

Schedule 6

CYANIDES
cross reference: FERRICYANIDES, FERROCYANIDES

Schedule 7
Appendix E, clause 3
Appendix F, clause 4

CYANOACRYLATE ESTERS

Schedule 5

CYANOACRYLIC ACID ESTERS

Appendix E, clause 3

4CYANO2DIMETHYLAMINO4,4'DIPHENYLBUTANE
cross reference: METHADONE INTERMEDIATE (CAS No. 125-79-1)

Schedule 9

CYANOGEN
cross reference: ETHANEDINITRILE, OXALONITRILE

Schedule 7
Appendix J, clause 1

4CYANO1METHYL4PHENYLPIPERIDINE
cross reference: PETHIDINE INTERMEDIATE A

Schedule 8

CYANTRANILIPROLE

Schedule 5

CYANURIC ACID

Schedule 5
Appendix E, clause 3
Appendix F, clause 4

CYAZOFAMID

Schedule 5

CYCLAMIC ACID

Appendix B, clause 3

CYCLANDELATE

Schedule 4

CYCLANILIDE

Schedule 6

CYCLANILIPROLE

Appendix B

CYCLIZINE

Schedule 4
Schedule 3
Appendix K, clause 1

CYCLOBARBITAL

Schedule 8
Appendix K, clause 1

CYCLOBARBITONE
cross reference: CYCLOBARBITAL

CYCLOBENZAPRINE

Schedule 4

CYCLOBUTRIFLURAM

Appendix B, clause 3

CYCLOFENIL

Schedule 4
Appendix D, clause 1

CYCLOHEXANE

Appendix B, clause 3

CYCLOHEXANOL ACETATE

Appendix B, clause 3

CYCLOHEXANONE PEROXIDE

Schedule 5
Appendix E, clause 3
Appendix F, clause 4

CYCLOHEXIMIDE

Schedule 4

NCYCLOHEXYLDIAZENIUMDIOXYPOTASSIUM
cross reference: KHDO

Schedule 6

CYCLOHEXYLPHENOLS

Schedule 9

CYCLOPENTHIAZIDE

Schedule 4

CYCLOPENTOLATE

Schedule 4

CYCLOPHOSPHAMIDE

Schedule 4

CYCLOPROPANE

Schedule 4

CYCLOPROTHRIN

Schedule 5

CYCLOSERINE

Schedule 4
Appendix J, clause 1

CYCLOSILAZANES, DIME, ME HYDROGEN, POLYMERS WITH DIME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3(TRIETHOXYSILYL)1PROPANAMINE (CAS 475645842)

Schedule 7
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

CYCLOSPORIN
cross reference: CICLOSPORIN

CYCLOTHIAZIDE

Schedule 4

CYCLOXYDIM

Schedule 5

CYCRIMINE

Schedule 4
Appendix E, clause 3
Appendix F, clause 4

CYFLUFENAMID

Schedule 5

CYFLUMETOFEN

Schedule 5

CYFLUTHRIN

Schedule 6
Schedule 5

CYHALOFOPBUTYL

Schedule 5

CYHALOTHRIN

Schedule 7

CYHEXATIN

Schedule 7

CYMARIN

Schedule 4

CYMIAZOLE

Schedule 5

CYNOGLOSSUM spp.

Schedule 10

CYOMETRINIL

Schedule 6

CYPERMETHRIN
cross reference: ALPHACYPERMETHRIN AND BETACYPERMETHRIN, ZETACYPERMETHRIN

Schedule 6
Schedule 5

CYPHENOTHRIN

Schedule 6
Schedule 5

CYPRINID HERPESVIRUS3

Appendix B, clause 3

CYPROCONAZOLE

Schedule 5

CYPRODINIL

Schedule 5

CYPROHEPTADINE

Schedule 4
Schedule 3
Appendix K, clause 1

CYPROTERONE

Schedule 4

CYROMAZINE

Appendix B, clause 3

CYSTEAMINE
cross reference: MERCAPTAMINE

CYTARABINE

Schedule 4

CYTHIOATE

Schedule 6
Schedule 5

D

2,4D

Schedule 6
Schedule 5

DABIGATRAN

Schedule 4

DABRAFENIB MESILATE

Schedule 4

DACARBAZINE

Schedule 4

DACLATASVIR

Schedule 4

DACLIZUMAB

Schedule 4

DACTINOMYCIN

Schedule 4

DALFOPRISTIN

Schedule 4

DALTEPARIN

Schedule 4

DAMINOZIDE

Schedule 5

DANAPAROID

Schedule 4

DANAZOL

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

DANTHRON

Schedule 4

DANTROLENE

Schedule 4

Appendix K, clause 1

DAPAGLIFLOZIN

Schedule 4

DAPOXETINE

Schedule 4

DAPSONE

Schedule 4

DAPTOMYCIN

Schedule 4

DARATUMUMAB

Schedule 4

DARBEPOETIN

Schedule 4
Appendix D, clause 5

DARIFENACIN

Schedule 4

DAROLUTAMIDE

Schedule 4

DARUNAVIR

Schedule 4

DASABUVIR

Schedule 4

DASATINIB

Schedule 4

DATURA spp.

Schedule 4
Schedule 2

DATURA STRAMONIUM
cross reference: STRAMONIUM

Schedule 4
Schedule 2

DATURA TATULA
cross reference: STRAMONIUM

Schedule 4
Schedule 2

DAUNORUBICIN

Schedule 4

DAZOMET

Schedule 6

2,4DB

Schedule 5

DEANOL
cross reference: 2(DIMETHYLAMINO)ETHANOL, DMEA, DIMETHYL MEA

Schedule 4

DEBRISOQUINE

Schedule 4

DECAMETHONIUM

Schedule 4

DECITABINE

Schedule 4

DECOQUINATE

Schedule 5

DEFERASIROX

Schedule 4

DEFERIPRONE

Schedule 4

DEFIBROTIDE

Schedule 4

DEFLAZACORT

Schedule 4

DEGARELIX 

Schedule 4

DEHYDROCHLOROMETHYLTESTOSTERONE
cross reference: CHLOROMESTERONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

DEHYDROCORTICOSTERONE

Schedule 4

DELAVIRDINE
cross reference: DELAVIRDINE MESILATE

DELAVIRDINE MESILATE

Schedule 4

DELPHINIUM STAPHISAGRIA
cross reference: STAPHISAGRIA

Schedule 2

DELTAMETHRIN

Schedule 7
Schedule 6
Schedule 5

DEMBREXINE

Schedule 5
Schedule 4

DEMECARIUM

Schedule 4

DEMECLOCYCLINE

Schedule 4

DEMETON

Schedule 7

DEMETONOMETHYL

Schedule 7

DEMETONSMETHYL

Schedule 7

DENGUE VACCINE
cross reference: LIVE ATTENUATED CHIMERIC DENGUE VIRUS (SEROTYPES 1, 2, 3 and 4)

Schedule 4

DENOSUMAB

Schedule 4

DEOXYCHOLIC ACID

Schedule 4

DEOXYCORTONE

Schedule 4

1DEOXY1(METHYLAMINO)DGLUCITOL NCOCO ACYL DERIVATIVES
cross reference: COCOYL METHYL GLUCAMAIDE

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

DEOXYRIBONUCLEASE

Schedule 4

DERACOXIB

Schedule 4

DERMATOPHAGOIDES PTERONYSSINUS AND DERMATOPHAGOIDES FARINAE EXTRACT

Schedule 4

DERQUANTEL

Schedule 6

2,4DES

Schedule 5

DESCHLOROETIZOLAM

cross reference: CAS No. 40054-73-7

Schedule 9

DESFERRIOXAMINE

Schedule 4

DESFLURANE

Schedule 4

DESIPRAMINE

Schedule 4
Appendix K, clause 1

DESIRUDIN

Schedule 4

DESLANOSIDE

Schedule 4

DESLORATADINE

Schedule 4
Schedule 2

DESLORELIN

Schedule 4

DESMOPRESSIN
cross reference: D.D.A.V.P.

Schedule 4

DESOGESTREL

Schedule 4

DESOMORPHINE

cross reference: CAS No. 427-00-9

Schedule 9

DESONIDE

Schedule 4

DESOXYMETHASONE

Schedule 4

DESVENLAFAXINE

Schedule 4

DETOMIDINE

Schedule 4

DEUCRAVACITINIB

Schedule 4

DEUTETRABENAZINE

Schedule 4
Appendix K, clause 1

DEXAMETHASONE

Schedule 4

DEXAMFETAMINE
cross reference: DEXAMPHETAMINE

Schedule 8

DEXCHLORPHENAMINE
cross reference: DEXCHLORPHENIRAMINE

Schedule 4
Schedule 3
Schedule 2
Appendix K, clause 1

DEXCHLORPHENIRAMINE
cross reference: DEXCHLORPHENAMINE

DEXFENFLURAMINE

Schedule 4

DEXMEDETOMIDINE

Schedule 4

DEXTRANS

Appendix A

DEXTROMETHORPHAN

Schedule 4
Schedule 2

DEXTROMORAMIDE
cross reference: MORAMIDE

Schedule 8
Appendix K, clause 1

DEXTROPROPOXYPHENE

Schedule 8
Schedule 4
Appendix D, clause 5
Appendix K, clause 1

DEXTRORPHAN

Schedule 4

N,NDIALKYLAMINOCYCLOHEXYL ALKYL BENZAMIDES
cross reference: 3,4DICHLORON[(1R,2R)2(DIMETHYLAMINO)CYCLOHEXYL]NMETHYLBENZAMIDE *(U47700) (CAS No. 82657-23-6)

Schedule 9

N,NDIALKYLAMINOCYCLOHEXYLMETHYL ALKYL BENZAMIDES
Cross reference: 3,4DICHLORON{[1(DIMETHYLAMINO)CYCLOHEXYL]METHYL}BENZAMIDE *(AH7921) (CAS No. 55154-30-8)

Schedule 9

4,4DIAMINODIPHENYLMETHANE
cross reference: METHYLENE DIANILINE

Schedule 7
Appendix F, clause 4
Appendix J, clause 1

2,4DIAMINO5METHYLPHENETOLE
cross reference: PHENYLENEDIAMINES

2,4DIAMINOPHENOXYETHANOL

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

DIAFENTHIURON

Schedule 5

DIALIFOS

Schedule 7

N,NDIALLYLDICHLOROACETAMIDE

Schedule 5

DIAMPROMIDE

cross reference: CAS No. 552-25-0

Schedule 9

DIAMTHAZOLE

Schedule 4

DIAVERIDINE

Schedule 4

DIAZEPAM

Schedule 4
Appendix D, clause 5 (benzodiazepine derivatives)
Appendix K, clause 1

DIAZINON

Schedule 6
Schedule 5

DIAZOXIDE

Schedule 4

DIBENZEPIN

Schedule 4

DIBENZOPYRANS

Schedule 9

DIBOTERMIN

Schedule 4

1,2DIBROMO3CHLOROPROPANE

Schedule 7
Appendix J, clause 1

DIBROMOPROPAMIDINE

Schedule 4
Schedule 2

DIBUTYL PHTHALATE

cross reference: CAS No. 84-74-2

Schedule 10

DICAMBA

Schedule 6
Schedule 5

DICLAZEPAM

cross reference: CAS No. 2894-68-0

Schedule 9

DICHLOBENIL

Schedule 6

oDICHLOROBENZENE

Appendix F, clause 4

DICHLOEOETHYL ETHER

Appendix F, clause 4

DICHLOFENTHION

Schedule 6

DICHLOFLUANID

Schedule 6

DICHLONE

Schedule 5

DICHLORALPHENAZONE

Schedule 4

DICHLOROBENZENE

Schedule 6
Schedule 5
Appendix E, clause 3

3,4DICHLORON[(1R,2R)2(DIMETHYLAMINO)CYCLOHEXYL]NMETHYLBENZAMIDE (U47700)
cross reference: N,NDIALKYLAMINOCYCLOHEXYL ALKYL BENZAMIDES (CAS No. 82657-23-6)

Schedule 9

DICHLOROETHYL ETHER

Schedule 6
Appendix E, clause 3

DICHLOROETHYLENE

Appendix F, clause 4

DICHLOROISOCYANURIC ACID
cross reference: CHLORINE, CHLORINATING COMPOUNDS, DICHLOROISOCYANURATES, SODIUM DICHLOROISOCYANURATE

Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

DICHLOROMETHANE
cross reference: METHYLENE CHLORIDE

Schedule 5
Appendix E, clause 3
Appendix F, clause 4

3,4DICHLORON{[1DIMETHYLAMINO)CYCLOHEXYL]METHYL}
BENZAMIDE
cross reference: AH7921 (CAS No. 55154-30-8)

Schedule 9

4,5DICHLORO2NOCTYL3(2H)ISOTHIAZOLONE

Schedule 6

DICHLOROPHEN

Schedule 6
Schedule 5
Schedule 4

2,4DICHLORPROP

Schedule 6

1,2DICHLOROPROPANE

Schedule 6

1,3DICHLOROPROPENE

Schedule 7
Appendix J, clause 1

DICHLORPHENAMIDE

Schedule 4

DICHLORVOS

Schedule 7
Schedule 6
Schedule 5

DICHROMATES

Appendix E, clause 3

DICLAZURIL

Appendix B, clause 3

DICLOBUTRAZOL

Schedule 5

DICLOFENAC

Schedule 4
Schedule 3
Schedule 2
Appendix F, clause 4
Appendix H, clause 1

DICLOFOPMETHYL

Schedule 6

DICLORAN

Schedule 5

DICLOXACILLIN

Schedule 4

DICOFOL

Schedule 5

DICOPHANE
cross reference: DDT (CAS No. 50-29-3)

Schedule 10

DICROTOPHOS

Schedule 7

DICYCLANIL

Schedule 6

DICYCLOMINE

Schedule 4

DIDANOSINE

Schedule 4

DIDECYLDIMETHYLAMMONIUM SALTS

Schedule 6

DIELDRIN

Schedule 6

DIENESTROL

Schedule 4
Appendix F, clause 4
Appendix L, clause 2

DIENOGEST

Schedule 4

DIESEL

Appendix E, clause 3

DIETHANOLAMINE

Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

DIETHAZINE

Schedule 4

DIETHYL CARBONATE

Appendix B, clause 3

DIETHYLCARBAMAZINE

Schedule 4

DIETHYLENE GLYCOL
cross reference: DENATONIUM BENZOATE (CAS No. 111-46-6)

Schedule 10
Schedule 6
Schedule 5

DIETHYLENE GLYCOL MONOBUTYL ETHER

Schedule 5
Appendix E, clause 3
Appendix F, clause 4

DIETHYLENE GLYCOL MONOMETHYL ETHER

cross reference: CAS No. 111-77-3

Schedule 10
Schedule 6

DIETHYLHEXYL PHTHALATE

cross reference: DEHP (CAS No. 117-81-7)

Schedule 10

DIETHYLPHTHALATE

cross reference: CAS No. 84-66-2

Schedule 10

DIETHYLPROPION

Schedule 4

DIETHYLTHIAMBUTENE

cross reference: CAS No. 86-14-6, DIETHYLTHIAMBUTENE HYDROCHLORIDE (CAS No. 132-19-4)

Schedule 9

DIETHYLTOLUAMIDE (DEET)

Schedule 5
Appendix F, clause 4

N,NDIETHYLTRYPTAMINE
cross reference: DET (CAS No. 61-51-8)

Schedule 9

DIFELIKEFALIN

Schedule 4
Appendix K, clause 1

DIFENACOUM

Schedule 7
Schedule 6
Appendix J, clause 1

DIFENOCONAZOLE

Schedule 5

DIFENOXIN

Schedule 8
Schedule 4
Appendix K, clause 1

DIFENZOQUAT

Schedule 6

DIFETHIALONE

Schedule 7
Schedule 6

DIFLORASONE

Schedule 4

DIFLOXACIN

Schedule 4

DIFLUBENZURON

Schedule 5

DIFLUCORTOLONE

Schedule 4

DIFLUFENICAN

Appendix B, clause 3

DIFLUNISAL

Schedule 4

DIGITALIS LANATA

Schedule 4

DIGITALIS PURPUREA

Schedule 4

DIGITOXIN

Schedule 4

DIGOXIN

Schedule 4

DIGOXINSPECIFIC ANTIBODY FRAGMENT F (Ab)

Schedule 4

DIHYDRALAZINE

Schedule 4

DIHYDROCODEINE

Schedule 8
Schedule 4
Schedule 3
Appendix K, clause 1

DIHYDROERGOTOXINE

Schedule 4

DIHYDROLONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

2,5DIHYDRO2(1METHYL1PHENYLETHYL)5PENTYL1HPYRIDO[4,3B]INDOL1ONE (SGT151)
cross reference: SGT151, CUMYLPEGACLONE (CAS No. 2160555-55-3)

Schedule 9

DIHYDROMORPHINE

Schedule 8

DIHYDROSTREPTOMYCIN

Schedule 4

DIHYDROTACHYSTEROL

Schedule 4

5,6DIHYDROXYINDOLINE

cross reference: CAS No. 29539-03-5, 5,6-DIHYDROXYINDOLINE HYDROBROMIDE (CAS No. 138937-28-7)

Schedule 10
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

DIIODOHYDROXYQUINOLINE
cross reference: IODOQUINOL (CAS No. 83-73-8)

Schedule 10
Schedule 4
Schedule 3

DIIODOHYDROXYQUINOLINE
cross reference: DIIODOHYDROXYQUINOLINE

DIISOBUTYL PHTHALATE

cross reference: CAS No. 84-69-5

Schedule 10

DIISOPROPYLAMINE DICHLOROACETATE

Schedule 4

DIKEGULACSODIUM

Appendix B, clause 3

DILTIAZEM

Schedule 4

DIMEFOX

Schedule 7

DIMENHYDRINATE

Schedule 4
Schedule 3
Schedule 2
Appendix H, clause 1
Appendix K, clause 1

DIMENOXADOL

cross reference: CAS No. 509-78-4, DIMENOXADOL HYDROCHLORIDE (CAS No. 2424-75-1)

Schedule 9

DIMEPHEPTANOL

cross reference: CAS No. 545-90-4

Schedule 9

DIMERCAPROL

Schedule 4

DIMETHANDROSTANOLONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

DIMETHAZINE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

DIMETHENAMIDP

Schedule 6

DIMETHICODIETHYLBENZALMALONATE
cross reference: POLYSILICONE15

Schedule 5

DIMETHICONE
cross reference: DIMETICONE

DIMETHINDENE

Schedule 4
Appendix K, clause 1

DIMETHIPIN

Schedule 6

DI(METHYLOXYETHYL) PHTHALATE

cross reference: CAS No. 117-82-8

Schedule 10

1,4DIMETHYLPENTYLAMINE (DMPA)
cross reference: 1,4DIMETHYLAMYLAMINE (DMAA) (CAS No. 28292-43-5)

Schedule 10

DIMETHIRIMOL

Schedule 5

DIMETHOATE

Schedule 6

DIMETHOMORPH

Schedule 5

DIMETHOTHIAZINE

Schedule 4

DIMETHOXANATE

Schedule 4

2,5DIMETHOXYAMFETAMINE
cross reference: 2,5DIMETHOXYAMPHETAMINE, DMA (CAS No. 2801-68-5), DMA HYDROCHLORIDE (CAS No. 24973-25-9)

Schedule 9

2,5DIMETHOXY4BROMOAMFETAMINE
cross reference: 2,5DIMETHOXY4BROMOAMPHETAMINE, DOB (CAS No. 64638-07-9)

Schedule 9

2,5DIMETHOXY4ETHYLaAMFETAMINE
cross reference: 2,5DIMETHOXY4ETHYLaAMPHETAMINE, DOET (CAS No. 22004-32-6), DOET HYDROCHLORIDE (CAS No. 22139-65-7)

Schedule 9

2,5DIMETHOXY4ETHYLTHIOPHENETHYLAMINE
cross reference: 2CT2 (CAS No. 207740-24-7)

Schedule 9

2,5DIMETHOXY4IODOPHENETHYLAMINE
cross reference: 2CI (CAS No. 69587-11-7)

Schedule 9

2,5DIMETHOXY4(N)PROPYLTHIOPHENETHYLAMINE
cross reference: 2CT7 (CAS No. 207740-26-9)

Schedule 9

2,6DIMETHOXY3,5PYRIDINEDIAMINE

Schedule 6
Appendix F, clause 4

DIMETHYLACETAMIDE

Schedule 6
Schedule 5

N,NDIMETHYLAMFETAMINE
cross reference: N,NDIMETHYLAMPHETAMINE, DIMETAMFETAMINE (CAS No. 4075-96-1), DIMETAMFETAMINE S-ISOMER (CAS No. 17279-39-9)

Schedule 9

4DIMETHYLAMINOAZOBENZENE
cross reference: MOCA, N,NDIMETHYL4[PHENYLAZO]BENZENAMINE

Schedule 7
Appendix J, clause 1

3(2DIMETHYLAMINOETHYL)4HYDROXYINDOLE
cross reference: PSILOCINE, PSILOTSIN (CAS No. 520-53-6)

Schedule 9

1,3DIMETHYLAMYLAMINE
cross reference: 4METHYLHEXANE2AMINE, DMAA (CAS No. 105-41-9)

Schedule 10

1,3DIMETHYLBUTYLAMINE (DMBA)
cross reference: OCTODRINE, 1AMINOISOHEPTANE, DMHA, 1,5DIMETHYLHEXYLAMINE, 4METHYLHEXANE2AMINE, 1,3DIMETHYLAMYLAMINE, DMAA, 4AMINO2METHYLPENTANE CITRATE (AMP CITRATE), (CAS No. 108-09-8)

Schedule 10

4,4DIMETHYL1CYCLOHEXENE1PROPANAL

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

N,NDIMETHYLDECANAMIDE

Schedule 6

DIMETHYL ETHER

Appendix B, clause 3

1(1,1DIMETHYLETHYL)2METHOXY4METHYL3,5DINITROBENZENE (musk ambrette)
cross reference: AMBER MUSK (CAS No. 83-66-9)

Schedule 10

DIMETHYLFORMAMIDE
cross reference: DESIGNATED SOLVENT

Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

DIMETHYL FUMARATE

Schedule 4

3(1,2DIMETHYLHEPTYL)1HYDROXY7,8,9,10TETRAHYDRO6,6,9 TRIMETHYL6HDIBENZO (b,d) PYRAN
cross reference: DMHP (CAS No. 32904-22-6)

Schedule 9

1,5DIMETHYLHEXYLAMINE (DMHA)
cross reference: 1,3DIMETHYLBUTYLAMINE, DMBA, OCTODRINE, 1AMINOISOHEPTANE, DMHA, 4METHYLHEXANE2AMINE, 1,3DIMETHYLAMYLAMINE, DMAA, 4AMINO2METHYLPENTANE CITRATE (AMP CITRATE), (CAS No. 543-82-8), 1,5-DIMETHYLHEXYLAMINE HYDROCHLORIDE (CAS No. 5984-59-8), 1,5-DIMETHYLHEXYLAMINE S-ISOMER (CAS No. 70419-10-2), 1,5-DIMETHYLHEXYLAMINE R-ISOMER (CAS No. 70419-11-3)

Schedule 10

N, α DIMETHYL3,4(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA)
cross reference: 3,4METHYLENEDIOXYNαDIMETHYLPHENYLETHYLAMINE, MDMA, MIDOMAFETAMINE (CAS No. 42542-10-9), MDMA HYDROCHLORIDE (CAS No. 64057-70-1)

Schedule 9
Schedule 8
Appendix D, clause 5
Appendix D, clause 10

3,7DIMETHYL2,6OCTADIENAL
cross reference: CITRAL, NERAL, GERANIAL

Schedule 5

3,7DIMETHYL2,6OCTADIEN1OL
cross reference: GERANIOL, NEROL, CITROL

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

N,NDIMETHYLOCTANAMIDE

Schedule 6

DIMETHYLPHTHALATE

cross reference: CAS No. 131-11-3

Schedule 10

DIMETHYL SULFATE

Schedule 7
Appendix F, clause 4

DIMETHYL SULFOXIDE
cross reference: COPPER SALICYLATE, METHYL SALICYLATE

Schedule 6
Schedule 4
Appendix E, clause 3
Appendix F, clause 4

DIMETHYLTHIAMBUTENE

cross reference: CAS No. 524-84-5

Schedule 9

N,NDIMETHYLTRYPTAMINE
cross reference: DMT (CAS No. 61-50-7)

Schedule 9

DIMETICONE
cross reference: DIMETHICONE

Appendix B, clause 3

DIMETILAN

Schedule 7

DIMETRIDAZOLE

Schedule 4

DIMIRACETAM
cross reference: RACETAMS

Schedule 4

DIMPROPYRIDAZ

Schedule 6

Schedule 5

DINICONAZOLE

Schedule 5

2,4DINITROCHLOROBENZENE

Schedule 4

DINITROCRESOLS

Schedule 7
Schedule 6
Schedule 4
Appendix E, clause 3
Appendix J, clause 1

DINITRONAPHTHOLS

Schedule 4

2,4DINITROPHENOL
cross reference: CAS No. 51285
Schedule 10

DINITROPHENOLS

Schedule 10

Schedule 7
Schedule 6
Schedule 4
Appendix E, clause 3
Appendix F, clause 4
Appendix J, clause 1

DINITROTHYMOLS

Schedule 4

DINOCAP

Schedule 7
Appendix F, clause 4

DINOPROST

Schedule 4
Appendix D, clause 1

DINOPROSTONE

Schedule 4
Appendix D, clause 1

DINOSEB

Schedule 7
Appendix J, clause 1

DINOTEFURAN

Schedule 5

DInPROPYL ISOCINCHOMERONATE (previously diN propyl isocinchomeronate)

Schedule 5

DIOXACARB

Schedule 6

DIOXANE

Schedule 6
Appendix E, clause 3
Appendix F, clause 4
Appendix G, clause 1

DIOXAPHETYL BUTYRATE

cross reference: CAS No. 467-86-7

Schedule 9

DIPERODON

Schedule 4

DIPHACINONE

Schedule 6

DIPHEMANIL

Schedule 4

DIPHENAMID

Schedule 5

DIPHENHYDRAMINE

Schedule 4
Schedule 3
Schedule 2
Appendix K, clause 1

DIPHENIDOL

Schedule 4

DIPHENOXYLATE

Schedule 8
Schedule 4
Schedule 3
Appendix F, clause 4
Appendix H, clause 1
Appendix K, clause 1

DIPHENYLAMINE

Appendix B, clause 3

DIPHENYLPYRALINE

Schedule 4
Appendix K, clause 1

DIPHTHERIA TOXOID

cross reference: TRIPLE ANTIGEN VACCINE

Schedule 4

DIPIPANONE

Schedule 8

DIPIVEFRIN

Schedule 4

DIPROPYLENE GLYCOL

Appendix B, clause 3

DIPYRIDAMOLE

Schedule 4

DIQUAT

Schedule 7
Schedule 6

DIRECT RED 254
cross reference: 2NAPHTHALENESULFONIC ACID, 7AMINO4HYDROXY3[[p[(pSULFOPHENYL)AZO]PHENYL]AZO], (3Z)7AMINO4OXO3[[4[(4SULFOPHENYL)DIAZENYL]PHENYL]HYDRAZINYLIDENE]NAPHTHALENE2SULFONIC ACID, (3Z)7AMINO4OXO3[[4[(4SULFOPHENYL)DIAZENYL]PHENYL]HYDRAZINYLIDENE]NAPHTHALENE2SULFONIC ACID BIS(TRIETHANOLAMINE) SALT, (3Z)7AMINO4OXO3[[4[(4SULFOPHENYL)DIAZENYL]PHENYL]HYDRAZINYLIDENE]NAPHTHALENE2SULFONIC ACID DISODIUM SALT

Schedule 6
Schedule 5

DIRITHROMYCIN

Schedule 4

DIRLOTAPIDE

Schedule 4

DIROXIMEL FUMARATE

Schedule 4

DISODIUM MANGANESE EDTA

Appendix B, clause 3

DISOPHENOL

Schedule 4

DISOPYRAMIDE

Schedule 4

DISPERSE YELLOW 3

cross reference: CAS No. 2832-40-8

Schedule 10
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

DISTIGMINE

Schedule 4

DISTILLATE

Appendix E, clause 3

DISULFIRAM

Schedule 6
Schedule 4

DISULFOTON

Schedule 7
Schedule 6

DISULPHAMIDE

Schedule 4

DITHIANON

Schedule 6

DITHIAZANINE

Schedule 6
Schedule 4

DITHIOPYR

Schedule 5

DITHRANOL

Schedule 3

DITIOCARB

Schedule 4

DIUREDOSAN

Schedule 6

DIURON

Appendix B, clause 3

DOBUTAMINE

Schedule 4

DOCETAXEL

Schedule 4

DOCUSATE SODIUM
cross reference: DIOCTYL SODIUM SULFOSUCCINATE

Appendix B, clause 3

N(NDODECYL)2PYRROLIDONE
cross reference: DESIGNATED SOLVENT, N(NOCTYL)2PYRROLIDONE, NMETHYL2PYRROLIDONE

Schedule 6
Schedule 5
Appendix E, clause 3

DODINE

Schedule 6

DOFETILIDE

Schedule 4

DOLASETRON

Schedule 4

DOLUTEGRAVIR

Schedule 4

DOMPERIDONE

Schedule 4

DONEPEZIL

Schedule 4

DOPAMINE

Schedule 4

DOPEXAMINE

Schedule 4

DORAMECTIN

Schedule 7
Schedule 6
Schedule 5

DORAVIRINE

Schedule 4

DORIPENEM

Schedule 4

DORNASE

Schedule 4

DORZOLAMIDE

Schedule 4

DOSULEPIN
cross reference: DOTHIEPIN.

Schedule 4
Appendix K, clause 1

DOTHIEPIN
cross reference: DOSULEPIN

DOXANTRAZOLE

Schedule 4

DOXAPRAM

Schedule 4

DOXAZOSIN

Schedule 4

DOXEPIN

Schedule 4
Appendix K, clause 1

DOXORUBICIN

Schedule 4

DOXYCYCLINE

Schedule 4

DOXYLAMINE

Schedule 4
Schedule 3
Schedule 2
Appendix K, clause 1

2,2DPA
cross reference: SODIUM 2,2DICHLOROPROPIONATE

Appendix B, clause 3

DROMETRIZOLE TRISILOXANE

Appendix B, clause 3

DRONABINOL
cross reference: DELTA9TETRAHYDROCANNABINOL, NABIXIMOLS

Schedule 8
Appendix D, clause 3
Appendix K, clause 1

DRONEDARONE

Schedule 4

DROPERIDOL

Schedule 4
Appendix K, clause 1

DROSPIRENONE

Schedule 4

DROSTANOLONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

DROTEBANOL

Schedule 8

DROTRECOGIN

Schedule 4

DSMA

Schedule 7
Schedule 6

DUBOISIA LEICHHARDTII

Schedule 4
Schedule 2

DUBOISIA MYOPOROIDES

Schedule 4
Schedule 2

DUDDINGTONIA FLAGRANS, STRAIN IAH 1297

Appendix B, clause 3

DULAGLUTIDE

Schedule 4

DULCIN

cross reference: CAS No. 150-69-6

Schedule 10

DULOXETINE

Schedule 4
Appendix K, clause 1

DUPILUMAB

Schedule 4

DURVALUMAB

Schedule 4

DUTASTERIDE

Schedule 4

DYDROGESTERONE

Schedule 4

E

(E)(S)1(4CHLOROPHENYL)4,4DIMETHYL2(1H1,2,4TRIAZOL1YL)PENT1EN3OL
cross reference: UNICONAZOLEP

Schedule 6

ECGONINE

cross reference: CAS No. 481-37-8, ECGONINE HYDROCHLORIDE (CAS No. 5796-31-6), ECGONINE RACEMATE (CAS No. 876657-17-9)

Schedule 9

ECONAZOLE

Schedule 6
Schedule 4
Schedule 3
Schedule 2
Appendix F, clause 4
Appendix H, clause 1

ECOTHIOPATE
cross reference: ECOTHIOPATE IODIDE

Schedule 4

ECTYLUREA

Schedule 4

ECULIZUMAB

Schedule 4

EDARAVONE

Schedule 4

EDETIC ACID
cross reference: DICOBALT EDETATE

Schedule 4

EDOXUDINE

Schedule 4

EDROPHONIUM

Schedule 4

EFALIZUMAB

Schedule 4

EFAVIRENZ

Schedule 4

EFLORNITHINE

Schedule 4

EFORMOTEROL
cross reference: FORMOTEROL

ELBASVIR

Schedule 4

ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS or LAMPS

Appendix A, clause 1

ELECTRONIC COMPONENTS

Appendix A, clause 1

ELETRIPTAN

Schedule 4
Schedule 3
Appendix H, clause 1

ELEXACAFTOR

Schedule 4

ELOSULFASE ALFA

Schedule 4

ELOTUZUMAB

Schedule 4

ELTENAC

Schedule 4

ELTROMBOPAG

Schedule 4

ELUXADOLINE

Schedule 4

ELVITEGRAVIR

Schedule 4

EMAMECTIN

Schedule 7
Schedule 6
Schedule 5

EMEPRONIUM

Schedule 4

EMETINE
cross reference: CEPHAELIS ACUMINATA

Schedule 4

EMODEPSIDE

Schedule 6
Schedule 5

EMPAGLIFLOZIN

Schedule 4

EMTRICITABINE

Schedule 4

ENALAPRIL

Schedule 4

ENASIDENIB

Schedule 4

ENCORAFENIB

Schedule 4

ENDOSULFAN

Schedule 7
Schedule 6

ENDOTHAL

Schedule 7
Schedule 6

ENDRIN

Schedule 7

ENESTEBOL

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

ENFLURANE

Schedule 4

ENFORTUMAB VEDOTIN

Schedule 4

ENFUVIRTIDE

Schedule 4

ENHANCING AGENTS
cross reference: MAGNETIC RESONANCE IMAGING ENHANCING AGENTS, ULTRASONIC AND MAGNETIC RESONANCE IMAGING ENHANCING

Appendix A, clause 1

ENOBOSARM

Schedule 4
Appendix D, clause 5 (SELECTIVE ANDROGEN RECEPTOR MODULATORS)

ENOXACIN

Schedule 4

ENOXAPARIN

Schedule 4

ENOXIMONE

Schedule 4

ENPROSTIL

Schedule 4

ENROFLOXACIN

Schedule 4

ENTACAPONE

Schedule 4

ENTECAVIR

Schedule 4

ENTRECTINIB

Schedule 4

ENZALUTAMIDE

Schedule 4
Appendix D, clause 6
Appendix F, clause 4
Appendix L, clause 2

EPHEDRA spp.

Schedule 4

EPHEDRINE
cross reference: EPHEDRA

Schedule 4
Appendix D, clause 5
Appendix F, clause 4

EPICHLOROHYDRIN

Schedule 7
Appendix F, clause 4
Appendix J, clause 1

EPICILLIN

Schedule 4

EPIDERMAL GROWTH FACTOR
cross reference: SHOLIGOPEPTIDE1, RHOLIGOPEPTIDE1

Schedule 7
Appendix G, clause 1
Appendix J, clause 1

EPINASTINE

Schedule 4

EPINEPHRINE
cross reference: ADRENALINE

EPIRUBICIN

Schedule 4

EPITIOSTANOL

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

EPLERENONE

Schedule 4

EPOETINS
cross reference: METHOXY POLYETHYLENE GLYCOLEPOETIN BETA

Schedule 4
Appendix D, clause 5

EPOPROSTENOL

Schedule 4

EPOXICONAZOLE

Schedule 5

EPOXY RESINS, LIQUID
cross reference: RESINS

Schedule 5
Appendix E, clause 3
Appendix F, clause 4

EPRINOMECTIN

Schedule 7
Schedule 6
Schedule 5

EPROSARTAN

Schedule 4

EPSIPRANTEL

Appendix B, clause 3

EPTC

Schedule 6

EPTIFIBATIDE

Schedule 4

EQUINE ANTIHUMAN THYMOCYTE IMMUNOGLOBULIN
cross reference: IMMUNOGLOBULINSERGOMETRINE

Schedule 4

ERENUMAB

Schedule 4

ERGOT

Schedule 4

ERGOTAMINE

Schedule 4

ERGOTOXINE

Schedule 4

ERIBULIN MESILATE
cross reference: ERIBULIN MESYLATE

Schedule 4

ERLOTINIB

Schedule 4

ERTAPENEM

Schedule 4

ERTUGLIFLOZIN

Schedule 4

ERYSIMUM spp.

Schedule 4
Appendix G, clause 1

ERYTHRITYL TETRANITRATE

Schedule 3

ERYTHROMYCIN

Schedule 4

ERYTHROPOIETIN

Schedule 4
Appendix D, clause 5

ERYTHROPOIETINS

Schedule 4
Appendix D, clause 5

ESBIOTHRIN

Schedule 6
Schedule 5

ESCITALOPRAM

Schedule 4

ESFENVALERATE

Schedule 6
Schedule 5

ESKETAMINE

Schedule 8
Appendix K, clause 1

ESLICARBAZEPINE ACETATE

Schedule 4

ESMOLOL

Schedule 4

ESOMEPRAZOLE

Schedule 4
Schedule 2
Appendix H, clause 1

ESTETROL MONOHYDRATE

Schedule 4

ESTRADIOL

Schedule 5
Schedule 4
Appendix G, clause 1

ESTRAMUSTINE

Schedule 4

ESTRIOL

Schedule 4

ESTROGENS

Schedule 4

ESTRONE

Schedule 4
Appendix G, clause 1

ESTROPIPATE
cross reference: PIPERAZINE ESTRONE SULFATE

Schedule 4

ETACONAZOLE

Schedule 7
Appendix J, clause 1

ETACRYNIC ACID

Schedule 4

ETAFEDRINE

Schedule 2

ETANERCEPT

Schedule 4

ETHACRYNIC ACID
cross reference: ETACRYNIC ACID

ETHALFLURALIN

Schedule 7

ETHAMBUTOL

Schedule 4

ETHAMETSULFURONMETHYL

Appendix B, clause 3

ETHAMIVAN

Schedule 4

1,2ETHANEDIAMINE POLYMER WITH (CHLOROMETHYL)OXIRANE AND NMETHYLMETHANAMINE
cross reference: NMETHYLMETHANAMINE

Schedule 5

ETHANOL
cross reference: ETHYL ALCOHOL

ETHANOLAMINE
cross reference: MONOETHANOLAMINE

ETHCHLORVYNOL

Schedule 4

ETHEPHON

Schedule 6

ETHER

Schedule 6
Schedule 5
Schedule 4
Schedule 2
Appendix E, clause 3
Appendix F, clause 4

ETHERIFIED STARCHES

Appendix A

ETHINAMATE

Schedule 4

ETHINYLESTRADIOL

Schedule 4

ETHINYLOESTRADIOL
cross reference: ETHINYLESTRADIOL

ETHIOFENCARB

Schedule 6

ETHION

Schedule 7

ETHIONAMIDE

Schedule 4

ETHISTERONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

ETHOATEMETHYL

Schedule 6

ETHOFUMESATE

Schedule 5

ETHOGLUCID

Schedule 4

ETHOHEPTAZINE

Schedule 4

ETHOPABATE

Appendix B, clause 3

ETHOPROPAZINE

Schedule 4

ETHOPROPHOS
cross reference: LINSEED OIL

Schedule 7
Schedule 6

ETHOSUXIMIDE

Schedule 4

ETHOTOIN

Schedule 4

2ETHOXYETHANOL

Schedule 7
Appendix F, clause 4

ETHOXYETHYLMERCURIC CHLORIDE

Appendix F, clause 4

ETHOXYQUIN

Schedule 5

ETHOXYSULFURON

Schedule 5

ETHOXZOLAMIDE

Schedule 4

ETHYL ACETATE

Appendix B, clause 3

ETHYL ALCOHOL

Appendix B, clause 3

ETHYL BROMIDE

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

ETHYL BUTYRATE

Appendix B, clause 3

ETHYL CHLORIDE

Schedule 4

ETHYL FORMATE

Schedule 6

ETHYL LACTATE

Appendix B, clause 3

ETHYL METHACRYLATE

Schedule 5
Appendix F, clause 4

ETHYLAMFETAMINE
cross reference: ETHYLAMPHETAMINE

Schedule 8

ETHYLBUTYLACETYL

Appendix B, clause 3

ETHYLDIENOLONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

ETHYLENE CHLOROHYDRIN

Schedule 6
Appendix F, clause 4

ETHYLENE DIBROMIDE

Schedule 7
Appendix J, clause 1

ETHYLENE DICHLORIDE

Schedule 6

ETHYLENE GLYCOL
cross reference: DENATONIUM BENZOATE (CAS No. 107-21-1)

Schedule 10
Schedule 6
Schedule 5
Appendix E, clause 3

ETHYLENE GLYCOL MONOALKYL ETHERS

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

ETHYLENE OXIDE

Schedule 7
Appendix E, clause 3
Appendix F, clause 4
Appendix J, clause 1

ETHYLESTRENOL
cross reference: ETHYLOESTRENOL

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

ETHYLHEXANEDIOL

cross reference: ETHOHEXADIOL
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

2ETHYLHEXANOIC ACID

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

ETHYLMERCURIC CHLORIDE

Appendix F, clause 4

NETHYLαMETHYL3,4(METHYLENEDIOXY)PHENETHYLAMINE
cross reference: NETHYL MDA (CAS No. 82801-81-8), N-ETHYL MDA HYDROCHLORIDE (CAS No. 74341-78-9)

Schedule 9

ETHYLMETHYLTHIAMBUTENE

cross reference: CAS No: 441-61-2

Schedule 9

ETHYLMORPHINE

Schedule 8
Schedule 4
Schedule 2
Appendix K, clause 1

ETHYLOESTRENOL
cross reference: ETHYLESTRENOL

ETHYNODIOL
cross reference: ETYNODIOL

ETICYCLIDINE
cross reference: PCE (CAS No. 2201-15-2)

Schedule 9

ETIDOCAINE

Schedule 4

ETIDRONIC ACID
cross reference: ETIDRONATE DISODIUM

Schedule 4

ETILEFRIN

Schedule 4

ETIPROSTON

Schedule 4

ETODESNITAZENE

cross reference: CAS No. 14030-76-3, ETAZENE

Schedule 9

ETODOLAC

Schedule 4

ETOFENAMATE

Schedule 4
Schedule 2

ETOFENPROX

Appendix B, clause 3

ETONITAZENE

cross reference: CAS No. 911-65-9

Schedule 9

ETONITAZEPIPNE

cross reference: CAS No. 734496-28-7, N-PIPERIDINO ETONITAZENE

Schedule 9

ETONITAZEPYNE

cross reference: CAS No. 2785346-75-8, N-PYRROLIDINO ETONITAZENE

Schedule 9

ETONOGESTREL

Schedule 4

ETOPOSIDE

Schedule 4

ETORICOXIB

Schedule 4

ETORPHINE

cross reference: CAS No. 14521-96-1

Schedule 9

ETOXAZOLE

Appendix B, clause 3

ETOXERIDINE

cross reference: CAS No. 469-82-9

Schedule 9

ETRAVIRINE

Schedule 4

ETRETINATE

Schedule 4
Appendix D, clause 5
Appendix F, clause 4
Appendix L, clause 2

ETRIDIAZOLE

Schedule 5

ETRIMFOS

Schedule 6

ETYNODIOL
cross reference: ETHYNODIOL

Schedule 4

EUBACTERIUM sp. strain DSM11798

Appendix B, clause 3

EUCALYPTUS OIL

Schedule 6
Appendix E, clause 3

EUGENOL

Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

EUPATORIUM CANNABINUM
cross reference: HEMP AGRIMONY

Schedule 10

EVEROLIMUS

Schedule 4

EXEMESTANE

Schedule 4

EXENATIDE

Schedule 4

EXPLOSIVES

Appendix A, clause 1

EXTRACT OF LEMON EUCALYPTUS
cross reference: CORYMBIA CITRIODORA, OIL OF LEMON EUCALYPTUS

Schedule 5

EZETIMIBE

Schedule 4

F

FAMCICLOVIR

Schedule 4
Schedule 3

Appendix H, clause 1

FAMOTIDINE

Schedule 4
Schedule 2
Appendix F, clause 4

FAMOXADONE

Schedule 6

FAMPHUR

Schedule 7
Schedule 6

FARFUGIUM JAPONICUM

Schedule 10

FARICIMAB

Schedule 4
Appendix L, clause 2

FASORACETAM
cross reference: RACETAMS

Schedule 4

FEBANTEL

Schedule 6

FEBUXOSTAT

Schedule 4

FELBINAC

Schedule 4
Schedule 2

FELODIPINE

Schedule 4

FELYPRESSIN

Schedule 4

FENAMIPHOS

Schedule 7
Schedule 6

FENARIMOL

Schedule 5

FENAZAFLOR

Schedule 6

FENBENDAZOLE

Schedule 5

FENBUCONAZOLE

Schedule 5

FENBUFEN

Schedule 4

FENBUTATIN OXIDE

Schedule 6

FENCAMFAMIN

Schedule 4

FENCHLORAZOLEETHYL

Schedule 5

FENCHLORPHOS

Schedule 6

FENCLOFENAC

Schedule 4

FENETYLLINE

cross reference: CAS No. 3736-08-1, FENETYLLINE HYDROCHLORIDE (CAS No. 1892-80-4)

Schedule 9

FENFLURAMINE

Schedule 4
Appendix K, clause 1

FENFURAM

Appendix B, clause 3

FENHEXAMID

Appendix B, clause 3

FENITROTHION

Schedule 6

FENNEL OIL

Schedule 5
Appendix E, clause 3

FENOFIBRATE

Schedule 4

FENOLDOPAM

Schedule 4

FENOPROFEN

Schedule 4

FENOPROP

Schedule 5

FENOTEROL

Schedule 4

FENOXACRIM

Schedule 7
Schedule 6

FENOXAPROPETHYL

Schedule 5

FENOXAPROPpETHYL

Schedule 5

FENOXYCARB

Appendix B, clause 3

FENPIPRAMIDE

Schedule 4

FENPIPRANE

Schedule 4

FENPROPIDIN

Schedule 6

FENPROPOREX

Schedule 4

FENPROSTALENE

Schedule 4

FENPYRAZAMINE

Schedule 5

FENPYROXIMATE

Schedule 6

FENSON

Schedule 5

FENSULFOTHION

Schedule 7

FENTANYL

Schedule 8
Appendix K, clause 1

FENTEROL

Appendix F, clause 4

FENTHION

Schedule 7
Schedule 6
Schedule 5

FENTHIONETHYL

Schedule 7

FENVALERATE

Schedule 6

FERRIC DERISOMALTOSE

Schedule 4

FEXOFENADINE

Schedule 4
Schedule 2

FIBRINOLYSIN

Schedule 4

FIBROBLAST GROWTH FACTORS

Schedule 4
Appendix D, clause 5

FIDAXOMICIN

Schedule 4

FILGOTINIB

Schedule 4

FILGRASTIM

Schedule 4

FINASTERIDE

Schedule 4

FINERENONE

Schedule 4

Appendix L, clause 2

FINGOLIMOD

Schedule 4
Appendix L, clause 2

FIPRONIL

Schedule 6
Schedule 5

FIROCOXIB

Schedule 4

FLAMPROPMETHYL

Schedule 5

FLAMPROPMMETHYL

Schedule 5

FLAVOXATE

Schedule 3

FLAZASULFURON

Schedule 5

FLECAINIDE

Schedule 4

FLEROXACIN

Schedule 4

FLOCOUMAFEN

Schedule 7
Schedule 6

FLOCTAFENINE

Schedule 4

FLONICAMID

Schedule 6

FLORASULAM

Schedule 5

FLORFENICOL

Schedule 4

FLORPYRAUXIFENBENZYL

Appendix B, clause 3

FLORYLPICOXAMID

Appendix B, clause 3

FLUANISONE

Schedule 4

FLUAZAINDOLIZINE

Schedule 6
Schedule 5

FLUAZIFOPBUTYL

Schedule 6

FLUAZIFOPpBUTYL

Schedule 6

FLUAZINAM

Schedule 6

FLUAZURON

Schedule 5

FLUBENDAZOLE

Schedule 5

FLUBENDIAMIDE

Schedule 5

FLUBROMAZEPAM

cross reference: CAS No. 2647-50-9

Schedule 9

FLUBROMAZOLAM

cross reference: CAS No. 612526-40-6

Schedule 9

FLUCHLORALIN

Schedule 5

FLUCLOROLONE

Schedule 4

FLUCLOXACILLIN

Schedule 4

FLUCOFURON

Schedule 7
Schedule 6

FLUCONAZOLE

Schedule 4
Schedule 3
Appendix F, clause 4
Appendix H, clause 1

FLUCYTHRINATE

Schedule 7

FLUCYTOSINE

Schedule 4

FLUDARABINE

Schedule 4

FLUDIOXONIL

Schedule 5

FLUDROCORTISONE

Schedule 4

FLUENSULFONE

Schedule 6

FLUFENAMIC ACID

Schedule 4

FLUFENOXURON

Appendix B, clause 3

FLUMAZENIL

Schedule 4

FLUMETASONE
cross reference: FLUMETHASONE

Schedule 4

FLUMETHASONE
cross reference: FLUMETASONE

FLUMETHIAZIDE

Schedule 4

FLUMETHRIN

Schedule 6
Schedule 5

FLUMETSULAM

Appendix B, clause 3

FLUMICLORAC PENTYL

Schedule 5

FLUMIOXAZIN

Schedule 7
Schedule 6

FLUNISOLIDE

Schedule 4

FLUNITAZENE

cross reference: CAS No. 2728-91-8

Schedule 9

FLUNITRAZEPAM

Schedule 8
Appendix D, clause 5 (Benzodiazepine derivatives)
Appendix K, clause 1

FLUNIXIN MEGLUMINE

Schedule 4

FLUOCINOLONE

Schedule 4

FLUOCINONIDE

Schedule 4

FLUOCORTIN

Schedule 4

FLUOCORTOLONE

Schedule 4

FLUOMETURON

Appendix B, clause 3

FLUOPICOLIDE

Appendix B, clause 3

FLUOPYRAM

Schedule 5

FLUORESCEIN

Schedule 4

FLUORIDES
cross reference: SILICOFLUORIDES

Schedule 6
Schedule 5
Schedule 4
Schedule 3
Schedule 2
Appendix E, clause 3
Appendix F, clause 4

Appendix H, clause 1

FLUOROACETAMIDE

Schedule 7

FLUOROACETIC ACID

Schedule 7
Appendix J, clause 1

FLUOROMETHOLONE

Schedule 4

4FLUORONMETHYLAMFETAMINE
cross reference: 4FLUORONMETHYLAMPHETAMINE, 4FLUORONMETHAMFETAMINE (CAS No. 351-03-1)

Schedule 9

1(5FLUOROPENTYL)3(2IODOBENZOYL)INDOLE
cross reference: AM694 (CAS No. 335161-03-0)

Schedule 9

FLUOROURACIL

Schedule 4

FLUOXETINE

Schedule 4

FLUOXYMESTERONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

FLUPENTIXOL
cross reference: FLUPENTHIXOL

Schedule 4
Appendix K, clause 1

FLUPHENAZINE

Schedule 4
Appendix K, clause 1

FLUPROPANATE
cross reference: TETRAPION

Schedule 6

FLUPROSTENOL

Schedule 4

FLUPYRADIFURONE

Schedule 6

FLUQUINCONAZOLE

Schedule 6

 

FLURALANER
crossreference: CARBAMOYL BENZAMIDE, PHENYL ISOXAZOLINE

Schedule 5

Schedule 4

FLURANDRENOLONE

Schedule 4

FLURAZEPAM

Schedule 4
Appendix D, clause 5 (Benzodiazepine derivatives)
Appendix K, clause 1

FLURBIPROFEN

Schedule 4
Schedule 2

FLUOROACETAMIDE

Appendix J, clause 1

FLUOXAPIPROLIN

Appendix B, clause 3

FLUROXENE

Schedule 4

FLUROXYPYR

Appendix B, clause 3

FLUSILAZOL

Schedule 6

FLUSPIRILENE

Schedule 4

FLUTAMIDE

Schedule 4

FLUTICASONE
cross reference: FLUTICASONE FUROATE, FLUTICASONE PROPIONATE

Schedule 4

FLUTICASONE FUROATE
cross reference FLUTICASONE

FLUTICASONE PROPIONATE

cross reference: FLUTICASONE

Schedule 4
Schedule 2

FLUTOLANIL

Appendix B, clause 3

FLUTRIAFOL

Schedule 6

FLUVALINATE

Schedule 6
Schedule 5

FLUVASTATIN

Schedule 4

FLUVOXAMINE

Schedule 4

FLUXAPYROXAD

Schedule 5

FOLIC ACID

Schedule 4
Schedule 2

FOLINIC ACID
cross reference: CALCIUM FOLINATE

Schedule 4
Schedule 2

FOLLICLESTIMULATING HORMONE

Schedule 4
Appendix D, clause 1

FOLLISTATIN

Schedule 4
Appendix D, clause 5

FOLLITROPIN ALFA
cross reference: FOLLICLESTIMULATING HORMONE, RECOMBINANT HUMAN

Schedule 4
Appendix D, clause 1

FOLLITROPIN BETA
cross reference: FOLLICLESTIMULATING HORMONE, RECOMBINANT HUMAN

Schedule 4
Appendix D, clause 1

FOLLITROPIN DELTA
cross reference: FOLLICLESTIMULATING HORMONE, RECOMBINANT HUMAN

Schedule 4
Appendix D, clause 1

FOLPET

Schedule 7
Appendix J, clause 1

FOMEPIZOLE

Schedule 4

FOMESAFEN SODIUM

Schedule 6

FOMIVIRSEN

Schedule 4

FONDAPARINUX

Schedule 4

FOOD

Appendix A, clause 1

FORAMSULFURON

Schedule 5

FORCHLORFENURON

Appendix B, clause 3

FORMALDEHYDE
cross reference: FORMALDEHYDE CONDENSATION PRODUCT, FREE FORMALDEHYDE, METACRESOLSULPHONIC ACID, METHYLENE GLYCOL (CAS No. 50-00-0)

Schedule 10
Schedule 6
Schedule 2
Appendix E, clause 3
Appendix F, clause 4

FORMALDEHYDE CONDENSATION PRODUCT

Schedule 6

FORMEBOLONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

FORMESTANE

Schedule 4

FORMETANATE

Schedule 7

FORMIC ACID

Schedule 5
Appendix E, clause 3
Appendix F, clause 4

FORMOTEROL

Schedule 4

FORMOTHION

Schedule 6

FOSAMPRENAVIR

Schedule 4

FOSAPREPITANT

Schedule 4

FOSCARNET

Schedule 4

FOSFESTROL
cross reference: DIETHYLSTILBESTROL DIPHOSPHATE

Schedule 4

FOSFOMYCIN

Schedule 4

FOSINOPRIL

Schedule 4

FOSNETUPITANT

Schedule 4

FOSPHENYTOIN

Schedule 4

FOSPIRATE

Schedule 6
Schedule 5

FOSTEMSAVIR

Schedule 4

FOSTHIAZATE

Schedule 7

FOTEMUSTINE

Schedule 4

FRAMYCETIN

Schedule 4

FRITTED GLAZING OR ENAMELLING PREPARATIONS

Appendix A, clause 1

FULLERS EARTH

Appendix B, clause 3

FULVESTRANT

Schedule 4

FUMAGILLIN

Schedule 6

FUNGAL PROTEASE derived from Aspergillus niger

Appendix B, clause 3

FURALAXYL

Schedule 5

FURALTADONE

Schedule 4

FURATHIOCARB

Schedule 7
Schedule 5

FURAZABOL

Schedule 4

FURAZOLIDONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

FURETHIDINE

cross reference: CAS No. 2385-81-1

Schedule 9

FURFURAL
cross reference: 2FURANCARBOXALDEHYDE

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

FUROSEMIDE
cross reference: FRUSEMIDE

Schedule 4

FUSIDIC ACID

Schedule 4

G

GABAPENTIN

Schedule 4
Appendix K, clause 1

GALANTAMINE

Schedule 4

GALANTHUS spp.

Schedule 4

GALCANEZUMAB

Schedule 4

GALLAMINE

Schedule 4

GALSULFASE

Schedule 4

GAMMA BUTYROLACTONE

cross reference: CAS No. 96-48-0

Schedule 10

GAMMA HYDROXYBUTYRATE
cross reference: 4HYDROXYBUTANOIC ACID, GHB, SODIUM OXYBATE

Schedule 9

GAMMACYHALOTHRIN

Schedule 7
Schedule 5

GANCICLOVIR

Schedule 4

GANIRELIX

Schedule 4

GATIFLOXACIN

Schedule 4

GEFITINIB

Schedule 4

GELATIN – SUCCINYLATED

Appendix A

GELSEMIUM SEMPERVIRENS

Schedule 2
Appendix G, clause 1

GEMCITABINE

Schedule 4
Appendix K, clause 1

GEMEPROST

Schedule 4

GEMFIBROZIL

Schedule 4

GEMIFLOXACIN

Schedule 4

GEMTUZUMAB OZOGAMICIN

Schedule 4

GENTAMICIN

Schedule 4

GENTIAN VIOLET
cross reference: METHYLROSANILINIUM CHLORIDE, CRYSTAL VIOLET

GERANIUM OIL

Appendix B, clause 3

GESTODENE

Schedule 4

GESTONORONE

Schedule 4

GESTRINONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

GHRH INJECTABLE PLASMID

Schedule 4

GIBBERELLIC ACID

Appendix B, clause 3

GILTERITINIB

Schedule 4

GITALIN

Schedule 4

GIVOSIRAN

Schedule 4

GLASS
cross reference: CRYSTAL WARE

Appendix A, clause 1

GLATIRAMER ACETATE

Schedule 4

GLAZED POTTERY

Appendix A, clause 1

GLECAPREVIR

Schedule 4

GLIBENCLAMIDE

Schedule 4

GLIBORNURIDE

Schedule 4

GLICLAZIDE

Schedule 4

GLIMEPIRIDE

Schedule 4

GLIPIZIDE

Schedule 4

GLIPTINS

Schedule 4

GLISOXEPIDE

Schedule 4

GLOFITAMAB

Schedule 4

GLUCAGON

Schedule 3
Appendix G, clause 1

Appendix H, clause 1

αGLUCANASE derived from Aspergillus niger

Appendix B, clause 3

GLUFOSINATEAMMONIUM

Schedule 5

GLUTARAL

Schedule 6
Schedule 5
Schedule 2
Appendix E, clause 3
Appendix F, clause 4

GLUTARALDEHYDE
cross reference: GLUTARAL

GLUTATHIONE

Schedule 4

GLUTETHIMIDE

Schedule 4
Appendix D, clause 5
Appendix K, clause 1

GLYCERYL THIOGLYCOLLATE

Schedule 6

GLYCERYL TRINITRATE

Schedule 4
Schedule 3
Appendix G, clause 1
Appendix H, clause 1

GLYCOLIC ACID

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

GLYCOPYRRONIUM

Schedule 4
Schedule 3

GLYCOSYLATED HYDROQUINONE
cross reference: HYDROQUINONE

GLYMIDINE

Schedule 4

GLYPHOSATE

Schedule 5

GnRH VACCINE

Schedule 4

GOLIMUMAB

Schedule 4

GONADORELIN

Schedule 4

GONADOTROPHIC HORMONES

Schedule 4

GOSERELIN

Schedule 4

GRAMICIDIN

Schedule 4

GRANISETRON

Schedule 4

GRAPIPRANT

Schedule 4

GRAZOPREVIR

Schedule 4

GREPAFLOXACIN

Schedule 4

GRISEOFULVIN

Schedule 4

GROWTH HORMONE RELEASING HORMONES *(GHRHs)

Schedule 4
Appendix D, clause 5

GROWTH HORMONE RELEASING PEPTIDE6 (GHRP6)

Schedule 4
Appendix D, clause 5

GROWTH HORMONE RELEASING PEPTIDE *(GHRPs)

Schedule 4
Appendix D, clause 5

GROWTH HORMONE SECRETAGOGUES *(GHSs)

Schedule 4
Appendix D, clause 5

GUAIFENESIN
cross reference: PARACETAMOL

Schedule 4
Schedule 2

GUAIPHENESIN
cross reference: GUAIFENESIN

GUANABENZ

Schedule 4

GUANACLINE

Schedule 4

GUANETHIDINE

Schedule 4

GUANFACINE

Schedule 4
Appendix K, clause 1

GUANIDINE

Schedule 6
Schedule 4
Appendix E, clause 3

GUAZATINE

Schedule 6

GUSELKUMAB

Schedule 4

H

HACHIMYCIN

Schedule 4

HAEMATIN

Schedule 4

HAEMOPHILUS INFLUENZAE VACCINE

Schedule 4

HALAUXIFEN METHYL

Appendix B, clause 3

HALCINONIDE

Schedule 4

HALOFANTRINE

Schedule 4

HALOFENATE

Schedule 4

HALOFUGINONE

Schedule 7
Schedule 4
Appendix J, clause 1

HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS
cross reference: DIBENZODIOXINS, HALOGENATED DIBENZOFURANS, HALOGENATED, DIOXINS

Schedule 7
Appendix J, clause 1

HALOPERIDOL
cross reference: BUTYPHENONES

Schedule 4
Appendix G, clause 1
Appendix K, clause 1

HALOSULFURONMETHYL

Schedule 5

HALOTHANE

Schedule 4

HALOXON

Schedule 6

HALOXYFOP

Schedule 6

HARMALA ALKALOIDS

Schedule 9

HC RED 13
cross reference: 2,2'[(4AMINO3NITROPHENYL)IMINO]BISETHANOL

HC VIOLET 1
cross reference: 2[(4AMINO2METHYL5NITROPHENYL)AMINO]ETHANOL

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

HCB

Schedule 7
Appendix J, clause 1

HELIONAL

Appendix B, Part 3

HELIOTROPIUM spp.

Schedule 10

HEMEROCALLIS

Schedule 4

HEMP SEED OIL
cross reference: CANNABIDIOL, CANNABIS, TETRAHYDROCANNABINOLS

HEPARINS

Schedule 4

HEPATITIS A VACCINE

Schedule 4

HEPATITIS B VACCINE

Schedule 4

HEPTACHLOR

Schedule 6

HEROIN

cross reference: CAS No. 561-27-3, HEROIN HYDROCHLORIDE (CAS No. 1502-95-0)

Schedule 9

HETACILLIN

Schedule 4

HEXACHLOROPHANE
cross reference: HEXACHLOROPHENE

HEXACHLOROPHENE
cross reference: HCB

Schedule 6
Schedule 4
Schedule 2
Appendix E, clause 3
Appendix F, clause 4

HEXACONAZOLE

Schedule 5

HEXAFLURON

Appendix B, clause 3

HEXAMETHONIUM

Schedule 4

HEXARELIN

Schedule 4
Appendix D, clause 5

HEXAZINONE

Schedule 6
Schedule 5

HEXETIDINE

Schedule 4

HEXLOXYETHANOL

Appendix F, clause 4

HEXOBENDINE

Schedule 4

HEXOCYCLIUM

Schedule 4

HEXOPRENALINE

Schedule 4

HEXYL ACETATE

Appendix B, clause 3

HEXYL AMINOLEVULINATE (AS HYDROCHLORIDE)

Schedule 4

HEXYL CINNAMALDEHYDE

Appendix B, clause 3

3HEXYL1HYDROXY7,8,9,10TETRAHYDRO6,6,9TRIMETHYL6HDIBENZO (b,d) PYRAN
cross reference: PARAHEXYL (CAS No. 117-51-1)

Schedule 9

HEXYLOXYETHANOL

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

HEXYTHIAZOX

Appendix B, clause 3

HISTAMINE

Schedule 4

HMGCoA REDUCTASE INHIBITORS
cross reference: STATINS

Schedule 4

HOMATROPINE

Schedule 4

HUMAN BLOOD PRODUCTS
cross reference: ALBUMIN, ANTICOAGULATION COMPLEX, C1 ESTERASE INHIBITORS, CLOTTING FACTORS, CRYOPRECIPITATE, FIBRINOGEN, PLASMA, PLATELETS, PROTEIN C, PROTHROMBIN COMPLEX CONCENTRATE (PCC), RED CELLS, THROMBIN, WHOLE BLOOD, STEM CELLS

Appendix A, clause 1

HUMAN CHORIONIC GONADOTROPHIN

Schedule 4

HUMAN OSTEOGENIC PROTEIN1 (OP1)

Appendix B, clause 3

HUMAN PAPILLOMAVIRUS VACCINE

Schedule 4

HYALURONIC ACID

Schedule 4

HYALURONIC ACID AND ITS POLYMERS

Schedule 4

HYDRALAZINE

Schedule 4

HYDRAMETHYLNON

Schedule 6
Schedule 5

HYDRARGAPHEN

Schedule 4

HYDRAZINE

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

HYDROCARBONS LIQUID AROMATIC
cross reference: AROMATIC EXTRACT OILS,

Schedule 7
Appendix F, clause 4

HYDROCARBONS, LIQUID 
cross reference: BENZENE, DESIGNATED SOLVENT, DIESEL (DISTILLATE), DRY CLEANING FLUID, KEROSENE, LAMP OIL, LIGHT MINERAL OILS, LIQUID HYDROCARBONS, MINERAL OILS, MINERAL TURPENTINE, NAPHTHALENE, PARAFFIN OILS, PETROL, PETROLEUM OILS, REDUCERS, THINNERS, TOLUENE, WHITE SPIRIT, WHITE PETROLEUM SPIRIT, WHITE MINERAL OILS, XYLENE

Schedule 5
Appendix E, clause 3

HYDROCHLORIC ACID

Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

HYDROCHLOROTHIAZIDE

Schedule 4

HYDROCODONE

Schedule 8
Appendix K, clause 1

HYDROCORTISONE

Schedule 4
Schedule 3
Schedule 2
Appendix F, clause 4
Appendix H, clause 1

HYDROCORTISONE ACETATE

Schedule 3
Schedule 2

HYDROCYANIC ACID
cross reference: CYANIDES, APRICOT KERNELS

Schedule 7
Schedule 4
Appendix F, clause 4
Appendix G, clause 1
Appendix J, clause 1

HYDROFLUMETHIAZIDE

Schedule 4

HYDROFLUORIC ACID
cross reference: HYDROGEN FLUORIDE

Schedule 7
Schedule 6
Schedule 5

Appendix E, clause 3

Appendix F, clause 4
Appendix J, clause 1

HYDROGEN PEROXIDE

cross reference: CAS No. 7722-84-1

Schedule 10
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

HYDROGEN SULFIDE

Schedule 7

HYDROMORPHINOL

Schedule 8

HYDROMORPHONE

Schedule 8
Appendix K, clause 1

HYDROPRENE

Appendix B, clause 3

HYDROQUINONE
cross reference: ARBUTIN, GLYCOSYLATED HYDROQUINONE, MONOBENZONE

Schedule 6
Schedule 4
Schedule 2
Appendix E, clause 3
Appendix F, clause 4

HYDROSILICOFLUORIC ACID
cross reference: FLUOROSILICIC ACID, HEXAFLUOROSILIC ACID, HYDROFLUOSILICIC ACID, SILICOFLUORIC ACID

Schedule 7
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

4HYDROXYBUTANOIC ACID

cross reference: CAS No. 591-81-1, SODIUM OXYBATE (CAS No. 502-85-2)

Schedule 9

HYDROXYCARBAMIDE

Schedule 4

HYDROXYCHLOROQUINE

Schedule 4
Appendix D, clause 8

2[(1R,3S)3HYDROXYCYCLOHEXYL]5(2METHYLNONAN2YL)PHENOL             
cross reference: CANNABICYCLOHEXANOL (CAS No. 70434-92-3), CP 47,497 C8 HOMOLOGUE, CP 47,497 (CAS No. 70434-82-1)

Schedule 9

HYDROXYEPHEDRINE

Schedule 4

4[(2HYDROXYETHYL)AMINO]3NITROPHENOL
cross reference: 3NITROpHYDROXYETHYLAMINOPHENOL

2HYDROXYETHYL METHACRYLATE

Schedule 5
Appendix E, clause 3
Appendix F, clause 4

HYDROXYETHYL3,4METHYLENEDIOXYANILINE

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

[7HYDROXY8[(2 METHOXYPHENYL)AZO]2NAPHTHYL]TRIMETHYLAMMONIUM CHLORIDE (CAS No. 68391300)
cross reference: BASIC RED 76 (CAS No. 68391300)

HYDROXYPETHIDINE

cross reference: CAS No. 468-56-4

Schedule 9

HYDROXYPHENAMATE

Schedule 4

HYDROXYPROGESTERONE

Schedule 4

HYDROXYPROPYL CELLULOSE

Appendix B, clause 3

2HYDROXYPROPYL METHACRYLATE

Schedule 5

8HYDROXYQUINOLINE
cross reference: OXYQUINOLINE

HYDROXYSTENOZOL

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

HYDROXYUREA
cross reference: HYDROXYCARBAMIDE

HYDROXYZINE

Schedule 4
Appendix K, clause 1

HYGROMYCIN

Schedule 4

HYOSCINE
cross reference: HYOSCINE BUTYLBROMIDE

Schedule 4
Schedule 2
Appendix G, clause 1

HYOSCINE BUTYLBROMIDE

Schedule 4

Schedule 3

Schedule 2

Appendix H, clause 1

HYOSCYAMINE

Schedule 4

Schedule 2

Appendix G, clause 1

HYOSCYAMUS NIGER

Schedule 4

Schedule 2

Appendix G, clause 1

HYPOTHALAMIC RELEASING FACTORS

Schedule 4
Appendix G, clause 1

HYPROMELLOSE

Schedule 4

I

IBAFLOXACIN

Schedule 4

IBANDRONIC ACID

Schedule 4

IBOGAINE

Schedule 4

IBRITUMOMAB

Schedule 4

IBRUTINIB

Schedule 4

IBUFENAC

Schedule 4

IBUPROFEN
cross reference: PARACETAMOL

Schedule 4
Schedule 3
Schedule 2
Appendix F, clause 4
Appendix H, clause 1

IBUTAMOREN
cross reference: MK677, NUTROBAL

Schedule 4
Appendix D, clause 5

IBUTEROL

Schedule 4

IBUTILIDE

Schedule 4

ICATIBANT

Schedule 4

ICODEXTRIN

Appendix B, clause 3

IDARUBICIN

Schedule 4

IDARUCIZUMAB

Schedule 4

IDEBENONE

Schedule 4

IDOXURIDINE

Schedule 4

IDURSULFASE

Schedule 4

IFOSFAMIDE

Schedule 4

ILOPROST

Schedule 4

IMATINIB

Schedule 4

IMAZALIL
cross reference: ENILCONAZOLE

Schedule 5

IMAZAMOX

Schedule 5

IMAZAPIC

Schedule 5

IMAZAPYR

Schedule 5

IMAZETHAPYR

Schedule 5

IMDEVIMAB

Schedule 4

IMEPITOIN

Schedule 4

IMIDACLOPRID

Schedule 6
Schedule 5

IMIDAPRIL

Schedule 4

IMIDOCARB

Schedule 6

IMIGLUCERASE

Schedule 4

IMINOCTADINE TRIALBESILATE

Schedule 6

IMIPENEM

Schedule 4

IMIPRAMINE

Schedule 4
Appendix K, clause 1

IMIPROTHRIN

Schedule 6
Schedule 5

IMIQUIMOD

Schedule 4

IMLIFIDASE

Schedule 4

IMMUNOGLOBULINS
cross reference: EQUINE ANTIHUMAN THYMOCYTE IMMUNOGLOBULIN

Schedule 4

IN VITRO DIAGNOSTIC AND ANALYTICAL PREPARATIONS

Appendix A, clause 1

INCLISIRAN

Schedule 4

INDACATEROL

Schedule 4

INDANAZOLINE

Schedule 2

INDAPAMIDE

Schedule 4

INDAZIFLAM

Schedule 6

INDINAVIR

Schedule 4

INDOLE3ACETIC ACID

Appendix B, clause 3

INDOMETACIN

Schedule 4
Schedule 2
Appendix G, clause 1

INDOMETHACIN
cross reference: INDOMETACIN

INDOPROFEN

Schedule 4

INDORAMIN

Schedule 4

INDOXACARB

Schedule 6
Schedule 5

INFIGRATINIB

Schedule 4

INFLIXIMAB

Schedule 4

INFLUENZA AND CORYZA VACCINES
cross reference: H5N1 INFLUENZA VIRUS HAEMAGGLUTININ

Schedule 4

INGENOL MEBUTATE

Schedule 4

INOTUZUMAB OZOGAMICIN

Schedule 4

INOSITOL NICOTINATE

Schedule 3

INPYRFLUXAM

Schedule 6

INSULIN DEGLUDEC

Schedule 4

INSULIN GLARGINE

Schedule 4

INSULINLIKE GROWTH FACTOR I

Schedule 4

INSULINLIKE GROWTH FACTORS

Schedule 4
Appendix D, clause 5

INSULINS

Schedule 4

INTERFERONS

Schedule 4

INTERLEUKINS

Schedule 4

INTRAOCULAR VISCOELASTIC PRODUCTS

Appendix A, clause 1

IODINE
cross reference: IODOPHORS

Schedule 6
Schedule 2
Appendix E, clause 3
Appendix F, clause 4

IODOMETHANE

Schedule 7
Appendix J, clause 1

IODOPHORS
cross reference: IODINE

Schedule 6
Appendix E, clause 3

3IODO2PROPYNYL BUTYL CARBAMATE
cross reference: IODOCARB

Schedule 6
Schedule 5

IODOSULFURONMETHYLSODIUM

Schedule 5

IODOTHIOURACIL

Schedule 4

IOXYNIL

Schedule 6

IPAMORELIN

Schedule 4,
Appendix D, clause 5

IPCONAZOLE

Schedule 6
Schedule 5

IPFLUFENOQUIN

Appendix B, Part 3

IPILIMUMAB

Schedule 4

IPRATROPIUM

Schedule 4
Schedule 2

IPRATROPIUM BROMIDE

Appendix F, clause 4

IPRIFLAVONE

Schedule 4

IPRINDOLE

Schedule 4

IPRODIONE

Appendix B, clause 3

IPRONIAZID

Schedule 4

IRBESARTAN

Schedule 4

IRINOTECAN

Schedule 4

IRON COMPOUNDS
cross reference: IRON OXIDES

Schedule 6
Schedule 5
Schedule 4
Schedule 2

ISAVUCONAZOLE

Schedule 4
Appendix L, clause 2

ISETHIONATE

Appendix B, clause 3

ISOAMINILE

Schedule 4

ISOAMYL NITRITE

Schedule 4
Appendix E, clause 3

ISOBUTYL NITRITE

Schedule 4
Appendix E, clause 3

ISOCARBOPHOS

Schedule 7

ISOCARBOXAZID

Schedule 4

ISOCONAZOLE

Schedule 6
Schedule 4
Schedule 3
Schedule 2
Appendix H, clause 1

ISOCYANATES

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

ISOCYCLOSERAM

Schedule 6

ISOETARINE

Schedule 4

ISOEUGENOL

Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

ISOFENPHOS

Schedule 7

ISOFETAMID

Appendix B, clause 3

ISOFLURANE

Schedule 4

ISOMETHADONE

cross reference: CAS No. 466-40-0

Schedule 9

ISOMETHEPTENE

Schedule 4

ISONIAZID

Schedule 4

ISOPHORONE

Schedule 5
Appendix E, clause 3

ISOPRENALINE

Schedule 4
Appendix F, clause 4

ISOPRENE ALCOHOL

Appendix B, clause 3

ISOPRINOSINE

Schedule 4

ISOPROPAMIDE

Schedule 4
Schedule 2

ISOPROPYL NITRITE

cross reference: CAS No. 541-42-4

Schedule 10

ISOPROTURON

Schedule 7

ISOPYRAZAM

Schedule 6

ISOSORBIDE DINITRATE

Schedule 4
Schedule 3

ISOSORBIDE MONONITRATE

Schedule 4

ISOSTEARYL ALCOHOL ETHOXYLATE

Appendix B, clause 3

ISOTIANIL

Schedule 6

ISOTONITAZENE

cross reference: CAS No. 14188-81-9

Schedule 9

ISOTRETINOIN

Schedule 4
Appendix D, clause 5
Appendix F, clause 4
Appendix L, clause 2

ISOXABEN

Schedule 5

ISOXAFLUTOLE

Schedule 5

ISOXICAM

Schedule 4

ISOXSUPRINE

Schedule 4

ISRADIPINE

Schedule 4

ITRACONAZOLE

Schedule 4

IVABRADINE

Schedule 4

IVACAFTOR

Schedule 4

IVERMECTIN

Schedule 7
Schedule 5
Schedule 4

IVOSIDENIB

Schedule 4

IXABEPILONE

Schedule 4

IXAZOMIB

Schedule 4

IXEKIZUMAB

Schedule 4

J

JAPANESE ENCEPHALITIS VACCINE

Schedule 4

JUNIPERUS SABINE
cross reference: SAVIN(E)

Schedule 10

K

KAMBO
cross reference: Secretion of the South American Giant Leaf Frog or Giant Monkey Frog (Phyllomedusa bicolor)

Schedule 10

KANAMYCIN

Schedule 4

KAOLIN

Appendix B, clause 3

KEROSENE

Appendix E, clause 3

KETAMINE

Schedule 8

KETANSERIN

Schedule 4

KETAZOLAM

Schedule 4
Appendix D, clause 5 (Benzodiazepine derivatives)

KETOBEMIDONE

cross reference: CAS No. 469-79-4, KETOBEMIDONE HYDROCHLORIDE (CAS No. 5965-49-1)

Schedule 9

KETOCONAZOLE

Schedule 4
Schedule 2

KETOPROFEN

Schedule 4
Schedule 3

Appendix H, clause 1

KETOROLAC

Schedule 4

KETOTIFEN

Schedule 4
Schedule 2

KHELLIN

Schedule 4

KINETIN

Appendix B, clause 3

KITASAMYCIN

Schedule 5
Schedule 4

KRATOM

cross reference: MITRAGYNA SPECIOSA, MITRAGYNINE

KRESOXIMMETHYL

Appendix B, clause 3

KUNZEA OIL

Appendix B, clause 3

L

LABETALOL

Schedule 4

LACIDIPINE

Schedule 4

LACOSAMIDE

Schedule 4

LAMBDACYHALOTHRIN

Schedule 7
Schedule 6
Schedule 5

LAMIVUDINE

Schedule 4

LAMOTRIGINE

Schedule 4
Appendix K, clause 1

LANADELUMAB

Schedule 4

LANATOSIDES

Schedule 4

LANREOTIDE

Schedule 4

LANSOPRAZOLE

Schedule 4
Schedule 3
Schedule 2
Appendix H, clause 1

LANTHANUM

Schedule 4

LAPATINIB

Schedule 4

LARONIDASE

Schedule 4

LAROPIPRANT

Schedule 4

LAROTRECTINIB

Schedule 4

LASALOCID

Schedule 6

LASIODIPLODIA PSEUDOTHEOBROMAE

Schedule 5

LATAMOXEF

Schedule 4

LATANOPROST

Schedule 4

LAUDEXIUM

Schedule 4

LAURETH CARBOXYLIC ACIDS

Schedule 6
Appendix E, clause 3

LAURIC ACID

Appendix B, clause 3

LAUROMACROGOLS
cross reference: LAURETH9

Schedule 4

LAURYL ALCOHOL
cross reference: 1DODECANOL

Appendix B, clause 3

LAURYL ISOQUINOLINIUM BROMIDE

Schedule 6
Appendix E, clause 3

LAURYL SULFATE SALTS
cross reference: SODIUM LAURYL SULPHATE, DODECYL SULFATES

Schedule 6
Appendix E, clause 3

LAVANDIN OIL
cross reference: CAMPHOR

Appendix B, clause 3

LAVENDER OIL

Appendix B, clause 3

LEAD
cross reference: GLAZING PREPARATIONS, PRINTING INKS or INK ADDITIVES, SELENIUM

Schedule 4

LEAD COMPOUNDS
cross reference: GLAZING PREPARATIONS, PRINTING INKS or INK ADDITIVES, SELENIUM

Schedule 10
Schedule 6
Appendix E, clause 3
Appendix F, clause 4 (in glazing preparations)
Appendix F, clause 4

LEAD METALLIC

Appendix B, clause 3

LEDIPASVIR

Schedule 4

LEFETAMINE

Schedule 4

LEFLUNOMIDE

Schedule 4
Appendix F, clause 4
Appendix L, clause 2

LEMBOREXANT

Schedule 4
Appendix K, clause 1

LEMON OIL

Schedule 5
Appendix E, clause 3
Appendix F, clause 4

LEMONGRASS OIL

Schedule 5

LENACAPAVIR

Schedule 4

LENALIDOMIDE

Schedule 4
Appendix D, clause 4
Appendix F, clause 4
Appendix L, clause 2

LENOGRASTIM

Schedule 4

LENVATINIB

Schedule 4

LEPIDOPTEROUS SEX PHEROMONES

Appendix B, clause 3

LEPIRUDIN

Schedule 4

LEPTAZOL

Schedule 4

LEPTOPHOS

Schedule 7

LEPTOSPERMUM SCOPARIUM OIL
cross reference: MANUKA OIL

Schedule 6
Appendix E, clause 3

LERCANIDIPINE

Schedule 4

LESINURAD

Schedule 4

LETERMOVIR

Schedule 4

LETROZOLE

Schedule 4

LEUPRORELIN

Schedule 4

LEVALLORPHAN

Schedule 4

LEVAMISOLE

Schedule 6
Schedule 5
Schedule 4

LEVAMFETAMINE
cross reference: LEVAMPHETAMINE

Schedule 8

LEVETIRACETAM

cross reference: RACETAMS

Schedule 4
Appendix K, clause 1

LEVOBUNOLOL

Schedule 4

LEVOBUPIVACAINE

Schedule 4

LEVOCABASTINE

Schedule 4
Schedule 2
Appendix F, clause 4
Appendix L, clause 2

LEVOCETIRIZINE

Schedule 4
Schedule 2
Appendix K, clause 1

LEVODOPA

Schedule 4

LEVOMEPROMAZINE
cross reference: METHOTRIMEPRAZINE

Schedule 4

LEVOMETHAMFETAMINE
cross reference: LEVOMETHAMPHETAMINE

Schedule 8

LEVOMETHORPHAN

cross reference: CAS No. 125-70-2

Schedule 9

LEVOMILNACIPRAN

Schedule 4

LEVOMORAMIDE

Schedule 8

LEVONORGESTREL

Schedule 4
Schedule 3

Appendix H, clause 1

LEVOPHENACYLMORPHAN

cross reference: CAS No. 10061-32-2

Schedule 9

LEVORPHANOL

Schedule 8

LEVOSIMENDAN

Schedule 4

LIDOCAINE

Schedule 5
Schedule 4
Schedule 2

LIDOFLAZINE

Schedule 4

LIFITEGRAST

Schedule 4

LIGNOCAINE
cross reference: LIDOCAINE

LIGULARIA DENTATA

Schedule 10

LIME OIL

Schedule 5
Appendix E, clause 3
Appendix F, clause 4

LIMONENE
cross reference: DIPENTENE

Appendix B, clause 3

LINACLOTIDE

Schedule 4

LINAGLIPTIN

Schedule 4

LINCOMYCIN

Schedule 4

LINDANE
cross reference: BHC

Schedule 6
Schedule 5
Schedule 4
Schedule 2

LINEZOLID

Schedule 4

LINOLEIC ACID

Appendix B, clause 3

LINSEED FATTY ACIDS

Appendix B, clause 3

LINURON

Appendix B, clause 3

LIOTHYRONINE
cross reference: TRIIODOTHYRONINE

Schedule 4

LIPEGFILGRASTIM

Schedule 4

LIQUORICE, DEGLYCYRRHISINISED

Appendix B, clause 3

LIRAGLUTIDE

Schedule 4

LISDEXAMFETAMINE

Schedule 8

LISINOPRIL

Schedule 4

LISURIDE

Schedule 4

LITHIUM

Schedule 4
Schedule 2

LITHIUM PERFLUOROOCTANE SULFONATE

Schedule 7

LIXISENATIDE

Schedule 4

LOBELIA INFLATA

Schedule 2

LOBELINE

Schedule 2

LODOXAMIDE

Schedule 4
Schedule 2

LOFEXIDINE

Schedule 4

LOGIPARIN

Schedule 4

LOMEFLOXACIN

Schedule 4

LOMUSTINE

Schedule 4

LOPERAMIDE

Schedule 4
Schedule 2
Appendix F, clause 4

LOPINAVIR

Schedule 4

LOPRAZOLAM

Schedule 4
Appendix D, clause 5 (Benzodiazepine derivatives)

LORACARBEF

Schedule 4

LORATADINE

Schedule 4
Schedule 2

LORAZEPAM

Schedule 4
Appendix D, clause 5 (Benzodiazepine derivatives)
Appendix K, clause 1

LORLATINIB

Schedule 4

LORMETAZEPAM

Schedule 4
Appendix D, clause 5 (Benzodiazepine derivatives)

LOSARTAN

Schedule 4

LOTEPREDNOL

Schedule 4

LOTILANER

Schedule 5

LOXAPINE

Schedule 4

LUBRICANTS

Appendix A, clause 1

LUFENURON

Schedule 5

LUMACAFTOR

Schedule 4

LUMEFANTRINE

Schedule 4

LUMIRACOXIB

Schedule 4

LURASIDONE

Schedule 4
Appendix K, clause 1

LURBINECTEDIN

Schedule 4

LUSPATERCEPT

Schedule 4

LUTEINISING HORMONE

Schedule 4
Appendix D, clause 1

LYMECYCLINE

Schedule 4

LYSERGIC ACID

cross reference: CAS No. 82-58-6

Schedule 9

LYSERGIDE

cross reference: CAS No. 50-37-3

Schedule 9

M

MACITENTAN

Schedule 4
Appendix D, clause 6
Appendix L, clause 2

MACROGOLS

Schedule 3
Schedule 2

MACROPHOMINA PHASEOLINA

Schedule 5

MADURAMICIN

Schedule 7
Schedule 5
Appendix J, clause 1

MAFENIDE

Schedule 6
Schedule 4

MAGNESIUM CHLORATE

Schedule 5
Appendix E, clause 3
Appendix F, clause 4

MAGNESIUM HYDROXIDE

Appendix B, clause 3

MAGNESIUM SULFATE

Schedule 3

MALACHITE GREEN

Schedule 7
Schedule 5

MALATHION
cross reference: MALDISON, ORGANOPHOSPHORUS COMPOUNDS

Schedule 6
Schedule 5
Schedule 3
Appendix E, clause 3

MALEIC HYDRAZIDE

Appendix B, clause 3

MANCOZEB

Schedule 5

MANDESTROBIN

Schedule 5

MANDIPROPAMID

Schedule 5

MANDRAGORA OFFICINARUM

Schedule 4

MANGANESE DIOXIDE

Appendix B, clause 3

MANNITYL HEXANITRATE

Schedule 3

MANNOMUSTINE

Schedule 4

MAPROTILINE

Schedule 4

MARAVIROC

Schedule 4

MARBOFLOXACIN

Schedule 4

MARJORAM OIL

Schedule 5
Appendix E, clause 3

MAROPITANT

Schedule 4

MATCHES

Appendix A, clause 1

MAVACAMTEN

Schedule 4

MAVACOXIB

Schedule 4

MAZIDOX

Schedule 7

MAZINDOL

Schedule 4
Appendix K, clause 1

MCPA

Schedule 6
Schedule 5

MCPB
cross reference: (4(4CHLORO2METHYLPHENOXY)BUTANOIC ACID

Schedule 6

MEASLES VACCINE

Schedule 4

MEBANAZINE

Schedule 4

MEBENDAZOLE

Schedule 6
Schedule 5
Schedule 2

MEBEVERINE

Schedule 4

MEBHYDROLIN

Schedule 4
Appendix K, clause 1

MEBOLAZINE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

MEBUTAMATE

Schedule 4

MECAMYLAMINE

Schedule 4

MECARBAM

Schedule 7

MECASERMIN

Schedule 4

MECILLINAM

Schedule 4

MECLOCYCLINE

Schedule 4

MECLOFENAMATE

Schedule 4

MECLOFENAMIC ACID

Schedule 5

MECLOFENOXATE

Schedule 4

MECLONAZEPAM

cross reference: CAS No. 58662-84-3

Schedule 9

MECLOQUALONE

cross reference: CAS No. 340-57-8

Schedule 9

MECLOZINE
cross reference: MECLIZINE

Schedule 4
Schedule 2
Appendix K, clause 1

MECOPROP

Schedule 6
Schedule 5

MECOPROPP

Schedule 6

MEDAZEPAM

Schedule 4
Appendix D, clause 5 (Benzodiazepine derivatives)
Appendix K, clause 1

MEDETOMIDINE

Schedule 4

MEDICAL AND VETERINARY ADHESIVES, GLUES AND CEMENTS

Appendix A, clause 1

MEDICAL DEVICES
cross reference: ANTICOAGULANT MEDICAL DEVICES, ARTIFICIAL TEARS, COLLAGEN, INJECTABLE TISSUE RECONSTRUCTIVE, AUGMENTATION AND RESTORATION MATERIALS, INTRAARTICULAR FLUIDS, URINARY CATHETERS

Appendix A, clause 1

MEDIGOXIN
cross reference: METHYLDIGOXIN

Schedule 4

MEDROXYPROGESTERONE

Schedule 4

MEDRYSONE

Schedule 4

MEFENAMIC ACID

Schedule 4
Schedule 2
Appendix F, clause 4

MEFENOREX

Schedule 4

MEFENPYRDIETHYL

Schedule 5

MEFENTRIFLUCONAZOLE

Schedule 5

MEFLOQUINE

Schedule 4

MEFLUIDIDE

Schedule 6

MEFRUSIDE

Schedule 4

MEGASPHAERA ELSDENII strain 41125

Appendix B, clause 3

MEGESTROL

Schedule 4

MELAGATRAN

Schedule 4

MELALEUCA OIL
cross reference: TEA TREE OIL

Schedule 6
Appendix E, clause 3

MELANOTAN II
cross reference: α–MELANOCYTE STIMULATING HORMONE

Schedule 4

MELATONIN

Schedule 4
Schedule 3
Appendix H, clause 1

MELENGESTROL

Schedule 4

MELENGESTROL ACETATE

Schedule 6

MELIA AZEDARACH

Schedule 10

MELOXICAM

Schedule 6

Schedule 4

MELPHALAN

Schedule 4

MEMANTINE

Schedule 4

MENAZON

Schedule 6

MENINGOCOCCAL VACCINE

Schedule 4

MENINGOCOCCAL GROUP B VACCINE
cross reference: Neisseria Meningitidis Serogroup B Recombinant LP2086 (MnB rLP2086) Subfamily A Protein and Subfamily B Protein

Schedule 4

MENOTROPHIN

Schedule 4

MEPACRINE

Schedule 4

MEPENZOLATE

Schedule 4

MEPHENESIN

Schedule 4

MEPHENTERMINE

Schedule 4

MEPINDOLOL

Schedule 4

MEPIQUAT

Schedule 5

MEPITIOSTANE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

MEPIVACAINE

Schedule 4

MEPROBAMATE

Schedule 4
Appendix K, clause 1

MEPTAZINOL

Schedule 4

MEPYRAMINE

Schedule 4
Schedule 3
Schedule 2
Appendix K, clause 1

MEQUITAZINE

Schedule 4

MERCAPTAMINE
cross reference: CYSTEAMINE

Schedule 6
Schedule 5
Schedule 4
Appendix K, clause 1

MERCAPTOACETIC ACID
cross reference: THIOGLYCOLIC ACID

Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

2MERCAPTOETHANOL

Schedule 6

MERCAPTOMERIN

Schedule 4

MERCAPTOPURINE

Schedule 4

MERCURIC CHLORIDE
cross reference: CALOMEL

Schedule 7
Appendix E, clause 3

MERCURIC IODIDE

Appendix E, clause 3

MERCURIC NITRATE

Appendix E, clause 3

MERCURIC OXIDE

Schedule 6
Appendix E, clause 3

MERCURIC POTASSIUM IODIDE

Appendix E, clause 3

MERCURIC THIOCYANATE

Appendix E, clause 3
Appendix F, clause 4

MERCUROCHROME

Schedule 6
Schedule 4
Schedule 2
Appendix E, clause 3

MERCUROUS CHLORIDE
cross reference: CORROSIVE SUBLIMATE

Appendix E, clause 3

MERCURY
cross reference: ETHOXYETHYLMERCURIC CHLORIDE, ETHOXYQUIN, PHENYL MERCURIC CHLORIDE

Schedule 7
Schedule 4
Schedule 2
Appendix G, clause 1
Appendix J, clause 1

MERCURY metallic

Appendix E, clause 3

MERCURY, organic compounds

Appendix E, clause 3

MEROPENEM

Schedule 4

MERSALYL

Schedule 4

MESABOLONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

MESALAZINE

Schedule 4

MESNA

Schedule 4

MESOSULFURONMETHYL

Appendix B, clause 3

MESOTRIONE

Schedule 5

MESTANOLONE
cross reference: ANDROSTALONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

MESTEROLONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

MESTRANOL

Schedule 4

METACRESOLSULPHONIC ACID

Schedule 6
Appendix F, clause 4

METAFLUMIZONE

Schedule 5

METALAXYL

Schedule 6
Schedule 5

METALDEHYDE

Schedule 6
Schedule 5
Appendix E, clause 3

METAMFETAMINE
cross reference: METHAMFETAMINE, METHAMPHETAMINE, METHYLAMFETAMINE, METHYLAMPHETAMINE

Schedule 8

METAMITRON

Schedule 6

METANDIENONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

METARAMINOL

Schedule 4

METARHIZIUM ANISOPLIAE

Appendix B, clause 3

METAZACHLOR

Schedule 5

METAZOCINE

cross reference: CAS No. 3734-52-9, METAZOCINE RACEMATE CIS-FORM (CAS No. 25144-79-0)

Schedule 9

METCAMIFEN

Appendix B, clause 3

METENOLONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

METERGOLINE

Schedule 4

METFORMIN

Schedule 4

METHABENZTHIAZURON

Schedule 5

METHACHOLINE

Schedule 4

METHACRIFOS

Schedule 7
Schedule 6
Appendix J, clause 1

METHACYCLINE

Schedule 4

METHADONE

Schedule 8
Appendix K, clause 1

METHALLENESTRIL
cross reference: METHALLENOESTRIL

Schedule 4

METHAM
cross reference: METHAM SODIUM

Schedule 6

METHAMIDOPHOS

Schedule 7

METHANDRIOL

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

METHANOL

cross reference: CAS No. 67-56-1

Schedule 10

Schedule 6

Schedule 5
Appendix E, clause 3
Appendix F, clause 4

METHANTHELINIUM

Schedule 4

METHAPYRILENE

Schedule 7

METHAQUALONE

cross reference: CAS No. 72-44-6, METHAQUALONE HYDROCHLORIDE (CAS No. 340-56-7)

Schedule 9

METHAZOLAMIDE

Schedule 4

METHAZOLE

Schedule 7

METHCATHINONE

cross reference: CAS No. 5650-44-2, METHCATHINONE HYDROCHLORIDE (CAS No. 49656-78-2)

Schedule 9

METHDILAZINE

Schedule 4
Schedule 3
Appendix K, clause 1

METHENAMINE
cross reference: 1,3,5,7TETRAAZATRICYLO[3.3.1.13,7] DECANE, HEXAMINE, HEXAMETHYLENETETRAMINE

Schedule 5

METHENOLONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

METHICILLIN

Schedule 4

METHIDATHION

Schedule 7

METHIMAZOLE
cross reference: THIAMAZOLE

Schedule 4

METHIOCARB

Schedule 7
Schedule 6
Schedule 5

METHISAZONE

Schedule 4

METHIOZOLIN

Schedule 5

METHIXENE

Schedule 4

METHOCARBAMOL

Schedule 4
Appendix K, clause 1

METHOFLUTHRIN

Schedule 5

METHOHEXITONE

Schedule 4

METHOIN

Schedule 4

METHOMYL
cross reference: DENATONIUM BENZOATE

Schedule 7
Schedule 6

METHOPRENE

Appendix B, clause 3

METHOTREXATE

Schedule 4

METHOXAMINE

Schedule 4
Schedule 2
Appendix F, clause 4

METHOXSALEN

Schedule 4

METHOXYCHLOR

Schedule 5

2METHOXYETHANOL

Schedule 7
Appendix F, clause 4

METHOXYETHYLMERCURIC ACETATE

Schedule 7
Appendix J, clause 1

METHOXYETHYLMERCURIC CHLORIDE

Schedule 7
Appendix J, clause 1

METHOXYFENOZIDE

Appendix B, clause 3

METHOXYFLURANE

Schedule 4

5METHOXY3,4METHYLENEDIOXYAMFETAMINE
cross reference: 5METHOXY3,4METHYLENEDIOXYAMPHETAMINE, MMDA (CAS No. 13674-05-0), MMDA HYDROCHLORIDE (CAS No. 60676-84-8)

Schedule 9

4METHOXY α –METHYLPHENYLETHYLAMINE
cross reference: PMA (CAS No. 64-13-1), PMA HYDROCHLORIDE (CAS No. 3706-26-1)

Schedule 9

5METHOXY α –METHYLTRYPTAMINE
cross reference: 5MeOAMT (CAS No. 1137-04-8)

Schedule 9

6METHOXYN2METHYL2,3PYRIDINEDIAMINE

Schedule 6

2METHOXY5NITROPHENOL

Schedule 6

METHOXYPHENAMINE

Schedule 2

2(2METHOXYPHENYL)1(1PENTYLINDOL3YL)ETHANONE
cross reference: JWH250 (CAS No. 864445-43-2)

Schedule 9

METHSUXIMIDE

Schedule 4

METHYCLOTHIAZIDE

Schedule 4

METHYL ACETATE

Appendix B, clause 3

METHYL (2S, 4aR, 6aR, 7R, 9S, 10aS, 10bR)9ACETOXY6a,10bDIMETHYL4,10DIOXODODECAHYDRO2(3FURYL)2HNAPHTHO[2,1c]PYRAN7CARBOXYLATE
cross reference: SALVINORIN A (CAS No. 83729-01-5)

Schedule 9

METHYL AMINOLEVULINATE

Schedule 4

pMETHYLAMINOPHENOL

Schedule 6
Appendix F, clause 4

4METHYLAMINOREX

cross reference: CAS No. 3568-94-3

Schedule 9

METHYLANDROSTANOLONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

METHYLATED SPIRIT(S)
cross reference: DENATONIUM BENZOATE, ETHANOL, FLUORESCEIN

Schedule 5
Appendix E, clause 3
Appendix F, clause 4

METHYL BENZOQUATE

Appendix B, clause 3

METHYL BROMIDE

Schedule 7
Appendix J, clause 1

METHYL CHLORIDE

Appendix F, clause 4

METHYLCHLOROISOTHIAZOLINONE
cross reference: METHYLISOTHIAZOLINONE

Schedule 6
Appendix F, clause 4

METHYLCLOSTEBOL

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL

Schedule 7
Schedule 6

1METHYLCYCLOPROPENE

Appendix B, clause 3

METHYLDESORPHINE

cross reference: CAS No. 16008-36-9

Schedule 9

METHYLDIBROMO GLUTARONITRILE

cross reference: CAS No. 35691-65-7

Schedule 10
Schedule 6
Appendix F, clause 4

METHYLDIHYDROMORPHINE

Schedule 8

METHYLDOPA

Schedule 4

4,4'METHYLENEBIS[2CHLOROANILINE]

Schedule 7
Appendix J, clause 1

METHYLENE BISTHIOCYANATE

Schedule 6
Appendix F, clause 4

METHYLENE BLUE

Schedule 7
Schedule 5
Schedule 4

3,4METHYLENEDIOXYAMFETAMINE
cross reference: 3,4METHYLENEDIOXYAMPHETAMINE, MDA, TENAMFETAMINE (CAS No. 4764-17-4)

Schedule 9

3,4METHYLENEDIOXYPYROVALERONE
cross reference: MDPV (CAS No. 687603-66-3)

Schedule 9

METHYLEPHEDRINE

Schedule 2

METHYLERGOMETRINE

Schedule 4

METHYL ETHYL KETONE
cross reference: DESIGNATED SOLVENT

Schedule 5
Appendix E, clause 3
Appendix F, clause 4

METHYL ETHYL KETONE OXIME

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

METHYL ETHYL KETONE PEROXIDE

Schedule 5
Appendix E, clause 3
Appendix F, clause 4

METHYLEUGENOL

Schedule 6
Appendix E, clause 3,
Appendix F, clause 4

3METHYLFENTANYL

cross reference: CAS No. 42045-86-3

Schedule 9

METHYLPHENYLPIRACETAM
cross reference: RACETAMS

Schedule 4

METHYL pHYDROXYBENZOATE

Appendix B, clause 3

METHYL ISOAMYL KETONE
cross reference: DESIGNATED SOLVENT

Schedule 5
Appendix E, clause 3

METHYL ISOBUTYL KETONE
cross reference: DESIGNATED SOLVENT, METHYLATED SPIRIT(S)

Schedule 5
Appendix E, clause 3

METHYL ISOTHIOCYANATE

Schedule 6

METHYLISOTHIAZOLINONE
cross reference: METHYLCHLOROISOTHIAZOLINONE

Schedule 6
Appendix F, clause 4

METHYLMERCURY

Schedule 4
Appendix G, clause 1

METHYL METHACRYLATE

cross reference: CAS No. 80-62-6

Schedule 10
Schedule 6
Appendix F, clause 4

4METHYLMETHCATHINONE
cross reference: MEPHEDRONE (CAS No. 1189805-46-6)

Schedule 9

NMETHYL1(3,4METHYLENEDIOXYPHENYL)2BUTANAMINE
cross reference: MBDB (CAS No. 135795-90-3)

Schedule 9

N α [METHYL3,4(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE
cross reference: NHYDROXY MDA (CAS No. 74698-47-8)

Schedule 9

2METHYL3MORPHOLINO1, 1DIPHENYLPROPANE CARBOXYLIC ACID             
cross reference: MORAMIDE INTERMEDIATE (CAS No. 3626-55-9)

Schedule 9

METHYLNALTREXONE

Schedule 4

METHYL NEODECANAMIDE

Schedule 6

METHYLNORBORNYLPYRIDINE

Schedule 6

METHYLONE *(MDMC)

cross reference: CAS No. 186028-79-5, MDMC HYDROCHLORIDE (CAS No. 186028-80-8)

Schedule 9

METHYLPENTYNOL

Schedule 4

METHYLPHENIDATE

Schedule 8

METHYLPHENOBARBITAL
cross reference: BARBITURATE METHYLPREDNISOLONE

Schedule 4
Appendix K, clause 1

METHYLPHENOBARBITONE
cross reference: METHYLPHENOBARBITAL, BARBITURATE METHYLPREDNISOLONE

1METHYL4PHENYL4PIPERIDINOL PROPIONATE
cross reference: ACIDMPPP (CAS No. 13147-09-6), MPPP HYDROCHLORIDE (CAS No. 4968-48-3)

Schedule 9

1METHYL4PHENYLPIPERIDINE4CARBOXYLIC ACID
cross reference: PETHIDINE INTERMEDIATE C

Schedule 8

METHYLPREDNISOLONE

Schedule 4

NMETHYL2PYRROLIDONE

Schedule 6

Schedule 5
Appendix E, clause 3

2METHYLRESORCINOL

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

METHYLROSANILINIUM CHLORIDE
cross reference: CRYSTAL VIOLET (CAS No. 548-62-9), GENTIAN VIOLET, ACID VIOLET 49 (CAS No. 1694-09-3), ETHYL VIOLET (CAS No. 2390-59-2), BASIC BLUE 7 (CAS No. 2390-60-5), BASIC BLUE 26 (CAS No. 2580-56-5)

Schedule 10
Schedule 6
Schedule 4

METHYL SALICYLATE

Schedule 6
Schedule 5
Schedule 4

METHYL SALICYLATE LIQUID

Appendix E, clause 3

METHYLTESTOSTERONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

4METHYLTHIOAMFETAMINE
cross reference: 4METHYLTHIOAMPHETAMINE (CAS No. 14116-06-4)

Schedule 9

3METHYLTHIOFENTANYL

cross reference: CAS No. 86052-04-2

Schedule 9

2METHYLTHIO4(2METHYLPROP2YL) AMINO6CYCLOPROPYLAMINO5 TRIAZINE

Schedule 5

METHYLTHIOURACIL

Schedule 4

METHYLTRIENOLONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

METHYPRYLONE

Schedule 4

METHYSERGIDE

Schedule 4

METIRAM

Schedule 5

METOBROMURON

Schedule 5

METOCLOPRAMIDE

Schedule 4
Schedule 3

METODESNITAZENE

cross reference: CAS No. 14030-77-4, METAZENE

Schedule 9

METOFLUTHRIN

Schedule 6
Schedule 5

METOLACHLOR

Schedule 5

METOLAZONE

Schedule 4

METONITAZENE

cross reference: CAS No. 14680-51-4

Schedule 9

METOPON

cross reference: CAS No. 143-52-2

Schedule 9

METOPROLOL

Schedule 4

METOSULAM

Schedule 6

METRAFENONE

Schedule 6
Schedule 5

METRIBOLONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

METRIBUZIN

Schedule 6

METRIFONATE
cross reference: TRICHLORFON

Schedule 4

METRONIDAZOLE
cross reference: BENZOYL METRONIDAZOLE

Schedule 4

METSULFURONMETHYL

Appendix B, clause 3

METYRAPONE

Schedule 4

MEVINPHOS

Schedule 7

MEXILETINE

Schedule 4

MEZLOCILLIN

Schedule 4

MIANSERIN

Schedule 4
Appendix K, clause 1

MIBEFRADIL

Schedule 4

MIBOLERONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

MICAFUNGIN

Schedule 4

MICONAZOLE

Schedule 6
Schedule 4
Schedule 3
Schedule 2
Appendix F, clause 4
Appendix H, clause 1

MIDAZOLAM

Schedule 4
Appendix D, clause 5 (Benzodiazepine derivatives)

Appendix K, clause 1

MIDODRINE

Schedule 4

MIDOSTAURIN

Schedule 4

MIFEPRISTONE

Schedule 4

MIGALASTAT

Schedule 4

MIGLITOL

Schedule 4

MIGLUSTAT

Schedule 4

MILBEMECTIN

Schedule 6
Schedule 5

MILNACIPRAN

Schedule 4

MILBEMYCIN OXIME

Schedule 5
Schedule 4

MILRINONE

Schedule 4

MINOCYCLINE

Schedule 4

MINOXIDIL

Schedule 4
Schedule 2

MIPAFOX

Schedule 7

MIRABEGRON

Schedule 4

MIREX

Schedule 7
Appendix J, clause 1

MIRIKIZUMAB

Schedule 4

MIRTAZAPINE

Schedule 4
Appendix K, clause 1

MISOPROSTOL

Schedule 4
Appendix F, clause 4
Appendix L, clause 2

MITOBRONITOL

Schedule 4

MITOMYCIN

Schedule 4

MITOTANE

Schedule 4

MITOXANTRONE

Schedule 4

MITRAGYNA SPECIOSA
cross reference: KRATOM; MITRAGYNINE (CAS No. 4098-40-2)
Schedule 9

MITRAGYNINE
cross reference: (CAS No. 4098-40-2), KRATOM; MITRAGYNA SPECIOSA

Schedule 9

MITRATAPIDE

Schedule 4

MIVACURIUM CHLORIDE

Schedule 4

MOBOCERTINIB

Schedule 4

MOCLOBEMIDE

Schedule 4

MODAFINIL

Schedule 4

MOLGRAMOSTIM

Schedule 4

MOLINATE

Schedule 7
Appendix J, clause 1

MOLINDONE

Schedule 4

MOLNUPIRAVIR

Schedule 4

MOMETASONE

Schedule 4

Schedule 3
Schedule 2

MOMFLUOROTHRIN

Schedule 6

MONENSIN

Schedule 6
Schedule 5
Schedule 4

MONEPANTEL

Schedule 5

MONOBENZONE
cross reference: HYDROQUINONE

Schedule 4

MONOCLONAL ANTIBODIES

Schedule 4

MONOCROTOPHOS

Schedule 7

MONOETHANOLAMINE

Schedule 6
Schedule 5
Schedule 4
Appendix E, clause 3
Appendix F, clause 4

MONTELUKAST

Schedule 4

MOPERONE

Schedule 4

MORANTEL

Schedule 6
Schedule 5

MORAZONE

Schedule 4

MORICIZINE

Schedule 4

MORPHERIDINE

cross reference: CAS No. 469-81-8

Schedule 9

MORPHINE

Schedule 8
Appendix K, clause 1

MORPHINE METHOBROMIDE

Schedule 8

MORPHINENOXIDE

Schedule 8

(1(2MORPHOLIN4YLETHYL)INDOL3YL)NAPTHALEN1 YLMETHANONE
cross reference: JWH200 (CAS No. 103610-04-4)

Schedule 9

MOTOR, HEATING or FURNACE FUELS
cross reference: FUELS, FUELS, HOBBY FUELS, TOY, KEROSENE, METHANOL, PETROL

Appendix A, clause 1

MOTRAZEPAM

Schedule 4

MOTRETINIDE

Schedule 4

MOXIDECTIN

Schedule 7
Schedule 6
Schedule 5
Schedule 4

MOXIFLOXACIN

Schedule 4

MOXONIDINE

Schedule 4

MSMA

Schedule 7
Schedule 6

MUMPS VACCINE

Schedule 4

MUPIROCIN

Schedule 4

MURAGLITAZAR

Schedule 4

MUROMONAB

Schedule 4

MUSCIMOL

cross reference: CAS No. 2763-96-4, MUSCIMOL HYDROBROMIDE (CAS No. 18174-72-6)

Schedule 9

MUSTINE
cross reference: NITROGEN MUSTARD

Schedule 4

MYCLOBUTANIL

Schedule 5

MYCOPHENOLIC ACID
cross reference: MYCOPHENOLATE MOFETIL

Schedule 4

MYRISTIC ACID

Appendix B, clause 3

MYROPHINE

cross reference: CAS No. 467-18-5

Schedule 9

N

NAA
cross reference: NAPTHALENEACETIC ACID

Schedule 5

NABILONE

Schedule 8

NABIXIMOLS
cross reference: CANNABICHROMENE, CANNABIDIOL, CANNABIDIOLIC ACID, CANNABIDIVAROL, CANNABIGEROL, CANNABINOIDS, CANNABINOL, CANNABIS SATIVA, TETRAHYDROCANNABINOLIC ACID, TETRAHYDROCANNABINOLS, TETRAHYDROCANNABIVAROL

Schedule 8
Appendix D, clause 1
Appendix K, clause 1

NABUMETONE

Schedule 4

NADOLOL

Schedule 4

NADROPARIN

Schedule 4

NAFARELIN

Schedule 4

NAFTIDROFURYL

Schedule 4

NALBUPHINE

Schedule 4
Appendix K, clause 1

NALED

Schedule 6
Schedule 5

NALIDIXIC ACID

Schedule 4

NALMEFENE

Schedule 4

NALORPHINE

Schedule 4

NALOXEGOL

Schedule 4

NALOXONE

Schedule 4
Schedule 3

Appendix H, clause 1

NALTREXONE

Schedule 4

NANDROLONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

NAPHAZOLINE

Schedule 2
Appendix F, clause 4

NAPHTHALENE

cross reference: CAS No. 91-20-3

Schedule 10
Schedule 6
Appendix E, clause 3
Appendix F, clause 4
Appendix G, clause 1

1,5NAPHTHALENEDIOL

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

2,7NAPTHALENEDIOL

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

NAPHTHALEN1YL(1BUTYLINDOL3YL)METHANONE
cross reference: JWH073 (CAS No. 208987-48-8)

Schedule 9

NAPHTHALOPHOS

Schedule 7

Schedule 6

1NAPHTHOL

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

NAPHTHOYLINDOLES

Schedule 9

NAPHTHOYLPYRROLES

Schedule 9

NAPHTHYLMETHYLINDENES

Schedule 9

NAPHTHYLMETHYLINDOLES

Schedule 9

NAPROPAMIDE

Appendix B, clause 3

NAPROXEN

Schedule 4
Schedule 3
Schedule 2
Appendix F, clause 4
Appendix H, clause 1

NAPTALAM

Schedule 5

NAPTHYL ACETAMIDE

Appendix B, clause 3

NARASIN

Schedule 6
Schedule 4

NARATRIPTAN

Schedule 4

NATALIZUMAB

Schedule 4

NATAMYCIN
cross reference: PIMARCIN

Schedule 4

NATEGLINIDE

Schedule 4

NEBACUMAB

Schedule 4

NEBIVOLOL

Schedule 4

NEBRACETAM
cross reference: RACETAMS

Schedule 4

NEDOCROMIL

Schedule 4

NEFAZODONE

Schedule 4

NEFIRACETAM
cross reference: RACETAMS

Schedule 4

NEFOPAM

Schedule 4

NELFINAVIR

Schedule 4

NEOMYCIN

Schedule 4

NEOSCYTALIDIUM NOVAEHOLLANDIAE

Schedule 5

NEOSTIGMIN

Schedule 4

NEPAFENAC

Schedule 4

NERATINIB

Schedule 4

NERIUM OLEANDER

Schedule 4
Appendix G, clause 1

NEROLI OIL

Appendix B, clause 3

NESIRITIDE

Schedule 4

NETILMICIN

Schedule 4

NETOBIMIN

Schedule 6
Schedule 5

NETUPITANT

Schedule 4

NEVIRAPINE

Schedule 4

NIALAMIDE

Schedule 4

NICARBAZIN

Appendix B, clause 3

NICARDIPINE

Schedule 4

NICERGOLINE

Schedule 4

NICKEL SULFATE

Schedule 6

NICLOSAMIDE

Schedule 2

NICOCODINE

cross reference: CAS No. 3688-66-2, NICOCODINE HYDROCHLORIDE (CAS No. 58263-01-7)

Schedule 9

NICODICODINE

cross reference: CAS No. 808-24-2

Schedule 9

NICOFURANOSE

Schedule 4

NICOMORPHINE

cross reference: CAS No. 639-48-5, NICOMORPHINE HYDROCHLORIDE (CAS No. 12040-41-4)

Schedule 9

NICORANDIL

Schedule 4

NICOTINE

Schedule 7
Schedule 4
Appendix D, clause 5
Appendix F, clause 4
Appendix J, clause 1

NICOTINIC ACID
cross reference: NICOTINAMIDE

Schedule 4
Schedule 3

NICOTINYL ALCOHOL

Schedule 3

NICOUMALONE

Schedule 4

NIFEDIPINE

Schedule 4

NIFENAZONE

Schedule 4

NIFOXIPAM

cross reference: CAS No. 74723-10-7

Schedule 9

NIKETHAMIDE

Schedule 4

NILOTINIB

Schedule 4

NILUTAMIDE

Schedule 4

NIMESULIDE

Schedule 4

NIMIDANE

Schedule 7
Schedule 6

NIMODIPINE

Schedule 4

NIMORAZOLE

Schedule 4

NINTEDANIB

Schedule 4

NIRAPARIB

Schedule 4

NIRIDAZOLE

Schedule 4

NIRMATRELVIR

Schedule 4

NISIN

Appendix B, clause 3

NISOLDIPINE

Schedule 4

NITENPYRAM

Schedule 6

NITISINONE

Schedule 4

NITRAZEPAM

Schedule 4
Appendix D, clause 5 (benzodiazepine derivatives)
Appendix K, clause 1

NITRENDIPINE

Schedule 4

NITRIC ACID

Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

NITRIC OXIDE

Schedule 4

NITROBENZENE

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

NITROFEN

Schedule 7
Appendix J, clause 1

NITROFURANTOIN

Schedule 4

NITROFURAZONE

Schedule 4

3NITROpHYDROXYETHYLAMINOPHENOL
cross reference: 4[(2HYDROXYETHYL)AMINO]3NITROPHENOL

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

NITROPHENOLS

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

NITROPRUSSIDES

Schedule 7
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

NITROSCANATE

Schedule 5

2NITROTOLUENE

Schedule 7

NITROUS OXIDE

Schedule 4

Schedule 6

Appendix E, clause 3

Appendix F, clause 4

NITROXOLINE

Schedule 4

NITROXYNIL

Schedule 6

NIVOLUMAB

Schedule 4

NIZATIDINE

Schedule 4
Schedule 2
Appendix F, clause 4

NOMEGESTROL

Schedule 4

NOMIFENSINE

Schedule 4

NONANOIC ACID

Schedule 5

NONOXINOL 9

Schedule 6
Schedule 5
Appendix E, clause 3

NORACYMETHADOL

cross reference: CAS No. 1477-39-0, NORACYMETHADOL HYDROCHLORIDE (CAS No. 5633-25-0)

Schedule 9

NORADRENALINE

Schedule 4
Appendix F, clause 4

19NORANDROSTENEDIOL

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

19NORANDROSTENEDIONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

NORANDROSTENOLONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

NORBOLETHONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

NORBORMIDE

Schedule 5

NORCLOSTEBOL

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

NORCODEINE

Schedule 8

NORELGESTROMIN

Schedule 4

NOREPINEPHRINE
cross reference: NORADRENALINE

NORETHANDROLONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

NORETHISTERONE

Schedule 4

NORFLOXACIN

Schedule 4

NORFLURAZON

Appendix B, clause 3

NORGESTREL

Schedule 4

NORIBOGAINE

Schedule 4

NORLEVORPHANOL

cross reference: CAS No. 1531-12-0, NORLEVORPHANOL HYDROBROMIDE (CAS No. 63732-85-4), NORLEVORPHANOL RACEMATE (CAS No. 39131-41-4)

Schedule 9

NORMAL HUMAN IMMUNOGLOBULIN

Schedule 4

NORMETHADONE

Schedule 8
Appendix K, clause 1

NORMETHANDRONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

NORMORPHINE

cross reference: CAS No. 466-97-7, NORMORPHINE HYDROCHLORIDE (CAS No. 3372-02-9)

Schedule 9

NORPIPANONE

cross reference: CAS No. 561-48-8, NORPIPANONE HYDROCHLORIDE (CAS No. 6033-41-6), NORPIPANONE HYDROBROMIDE (CAS No. 6033-42-7)

Schedule 9

NORTRIPTYLINE

Schedule 4
Appendix K, clause 1

NOSCAPINE

Schedule 2

NOVALURON

Appendix B, clause 3

NOVOBIOCIN

Schedule 4

NOXIPTYLINE

Schedule 4

NUCLEAR POLYHEDROSIS VIRUS OF Helicoverpa armigera occlusion bodies

Appendix B, clause 3

NUSINERSEN

Schedule 4

NUTMEG OIL

Schedule 5

NUTRITION REPLACEMENT PREPARATIONS FOR PARENTERAL ADMINISTRATION

Appendix A, clause 1

NYSTATIN

Schedule 4
Schedule 3
Schedule 2
Appendix F, clause 4
Appendix H, clause 1

O

OBETICHOLIC ACID

Schedule 4

OCLACITINIB

Schedule 4

OCRELIZUMAB

Schedule 4

OCRIPLASMIN

Schedule 4

OCTAMYLAMINE

Schedule 4

OCTATROPINE

Schedule 4

1OCTEN3OL

Schedule 6

OCTHILINONE

Schedule 6

OCTREOTIDE

Schedule 4

OCTYL ALCOHOLS

Appendix B, clause 3

NOCTYL BICYCLOHEPTENE DICARBOXIMIDE

cross reference: OCTYLBICYCLOHEPTENEDICARBOXIMIDE

Schedule 5

OCTYL NITRITE

Schedule 4
Appendix E, clause 3

N(NOCTYL)2PYRROLIDONE
cross reference: DESIGNATED SOLVENT, N(NDODECYL)2PYRROLIDONE, NMETHYL2PYRROLIDONE

Schedule 6
Schedule 5
Appendix E, clause 3

OESTRADIOL
cross reference: ESTRADIOL

OESTRIOL
cross reference: ESTRIOL

OESTROGENS
cross reference: ESTROGENS

OESTRONE
cross reference: ESTRONE

OFATUMUMAB

Schedule 4

OFLOXACIN

Schedule 4

OLANZAPINE

Schedule 4
Appendix K, clause 1

OLAPARIB

Schedule 4

OLAQUINDOX

Schedule 6

OLARATUMAB

Schedule 4

OLEANDOMYCIN

Schedule 5
Schedule 4

OLEANDRIN

Schedule 4

OLEIC ACID

Appendix B, clause 3

NOLEYL1,3DIAMINOPROPANE

Schedule 6

OLIPUDASE ALFA

Schedule 4

OLMESARTAN

Schedule 4

OLODATEROL

Schedule 4

OLOPATADINE

Schedule 4

OLSALAZINE

Schedule 4

OMBERACETAM
cross reference: RACETAMS

Schedule 4

OMBITASVIR

Schedule 4

OMALIZUMAB

Schedule 4

OMEGA3ACID ETHYL ESTERS

Schedule 4

OMEPRAZOLE

Schedule 4
Schedule 3
Schedule 2
Appendix H, clause 1

OMETHOATE

Schedule 7
Schedule 6
Schedule 5

ONASEMNOGENE ABEPARVOVEC

Schedule 4

ONDANSETRON

Schedule 4

OPICAPONE

Schedule 4

OPIPRAMOL

Schedule 4

OPIUM
cross reference: NOSCAPINE, PAPAVERINE

Schedule 8
Appendix K, clause 1

ORANGE OIL (BITTER)

Schedule 5
Appendix E, clause 3

ORANGE OIL, SWEET

Appendix B, clause 3

ORBIFLOXACIN

Schedule 4

ORCIPRENALINE

Schedule 4
Appendix F, clause 4

ORGANOPHOSPHORUS COMPOUNDS
cross reference: MALATHION

Schedule 4

ORLISTAT

Schedule 4
Schedule 3

ORNIDAZOLE

Schedule 4

ORNIPRESSIN

Schedule 4

ORPHENADRINE

Schedule 4

ORTHOPTERIN

Schedule 4

OSELTAMIVIR

Schedule 4

OSILODROSTAT

Schedule 4

OSIMERTINIB

Schedule 4

OUABAIN

Schedule 4

OVANDROTONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

OXABETRINIL

Appendix B, clause 3

OXABOLONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

OXACILLIN

Schedule 4

OXADIARGYL

Schedule 5

OXADIAZON

Schedule 6

OXADIXYL

Schedule 5

OXALATES

Appendix F, clause 4

OXALIC ACID

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

OXALIPLATIN

Schedule 4

OXAMYL

Schedule 7

OXANDROLONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

OXANTEL EMBONATE

Schedule 5

OXAPROZIN

Schedule 4

OXAZEPAM

Schedule 4
Appendix D, clause 5 (Benzodiazepine derivatives)
Appendix K, clause 1

OXCARBAZEPINE

Schedule 4

OXATHIAPIPROLIN

Appendix B, clause 3

OXEDRINE
cross reference: SYNEPHRINE

Schedule 4

OXETACAINE
cross reference: OXETHAZAINE

Schedule 4
Schedule 2

OXFENDAZOLE

Schedule 5

OXIBENDAZOLE

Schedule 5

OXICONAZOLE

Schedule 4
Schedule 3
Schedule 2
Appendix H, clause 1

OXIRACETAM
cross reference: RACETAMS

Schedule 4

OXITROPIUM

Schedule 4

OXOLAMINE

Schedule 4

OXOLINIC ACID

Schedule 4

OXPENTIFYLLINE
cross reference: PENTOXIFYLLINE

OXPRENOLOL

Schedule 4

OXYBUPROCAINE

Schedule 4

OXYBUTYNIN

Schedule 4

OXYCARBOXIN

Schedule 5

OXYCLOZANIDE

Schedule 6

OXYCODONE

Schedule 8
Appendix K, clause 1

OXYDEMETON METHYL

Schedule 7

OXYFLUORFEN

Appendix B, clause 3

OXYMESTERONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

OXYMETAZOLINE

Schedule 2
Appendix F, clause 4

OXYMETHOLONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

OXYMORPHONE

Schedule 8

OXYPHENBUTAZONE

Schedule 4

OXYPHENCYCLIMINE

Schedule 4

OXYPHENISATIN

cross reference: CAS No. 125-13-3

Schedule 10

OXYPHENONIUM

Schedule 4

OXYQUINOLINE

Schedule 2
Appendix F, clause 4

OXYTETRACYCLINE

Schedule 5
Schedule 4

OXYTHIOQUINOX

Schedule 5

OXYTOCIN

Schedule 4
Appendix G, clause 1

OZANIMOD

Schedule 4

P

PACLITAXEL

Schedule 4

PACLOBUTRAZOL

Schedule 5

PAECILOMYCES LILACINUS STRAIN 251

Schedule 6

PAINT

Appendix F, clause 4

PALBOCICLIB

Schedule 4

PALIFERMIN

Schedule 4

PALIPERIDONE

Schedule 4
Appendix K, clause 1

PALIVIZUMAB

Schedule 4

PALMAROSA OIL

Appendix B, clause 3

PALMITIC ACID

Appendix B, clause 3

PALONOSETRON

Schedule 4

PAMAQUIN

Schedule 4

PAMIDRONIC ACID
cross reference: PAMIDRONATE DISODIUM

Schedule 4

PANCREATIC ENZYMES
cross reference: LIPASE

Schedule 4

PANCURONIUM

Schedule 4

PANITUMUMAB

Schedule 4

PANOBINOSTAT

Schedule 4

PANTOPRAZOLE

Schedule 4
Schedule 3
Schedule 2
Appendix H, clause 1

PAPAVERETUM

Appendix K, clause 1

PAPAVERINE
cross reference: OPIUM

Schedule 4
Schedule 2

PAPER

Appendix A, clause 1

PARAAMINOPROPIOPHENONE (PAPP)
cross reference: 4AMINOPROPIOPHENONE

PARACETAMOL
cross reference: ASPIRIN, IBUPROFEN, METOCLOPRAMIDE, SALICYLAMIDE, CAFFEINE

Schedule 4
Schedule 3
Schedule 2
Appendix F, clause 4

Appendix H, clause 1

paraDICHLOROBENZENE
cross reference: PDB

Appendix F, clause 4

PARAFLUOROFENTANYL

cross reference: CAS No. 90736-23-5

Schedule 9

PARAFORMALDEHYDE
cross reference: FREE FORMALDEHYDE (CAS No. 30525-89-4)

Schedule 10
Schedule 6
Schedule 2
Appendix E, clause 3

PARALDEHYDE

Schedule 4

PARAMETHADIONE

Schedule 4

PARAMETHASONE

Schedule 4

PARAQUAT

Schedule 7

PARATHION

Schedule 7

PARATHIONMETHYL

Schedule 7
Schedule 6

PARBENDAZOLE

Schedule 6

PARECOXIB

Schedule 4

PARICALCITOL

Schedule 4

PARITAPREVIR

Schedule 4

PAROMOMYCIN

Schedule 4

PAROXETINE

Schedule 4

PASIREOTIDE

Schedule 4

PATCHOULI OIL

Appendix B, clause 3

PATIROMER SORBITEX CALCIUM

Schedule 4

PATISIRAN

Schedule 4

PAZOPANIB

Schedule 4

PEBULATE

Schedule 6

PECAZINE

Schedule 4

PECTINASE derived from Aspergillus niger

Appendix B, clause 3

PEFLOXACIN

Schedule 4

PEGAPTANIB

Schedule 4

PEGASPARGASE

Schedule 4

PEGBOVIGRASTIM

Appendix B, clause 3

PEGCETACOPLAN

Schedule 4

PEGFILGRASTIM

Schedule 4

PEGINTERFERON

Schedule 4

PEGVALIASE

Schedule 4

PEGVISOMANT

Schedule 4

PEMIGATINIB

Schedule 4

PERAMIVIR

Schedule 4

PHENOLS

Appendix E, clause 3

PEMBROLIZUMAB

Schedule 4

PEMETREXED

Schedule 4

PEMOLINE

Schedule 4

PEMPIDINE

Schedule 4

PENBUTOLOL

Schedule 4

PENCICLOVIR

Schedule 4

PENCONAZOLE

Schedule 5

PENCYCURON

Appendix B, clause 3

PENDIMETHALIN

Schedule 5

PENETHAMATE

Schedule 4

PENFLUFEN

Schedule 5

PENICILLAMINE

Schedule 4

PENNYROYAL OIL

Schedule 6
Appendix E, clause 3

PENTACHLOROPHENOL

Schedule 7
Schedule 6
Appendix F, clause 4

PENTADECANOIC ACID

Appendix B, clause 3

PENTAERYTHRITYL TETRANITRATE

Schedule 4

PENTAGASTRIN

Schedule 4

PENTAMETHONIUM

Schedule 4

PENTAMIDINE

Schedule 4

PENTAZOCINE

Schedule 8
Appendix K, clause 1

PENTHIENATE

Schedule 4

PENTHIOPYRAD

Schedule 5

PENTOBARBITONE
cross reference: PENTOBARBITAL

PENTOBARBITAL

Schedule 8
Schedule 4
Appendix D, clause 9
Appendix K, clause 1

PENTOLINIUM

Schedule 4

PENTOSAN POLYSULFATE SODIUM

Schedule 4

PENTOXIFYLLINE

Schedule 4

1PENTYL3(1NAPHTHOYL)INDOLE
cross reference: JWH018 (CAS No. 209414-07-3)

Schedule 9

1PENTYL3(4METHYL1NAPTHOYL)INDOLE
cross reference: JWH122 (CAS No. 619294-47-2)

Schedule 9

PEPPERMINT OIL

Appendix B, clause 3

PERACETIC ACID

Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

PERAMPANEL

Schedule 4
Appendix D, clause 5
Appendix K, clause 1

PERFLUIDONE

Schedule 6

PERGOLIDE

Schedule 4

PERHEXILINE

Schedule 4

PERICIAZINE

Schedule 4
Appendix K, clause 1

PERICYAZINE
cross reference: PERICIAZINE

PERINDOPRIL

Schedule 4

PERMANGANATES
cross reference: POTASSIUM PERMANGANATE

Schedule 6
Appendix F, clause 4

PERMETHRIN

Schedule 6
Schedule 5
Schedule 4

PERPHENAZINE

Schedule 4
Appendix K, clause 1

PERTUSSIS ANTIGEN

cross reference: TRIPLE ANTIGEN VACCINE

Schedule 4

PERTUZUMAB

Schedule 4

PETASITES spp.

Schedule 10

PETHIDINE

Schedule 8
Appendix K, clause 1

PETROL

Schedule 5
Appendix E, clause 3

PHEDRAZINE

Schedule 2

PHENACEMIDE

Schedule 4

PHENACETIN

Schedule 4

PHENADOXONE

cross reference: CAS No. 467-84-5, PHENADOXONE HYDROCHLORIDE (CAS No. 545-91-5)

Schedule 9

PHENAGLYCODOL

Schedule 4

PHENAMPROMIDE

cross reference: CAS No. 129-83-9

Schedule 9

PHENAZOCINE

cross reference: CAS No. 127-35-5, PHENAZOCINE RACEMATE (CAS No. 58073-76-0), PHENOAZOCINE HYDROBROMIDE (CAS No. 1239-04-9)

Schedule 9

PHENAZONE

Schedule 5
Schedule 4
Schedule 2

PHENAZOPYRIDINE

Schedule 4

PHENCYCLIDINE
cross reference: PCP (CAS No. 77-10-1), PHENCYCLIDINE HYDROCHLORIDE (CAS No. 956-90-1)

Schedule 9

PHENDIMETRAZINE

Schedule 8

PHENELZINE

Schedule 4
Appendix K, clause 1

NPHENETHYL4PIPERIDONE

cross reference: CAS No. 39742-60-4

Schedule 9

PHENETICILLIN

Schedule 4

PHENFORMIN

Schedule 4

PHENGLUTARIMIDE

Schedule 4

PHENIBUT
cross reference: BETAPHENYLGAMMAAMINOBUTYRIC ACID (CAS No. 1078-21-3), PHENIBUT HYDROCHLORIDE (CAS No. 3060-41-1), PHENIBUT HYDROBROMIDE (CAS No. 103095-38-1)

Schedule 9

PHENINDIONE

Schedule 4

PHENIRAMINE

Schedule 4
Schedule 3
Schedule 2
Appendix K, clause 1

PHENISATIN

Schedule 4

PHENISOPHAM

Schedule 5

PHENMEDIPHAM

Appendix B, clause 3

PHENMETRAZINE

Schedule 8

PHENOBARBITAL

Schedule 4
Appendix K, clause 1

PHENOBARBITONE
cross reference: PHENOBARBITAL

PHENOL
cross reference: CREOSOTE, PHENOLS, TAR, XYLENOLS

Schedule 6
Schedule 5
Schedule 4
Schedule 2
Appendix E, clause 3
Appendix F, clause 4

PHENOLPHTHALEIN

Schedule 4

PHENOMORPHAN

cross reference: CAS No. 468-07-5

Schedule 9

PHENOPERIDINE

Schedule 8
Appendix K, clause 1

PHENOTHIAZINE

Schedule 6

dPHENOTHRIN

Appendix B, clause 3

PHENOXYBENZAMINE

Schedule 4

2PHENOXYETHANOL

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

PHENOXYMETHYL OXIRANE

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

PHENOXYMETHYLPENICILLIN

Schedule 4

PHENPROMETHAMINE

cross reference: CAS No. 93-88-9

Schedule 10

PHENSUXIMIDE

Schedule 4

PHENTERMINE

Schedule 4
Appendix D, clause 5

PHENTHIMENTONIUM

Schedule 4

PHENTOLAMINE

Schedule 4

PHENYLACETYLINDOLES

Schedule 9

PHENYLBUTAZONE

Schedule 4

PHENYLENEDIAMINES
cross reference: ALKYLATED, ARYLATED, HALOGENATED and NITROPHENYLENEDIAMINES, DIETHYLPARAPHENYLENEDIAMINE, DIMETHYLPARAPHENYLENEDIAMINE

Schedule 10
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

PHENYLEPHRINE
cross reference: CODEINE, IBUPROFEN, PARACETAMOL

Schedule 4
Schedule 2
Appendix F, clause 4

1PHENYLETHYL4PHENYL4PIPERIDINOL ACETATE
cross reference: PEPAP (CAS No. 64-52-8)

Schedule 9

PHENYLMERCURIC ACETATE
cross reference: MERCURY

Schedule 7
Appendix J, clause 1

PHENYL METHYL KETONE
cross reference: DESIGNATED SOLVENT

Schedule 5
Appendix E, clause 3

oPHENYLPHENOL

Schedule 5

Appendix E, clause 3
Appendix F, clause 4

4PHENYLPIPERIDINE4CARBOXYLIC ACID ETHYL ESTER
cross reference: PETHIDINE INTERMEDIATE B

Schedule 8

PHENYL METHYL PYRAZOLONE

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

PHENYLPIRACETAM
cross reference: RACETAMS

Schedule 4

PHENYLPROPANOLAMINE

Schedule 4

PHENYLTOLOXAMINE

Schedule 4
Appendix K, clause 1

PHENYTOIN

Schedule 4
Appendix F, clause 4

PHLEUM PRATENSE POLLEN EXTRACT (Timothygrass pollen extract)

Schedule 4

PHOLCODINE

Schedule 8
Schedule 4
Schedule 2
Appendix K, clause 1

PHORATE

Schedule 7

PHOSALONE

Schedule 6

PHOSFOLAN

Schedule 7

PHOSMET

Schedule 6

PHOSPHIDES, METALLIC
cross reference: ALUMINIUM PHOSPHIDE, MAGNESIUM PHOSPHIDE, ZINC PHOSPHIDE

Schedule 7
Appendix J, clause 1

PHOSPHINE

Schedule 7
Appendix J, clause 1

PHOSPHODIESTERASE TYPE 5 INHIBITORS

Schedule 4

PHOSPHONIC ACID
cross reference: PHOSPHOROUS ACID

Schedule 5
Appendix E, clause 3
Appendix F, clause 4

PHOSPHORIC ACID

Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

PHOSPHORUS

Appendix G, clause 1

PHOSPHORUS, YELLOW

Schedule 7

Appendix E, clause 3

Appendix F, clause 4

PHOTOGRAPHIC PAPER or FILM

Appendix A, clause 1

PHOXIM

Schedule 6

oPHTHALADEHYDE

Appendix F, clause 4

oPHTHALALDEHYDE

Appendix E, clause 3

PHTHALALDEHYDE

Schedule 6
Schedule 5

PHTHALYLSULFATHIAZOLE

Schedule 4

PHYSOSTIGMINE

Schedule 4

PHYTASE

Appendix B, clause 3

PIBRENTASVIR

Schedule 4

PICARIDIN

Schedule 5

PICLORAM

Appendix B, clause 3

PICOLINAFEN

Appendix B, clause 3

PICRAMIC ACID (including its salts)
cross reference: 2AMINO4,6DINITROPHENOL

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

PICRIC ACID

Appendix E, clause 3
Appendix F, clause 4

PICROTOXIN

Schedule 4

PIGMENTS

Appendix A, clause 1

PILOCARPINE

Schedule 4

PIMECROLIMUS

Schedule 4

PIMELIC ACID

Appendix B, clause 3

PIMINODINE

cross reference: CAS No. 13495-09-5, PIMINODINE DIHYDROCHLORIDE (CAS No. 113862-30-9). PIMINODINE ESILATE (CAS No. 7081-52-9)

Schedule 9

PIMOBENDAN

Schedule 4

PIMOZIDE

Schedule 4
Appendix K, clause 1

PINACIDIL

Schedule 4

PINDOLOL

Schedule 4

PINDONE

Schedule 6

PINE OILS

Schedule 6
Schedule 5

PINOXADEN

Schedule 6
Schedule 5

PIOGLITAZONE

Schedule 4

PIPECURONIUM

Schedule 4

PIPEMIDIC ACID

Schedule 4

PIPENZOLATE

Schedule 4

PIPER METHYSTICUM
cross reference: KAVA, KAVALACTONES

Schedule 4

PIPERACILLIN

Schedule 4

PIPERAZNE

Schedule 5
Schedule 2

PIPERIDINE

Schedule 4

PIPERIDOLATE

Schedule 4

PIPERONYL BUTOXIDE

Appendix B, clause 3

PIPEROPHOS

Schedule 6

PIPOBROMAN

Schedule 4

PIPOTHIAZINE

Schedule 4

PIPRADROL

Schedule 4

PIRACETAM

cross reference: RACETAMS

Schedule 4

PIRBUTEROL

Schedule 4

PIRENOXINE
cross reference: CATALIN

Schedule 4

PIRENZEPINE

Schedule 4

PIRETANIDE

Schedule 4

PIRFENIDONE

Schedule 4

PIRIMICARB

Schedule 6

Schedule 5

PIRIMIPHOSETHYL

Schedule 6

PIRIMIPHOSMETHYL

Schedule 6

PIRITRAMIDE

Schedule 8

PIROXICAM

Schedule 4

PIRPROFEN

Schedule 4

PITAVASTATIN

Schedule 4

PITUITARY HORMONES

Schedule 4

PIVAMPICILLIN

Schedule 4

PIZOTIFEN

Schedule 4
Appendix K, clause 1

PLASMID DNA (rE. coli DH5α pINGhT)
cross reference: VACCINES – PLASMID DNA

PLERIXAFOR

Schedule 4

PLICAMYCIN

Schedule 4

PLITIDEPSIN

Schedule 4
Appendix L, clause 2

PNEUMOCOCCAL VACCINE

Schedule 4

PODOPHYLLOTOXIN
cross reference: PODOPHYLLIN

Schedule 4
Schedule 3
Schedule 2
Appendix F, clause 4

Appendix H, clause 1

PODOPHYLLUM EMODI
cross reference: PODOPHYLLIN

Schedule 4
Schedule 3
Schedule 2
Appendix F, clause 4

Appendix H, clause 1

PODOPHYLLUM PELTATUM
cross reference: PODOPHYLLIN

Schedule 4
Schedule 3

Schedule 2
Appendix F, clause 4

Appendix H, clause 1

PODOPHYLLUM RESIN
cross reference: PODOPHYLLIN

Appendix G, clause 1

POLIHEXANIDE

cross reference: 1(DIAMINOMETHYLIDENE)2HEXYLGUANIDINE, POLY (IMINOCARBONIMIDOYLIMINOCARBONIMIDOYL IMINO1,6HEXANEDIYL), POLYHEXAMETHYLENE BIGUANIDE (PHMB)

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

POLIOMYELITIS VACCINE

Schedule 4

POLIXETONIUM SALTS

Schedule 6
Schedule 5

POLOXALENE

Appendix B, clause 3

POLY (GNRF) OVALBUMIN

Appendix B, clause 3

POLY DIALLYL DIMETHYL AMMONIUM CHLORIDE
cross reference: POLYDADMAC

Appendix B, clause 3

POLY(OXY1,2ETHANEDIYL), α [2[(2HYDROXYETHYL)AMINO]2OXOETHYL] α HYDROXY,MONOC1315ALKYL ETHERS

Schedule 5
Appendix E, clause 3

POLYACRYLAMIDE

Schedule 4

POLYCAPROLACTONE

Schedule 4

POLYESTRADIOL

Schedule 4

POLYETHANOXY (15) TALLOW AMINE

Schedule 5
Appendix E, clause 3

POLYHEDROSIS VIRUS of Helico zea occlusion bodies

Appendix B, clause 3

POLYLACTIC ACID

Schedule 4

POLYMYXIN

Schedule 4

POLYOXIN D ZINC SALT

Schedule 5

POLYSORBATE 20

Appendix B, clause 3

POLYSULFATED GLYCOSAMINOGLYCANS

Schedule 4

POLYTHIAZIDE

Schedule 4

POMALIDOMIDE

Schedule 4
Appendix D, clause 4
Appendix F, clause 4
Appendix L, clause 2

PONATINIB

Schedule 4

PONESIMOD

Schedule 4

Appendix L, clause 2

PORACTANT

Schedule 4

PORCELAIN

Appendix A, clause 1

PORCINE SOMATOTROPHIN

Appendix B, clause 3

POSACONAZOLE

Schedule 4

POTASSIUM AZELOYL DIGLYCINATE

Schedule 6

POTASSIUM BICARBONATE

Appendix B, clause 3

POTASSIUM BROMATE

Schedule 6
Appendix E, clause 3

POTASSIUM BROMIDE

Schedule 4

POTASSIUM CHLORATE

Schedule 5
Schedule 2
Appendix E, clause 3

POTASSIUM CHLORIDE

Schedule 4

POTASSIUM CYANATE

Schedule 6
Appendix E, clause 3

POTASSIUM HYDROXIDE

cross reference: CAS No. 1310-58-3

Schedule 10
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

POTASSIUM METABISULPHITE

Schedule 5
Appendix F, clause 4

POTASSIUM NITRITE

Schedule 7
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

POTASSIUM PERCHLORATE

Schedule 4

POTASSIUM PEROXOMONOSULFATE TRIPLE SALT

Schedule 6
Schedule 5

POTASSIUM PERSULFATE

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

POTASSIUM SORBATE

Appendix B, clause 3

POTASSIUM SULFIDE

Schedule 5
Appendix E, clause 3
Appendix F, clause 4

PRACTOLOL

Schedule 4

PRADOFLOXACIN

Schedule 4

PRALATREXATE

Schedule 4

PRALIDOXIME

Schedule 4

PRALLETHRIN

Schedule 6
Schedule 5

PRALMORELIN (GROWTH HORMONE RELEASING PEPTIDE2) (GHRP2)

Schedule 4
Appendix D, clause 5

PRALSETINIB

Schedule 4

PRAMIPEXOLE

Schedule 4

PRAMIRACETAM

cross reference: RACETAMS

Schedule 4

PRAMOCAINE

Schedule 4

PRAMPINE

Schedule 4

PRASTERONE
cross reference: DEHYDROEPIANDROSTERONE, DEHYDROISOANDROSTERONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

PRASUGREL

Schedule 4

PRAVASTATIN

Schedule 4

PRAZEPAM

Schedule 4
Appendix D, clause 5 (Benzodiazepine derivatives)
Appendix K, clause 1

PRAZIQUANTEL

Schedule 4

PRAZOSIN

Schedule 4

PREDNISOLONE

Schedule 4

PREDNISONE

Schedule 4

PREGABALIN

Schedule 4
Appendix K, clause 1

PREGNENOLONE

Schedule 4

PRENALTEROL

Schedule 4

PRENYLAMINE

Schedule 4

PRILOCAINE

Schedule 4
Schedule 2

PRIMAQUINE

Schedule 4

PRIMIDONE

Schedule 4

PRINTING INKS or INK ADDITIVES

Appendix A, clause 1

PROBENECID

Schedule 4

PROBUCOL

Schedule 4

PROCAINAMIDE

Schedule 4

PROCAINE

Schedule 4

PROCAINE BENZYLPENICILLIN

Schedule 4

PROCAINE PENICILLIN
cross reference: PROCAINE BENZYLPENICILLIN

PROCARBAZINE

Schedule 4

PROCHLORAZ

Schedule 6

PROCHLORPERAZINE

Schedule 4
Schedule 3
Appendix K, clause 1

PROCYCLIDINE

Schedule 4
Schedule 2

PROCYMIDONE

Schedule 7

PROFENOFOS

Schedule 6

PROFOXYDIM

Schedule 5

PROGESTERONE

Schedule 5
Schedule 4
Appendix G, clause 1

PROGESTOGENS

Schedule 4

PROGLUMIDE

Schedule 4

PROGUANIL

Schedule 4

PROHEPTAZINE

cross reference: CAS No. 77-14-5

Schedule 9

PROHEXADIONE CALCIUM

Schedule 5

PROLINTANE

Schedule 4

PROMACYL

Schedule 6

PROMAZINE

Schedule 4
Appendix K, clause 1

PROMETHAZINE

Schedule 4
Schedule 3
Schedule 2
Appendix K, clause 1

PROMETRYN

Schedule 5

PROMOXOLANE

Schedule 4

PROPACHLOR

Schedule 6

PROPAFENONE

Schedule 4

PROPAMIDINE

Schedule 4
Schedule 2

PROPAMOCARB

Schedule 5

PROPANIDID

Schedule 4

PROPANIL

Schedule 5

PROPANTHELINE

Schedule 4

PROPAQUIZAFOP

Schedule 5

PROPARGITE

Schedule 6

PROPENTOFYLLINE

Schedule 4

PROPERIDINE

cross reference: CAS No. 561-76-2

Schedule 9

PROPETAMPHOS

Schedule 6

PROPETANDROL

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

PROPICONAZOLE

Schedule 6
Schedule 5

PROPINEB

Schedule 6

PROPIONIBACTERIUM ACNES

Schedule 4

PROPIONIC ACID

Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

PROPIRAM

Schedule 8

PROPOFOL

Schedule 4

PROPOXUR

Schedule 6
Schedule 5

PROPRANOLOL

Schedule 4
Appendix G, clause 1

PROPYL ACETATES

Appendix B, clause 3

nPROPYL ALCOHOL

Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

nPROPYL NITRITE

cross reference: CAS No. 543-67-9

Schedule 10

PROPYLENE GLYCOL

Appendix B, clause 3

2PROPYLENE GLYCOL 1MONOMETHYL

Appendix B, clause 3

PROPYLENE OXIDE

Schedule 7
Appendix J, clause 1

PROPYLHEXEDRINE

Schedule 4

PROPYLTHIOURACIL

Schedule 4

PROPYPHENAZONE

Schedule 4

PROPYZAMIDE

Schedule 5

PROQUAZONE

Schedule 4

PROQUINAZID

Schedule 6

PROSCILLARIDIN

Schedule 4

PROSTAGLANDINS

Schedule 4

PROSTIANOL

Schedule 4

PROSULFOCARB

Schedule 6

PROSULFURON

Schedule 6

PROTAMINE

Schedule 4

PROTHIOCONAZOLE

Appendix B, clause 3

PROTHIOCONAZOLEDESCHLORO

Schedule 5

PROTHIOCONAZOLETRIAZOLIDINETHIONE

Schedule 5

PROTHIOFOS

Schedule 6

PROTHIONAMIDE

Schedule 4

PROTHIPENDYL

Schedule 4

PROTIRELIN

Schedule 4

PROTONITAZENE

cross reference: CAS No. 95958-84-2

Schedule 9

PROTOVERATRINES

Schedule 4

PROTRIPTYLINE

Appendix K, clause 1

PROTRIPTYLINE

Schedule 4

PROXYMETACAINE

Schedule 4

PRUCALOPRIDE

Schedule 4

PSEUDOEPHEDRINE

Schedule 4
Schedule 3

PSEUDOMONAS FLUORESCENS

Appendix B, clause 3

PSILOCYBINE

cross reference: CAS No. 520-52-5

Schedule 9
Schedule 8
Appendix D, clause 5
Appendix D, clause 10

PTERIDIUM spp.

Schedule 10

dPULEGONE

Schedule 6
Appendix E, clause 3

PULMONARIA spp.

Schedule 10

PYDIFLUMETOFEN

Appendix B, clause 3

PYMETROZINE

Schedule 5

PYRACLOFOS

Schedule 6

PYRACLOSTROBIN

Schedule 5

PYRAFLUFENETHYL

Schedule 5

PYRANTEL

Schedule 2

PYRASULFOTOLE

Schedule 5

PYRAZINAMIDE

Schedule 4

PYRAZOLAM

cross reference: CAS No. 39243-02-2

Schedule 9

PYRAZOPHOS

Schedule 6

PYRETHRINS
cross reference: CHRYSANTHEMIC ACID ESTERS, CINEROLONE, JASMOLONE, PYRETHRIC ACIDS, PYRETHROLONE

Schedule 5
Schedule 2

PYRIDABEN

Schedule 6
Schedule 5

PYRIDALYL

Schedule 6

PYRIDATE

Schedule 6

PYRIDINOLCARBAMATE

Schedule 4

PYRIDOSTIGMINE

Schedule 4

PYRIDOXAL

Schedule 4

PYRIDOXAMINE

Schedule 4

PYRIDOXINE

Schedule 4

PYRIFENOX

Schedule 5

PYRIMETHAMINE

Schedule 4

PYRIMETHANIL

Appendix B, clause 3

PYRINURON

Schedule 7
Appendix J, clause 1

PYRIOFENONE

Schedule 6
Schedule 5

PYRIPROLE

Schedule 6

PYRIPROXYFEN

Appendix B, clause 3

PYRITHIOBAC SODIUM

Schedule 5

PYRITHIONE COPPER

Schedule 6

PYRITHIONE ZINC

Schedule 6
Schedule 5
Schedule 2
Appendix E, clause 3

PYROVALERONE

Schedule 4

PYROXASULFONE

Schedule 6

PYROXSULAM

Schedule 6

PYRVINIUM
cross reference: VIPRYNIUMA

Schedule 4

Q

QUASSIA

Appendix B, clause 3

QUATERNARY AMMONIUM COMPOUNDS
cross reference: BENZALKONIUM CHLORIDE, DIALKYL and DIALKOYL QUATERNARY AMMONIUM COMPOUNDS

Schedule 6
Schedule 5

Appendix E, clause 3

QUAZEPAM

Schedule 4
Appendix D, clause 5 (Benzodiazepine derivatives)

QUETIAPINE

Schedule 4
Appendix K, clause 1

QUINAGOLIDE

Schedule 4

QUINALBARBITONE
cross reference: SECOBARBITAL

QUINAPRIL

Schedule 4

QUINBOLONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

QUINCLORAC

Schedule 5

QUINETHAZONE

Schedule 4

QUINIDINE

Schedule 4

QUININE
cross reference: QUININE (CAS No. 130950), QUININE SULFATE (1:1) (CAS No. 549564), QUININE SULFATE (2:1) (CAS No. 804637), QUININE SULFATE (2:1) DIHYDRATE (CAS No. 6119706), QUININE SULFATE (1:1) HEPTAHYDRATE (CAS No. 6183682), QUININE DIHYDROCHLORIDE (CAS No. 60935), QUININE MONOHYDROCHLORIDE (CAS No. 130892), QUININE HYDROCHLORIDE DIHYDRATE (CAS No. 6119477), QUININE HYDROCHLORIDE (UNSPECIFIED) (CAS No. 7549431)

Schedule 7
Schedule 6
Schedule 5
Schedule 4
Appendix F, clause 4

QUINISOCAINE
cross reference: DIMETHISOQUINE

Schedule 4

QUINOLINE
cross reference: 2,3BENZAPYRIDINE

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

QUINOXYFEN

Appendix B, clause 3

QUINTOZENE
cross reference: PENTACHLORONITROBENZENE

Schedule 5

QUINUPRISTIN

Schedule 4

QUIZALOFOP ETHYL
cross reference: QUIZALOFOP ETHYL (D + ISOMER)

Schedule 6

QUIZALOFOPpETHYL

Schedule 6
Schedule 5

QUIZALOFOPpTEFURYL

Schedule 6

R

RABEPRAZOLE

Schedule 4
Schedule 3
Schedule 2
Appendix H, clause 1

RABIES VACCINE

Schedule 4

RACEMETHORPHAN

cross reference: CAS No. 510-53-2

Schedule 9

RACEMORAMIDE

Schedule 8

RACEMORPHAN

cross reference: CAS No. 297-90-5

Schedule 9

RACETAMS

Schedule 4

RACTOPAMINE

Schedule 5
Schedule 4

RADIOGRAPHIC CONTRAST MEDIA
cross reference: RADIOPAQUES

Appendix A, clause 1

RADIOISOTOPES

Appendix A, clause 1

RALOXIFENE

Schedule 4

RALTEGRAVIR

Schedule 4

RALTITREXED

Schedule 4

RAMIPRIL

Schedule 4

RAMUCIRUMAB

Schedule 4

RANIBIZUMAB

Schedule 4

RANITIDINE

Schedule 4
Schedule 2
Appendix F, clause 4

RANOLAZINE

Schedule 4

RAPACURONIUM

Schedule 4

RASAGILINE

Schedule 4

RASBURICASE

Schedule 4

RAUWOLFIA SERPENTINA

Schedule 4

RAUWOLFIA VOMITORIA

Schedule 4

RAZOXANE

Schedule 4

REBOXETINE

Schedule 4

RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN

Schedule 4

RED YEAST RICE

Schedule 4

REGDANVIMAB

Schedule 4

REGORAFENIB

Schedule 4

REMIFENTANIL

Schedule 8

REMDESIVIR

Schedule 4

REMOXIPRIDE

Schedule 4

REPAGLINIDE

Schedule 4

RESCALURE

cross reference: (3S,6R)(3S,6S)6isopropenyl3methyldec9en1yl acetate

Schedule 6

RESERPINE

Schedule 4

RESLIZUMAB

Schedule 4

RESMETHRIN

Schedule 6
Schedule 5

RESORCINOL
cross reference: 1,3BENZENEDIOL

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

RETAPAMULIN

Schedule 4

RETEPLASE

Schedule 4

RETIGABINE

Schedule 4
Appendix K, clause 1

RHIZOBIUM RHIZOGENES

Appendix B, clause 3

RIBAVIRIN

Schedule 4

RIBOCICLIB

Schedule 4

RIDAFOROLIMUS

Schedule 4

RIFABUTIN

Schedule 4

RIFAMPICIN

Schedule 4

RIFAMYCIN

Schedule 4

RIFAPENTINE

Schedule 4

RIFAXIMIN

Schedule 4

RILPIVIRINE

Schedule 4

RILUZOLE

Schedule 4

RIMEGEPANT

Schedule 4

RIMEXOLONE

Schedule 4

RIMITEROL

Schedule 4

RIMONABANT

Schedule 4

RIMSULFURON

Schedule 5

RIOCIGUAT

Schedule 4
Appendix D, clause 4
Appendix L, clause 2

RIPRETINIB

Schedule 4

RISANKIZUMAB

Schedule 4

RISDIPLAM

Schedule 4

RISEDRONIC ACID

Schedule 4

RISPERIDONE

Schedule 4
Appendix K, clause 1

RITODRINE

Schedule 4

RITONAVIR

Schedule 4

RITUXIMAB

Schedule 4

RIVAROXABAN

Schedule 4

RIVASTIGMINE

Schedule 4

RIZATRIPTAN

Schedule 4
Schedule 3
Appendix H, clause 1

ROBENACOXIB

Schedule 4

ROBENIDINE

Schedule 5

ROFECOXIB

Schedule 4

ROFLUMILAST

Schedule 4

ROLICYCLIDINE
cross reference: PCPY, PHP (CAS No. 2201-39-0)

Schedule 9

ROLITETRACYCLINE

Schedule 4

ROLZIRACETAM

cross reference: RACETAMS

Schedule 4

ROMIDEPSIN

Schedule 4

ROMIFIDINE

Schedule 4

ROMIPLOSTIM

Schedule 4

ROMOSOZUMAB

Schedule 4

RONIDAZOLE

Schedule 4

ROPINIROLE

Schedule 4

ROPIVACAINE

Schedule 4

ROSEMARY OIL

Appendix B, clause 3

ROSIGLITAZONE

Schedule 4

ROSIN
cross reference: COLOPHONY

Schedule 5

ROSOXACIN

Schedule 4

ROSUVASTATIN

Schedule 4

ROTENONE
cross reference: CUBE

Schedule 6

ROTIGOTINE

Schedule 4
Appendix K, clause 1

ROXIBOLONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

ROXITHROMYCIN

Schedule 4

RUBELLA VACCINE

Schedule 4

RUBOXISTAURIN

Schedule 4

RUFINAMIDE

Schedule 4
Appendix K, clause 1
Appendix L, clause 2

RUPATADINE

Schedule 4
Appendix K, clause 1

RUXOLITINIB

Schedule 4

S

SACITUZUMAB GOVITECAN

Schedule 4

SACUBITRIL

Schedule 4

SAFINAMIDE

Schedule 4

SAFLUFENACIL

Schedule 7
Schedule 5

SAFROLE
cross reference: CAS No. 94-59-7, SASSAFRAS OIL

Schedule 10
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

SAGE OIL
cross reference: DALMATIAN, THUJONE

Schedule 6
Appendix E, clause 3

SAGE OIL (Spanish)
cross reference: CAMPHOR

Appendix B, clause 3

SALBUTAMOL

Schedule 4
Schedule 3
Appendix F, clause 4

SALCATONIN
cross reference: CALCITONIN SALMON

SALICYLAMIDE
cross reference: ASPIRIN, CAFFEINE, PARACETAMOL

Schedule 4
Schedule 2
Appendix F, clause 4

SALICYLANILIDE

Schedule 5

SALICYLIC ACID
cross reference: CHOLINE SALICYLATE

Schedule 3

Appendix H, clause 1

SALINOMYCIN

Schedule 6
Schedule 4

SALMETEROL

Schedule 4

SALVIA DIVINORUM

Schedule 9

SANDALWOOD OIL

Appendix B, clause 3

SANGUINARIA CANADENSIS (bloodroot)

Schedule 10

SANGUINARINE
cross reference: CAS No. 2447-54-3, SANGUINARIA CANADENSIS (bloodroot)

SANTONIN

Schedule 3

SAPROPTERIN

Schedule 4

SAQUINAVIR

Schedule 4

SARILUMAB

Schedule 4

SAROLANER

Schedule 6
Schedule 5

SARSCOV2 (COVID19) VACCINE

Schedule 4

SASSAFRAS OIL
cross reference: SAFROLE

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

SAXAGLIPTIN

Schedule 4

SCHOENOCAULON OFFICINALE
cross reference: SABADILLA

Schedule 4

SCHRADAN

Schedule 7

SCOPOLIA CARNIOLICA

Schedule 4

SEAWEED

Appendix B, clause 3

SEBELIPASE ALFA

Schedule 4

SECBUTOBARBITAL

Schedule 8
Appendix K, clause 1

SECBUTOBARBITONE
cross reference: SECBUTOBARBITAL

SECOBARBITAL

Schedule 8
Appendix K, clause 1

SECUKINUMAB

Schedule 4

SEDAXANE

Schedule 5

SEEDS

Appendix A, clause 1

SELAMECTIN

Schedule 5

SELECTIVE ANDROGEN RECEPTOR MODULATORS
cross reference: SARM

Schedule 4
Appendix D, clause 5

SELEGILINE

Schedule 4

SELENIUM
cross reference: BARIUM SELENATE, SELENIUM COMPOUNDS, SELENIUM ARSENIDE, SELENIUM SULFIDE

Schedule 7
Schedule 6
Schedule 4
Schedule 2
Appendix E, clause 3
Appendix F, clause 4
Appendix G, clause 1

SELETRACETAM

Cross reference RACETAMS

Schedule 4
Appendix K, clause 1

SELEXIPAG

Schedule 4

SELINEXOR

Schedule 4

Appendix L, clause 2

SELPERCATINIB

Schedule 4

SELUMETINIB

Schedule 4

Appendix L, clause 2

SEMAGLUTIDE

Schedule 4

SEMDURAMICIN

Schedule 7
Schedule 6

SENECIO spp.

Schedule 10

SERELAXIN

Schedule 4

SERMORELIN

Schedule 4

SERTINDOLE

Schedule 4

SERTRALINE

Schedule 4

SETHOXYDIM

Schedule 5

SEVELAMER

Schedule 4

SEVOFLURANE

Schedule 4

SEX HORMONES

Schedule 4

SHOLIGOPEPTIDE1, RHOLIGOPEPTIDE1
cross reference: EPIDERMAL GROWTH FACTOR

SIBUTRAMINE

Schedule 4

SIDURON

Schedule 5

SILANDRONE

Schedule 4
Appendix D, clause 5 (Anabolic steroidal agent)

SILDENAFIL

Schedule 4

SILICOFLUORIDES
cross reference: BARIUM SILICOFLUORIDE, FLUORIDES, FLUOROSILICATES, HEXAFLUOROSILICATES MAGNESIUM FLUOSILICATE,

Schedule 6
Schedule 5

SILICONES

Schedule 10
Schedule 4
Appendix F, clause 4

SILODOSIN

Schedule 4

SILTUXIMAB

Schedule 4

SILVER

Schedule 2

SILVER NITRATE
cross reference: SILVER SALTS

Schedule 6
Appendix E, clause 3

SILVER OXIDE

Appendix B, clause 3

SILVER SULFADIAZINE

Schedule 4

SIMAZINE

Appendix B, clause 3

SIMEPREVIR

Schedule 4

SIMVASTATIN

Schedule 4

SINBIOALLETHRIN

Schedule 6
Schedule 5

SINGLEUSE TUBES

Appendix A, clause 1

SIPONIMOD

Schedule 4

SIROLIMUS

Schedule 4

SISOMICIN

Schedule 4

SITAGLIPTIN

Schedule 4

SITAXENTAN

Schedule 4
Appendix D, clause 6
Appendix F, clause 4
Appendix L, clause 2

SLIMICIDES

Appendix A, clause 1

SODIUM ALUMINATE

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

SODIUM BICARBONATE

Appendix B, clause 3

SODIUM BROMATE

Schedule 6
Appendix E, clause 3

SODIUM BROMIDE

Schedule 5
Schedule 4

SODIUM CELLULOSE PHOSPHATE

Schedule 4

SODIUM CHLORATE

Schedule 5
Appendix E, clause 3
Appendix F, clause 4

SODIUM CROMOGLYCATE

Schedule 4
Schedule 2

SODIUM DIACETATE

Schedule 5
Appendix E, clause 3

SODIUM DICHLOROISOCYANURATE

Appendix E, clause 3

SODIUM DODECYLBENZENE SULFONATE

Schedule 5
Appendix E, clause 3, Part
Appendix F, clause 4

SODIUM FLUORIDE

Appendix F, clause 4

SODIUM GLYCEROPHOSPHATE HYDRATE

Schedule 4

SODIUM HYDROGEN SULFATE

Schedule 5
Appendix E, clause 3
Appendix F, clause 4

SODIUM HYDROSULFITE

Schedule 5
Appendix F, clause 4

SODIUM HYDROXIDE
cross reference: CAS No. 1310-73-2, LYE WATER

Schedule 10
Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

SODIUM LAURETH6 CARBOXYLATE

Schedule 5
Appendix E, clause 3
Appendix F, clause 4

SODIUM METABISULPHITE

Schedule 5
Appendix E, clause 3
Appendix F, clause 4

SODIUM MORRHUATE

Schedule 4

SODIUM NITRITE

Schedule 7
Schedule 6
Schedule 5
Schedule 2
Appendix E, clause 3
Appendix F, clause 4

SODIUM NITROPRUSSIDE

Schedule 4

SODIUM OXYBATE

Schedule 8
Appendix D, clause 1
Appendix K, clause 1

SODIUM PERCARBONATE

Schedule 6
Schedule 5

Appendix E, clause 3

SODIUM PERSULFATE

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

SODIUM PHENYLBUTYRATE

Schedule 4

SODIUM PHOSPHATE

Schedule 4
Schedule 3

SODIUM PICOSULFATE

Schedule 3

SODIUM POLYSTYRENE SULPHONATE

Schedule 5
Schedule 4

SODIUM PROPIONATE

Appendix B, clause 3

SODIUM SALICYLATE

Schedule 4

SODIUM STANNATE

Schedule 5,
Appendix E, clause 3

SODIUM SULFIDE

Schedule 6

Schedule 5

Appendix E, clause 3

Appendix F, clause 4

SODIUM TETRADECYLSULFATE

Schedule 4

SODIUM TRICHLOROACETATE

Appendix E, clause 3

SODIUM ZIRCONIUM CYCLOSILICATE.

Schedule 4

SODIUMHYDROSULFITE

Appendix E, clause 3

SOFOSBUVIR

Schedule 4

SOLASODINE

Schedule 4

SOLIFENACIN

Schedule 4

SOMAPACITAN

Schedule 4

SOMATOSTATIN

Schedule 4

SOMATOTROPIN EQUINE

Schedule 4

SOMATROPIN
cross reference: HUMAN GROWTH HORMONE

Schedule 4
Appendix D, clause 5
Appendix G, clause 1

SONIDEGIB

Schedule 4

SONTOQUINE

Schedule 4

SORAFENIB

Schedule 4

SOTALOL

Schedule 4

SOTORASIB

Schedule 4

SOTROVIMAB

Schedule 4

SPARFLOXACIN

Schedule 4

SPARTEINE

Schedule 4

SPECTINOMYCIN

Schedule 4

SPESOLIMAB

Schedule 4

SPINETORAM

Schedule 5

SPINOSAD

Schedule 5

SPIRAMYCIN

Schedule 4

SPIRAPRIL

Schedule 4

SPIROMESIFEN

Schedule 5

SPIRONOLACTONE

Schedule 4

SPIROPIDION

Schedule 6

SPIROTETRAMAT

Schedule 6

SPIROXAMINE

Schedule 6

SQUILL

Schedule 2

STANOLONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

STANOZOLOL

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

STAR ANISE OIL

Schedule 5

STAVUDINE

Schedule 4

STENABOLIC (SR9009) and other synthetic REVERB agonists
cross reference: SR9011, GSK2945, GSK0999, GSK5072, GSK2667

Schedule 4
Appendix D, clause 5

STENBOLONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

STERIC ACID

Appendix B, clause 3

STEROID HORMONES

Schedule 4

STILBESTROL
cross reference: STILBOESTROL, DIETHYLSTILBESTROL

Schedule 4

STIRIPENTOL

Schedule 4
Appendix K, clause 1

STREPTODORNASE

Schedule 4

STREPTOKINASE

Schedule 4

STREPTOMYCES LYDICUS WYEC 108

Appendix B, clause 3

STREPTOMYCIN

Schedule 4

STRONTIUM RANELATE

Schedule 4

STROPHANTHINS

Schedule 4

STROPHANTHUS spp.

Schedule 4
Appendix G, clause 1

STRYCHNINE
cross reference: NUX VOMICA

Schedule 7
Schedule 4
Appendix E, clause 3
Appendix G, clause 1
Appendix J, clause 1

STRYCHNOS spp.

Schedule 4

STYRAMATE

Schedule 4

STYRENE
cross reference: DESIGNATED SOLVENT

Schedule 5
Appendix E, clause 3
Appendix F, clause 4

SUCCIMER

Schedule 4

SUCRALFATE

Appendix B, clause 3

SUCROFERRIC OXYHYDROXIDE

Schedule 4

SUFENTANIL

Schedule 8

SUGAMMADEX

Schedule 4

SULBACTAM

Schedule 4

SULCOFURON

Schedule 7
Schedule 6
Appendix E, clause 3
Appendix J, clause 1

SULCONAZOLE

Schedule 4
Schedule 2

SULESOMAB

Appendix B, clause 3

SULFACETAMIDE

Schedule 5
Schedule 4
Schedule 3

SULFADIAZINE

Schedule 5
Schedule 4

SULFADIMETHOXINE

Schedule 4

SULFADIMIDINE

Schedule 5
Schedule 4

SULFADOXINE

Schedule 4

SULFAFURAZOLE

Schedule 4

SULFAGUANIDINE

Schedule 4

SULFAMERAZINE

Schedule 5
Schedule 4

SULFAMETHIZOLE

Schedule 4

SULFAMETHOXAZOLE

Schedule 4

SULFAMETHOXYDIAZINE

Schedule 4

SULFAMETHOXYPYRIDAZINE

Schedule 4

SULFAMETROLE

Schedule 4

SULFAMIC ACID

Schedule 6
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

SULFAMONOMETHOXINE

Schedule 4

SULFAMOXOLE

Schedule 4

SULFAPHENAZOLE

Schedule 4

SULFAPYRIDINE

Schedule 4

SULFAQUINOXALINE

Schedule 4

SULFASALAZINE

Schedule 4

SULFATHIAZOLE

Schedule 5
Schedule 4

SULFATROXAZOLE

Schedule 4

SULFENTRAZONE

Schedule 7

SULFINPYRAZONE

Schedule 4

SULFLURAMID

Schedule 6

SULFOMETURONMETHYL

Schedule 5

SULFOMYXIN

Schedule 4

SULFONAMIDES
cross reference: SULFACETAMIDE, SULPHANILAMIDE

Schedule 4

SULFONMETHANE
cross reference: ALKYL SULFONALS, SULFONAL

Schedule 4

SULFOSULFURON

Appendix B, clause 3

SULFOTEP

Schedule 7

SULFOXAFLOR

Schedule 6
Schedule 5

SULFURIC ACID

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

SULFURYL FLUORIDE

Schedule 6

SULINDAC

Schedule 4

SULPHATED POLYSACCHARIDES

Appendix B, clause 3

SULPROFOS

Schedule 6

SULTAMICILLIN

Schedule 4

SULTHIAME

Schedule 4

SUMATRIPTAN

Schedule 4
Schedule 3
Appendix H, clause 1

SUNIFIRAM

cross reference: RACETAMS

Schedule 4

SUNITINIB

Schedule 4

SUPROFEN

Schedule 4

SUTILAINS

Schedule 4

SUVOREXANT

Schedule 4
Appendix K, clause 1

SUXAMETHONIUM

Schedule 4

SUXETHONIUM

Schedule 4

SYMPHYTUM spp.
cross reference: COMFREY

Schedule 10
Schedule 5
Appendix F, clause 4

SYNTHETIC CANNABINOMIMETICS

Schedule 9

T

2,4,5T

Schedule 6

TACRINE

Schedule 4

TACROLIMUS

Schedule 4

TADALAFIL

Schedule 4

TAFAMIDIS

Schedule 4

TAFASITAMAB

Schedule 4

TAFENOQUINE SUCCINATE

Schedule 4

TAFLUPROST

Schedule 4

TAGRAXOFUSP

Schedule 4

TALAZOPARIB

Schedule 4

TALIGLUCERASE ALFA

Schedule 4

TALIMOGENE LAHERPAREPVEC

Schedule 4

TALLOW ALKYLAMINE ACETATES

Schedule 6

NTALLOW ALKYL1,3PROPANEDIAMINE DIACETATE

Schedule 6

TAMOXIFEN

Schedule 4

TAMSULOSIN

Schedule 4

TANACETUM VULGARE
cross reference: OIL OF TANSY, TANSY OIL

Schedule 4

TANNIC ACID

Appendix B, clause 3

TANNIC ACID/BENZYL ALCOHOL PRODUCT

Appendix B, clause 3

TAPENTADOL

Schedule 8
Appendix K, clause 1

TAR ACIDS

Schedule 6

TASONERMIN

Schedule 4

TAZAROTENE

Schedule 4
Appendix F, clause 4

TAZOBACTAM

Schedule 4

TB500

Schedule 4
Appendix D, clause 5

2,3,6TBA

Schedule 5

TCELL RECEPTOR ANTIBODY

Schedule 4

TCMTB
cross reference: 2[THIOCYANOMETHYLTHIO]BENZOTHIAZOLE

Schedule 6

TDE
cross reference: 1,1DICHLORO2,2BIS[4CHLOROPHENYL]ETHANE

Schedule 6
Schedule 5

TEBUCONAZOLE
cross reference: TERBUCONAZOLE

Schedule 5

TEBUFENOZIDE

Schedule 5

TEBUFENPYRAD

Schedule 6

TEBUTHIURON

Schedule 6

TECLISTAMAB

Schedule 4

TEDUGLUTIDE

Schedule 4

TEFLUTHRIN

Schedule 7
Schedule 5

TEGAFUR

Schedule 4

TEGASEROD

Schedule 4

TEICOPLANIN

Schedule 4

TELAPREVIR

Schedule 4

TELBIVUDINE

Schedule 4

TELITHROMYCIN

Schedule 4

TELMISARTAN

Schedule 4

TELOTRISTAT ETHYL

Schedule 4

TEMAZEPAM

Schedule 4
Appendix D, clause 5 (Benzodiazepine derivatives)

Appendix K, clause 1

TEMEPHOS

Schedule 6
Schedule 5

TEMOZOLOMIDE

Schedule 4

TEMSIROLIMUS

Schedule 4

TENECTEPLASE

Schedule 4

TENIPOSIDE

Schedule 4

TENOCYCLIDINE
cross reference: TCP (CAS No. 21500-98-1)

Schedule 9

TENOFOVIR

Schedule 4

TENOXICAM

Schedule 4

TEPOTINIB

Schedule 4

TEPOXALIN

Schedule 4

TEPP

Schedule 8

TEPRALOXYDIM

Schedule 5

TERAZOSIN

Schedule 4

TERBACIL

Appendix B, clause 3,Part 3

TERBINAFINE

Schedule 4
Schedule 2

TERBUFOS

Schedule 7

TERBUTALINE

Schedule 4
Schedule 3
Appendix F, clause 4

TERBUTHYLAZINE

Schedule 6

TERBUTRYN

Schedule 5

TERFENADINE

Schedule 4
Appendix F, clause 4

TERIFLUNOMIDE

Schedule 4
Appendix F, clause 4
Appendix L, clause 2

TERIPARATIDE

Schedule 4
Appendix D, clause 1

TERLIPRESSIN

Schedule 4

TERMITE BARRIERS

Appendix A, clause 1

TERODILINE

Schedule 4

TEROPTERIN

Schedule 4

TERPENES, CHLORINATED
cross reference: CHLORINATED TERPENES

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

TESTOLACTONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

TESTOSTERONE

Schedule 6
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)
Appendix G, clause 1

TETANUS ANTITOXIN

Schedule 4

TETANUS TOXOID

cross reference: TRIPLE ANTIGEN VACCINE

Schedule 4

1,3,5,7TETRAAZATRICYLO[3.3.1.13,7] DECANE
cross reference: HEXAMINE, HEXAMETHYLENETETRAMINE, METHENAMINE

Schedule 5

TETRABENAZINE

Schedule 4

TETRACAINE
cross reference: AMETHOCAINE

Schedule 4
Schedule 2

TETRACHLOROETHANE

Schedule 7
Appendix E, clause 3
Appendix F, clause 4
Appendix J, clause 1

TETRACHLOROETHYLENE
cross reference: DESIGNATED SOLVENT

Schedule 6
Schedule 5
Schedule 2
Appendix E, clause 3
Appendix F, clause 4

TETRACHLORVINPHOS

Schedule 5

TETRACONAZOLE

Schedule 6
Schedule 5

TETRACOSACTIDE

Schedule 4

TETRACOSACTRIN
cross reference: TETRACOSACTIDE

TETRACYCLINE

Schedule 5
Schedule 4

TETRADIFON

Schedule 6

TETRAETHYLAMMONIUM

Schedule 4

TETRAHYDROCANNABINOLIC ACID
cross reference: NABIXIMOLS, TETRAHYDROCANNABINOLS, CANNABIS

TETRAHYDROCANNABINOLS
cross reference: CANNABIS, HEMP SEED OIL, NABIXIMOLS

Schedule 9
Schedule 8
Appendix D, clause 1
Appendix K, clause 1

TETRAHYDROCANNABIDIVAROL
cross reference: NABIXIMOLS, TETRAHYDROCANNABINOLS, CANNABIS

TETRAHYDROFURFURYL ALCOHOL

Schedule 6

TETRAHYDROZOLINE
cross reference: TETRYZOLINE

2,2',6,6'TETRAISOPROPYLDIPHENYLCARBODIIMIDE
cross reference: STABAXOL

Schedule 7

Schedule 6
Appendix J, clause 1

TETRAMETHRIN

Schedule 5

TETRAMISOLE

Schedule 6

TETRANILIPROLE

Schedule 5

TETROXOPRIM

Schedule 4

TETRYZOLINE
cross reference: TETRAHYDROZOLINE

Schedule 2
Appendix F, clause 4

TEZACAFTOR

Schedule 4

THALIDOMIDE

Schedule 4
Appendix D, clause 2
Appendix F, clause 4
Appendix L, clause 2

THALLIUM
cross reference: THALLIUM SULFATE

Schedule 7
Appendix J, clause 1

THAUMATIN

Appendix B, clause 3

THEBACON

Schedule 8

THEBAINE

Schedule 8

THENYLDIAMINE

Schedule 4
Appendix K, clause 1

THEOPHYLLINE

Schedule 4
Schedule 3

THEVETIA PERUVIANA

Schedule 4

THEVETIN

Schedule 4

THIABENDAZOLE

Schedule 5
Schedule 2

THIACETARSAMIDE

Schedule 4

THIACLOPRID

Schedule 6

THIAMBUTOSINE

Schedule 4

THIAMETHOXAM

Schedule 6
Schedule 5

THIAZAFLURON

Schedule 6

THIAZOPYR

Schedule 5

THIAZOSULFONE

Schedule 4

THIDIAZURON

Appendix B, clause 3

THIETHYLPERAZINE

Schedule 4
Appendix K, clause 1

THIFENSULFURON

Schedule 5

THIOACETAZONE

Schedule 4

THIOBENCARB

Schedule 5

THIOCARLIDE

Schedule 4

THIODICARB

Schedule 6
Schedule 5

THIOFANOX

Schedule 7

THIOFENTANYL

cross reference: CAS No. 1165-22-6

Schedule 9

THIOGUANINE
cross reference: TIOGUANINE

THIOMESTERONE
cross reference: TIOMESTERONE

Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

THIOMETON

Schedule 6

THIOPENTAL

Schedule 4

THIOPENTONE
cross reference: THIOPENTAL

THIOPHANATEMETHYL

Schedule 6
Schedule 5

THIOPROPAZATE

Schedule 4
Appendix K, clause 1

THIOPROPERAZINE

Schedule 4

THIORIDAZINE

Schedule 4
Appendix K, clause 1

THIOSTREPTON

Schedule 4

THIOTEPA
cross reference: TRIETHYLENE THIOPHOSPHORAMIDE

Schedule 4

THIOTHIXENE

Schedule 4
Appendix K, clause 1

THIOURACIL

Schedule 4

THIOUREA
cross reference: ALKYL THIOUREAS

Schedule 6
Schedule 4
Appendix E, clause 3
Appendix F, clause 4

THIRAM

Schedule 6

THUJONE

Schedule 6
Appendix E, clause 3

THYME OIL

Schedule 5
Appendix E, clause 3

THYMOL

Schedule 6

THYMOSIN BETA 4 (THYMOSIN β4)

Schedule 4
Appendix D, clause 5

THYMOXAMINE

Schedule 4

THYROID

Schedule 4

THYROTROPHIN
cross reference: TSH

Schedule 4

THYROXINE

Schedule 4
Appendix G, clause 1

TIAFENACIL

Appendix B, clause 3

TIAGABINE

Schedule 4

TIAMULIN

Schedule 4

TIANEPTINE

Schedule 4
Appendix D, clause 5

TIAPROFENIC ACID

Schedule 4

TIARAMIDE

Schedule 4

TIBOLONE

Schedule 4

TICAGRELOR

Schedule 4

TICARCILLIN

Schedule 4

TICLOPIDINE

Schedule 4

TIEMONIUM

Schedule 4

TIENILIC ACID

Schedule 4

TIGECYCLINE

Schedule 4

TIGILANOL TIGLATE

Schedule 4

TIGLOIDINE

Schedule 4

TIGOLANER

Schedule 6
Schedule 5

TILDIPIROSIN

Schedule 4

TILETAMINE

Schedule 4

TILIDINE

Schedule 8

TILMANOCEPT

Schedule 4

TILMICOSIN

Schedule 4

TILUDRONIC ACID
cross reference: DISODIUM TILUDRONATE

Schedule 4

TIMBER
cross reference: WALLBOARD

Appendix A, clause 1

TIMOLOL

Schedule 4

TIMOTHYGRASS POLLEN EXTRACT
cross reference: PHLEUM PRATENSE POLLEN EXTRACT

Schedule 4

TIN ORGANIC COMPOUNDS
cross reference: DIALKYL TIN COMPOUNDS, DIBUTYL TIN COMPOUNDS, DIETHYL TIN COMPOUNDS, DIMETHYL TIN DICHLORIDE, DIMETHYL TIN COMPOUNDS, DIPROPYL TIN COMPOUNDS, FENBUTATIN OXIDE, ORGANO TINCOMPOUNDS, TBTO, TRIALKYL TIN COMPOUNDS, TRIBUTYL TIN COMPOUNDS, TRIETHYL TIN COMPOUNDS, TRIMETHYL TIN COMPOUNDS, TRIPHENYL TIN COMPOUNDS, TRIPROPYL TIN COMPOUNDS

Schedule 7

TINIDAZOLE

Schedule 4

TINZAPARIN

Schedule 4

TIOCARBAZIL

Schedule 5

TIOCONAZOLE

Schedule 4
Schedule 3
Schedule 2

Appendix H, clause 1

TIOGUANINE
cross reference: THIOGUANINE

Schedule 4

TIOTROPIUM

Schedule 4

TIPEPIDINE

Schedule 4

TIPIRACIL

Schedule 4

TIPRANAVIR

Schedule 4

TIRBANIBULIN

Schedule 4

TIRILAZAD

Schedule 4

TIROFIBAN

Schedule 4

TIRZEPATIDE

Schedule 4

Appendix L, clause 2

TIXAGEVIMAB

Schedule 4

TOBRAMYCIN

Schedule 4

TOCAINIDE

Schedule 4

TOCERANIB

Schedule 4

TOCILIZUMAB

Schedule 4

TOFACITINIB

Schedule 4

TOLAZAMIDE

Schedule 4

TOLAZOLINE

Schedule 4

TOLBUTAMIDE

Schedule 4

TOLCAPONE

Schedule 4

TOLCLOFOSMETHYL

Schedule 5

TOLFENAMIC ACID

Schedule 4

oTOLIDINE

Schedule 7
Appendix E, clause 3
Appendix J, clause 1

TOLMETIN

Schedule 4

TOLONIUM

Schedule 4

TOLPROPAMINE

Schedule 4

TOLRESTAT

Schedule 4

TOLTERODINE

Schedule 4

TOLTRAZURIL

Schedule 5

TOLUENE
cross reference: XYLENE

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

2,4TOLUENEDIAMINE

cross reference: CAS No. 95-80-7

Schedule 10

TOLUENEDIAMINES

Schedule 10
Schedule 6
Appendix E, clause 3
Appendix F, clause 4

oTOLUIDINE

cross reference: CAS No. 95-53-4

Schedule 10

TOLVAPTAN

Schedule 4

TOLYLFLUANID

Schedule 6

TOPIRAMATE

Schedule 4

TOPOTECAN

Schedule 4

TOPRAMEZONE

Schedule 5

TORASEMIDE

Schedule 4

TOREMIFENE

Schedule 4

TOXOIDS

Schedule 4

TRABECTEDIN

Schedule 4
Appendix K, clause 1

TRALKOXYDIM

Schedule 5

TRAMADOL

Schedule 4
Appendix K, clause 1

TRAMAZOLINE

Schedule 2
Appendix F, clause 4

TRAMETINIB DIMETHYL SULFOXIDE

Schedule 4

TRANDOLAPRIL

Schedule 4

TRANEXAMIC ACID 
cross reference: CETYL TRANEXAMATE

Schedule 4

TRANSFLUTHRIN

Schedule 6

TRANYLCYPROMINE

Schedule 4
Appendix K, clause 1

TRASTUZUMAB

Schedule 4

TRASTUZUMAB DERUXTECAN

Schedule 4

Appendix L, clause 2

TRASTUZUMAB EMTANSINE

Schedule 4

TRAVOPROST

Schedule 4

TRAZODONE

Schedule 4

TRENBOLONE
cross reference: TRIENBOLONE, TRIENOLONE

Schedule 5
Schedule 4
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

TREOSULPHAN

Schedule 4

TREPROSTINIL

Schedule 4

TRESTOLONE

Schedule 4
Appendix D, clause 5 (androgenic steroidal agents)

TRETAMINE

Schedule 4

TRETINOIN

Schedule 4
Appendix D, clause 4
Appendix F, clause 4
Appendix L, clause 2

TRIACETYLOLEANDOMYCIN

Schedule 4

TRIADIMEFON

Schedule 6
Schedule 5

TRIADIMENOL

Schedule 5

TRIALLATE

Schedule 5

TRIAMCINOLONE

Schedule 4
Schedule 3
Schedule 2
Appendix F, clause 4, Part 2

Appendix H, clause 1

TRIAMIPHOS

Schedule 7

TRIAMTERENE

Schedule 4

TRIASULFURON

Appendix B, clause 3

TRIAZBUTIL

Schedule 7

TRIAZIQUONE

Schedule 4

TRIAZOLAM

Schedule 4
Appendix D, clause 5 (benzodiazepine derivatives)

TRIBENURONMETHYL

Schedule 5

TRIBUFOS
cross reference: s,s,sTRIBUTYLPHOSPHOROTRITHIOATE

Schedule 7

TRICHLORFON
cross reference: METRIFONATE

Schedule 6

TRICHLORMETHIAZIDE

Schedule 4

TRICHLOROACETIC ACID

Schedule 6
Schedule 5
Schedule 4
Appendix E, clause 3
Appendix F, clause 4

TRICHLOROACETIC ACID ALKALI SALTS

Schedule 5
Appendix E, clause 3

1,1,1TRICHLOROETHANE 
cross reference: CAS No. 71-55-6, DESIGNATED SOLVENT

Schedule 10
Schedule 5
Appendix E, clause 3
Appendix F, clause 4

TRICHLOROETHYLENE
cross reference: TRICHLOROETHENE

Schedule 6
Schedule 4
Appendix E, clause 3
Appendix F, clause 4

TRICHLOROISOCYANURIC ACID
cross reference: CHLORINATING COMPOUNDS

Appendix E, clause 3

TRICHLOROPHENOL

Schedule 6
Appendix F, clause 4

TRICHODERMA HARZIANUM

Appendix B, clause 3

TRICHODESMA AFRICANA

Schedule 10

TRICLABENDAZOLE

Schedule 6

TRICLOFOS

Schedule 4

TRICLOPYR

Schedule 6

TRICLOSAN

Schedule 6

TRICYCLAMOL

Schedule 4

TRIDEMORPH

Schedule 6

TRIDIHEXETHYL

Schedule 4

TRIDIPHANE

Schedule 5

TRIENTINE

Schedule 4

TRIETAZINE

Schedule 5

TRIETHANOLAMINE
cross reference: TROLAMINE

TRIETHYL PHOSPHATE

Schedule 6
Appendix E, clause 3

TRIETHYLENE GLYCOL

Appendix B, clause 3

TRIFAROTENE

Schedule 4

TRIFLOXYSTROBIN

Schedule 5

TRIFLOXYSULFURON

Appendix B, clause 3

TRIFLUDIMOXAZIN

Schedule 5

TRIFLUMIZOLE

Schedule 5

TRIFLUMURON

Schedule 5

TRIFLUOPERAZINE

Schedule 4
Appendix K, clause 1

TRIFLUOROMETHANESULFONIC ACID

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

1(3TRIFLUOROMETHYLPHENYL)PIPERAZINE
cross reference: TFMPP (CAS No. 15532-75-9), TFMPP HYDROCHLORIDE (CAS No. 16015-69-3)

Schedule 9

TRIFLUPERIDOL

Schedule 4

TRIFLUPROMAZINE

Schedule 4

TRIFLURALIN

Appendix B, clause 3

TRIFLURIDINE

Schedule 4

TRIFORINE

Appendix B, clause 3

TRIHEXYPHENIDYL
cross reference: BENZHEXOL

Schedule 4

TRIISOPROPANOLAMINE LAURYL ETHER SULFATE

Schedule 5
Appendix E, clause 3
Appendix F, clause 4

TRILOSTANE

Schedule 4

TRIMEPERIDINE

cross reference: CAS No. 29606-10-8

Schedule 9

TRIMEPRAZINE
cross reference: ALIMEMAZINE

TRIMETAPHAN

Schedule 4

TRIMETHOPRIM

Schedule 4

3,4,5TRIMETHOXY α –METHYLPHENYLETHYLAMINE
cross reference: TMA (CAS No. 1082-88-8), TMA HYDROCHLORIDE (CAS No. 5688-80-2)

Schedule 9

3,4,5TRIMETHOXYPHENETHYLAMINE
cross reference: MESCALINE, METHOXYPHENAMINE, METHOXYPHENYLETHYLAMINE (CAS No. 54-04-6), MESCALINE HYDROCHLORIDE (CAS No. 832-92-8), MESCALINE HYDROGEN SULFATE (CAS No. 5967-42-0), MESCALINE HEMISULFATE (CAS No. 642-73-9)

Schedule 9

1(3,4,5TRIMETHOXYPHENYL)2AMINOBUTANE

cross reference: CAS No. 17097-73-3

Schedule 9

TRIMIPRAMINE

Schedule 4
Appendix K, clause 1

TRIMUSTINE

Schedule 4

TRINEXAPACETHYL

Schedule 5

TRINITROPHENOL

Schedule 6
Schedule 4

3,6,9TRIOXAUNDECANEDIOIC ACID

Schedule 5
Appendix F, clause 4

TRIOXYSALEN

Schedule 4

TRIPARANOL

cross reference: CAS No. 78-41-1

Schedule 10

TRIPELENNAMINE

Schedule 4

TRIPLE ANTIGEN VACCINE

cross reference: DIPHTHERIA TOXOID, PERTUSSIS ANTIGEN, TETANUS TOXOID

TRIPROLIDINE

Schedule 4
Schedule 3
Schedule 2
Appendix K, clause 1

TRIPTORELIN

Schedule 4

TRISODIUM NITRILOTRIACETATE

Schedule 6

TRITICONAZOLE

Schedule 5

TROGLITAZONE

Schedule 4

TROLAMINE

Schedule 5
Schedule 4
Appendix E, clause 3
Appendix F, clause 4

TROMETAMOL

Schedule 4

TROPICAMIDE

Schedule 4

TROPISETRON

Schedule 4

TROVAFLOXACIN

Schedule 4

TROXIDONE

Schedule 4

TRYPTOPHAN

Schedule 4

TUAMINOHEPTANE

Schedule 2

TUCATINIB

Schedule 4

TUBERCULIN

Schedule 4

TUBOCURARINE

Schedule 4

TULATHROMYCIN

Schedule 4

TULOBUTEROL

Schedule 4

TURPENTINE OIL
cross reference: OIL OF TURPENTINE

Schedule 5
Appendix E, clause 3

TUSSILAGO FARFARA
cross reference: COLTSFOOT

Schedule 10

TYLOSIN

Schedule 4

TYMAZOLINE

Schedule 4
Appendix F, clause 4

TYPHOID VACCINE

Schedule 4

U

ULIPRISTAL

Schedule 4
Schedule 3
Appendix H, clause 1

ULOCLADIUM OUDEMANSII

Appendix B, clause 3

UMECLIDINIUM

Schedule 4

UNIFIRAM

cross reference: RACETAMS

Schedule 4

UNOPROSTONE

Schedule 4

UPADACITINIB

Schedule 4

URACIL

Schedule 4

URAPIDIL

Schedule 4

UREA

Appendix B, clause 3

URETHANE

Schedule 4

UROFOLLITROPIN
cross reference: FOLLICLESTIMULATING HORMONE, HUMAN

Schedule 4
Appendix D, clause 1

UROKINASE

Schedule 4

URSODEOXYCHOLIC ACID

Schedule 4

USTEKINUMAB

Schedule 4

V

VACCINES

Schedule 4

VACCINES – PLASMID DNA
cross reference: PLASMID DNA (rE. coli DH5α pINGhT)

Schedule 4

VACCINIA VIRUS VACCINE

Schedule 4

VADADUSTAT

Schedule 4
Appendix D, clause 5

VALACICLOVIR

Schedule 4

VALDECOXIB

Schedule 4

VALGANCICLOVIR

Schedule 4

VALNOCTAMIDE

Schedule 4

VALPROIC ACID

Schedule 4

VALSARTAN

Schedule 4

VAMIDOTHION

Schedule 6

VANCOMYCIN

Schedule 4

VANDETANIB

Schedule 4

VARDENAFIL

Schedule 4

VARENICLINE

Schedule 4

VARICELLA VACCINE

Schedule 4

VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN (RECOMBINANT)

cross reference: RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN

VASOPRESSIN

Schedule 4

VECURONIUM

Schedule 4

VEDAPROFEN

Schedule 4

VEDOLIZUMAB

Schedule 4

VELAGLIFLOZIN

Schedule 4

VELAGLUCERASE ALFA

Schedule 4

VELPATASVIR

Schedule 4

VEMURAFENIB

Schedule 4

VENETOCLAX

Schedule 4

VENLAFAXINE

Schedule 4

VERAPAMIL

Schedule 4

VERATRUM

Schedule 4

VERICIGUAT

Schedule 4

VERNAKALANT

Schedule 4

VERNOLATE

Schedule 5

VERTEPORFIN

Schedule 4

VETIVER OIL

Appendix B, clause 3

VIDARABINE

Schedule 4

VIGABATRIN

Schedule 4

VILANTEROL

Schedule 4

VILDAGLIPTIN

Schedule 4

VILOXAZINE

Schedule 4

VINBLASTINE

Schedule 4

VINCAMINE

Schedule 4

VINCLOZOLIN

Schedule 6
Appendix F, clause 4

VINCRISTINE

Schedule 4

VINDESINE

Schedule 4

VINFLUNINE

Schedule 4

VINORELBINE

Schedule 4

VINYL ACETATE MONOMER

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

VINYL CHLORIDE

Schedule 7
Appendix J, clause 1

VINYL ETHER

Schedule 4

VIRGINIAMYCIN

Schedule 5
Schedule 4

VISMODEGIB

Schedule 4

VISNADINE

Schedule 4

VITAMIN A

Schedule 4

VITAMIN D
cross reference: COLECALCIFEROL, ERGOCALCIFEROL

Schedule 4
Schedule 3
Appendix H, clause 1

VITAMIN K
cross reference: PHYTOMENADIONE

Appendix B, clause 3

VITREOUS ENAMELS

Appendix A, clause 1

VORAPAXAR

Schedule 4

VORETIGENE NEPARVOVEC

Schedule 4

VORICONAZOLE

Schedule 4

VORINOSTAT

Schedule 4

VORTIOXETINE

Schedule 4

VOSORITIDE

Schedule 4

VOXILAPREVIR

Schedule 4

W

WALLBOARD
cross reference: TIMBER

Appendix A, clause 1

WARFARIN

Schedule 6
Schedule 5
Schedule 4

WRITING CORRECTION PENS

Appendix A, clause 1

X

XAMOTEROL

Schedule 4

XANTHINOL NICOTINATE

Schedule 4

XANTHOPHYLL
cross reference: LUTEIN

Appendix B, clause 3

XIMELAGATRAN

Schedule 4

XIPAMIDE

Schedule 4

XYLANASE derived from Aspergillus niger

Appendix B, clause 3

XYLAZINE

Schedule 4

XYLENE
cross reference: TOLUENE

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

XYLOMETAZOLINE

Schedule 2
Appendix F, clause 4

Y

YLANG YLANG OIL

Appendix B, clause 3

YOHIMBINE
cross reference: ASPIDOSPERMA QUEBRACHO

Schedule 4

Z

(Z)9TRICOSENE
cross reference: TRICOSENE

Appendix B, clause 3

ZAFIRLUKAST

Schedule 4

ZALCITABINE

Schedule 4

ZALEPLON

Schedule 4

ZANAMIVIR

Schedule 4

ZANUBRUTINIB

Schedule 4

ZERANOL

Schedule 6
Schedule 4

ZETACYPERMETHRIN

Schedule 7
Schedule 6

ZIDOVUDINE

Schedule 4

ZILPATEROL

Schedule 4

ZIMELDINE

Schedule 4

ZINC BORATE

Schedule 6

ZINC CHLORIDE

Schedule 4

Schedule 2

Appendix E, clause 3

ZINC COMPOUNDS

Schedule 4

ZINC LACTATE

Schedule 6
Appendix F, clause 4

ZINC NAPHTHENATE

Appendix B, clause 3

ZINC paraPHENOLSULFONATE

Schedule 6

ZINC SULFATE

Schedule 6
Appendix E, clause 3
Appendix F, clause 4

ZINEB
cross reference: DITHIOCARBAMATES, MANCOZEB, PROPINEB, THIRAM

Schedule 5

ZIPRASIDONE

Schedule 4
Appendix K, clause 1

ZIRAM

Schedule 7
Schedule 6

ZOLAZEPAM

Schedule 4

ZOLEDRONIC ACID

Schedule 4

ZOLMITRIPTAN

Schedule 4
Schedule 3
Appendix H, clause 1

ZOLPIDEM

Schedule 4
Appendix K, clause 1

ZONISAMIDE

Schedule 4
Appendix K, clause 1

ZOPICLONE

Schedule 4
Appendix K, clause 1

ZOXAZOLAMINE

Schedule 4

ZUCLOPENTHIXOL

Schedule 4


[1] “Cultivation”, “production” and “manufacture” have the same meaning as in the Narcotic Drugs Act 1967